| X3063 |
12890 |
Activity of 13-week old females, total counts of fine movements and ambulatory activity [counts/unit time] |
Activity |
| X3352 |
12960 |
Activity of 13-week old males, total counts of fine movements and ambulatory activity [counts/unit time] |
Activity |
| X1093 |
15698 |
Activity (ambulations) at night, metabolic cage, chow diet, males [AUC] |
Activity |
| X2256 |
15699 |
Activity (ambulations) at night, metabolic cage, high fat diet, males [AUC] |
Activity |
| X830 |
17629 |
Activity (movement) at dark phase (night) _CD, males [AUC] |
Activity |
| X1516 |
17630 |
Activity (movement) at dark phase (night) _HFD, males [AUC] |
Activity |
| X2451 |
17631 |
Activity (rearing) at night _CD, males [AUC] |
Activity |
| X3938 |
17632 |
Activity (rearing) at night _HFD, males [AUC] |
Activity |
| X1892 |
17713 |
Activity (movement) during full day (24 hours), _CD, males [counts/hour] |
Activity |
| X908 |
17714 |
Activity (movement) during full day (24 hours), _HFD, males [counts/hour] |
Activity |
| X2130 |
17715 |
Activity (movement) during light phase (day), _CD, males [counts/hour] |
Activity |
| X2410 |
17716 |
Activity (movement) during light phase (day), _HFD, males [counts/hour] |
Activity |
| X1869 |
17717 |
Activity (movement) during dark phase (night), _CD, males [counts/hour] |
Activity |
| X1361 |
17718 |
Activity (movement) during dark phase (night), _HFD, males [counts/hour] |
Activity |
| X2500 |
17719 |
Activity (rearing) during full day (24 hours), _CD, males [counts/hour] |
Activity |
| X1574 |
17720 |
Activity (rearing) during full day (24 hours), _HFD, males [counts/hour] |
Activity |
| X4361 |
17721 |
Activity (rearing) during light phase (day), _CD, males [counts/hour] |
Activity |
| X2840 |
17722 |
Activity (rearing) during light phase (day), _HFD, males [counts/hour] |
Activity |
| X1281 |
17723 |
Activity (rearing) during dark phase (night), _CD, males [counts/hour] |
Activity |
| X1154 |
17724 |
Activity (rearing) during dark phase (night) _HFD, males [counts/hour] |
Activity |
| X1146 |
17733 |
Run distance untrained, treadmill at 10 degree incline at 23 weeks of age_CD, males [m] |
Activity |
| X2100 |
17734 |
Run distance untrained, treadmill at 0 degree incline at 23 weeks of age_HFD, males [m] |
Activity |
| X712 |
17735 |
Run distance trained, treadmill at 10 degree incline at 25 weeks of age_CD, males [m] |
Activity |
| X768 |
17736 |
Run distance trained, treadmill at 0 degree incline at 25 weeks of age_HFD, males [m] |
Activity |
| X2736 |
17737 |
Run distance improvement after 10 days of voluntary exercise, treadmill at 10 degree incline_CD, males [m] |
Activity |
| X1290 |
17738 |
Run distance improvement after 10 days of voluntary exercise, treadmill at 0 degree incline_HFD, males [m] |
Activity |
| X1964 |
17761 |
Locomotor activity, light phase (day) running distance, activity wheel at 25 weeks of age_CD, males [km] |
Activity |
| X1927 |
17762 |
Locomotor activity, dark phase (night) running distance, activity wheel at 25 weeks of age_CD, males [km] |
Activity |
| X1972 |
17763 |
Locomotor activity, light phase (day) running distance, activity wheel at 25 weeks of age_HFD, males [km] |
Activity |
| X453 |
17764 |
Locomotor activity, 24 h running distance, activity wheel at 25 weeks of age_CD, males [km] |
Activity |
| X1056 |
17765 |
Locomotor activity, dark phase (night) running distance, activity wheel at 25 weeks of age_HFD, males [km] |
Activity |
| X299 |
17766 |
Locomotor activity, 24 h running distance, activity wheel at 25 weeks of age_HFD, males [km] |
Activity |
| X379 |
10285 |
Novel open fled behavior, habituation measured as the difference in locomotion between 0-5 min and 26-30 min periods for males and females [cm] |
Anxiety |
| X370 |
10331 |
Novel open fled behavior, habituation measured as the difference in locomotion between 0-5 min and 26-30 min periods for males [cm] |
Anxiety |
| X4573 |
10332 |
Novel open fled behavior, habituation measured as the difference in locomotion between 0-5 min and 26-30 min periods for females [cm] |
Anxiety |
| X376 |
10505 |
Open-field activity following saline injection [number of crossings during 3 min] |
Anxiety |
| X3851 |
10896 |
Anxiety assay, closed arm entries in an elevated plus maze test [n] |
Anxiety |
| X2491 |
10898 |
Anxiety assay, open arm entries in an elevated plus maze test [n] |
Anxiety |
| X1253 |
10904 |
Anxiety assay, locomotion in the light compartment relative to total in a light-dark test [%] |
Anxiety |
| X910 |
10905 |
Anxiety assay, time in the center of an elevated plus maze [sec] |
Anxiety |
| X2119 |
10906 |
Novel open field behavior, time in the field center [sec] |
Anxiety |
| X4147 |
10907 |
Anxiety assay, percentage of time in light compartment of a light-dark test [%] |
Anxiety |
| X1020 |
10908 |
Anxiety assay, percentage of time in open arms of an elevated plus maze [%] |
Anxiety |
| X5021 |
10909 |
Anxiety assay, arm entries (total) in an elevated plus maze [n] |
Anxiety |
| X4155 |
10910 |
Novel open field behavior, locomotion from 0-30 min [cm] |
Anxiety |
| X288 |
10911 |
Novel open field behavior, locomotion from 0-5 min [cm] |
Anxiety |
| X3096 |
10912 |
Novel open field behavior, locomotion from 10-15 min [cm] |
Anxiety |
| X4398 |
10913 |
Novel open field behavior, locomotion from 15-20 min [cm] |
Anxiety |
| X4526 |
10914 |
Novel open field behavior, locomotion from 20-25 min [cm] |
Anxiety |
| X4397 |
10915 |
Novel open field behavior, locomotion from 25-30 min [cm] |
Anxiety |
| X4332 |
10916 |
Novel open field behavior, locomotion from 5-10 min [cm] |
Anxiety |
| X3300 |
10917 |
Anxiety assay, transitions between light and dark compartments in light/dark test [n] |
Anxiety |
| X2750 |
10955 |
Anxiety assay (S5_PDT), restraint stress (15 min) + saline treated (0.018 mL/g i.p.), percent distance traveled in light side using a light-dark box in 8-12 week-old males during 5 min session [%] |
Anxiety |
| X383 |
10957 |
Anxiety assay (S5_TLA) following restraint stress (15 min) and a saline injection (0.018 mL/g ip), distance traveled in light-dark box by 8-12 week-old males during a 5 min session [cm] |
Anxiety |
| X730 |
10960 |
Anxiety assay (S5_NT) following restraint stress (15 min) and a saline injection (0.018 mL/g ip), entries into light side of light-dark box by 8-12 week-old males during a 5 min session [n] |
Anxiety |
| X2449 |
10961 |
Anxiety assay (S5_NR) following restraint stress (15 min) and a saline injection (0.018 mL/g ip), rearing events in the light side using a light-dark box in 8-12 week-old males during a 5 min session [n] |
Anxiety |
| X187 |
10964 |
Anxiety assay (E5_PDT), after restraint stress (15 min) with ethanol treatment (1.8 g/kg i.p.), percent distance traveled in light side (cm) using a light-dark box in 8-12 week-old males during 5 min session |
Anxiety |
| X1081 |
10966 |
Anxiety assay (E5_TLA) following restraint stress (15 min) and ethanol injection (1.8 g/kg ip), locomotor activity in light-dark box by 8-12 week-old males during a 5 min session [cm] |
Anxiety |
| X2880 |
10969 |
Anxiety level following restraint stress (15 min) and ethanol treatment (1.8 g/kg i.p., E5 NT group) measured as the number of entries into light side of light-dark box in 8-12 week-old males (5 min session) |
Anxiety |
| X3717 |
10970 |
Anxiety assay following restraint stress (15 min) and ethanol injection (1.8 g/kg ip), rearing events in the light side using a light-dark box by 8-12 week-old males during a 5 min session [n] |
Anxiety |
| X982 |
10973 |
Anxiety assay following restraint stress (15 min) and saline injection (0.018 ml/g ip), percent distance in light side using a light-dark box by 8-12 week-old males during 10 min session [%] |
Anxiety |
| X493 |
10975 |
Anxiety assay (S10_TLA), restraint stress (15 min) and saline treated (0.018 ml/g ip), distance traveled in light-dark box, 8-12 week-old males during a 10 min session [cm] |
Anxiety |
| X428 |
10978 |
Anxiety assay (S10_NT), entries into light side of light-dark box after restraint stress (15 min) and saline control injection (0.018 ml/g ip) in 8-12 week-old males during a 10 min test [n] |
Anxiety |
| X2291 |
10979 |
Anxiety assay after restraint stress (15 min) and a saline injection (0.018 ml/g ip), rearing events in the light side using a light-dark box by 8-12 week-old males during a 10 min session [n] |
Anxiety |
| X398 |
10982 |
Anxiety assay (E10_PDT), restraint stress (15 min) + ethanol treated (1.8 g/kg i.p.), percent distance traveled in light side (cm) using a light-dark box in 8-12 week-old males during 10 min session [%] |
Anxiety |
| X433 |
10984 |
Anxiety assay (E10_TLA), restraint stress (15 min) + ethanol treated (1.8 g/kg i.p.), total distance traveled in light-dark box, using 8-12 week-old males during 10 min session [cm] |
Anxiety |
| X1793 |
10987 |
Anxiety assay (E10_NT), restraint stress (15 min) + ethanol treated (1.8 g/kg i.p.), number of entries into light side of light-dark box, using 8-12 week-old males during a 10 min session [n] |
Anxiety |
| X4646 |
10988 |
Anxiety assay after restraint stress (15 min) and an ethanol injection (1.8 g/kg ip), rearing events in the light side using a light-dark box by 8-12 week-old males during a 10 min session [n] |
Anxiety |
| X3095 |
11012 |
Anxiety assay, time in open arm of elevated plus maze in young adult males and females [sec] |
Anxiety |
| X4739 |
11013 |
Anxiety assay, number of closed arm entries using elevated plus maze [n] |
Anxiety |
| X3186 |
11014 |
Locomotor activity, distance, open field behavior [cm] |
Anxiety |
| X4514 |
11015 |
Anxiety assay, open field behavior, duration in center of field [sec] |
Anxiety |
| X1074 |
11341 |
Novel open field behavior, locomotion in the periphery from 0-15 min for males in the morphine test battery [n beam breaks] |
Anxiety |
| X3456 |
11342 |
Novel open field behavior, locomotion in the periphery from 15-30 min for males in the morphine test battery [n beam breaks] |
Anxiety |
| X2888 |
11343 |
Novel open field behavior, locomotion in the periphery from 30-45 min for males in the morphine test battery [n beam breaks] |
Anxiety |
| X3007 |
11344 |
Novel open field behavior, locomotion in the periphery from 45-60 min for males in the morphine test battery [n beam breaks] |
Anxiety |
| X1438 |
11345 |
Novel open field behavior, locomotion in the periphery from 0-15 min for males in the morphine test battery [cm] |
Anxiety |
| X3241 |
11346 |
Novel open field behavior, locomotion locomotion in the periphery from 15-30 min for males in the morphine test battery [cm] |
Anxiety |
| X3465 |
11347 |
Novel open field behavior, locomotion in the periphery from 30-45 min for males in the morphine test battery [cm] |
Anxiety |
| X2197 |
11348 |
Novel open field behavior, locomotion in the periphery from 45-60 min for males in the morphine test battery [cm] |
Anxiety |
| X1070 |
11349 |
Novel open field behavior, vertical activity (rears) from 0-15 min for males [n beam breaks] |
Anxiety |
| X355 |
11350 |
Novel open field behavior, vertical activity (rears) from 15-30 min for males [n beam breaks] |
Anxiety |
| X256 |
11351 |
Novel open field behavior, vertical activity (rears) from 30-45 min for males [n beam breaks] |
Anxiety |
| X245 |
11352 |
Novel open field behavior, vertical activity (rears) from 45-60 min for males [n beam breaks] |
Anxiety |
| X2452 |
11353 |
Novel open field behavior, locomotion in the center from 0-60 min for males [n beam breaks] |
Anxiety |
| X2855 |
11354 |
Novel open field behavior, locomotion in the center from 0-60 min for males [cm] |
Anxiety |
| X219 |
11355 |
Novel open field behavior, vertical activity (rears) in the center from 0-60 min for males [n beam breaks] |
Anxiety |
| X2629 |
11363 |
Novel open field behavior, urinations for males [n/test period] |
Anxiety |
| X2383 |
11385 |
Anxiety assay, time in dark side of a light-dark box for males [sec] |
Anxiety |
| X3331 |
11387 |
Anxiety assay, locomotion in the light compartment of a light-dark box for males [cm] |
Anxiety |
| X2384 |
11388 |
Anxiety assay, time in light side of a light-dark box for males [sec] |
Anxiety |
| X1882 |
11389 |
Anxiety assay, percentage of locomotion in light side of a light-dark box for males [%] |
Anxiety |
| X2390 |
11390 |
Anxiety assay, percentage of time in light side of a light-dark box for males [%] |
Anxiety |
| X2043 |
11391 |
Anxiety assay, transitions between light and dark sides of a light-dark box for males [n] |
Anxiety |
| X1248 |
11404 |
Open field behavior, percentage of distance in the center for males [%] |
Anxiety |
| X1991 |
11405 |
Open field behavior, percentage of time in center for males [%] |
Anxiety |
| X4313 |
11406 |
Open field behavior, time in corners for males [min] |
Anxiety |
| X1791 |
11407 |
Open field behavior, locomotion from 0-5 min for males [cm] |
Anxiety |
| X2290 |
11408 |
Open field behavior, locomotion from 10-15 min for males [cm] |
Anxiety |
| X1740 |
11409 |
Open field behavior, locomotion from 15-20 min for males [cm] |
Anxiety |
| X4442 |
11410 |
Open field behavior, locomotion from 5-10 min for males [cm] |
Anxiety |
| X1160 |
11411 |
Open field activity, habituation ratio for males (ratio of activity during last 5 min interval and first 5 min interval) [ratio n beam breaks] |
Anxiety |
| X2360 |
11412 |
Open field behavior, percentage time in perimeter minus time in corners for males [%] |
Anxiety |
| X3955 |
11413 |
Open field behavior, vertical activity (rears) from 0-20 min for males [n beam breaks] |
Anxiety |
| X3172 |
11414 |
Open field behavior, vertical activity (rears) from 0-5 min for males [n beam breaks] |
Anxiety |
| X2563 |
11415 |
Open field behavior, vertical activity (rears) 10-15 min for males [n beam breaks] |
Anxiety |
| X2202 |
11416 |
Open field behavior, vertical activity (rears) from 15-20 min for males [n beam breaks] |
Anxiety |
| X4181 |
11417 |
Open field behavior, vertical activity (rears) from 5-10 min for males [n beam breaks] |
Anxiety |
| X2683 |
11418 |
Open field behavior, locomotion for entire test period for males [cm] |
Anxiety |
| X1249 |
11419 |
Open field behavior, percentage of distance in the perimeter for males [%] |
Anxiety |
| X1990 |
11420 |
Open field behavior, percentage of time in perimeter for males [%] |
Anxiety |
| X1053 |
11434 |
Anxiety assay, entries in closed quadrants of a zero maze for males [n] |
Anxiety |
| X1031 |
11435 |
Anxiety assay, entries in open quadrants of a zero maze for males [n] |
Anxiety |
| X4508 |
11437 |
Anxiety assay, percentage of time in open quadrants of a zero maze for males [%] |
Anxiety |
| X4639 |
11438 |
Anxiety assay, time in closed quadrants of a zero maze for males [sec] |
Anxiety |
| X4640 |
11439 |
Anxiety assay, time in open quadrants of a zero maze for males [sec] |
Anxiety |
| X3859 |
11454 |
Anxiety assay, untreated baseline, entries into closed arms of a plus maze for males [n] |
Anxiety |
| X4966 |
11455 |
Anxiety assay, untreated baseline, entries into open arms of a plus maze for males [n] |
Anxiety |
| X2547 |
11456 |
Anxiety assay, untreated baseline, percentage of entries into closed arms of a plus maze for males [%] |
Anxiety |
| X4036 |
11457 |
Anxiety assay, untreated baseline, percent entries into open arms of an elevated plus maze for males [%] |
Anxiety |
| X3728 |
11458 |
Anxiety assay, untreated baseline, percent time in closed arms of a plus maze for males [%] |
Anxiety |
| X3814 |
11459 |
Anxiety assay, untreated baseline, percentage of time in open arms of a plus maze for males [%] |
Anxiety |
| X3727 |
11466 |
Anxiety assay, time in closed arms of an elevated plus maze for males [sec] |
Anxiety |
| X3531 |
11467 |
Anxiety assay, time in middle of an elevated plus maze for males [sec] |
Anxiety |
| X3818 |
11468 |
Anxiety assay, time in open arms of a plus maze for males [sec] |
Anxiety |
| X2918 |
11500 |
Novel open field behavior, locomotion in the center from 0-60 min for males [n beam breaks] |
Anxiety |
| X3192 |
11501 |
Novel open field behavior, locomotion in the center from 0-60 min for males [cm] |
Anxiety |
| X1529 |
11502 |
Novel open field behavior, vertical activity (rears) from 0-60 min in the center for males [n beam breaks] |
Anxiety |
| X3290 |
11506 |
Novel open field behavior, locomotion in the center from 0-15 min for males [n beam breaks] |
Anxiety |
| X2641 |
11507 |
Novel open field behavior, locomotion in the center from 15-30 min for males [n beam breaks] |
Anxiety |
| X2314 |
11508 |
Novel open field behavior, locomotion in the center from 30-45 min for males [n beam breaks] |
Anxiety |
| X2676 |
11509 |
Novel open field behavior, locomotion in the center from 45-60 min for males [n beam breaks] |
Anxiety |
| X3144 |
11510 |
Novel open field behavior, locomotion in the center from 0-15 min for males [cm] |
Anxiety |
| X2916 |
11511 |
Novel open field behavior, locomotion in the center from 15-30 min for males [cm] |
Anxiety |
| X2698 |
11512 |
Novel open field behavior, locomotion in the center from 30-45 min for males [cm] |
Anxiety |
| X2943 |
11513 |
Novel open field behavior, locomotion in the center from 45-60 min for males [cm] |
Anxiety |
| X1605 |
11514 |
Novel open field behavior, vertical activity (rears) from 0-15 min in the center for males [n beam breaks] |
Anxiety |
| X1378 |
11515 |
Novel open field behavior, vertical activity (rears) from 15-30 min in the center for males [n beam breaks] |
Anxiety |
| X2337 |
11516 |
Novel open field behavior, vertical activity (rears) from 30-45 min in the center for males [n beam breaks] |
Anxiety |
| X3329 |
11517 |
Novel open field behavior, vertical activity (rears) from 45-60 min in the center for males [n beam breaks] |
Anxiety |
| X4019 |
11518 |
Novel open field behavior, locomotion in the periphery from 0-15 min for males in the cocaine test battery [n beam breaks] |
Anxiety |
| X2605 |
11519 |
Novel open field behavior, locomotion in the periphery from 15-30 min for males in the cocaine test battery [n beam breaks] |
Anxiety |
| X2506 |
11520 |
Novel open field behavior, locomotion in the periphery from 30-45 min for males in the cocaine test battery [n beam breaks] |
Anxiety |
| X3341 |
11521 |
Novel open field behavior, locomotion in the periphery from 45-60 min for males in the cocaine test battery [n beam breaks] |
Anxiety |
| X3857 |
11522 |
Novel open field behavior, locomotion from 0-15 min in the periphery for males in the cocaine test battery [cm] |
Anxiety |
| X2422 |
11523 |
Novel open field behavior, locomotion from 15-30 min in the periphery for males in the cocaine test battery [cm] |
Anxiety |
| X3246 |
11524 |
Novel open field behavior, locomotion from 30-45 min in the periphery for males in the cocaine test battery [cm] |
Anxiety |
| X3917 |
11525 |
Novel open field behavior, locomotion from 45-60 min in the periphery for males in the cocaine test battery [cm] |
Anxiety |
| X1019 |
11526 |
Novel open field behavior, vertical activity (rears) in the periphery from 0-15 min for males [n beam breaks] |
Anxiety |
| X1729 |
11527 |
Novel open field behavior, vertical activity (rears) in the periphery from 15-30 min for males [n beam breaks] |
Anxiety |
| X1423 |
11528 |
Novel open field behavior, vertical activity (rears) in the periphery from 30-45 min for males [n beam breaks] |
Anxiety |
| X2162 |
11529 |
Novel open field behavior, vertical activity (rears) in the periphery from 45-60 min for males [n beam breaks] |
Anxiety |
| X1151 |
11530 |
Novel open field behavior, percentage of locomotion in the periphery for males [%] |
Anxiety |
| X3311 |
11531 |
Novel open field behavior, locomotion in the periphery from 0-60 min for males [n beam breaks] |
Anxiety |
| X2857 |
11532 |
Novel open field behavior, locomotion in the periphery from 0-60 min for males [cm] |
Anxiety |
| X1161 |
11533 |
Novel open field behavior, vertical activity (rears) in the periphery from 0-60 min for males [n beam breaks] |
Anxiety |
| X2481 |
11553 |
Novel open field behavior, locomotion in the center and periphery from 0-60 min for males in the cocaine test battery [n beam breaks] |
Anxiety |
| X2386 |
11554 |
Novel open field behavior, locomotion in the center and periphery from 0-60 min for males in the cocaine test battery [cm] |
Anxiety |
| X1134 |
11555 |
Novel open field behavior, vertical activity (rears) in the center and periphery from 0-60 min for males in the cocaine test battery [n beam breaks] |
Anxiety |
| X1836 |
11598 |
Novel open field behavior, locomotion in the periphery from 0-15 min for females in the morphine test battery [n beam breaks] |
Anxiety |
| X984 |
11599 |
Novel open field behavior, locomotion in the periphery from 15-30 min for females in the morphine test battery [n beam breaks] |
Anxiety |
| X682 |
11600 |
Novel open field behavior, locomotion in the periphery from 30-45 min for females in the morphine test battery [n beam breaks] |
Anxiety |
| X320 |
11601 |
Novel open field behavior, locomotion in the periphery from 45-60 min for females in the morphine test battery [n beam breaks] |
Anxiety |
| X1266 |
11602 |
Novel open field behavior, locomotion in the periphery from 0-15 min for females in the morphine test battery [cm] |
Anxiety |
| X529 |
11603 |
Novel open field behavior, locomotion in the periphery from 15-30 min for females in the morphine test battery [cm] |
Anxiety |
| X470 |
11604 |
Novel open field behavior, locomotion in the periphery from 30-45 min for females in the morphine test battery [cm] |
Anxiety |
| X235 |
11605 |
Novel open field behavior, locomotion in the periphery from 45-60 min for females in the morphine test battery [cm] |
Anxiety |
| X262 |
11606 |
Novel open field behavior, vertical activity (rears) from 0-15 for females [n beam breaks] |
Anxiety |
| X316 |
11607 |
Novel open field behavior, vertical activity (rears) from 15-30 min for females [n beam breaks] |
Anxiety |
| X377 |
11608 |
Novel open field behavior, vertical activity (rears) from 30-45 min for females [n beam breaks] |
Anxiety |
| X277 |
11609 |
Novel open field behavior, vertical activity (rears) from 45-60 min for females [n beam breaks] |
Anxiety |
| X890 |
11610 |
Novel open field behavior, locomotion in the center from 0-60 min for females [n beam breaks] |
Anxiety |
| X451 |
11611 |
Novel open field behavior, locomotion in the center from 0-60 min for females [cm] |
Anxiety |
| X1873 |
10204 |
TRBV4+ T cell levels among CD8+ T cells in spleen [%] |
Immune |
| X271 |
11612 |
Novel open field behavior, vertical activity (rears) in the center from 0-60 min for females [n beam breaks] |
Anxiety |
| X995 |
11620 |
Novel open field behavior, urinations for females [n/test period] |
Anxiety |
| X3155 |
11642 |
Anxiety assay, time in dark side of a light-dark box for females [sec] |
Anxiety |
| X4333 |
11644 |
Anxiety assay, locomotion in the light compartment of a light-dark box for females [cm] |
Anxiety |
| X3156 |
11645 |
Anxiety assay, time in light side of a light-dark box for females [sec] |
Anxiety |
| X2514 |
11646 |
Anxiety assay, percentage of locomotion in light side of a light-dark box for females [%] |
Anxiety |
| X3308 |
11647 |
Anxiety assay, percentage of time in the light side of a light-dark box for females [%] |
Anxiety |
| X1978 |
11648 |
Anxiety assay, transitions between light and dark sides of a light-dark box for females [n] |
Anxiety |
| X4691 |
11661 |
Open field behavior, percentage of distance in the center for females [%] |
Anxiety |
| X4570 |
11662 |
Open field behavior, percentage of time in center for females [%] |
Anxiety |
| X4768 |
11663 |
Open field behavior, time in corners for females [min] |
Anxiety |
| X2978 |
11664 |
Open field behavior, locomotion from 0-5 min for females [cm] |
Anxiety |
| X1324 |
11665 |
Open field behavior, locomotion from 10-15 min for females [cm] |
Anxiety |
| X703 |
11666 |
Open field behavior, locomotion from 15-20 min for females [cm] |
Anxiety |
| X2129 |
11667 |
Open field behavior locomotion from 5-10 min for females [cm] |
Anxiety |
| X2795 |
11668 |
Open field activity, habituation ratio for females (ratio of activity during last 5 min interval and first 5 min interval) [ratio n beam breaks] |
Anxiety |
| X4622 |
11669 |
Open field behavior, percentage time in perimeter minus time in corners for females [%] |
Anxiety |
| X2745 |
11670 |
Open field behavior, vertical activity (rears) from 0-20 min for females [n beam breaks] |
Anxiety |
| X2254 |
11671 |
Open field behavior, vertical activity (rears) from 0-5 min for females [n beam breaks] |
Anxiety |
| X3729 |
11672 |
Open field behavior, vertical activity (rears) from 10-15 min for females [n beam breaks] |
Anxiety |
| X2554 |
11673 |
Open field behavior, vertical activity (rears) from 15-20 min for females [n beam breaks] |
Anxiety |
| X1471 |
11674 |
Open field behavior, vertical activity (rears) from 5-10 min for females [n beam breaks] |
Anxiety |
| X2139 |
11675 |
Open field behavior, locomotion for entire test period for females [cm] |
Anxiety |
| X4692 |
11676 |
Open field behavior, percentage distance in the perimeter for females [%] |
Anxiety |
| X4569 |
11677 |
Open field behavior, percentage of time in perimeter for females [%] |
Anxiety |
| X2859 |
11691 |
Anxiety assay, entries in closed quadrants of a zero maze for females [n] |
Anxiety |
| X2836 |
11692 |
Anxiety assay, entries into open quadrants of a zero maze for females [n] |
Anxiety |
| X1800 |
11694 |
Anxiety assay, percentage time in open quadrants of a zero maze for females [%] |
Anxiety |
| X1753 |
11695 |
Anxiety assay, time in closed quadrants of a zero maze for females [sec] |
Anxiety |
| X1754 |
11696 |
Anxiety assay, time in open quadrants of a zero maze for females [sec] |
Anxiety |
| X2487 |
11711 |
Anxiety assay, untreated baseline, entries into closed arms of a plus maze for females [n] |
Anxiety |
| X2441 |
11712 |
Anxiety assay, untreated baseline, entries into open arms of a plus maze for females [n] |
Anxiety |
| X1779 |
11713 |
Anxiety assay, untreated baseline, percentage of entries into closed arms of a plus maze for females [%] |
Anxiety |
| X3102 |
11714 |
Anxiety assay, untreated baseline, percent entries into open arms of an elevated plus maze for females [%] |
Anxiety |
| X726 |
11715 |
Anxiety assay, untreated baseline, percent time in closed arms of a plus maze for females [%] |
Anxiety |
| X2321 |
11716 |
Anxiety assay, untreated baseline, percentage of time in open arms of a plus maze for females [%] |
Anxiety |
| X727 |
11723 |
Anxiety assay, time in closed arms of an elevated plus maze for females [sec] |
Anxiety |
| X1905 |
11724 |
Anxiety assay, time in middle of an elevated plus maze for females [sec] |
Anxiety |
| X1221 |
11725 |
Anxiety assay, time in open arms of an elevated plus maze for females [sec] |
Anxiety |
| X2168 |
11757 |
Novel open field behavior, locomotion in the center from 0-60 min for females [n beam breaks] |
Anxiety |
| X1686 |
11758 |
Novel open field behavior, locomotion in the center from 0-60 min for females [cm] |
Anxiety |
| X471 |
11759 |
Novel open field behavior, vertical activity (rears) from 0-60 min in the center for females [n beam breaks] |
Anxiety |
| X797 |
11763 |
Novel open field behavior, locomotion in the center from 0-15 min for females [n beam breaks] |
Anxiety |
| X2267 |
11764 |
Novel open field behavior, locomotion in the center from 15-30 min for females [n beam breaks] |
Anxiety |
| X2939 |
11765 |
Novel open field behavior, locomotion in the center from 30-45 min for females [n beam breaks] |
Anxiety |
| X2756 |
11766 |
Novel open field behavior, locomotion in the center from 45-60 min for females [n beam breaks] |
Anxiety |
| X1310 |
11767 |
Novel open field behavior, locomotion in the center from 0-15 min for females [cm] |
Anxiety |
| X1343 |
11768 |
Novel open field behavior, locomotion in the center from 15-30 min for females [cm] |
Anxiety |
| X2590 |
11769 |
Novel open field behavior, locomotion in the center from 30-45 min for females [cm] |
Anxiety |
| X2803 |
11770 |
Novel open field behavior, locomotion in the center from 45-60 min for females [cm] |
Anxiety |
| X944 |
11771 |
Novel open field behavior, vertical activity (rears) from 0-15 min in the center for females [n beam breaks] |
Anxiety |
| X371 |
11772 |
Novel open field behavior, vertical activity (rears) from15-30 min in the center for females [n beam breaks] |
Anxiety |
| X620 |
11773 |
Novel open field behavior, vertical activity (rears) from 30-45 min in the center for females [n beam breaks] |
Anxiety |
| X1777 |
11774 |
Novel open field behavior, vertical activity (rears) from 45-60 min in the center for females [n beam breaks] |
Anxiety |
| X1733 |
11775 |
Novel open field behavior, locomotion in the periphery from 0-15 min for females in the cocaine test battery [n beam breaks] |
Anxiety |
| X3307 |
11776 |
Novel open field behavior, locomotion in the periphery from 15-30 min for females in the cocaine test battery [n beam breaks] |
Anxiety |
| X3512 |
12542 |
Iron level of plasma of 120-day-old females fed 3 ppm Fe diet [ug/dL] |
Hematology |
| X2541 |
11777 |
Novel open field behavior, locomotion in the periphery from 30-45 min for females in the cocaine test battery [n beam breaks] |
Anxiety |
| X3430 |
11778 |
Novel open field behavior, locomotion in the periphery from 45-60 min for females in the cocaine test battery [n beam breaks] |
Anxiety |
| X3037 |
11780 |
Novel open field behavior, locomotion from 15-30 min in the periphery for females in the cocaine test battery [cm] |
Anxiety |
| X3072 |
11781 |
Novel open field behavior, locomotion from 30-45 min in the periphery for females in the cocaine test battery [cm] |
Anxiety |
| X3893 |
11782 |
Novel open field behavior, locomotion from 45-60 min in the periphery for females in the cocaine test battery [cm] |
Anxiety |
| X472 |
11783 |
Novel open field behavior, vertical activity (rears) in the periphery from 0-15 min for females [n beam breaks] |
Anxiety |
| X401 |
11784 |
Novel open field behavior, vertical activity (rears) in the periphery from 15-30 min for females [n beam breaks] |
Anxiety |
| X385 |
11785 |
Novel open field behavior, vertical activity (rears) in the periphery from 30-45 min for females [n beam breaks] |
Anxiety |
| X276 |
11786 |
Novel open field behavior, vertical activity (rears) in the periphery from 45-60 min for females [n beam breaks] |
Anxiety |
| X3377 |
11787 |
Novel open field behavior, percentage of locomotion in the periphery for females [%] |
Anxiety |
| X3304 |
11788 |
Novel open field behavior, locomotion in the periphery from 0-60 min for females [n beam breaks] |
Anxiety |
| X3183 |
11789 |
Novel open field behavior, locomotion in the periphery from 0-60 min for females [cm] |
Anxiety |
| X253 |
11790 |
Novel open field behavior, vertical activity (rears) in the periphery from 0-60 min for females [n beam breaks] |
Anxiety |
| X1569 |
11810 |
Novel open field behavior, locomotion in the center and periphery from 0-60 min for females in the cocaine test battery [n beam breaks] |
Anxiety |
| X1391 |
11811 |
Novel open field behavior, locomotion in the center and periphery from 0-60 min for females in the cocaine test battery [cm] |
Anxiety |
| X168 |
11812 |
Novel open field behavior, vertical activity (rears) in the center and periphery from 0-60 min for females in the cocaine test battery [n beam breaks] |
Anxiety |
| X3460 |
11855 |
Novel open field behavior, locomotion in the periphery from 0-15 min for males and females in the morphine test battery [n beam breaks] |
Anxiety |
| X2182 |
11856 |
Novel open field behavior, locomotion in the periphery from 15-30 min for males and females in the morphine test battery [n beam breaks] |
Anxiety |
| X1050 |
11857 |
Novel open field behavior, locomotion in the periphery from 30-45 min for males and females in the morphine test battery [n beam breaks] |
Anxiety |
| X467 |
11858 |
Novel open field behavior, locomotion in the periphery from 45-60 min for males and females in the morphine test battery [n beam breaks] |
Anxiety |
| X2944 |
11859 |
Novel open field behavior, locomotion in the periphery from 0-15 min for males and females in the morphine test battery [cm] |
Anxiety |
| X1385 |
11860 |
Novel open field behavior, locomotion locomotion in the periphery from 15-30 for males and females in the morphine test battery [cm] |
Anxiety |
| X1468 |
15570 |
Kramer RM, Lamkin T, and colleagues TAFI15 |
Immune |
| X673 |
11861 |
Novel open field behavior, locomotion in the periphery from 30-45 min for males and females in the morphine test battery [cm] |
Anxiety |
| X325 |
11862 |
Novel open field behavior, locomotion in the periphery from 45-60 min for males and females in the morphine test battery [cm] |
Anxiety |
| X326 |
11863 |
Novel open field behavior,vertical activity (rears) from 0-15 min for males and females [n beam breaks] |
Anxiety |
| X238 |
11864 |
Novel open field behavior, vertical activity (rears) from 15-30 min for males and females [n beam breaks] |
Anxiety |
| X191 |
11865 |
Novel open field behavior, vertical activity (rears) from min 30-45 for males and females [n beam breaks] |
Anxiety |
| X177 |
11866 |
Novel open field behavior, vertical activity (rears) from 45-60 min for males and females [n beam breaks] |
Anxiety |
| X1413 |
11867 |
Novel open field behavior, locomotion in the center from 0-60 min for males and females [n beam breaks] |
Anxiety |
| X799 |
11868 |
Novel open field behavior, locomotion in the center from 0-60 min for males and females [cm] |
Anxiety |
| X186 |
11869 |
Novel open field behavior, vertical activity (rears) in the center from 0-60 min for males and females [n beam breaks] |
Anxiety |
| X2669 |
11877 |
Novel open field behavior, urinations for males and females [n/test period] |
Anxiety |
| X3871 |
11899 |
Anxiety assay, time in dark side of a light-dark box for males and females [sec] |
Anxiety |
| X4308 |
11901 |
Anxiety assay, locomotion in the light compartment of a light-dark box for males and females [cm] |
Anxiety |
| X3872 |
11902 |
Anxiety assay, time in light side of a light-dark box for males and females [sec] |
Anxiety |
| X1899 |
11903 |
Anxiety assay, percentage of locomotion in light side of a light-dark box for males and females [%] |
Anxiety |
| X3931 |
11904 |
Anxiety assay, percentage time in light side of a light-dark box for males and females [%] |
Anxiety |
| X1948 |
11905 |
Anxiety assay, transitions between light and dark sides of a light-dark box for males and females [n] |
Anxiety |
| X2597 |
11918 |
Open field behavior, percentage of distance in the center for males and females [%] |
Anxiety |
| X2014 |
11919 |
Open field behavior, percentage of time in center for males and females [%] |
Anxiety |
| X3648 |
11920 |
Open field behavior, time in corners for males and females [min] |
Anxiety |
| X3571 |
11921 |
Open field behavior, locomotion from 0-5 min for males and females [cm] |
Anxiety |
| X2990 |
11922 |
Open field behavior, locomotion from 10-15 min for males and females [cm] |
Anxiety |
| X1752 |
11923 |
Open field behavior, locomotion from 15-20 min for males and females [cm] |
Anxiety |
| X4190 |
11924 |
Open field behavior, locomotion from 5-10 min for males and females [cm] |
Anxiety |
| X2700 |
11925 |
Open field activity, habituation ratio for males and females (ratio of activity during last 5 min interval and first 5 min interval) [ratio n beam breaks] |
Anxiety |
| X3461 |
11926 |
Open field behavior, percentage of time in perimeter minus time in corners for males and females [%] |
Anxiety |
| X2549 |
11927 |
Open field behavior, vertical activity (rears) from 0-20 min for males and females [n beam breaks] |
Anxiety |
| X2322 |
10205 |
TRBV4+ T cell levels among CD8+ T cells in peripheral blood [%] |
Immune |
| X2667 |
11928 |
Open field behavior, vertical activity (rears) from 0-5 min for males and females [n beam breaks] |
Anxiety |
| X3336 |
11929 |
Open field behavior, vertical activity (rears) from 10-15 min for males and females [n beam breaks] |
Anxiety |
| X2405 |
11930 |
Open field behavior, vertical activity (rears) from 15-20 min for males and females [n beam breaks] |
Anxiety |
| X2934 |
11931 |
Open field behavior, vertical activity (rears) from 5-10 min for males and females [n beam breaks] |
Anxiety |
| X2819 |
11932 |
Open field behavior, locomotion for entire test period for males and females [cm] |
Anxiety |
| X2596 |
11933 |
Open field behavior, percentage of distance in the perimeter for males and females [%] |
Anxiety |
| X2015 |
11934 |
Open field behavior, percentage of time in perimeter for males and females [%] |
Anxiety |
| X1372 |
11948 |
Anxiety assay, entries in closed quadrants of a zero maze for males and females [n] |
Anxiety |
| X1382 |
11949 |
Anxiety assay, entries into open quadrants of a zero maze for males and females [n] |
Anxiety |
| X2143 |
11950 |
Anxiety assay, latency to enter an open quadrant of a zero maze for males and females [sec] |
Anxiety |
| X3759 |
11951 |
Anxiety assay, percentage time in open quadrants of a zero maze for males and females [%] |
Anxiety |
| X2723 |
11952 |
Anxiety assay, time in closed quadrants of a zero maze for males and females [sec] |
Anxiety |
| X2724 |
11953 |
Anxiety assay, time in open quadrants of a zero maze for males and females [sec] |
Anxiety |
| X1444 |
11968 |
Anxiety assay, untreated baseline, entries into closed arms of a plus maze for males and females [n] |
Anxiety |
| X3159 |
11969 |
Anxiety assay, untreated baseline, entries into open arms of a plus maze for males and females [n] |
Anxiety |
| X3204 |
11970 |
Anxiety assay, untreated baseline, percentage of entries into closed arms of a plus maze for males and females [%] |
Anxiety |
| X3276 |
11971 |
Anxiety assay, untreated baseline, percent entries into open arms of an elevated plus maze for males and females [%] |
Anxiety |
| X1947 |
11972 |
Anxiety assay, untreated baseline, percent time in closed arms of a plus maze for males and females [%] |
Anxiety |
| X1657 |
11973 |
Anxiety assay, untreated baseline, percentage of time in open arms of plus maze for males and females [%] |
Anxiety |
| X1946 |
11980 |
Anxiety assay, time in closed arms of an elevated plus maze for males and females [sec] |
Anxiety |
| X1721 |
11981 |
Anxiety assay, time in middle of an elevated plus maze for males and females [sec] |
Anxiety |
| X1292 |
11982 |
Anxiety assay, time in open arms of an elevated plus maze for males and females [sec] |
Anxiety |
| X2090 |
12014 |
Novel open field behavior, locomotion in the center from 0-60 min for males and females [n beam breaks] |
Anxiety |
| X2447 |
12015 |
Novel open field behavior, locomotion in the center from 0-60 min for males and females [cm] |
Anxiety |
| X2000 |
12016 |
Novel open field behavior, vertical activity (rears) from 0-60 min in the center for males and females [n beam breaks] |
Anxiety |
| X1508 |
12020 |
Novel open field behavior, locomotion in the center from 0-15 min for males and females [n beam breaks] |
Anxiety |
| X3265 |
12543 |
Transferrin saturation of 120-day-old males fed 3 ppm iron diet [%] |
Hematology |
| X3021 |
12021 |
Novel open field behavior, locomotion in the center from 15-30 min for males and females [n beam breaks] |
Anxiety |
| X1849 |
12022 |
Novel open field behavior, locomotion in the center from 30-45 min for males and females [n beam breaks] |
Anxiety |
| X2181 |
12023 |
Novel open field behavior, locomotion in the center from 45-60 min for males and females [n beam breaks] |
Anxiety |
| X1785 |
12024 |
Novel open field behavior, locomotion in the center from 0-15 min for males and females [cm] |
Anxiety |
| X2811 |
12025 |
Novel open field behavior, locomotion in the center from 15-30 min for males and females [cm] |
Anxiety |
| X2666 |
12026 |
Novel open field behavior, locomotion in the center from 30-45 min for males and females [cm] |
Anxiety |
| X2110 |
12027 |
Novel open field behavior, locomotion in the center from 45-60 min for males and females [cm] |
Anxiety |
| X2132 |
12028 |
Novel open field behavior, vertical activity (rears) from 0-15 min in the center for males and females [n beam breaks] |
Anxiety |
| X1607 |
12029 |
Novel open field behavior, vertical activity (rears) from 15-30 min in the center for males and females [n beam breaks] |
Anxiety |
| X2206 |
12030 |
Novel open field behavior, vertical activity (rears) from 30-45 min in the center for males and females [n beam breaks] |
Anxiety |
| X2488 |
12031 |
Novel open field behavior, vertical activity (rears) from 45-60 min in the center for males and females [n beam breaks] |
Anxiety |
| X2822 |
12032 |
Novel open field behavior, locomotion in the periphery from 0-15 min for males and females in the cocaine test battery [n beam breaks] |
Anxiety |
| X2553 |
12033 |
Novel open field behavior, locomotion in the periphery from 15-30 min for males and females in the cocaine test battery [n beam breaks] |
Anxiety |
| X2635 |
12034 |
Novel open field behavior, locomotion in the periphery from 30-45 min for males and females in the cocaine test battery [n beam breaks] |
Anxiety |
| X3452 |
12035 |
Novel open field behavior, locomotion in the periphery from 45-60 min for males and females in the cocaine test battery [n beam breaks] |
Anxiety |
| X2933 |
12036 |
Novel open field behavior, locomotion from 0-15 min in the periphery for males and females in the cocaine test battery [cm] |
Anxiety |
| X2363 |
12037 |
Novel open field behavior, locomotion from 15-30 min in the periphery for males and females in the cocaine test battery [cm] |
Anxiety |
| X3247 |
12038 |
Novel open field behavior, locomotion from 30-45 min in the periphery for males and females in the cocaine test battery [cm] |
Anxiety |
| X3644 |
12039 |
Novel open field behavior, locomotion from 45-60 min in the periphery for males and females in the cocaine test battery [cm] |
Anxiety |
| X1133 |
12040 |
Novel open field behavior, vertical activity (rears) in the periphery from 0-15 min for males and females [n beam breaks] |
Anxiety |
| X762 |
12041 |
Novel open field behavior, vertical activity (rears) in the periphery from 15-30 min for males and females [n beam breaks] |
Anxiety |
| X548 |
12042 |
Novel open field behavior, vertical activity (rears) in the periphery from 30-45 min for males and females [n beam breaks] |
Anxiety |
| X518 |
12043 |
Novel open field behavior, vertical activity (rears) in the periphery from 45-60 min for males and females [n beam breaks] |
Anxiety |
| X926 |
12044 |
Novel open field behavior, percentage of locomotion in the periphery for males and females [%] |
Anxiety |
| X3318 |
12045 |
Novel open field behavior, locomotion in the periphery from 0-60 min for males and females [n beam breaks] |
Anxiety |
| X3236 |
12046 |
Novel open field behavior, locomotion in the periphery from 0-60 min for males and females [cm] |
Anxiety |
| X397 |
12047 |
Novel open field behavior, vertical activity (rears) in the periphery from 0-60 min for males and females [n beam breaks] |
Anxiety |
| X2146 |
12067 |
Novel open field behavior, locomotion in the center and periphery from 0-60 min for males and females in the cocaine test battery [n beam breaks] |
Anxiety |
| X2208 |
12068 |
Novel open field behavior, locomotion in the center and periphery from 0-60 min for males and females in the cocaine test battery [cm] |
Anxiety |
| X439 |
12069 |
Novel open field behavior, vertical activity (rears) in the center and periphery from 0-60 min for males and females in the cocaine test battery [n beam breaks] |
Anxiety |
| X4445 |
12335 |
Anxiety assay, baseline untreated control (BASE group), latency to enter an open quadrant using an elevated zero maze in 60 to 120-day-old females only [sec] |
Anxiety |
| X3472 |
12336 |
Anxiety assay, baseline untreated control (BASE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old females only during first 5 min [percentage of time] |
Anxiety |
| X4789 |
12337 |
Anxiety assay, baseline untreated control (BASE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old females only during last 5 min [percentage of time] |
Anxiety |
| X4176 |
12338 |
Anxiety assay, baseline untreated control (BASE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old females only during 10 min [percentage of time] |
Anxiety |
| X669 |
12339 |
Anxiety assay, baseline untreated control (BASE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during first 5 min [n beam breaks] |
Anxiety |
| X592 |
12340 |
Anxiety assay, baseline untreated control (BASE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during last 5 min [n beam breaks] |
Anxiety |
| X391 |
12341 |
Anxiety assay, baseline untreated control (BASE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during 10 min [n beam breaks] |
Anxiety |
| X1490 |
12342 |
Anxiety assay, baseline untreated control (BASE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during first 5 min [beam breaks/sec] |
Anxiety |
| X3543 |
12343 |
Anxiety assay, baseline untreated control (BASE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during last 5 min [beam breaks/sec] |
Anxiety |
| X2609 |
12344 |
Anxiety assay, baseline untreated control (BASE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during 10 min [beam breaks/sec] |
Anxiety |
| X1132 |
12345 |
Anxiety assay, baseline untreated control (BASE group), latency to enter an open quadrant using an elevated zero maze in 60 to 120-day-old males only [sec] |
Anxiety |
| X4087 |
12762 |
Anxiety (center-distance ratio) in open-field (OFA) in 8 week old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model [% of WT] |
Anxiety |
| X4207 |
12346 |
Anxiety assay, baseline untreated control (BASE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males only during first 5 min [percentage of time] |
Anxiety |
| X4299 |
12347 |
Anxiety assay, baseline untreated control (BASE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males only during last 5 min [percentage of time] |
Anxiety |
| X3672 |
12348 |
Anxiety assay, baseline untreated control (BASE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males only during 10 min [percentage of time] |
Anxiety |
| X1212 |
12349 |
Anxiety assay, baseline untreated control (BASE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during first 5 min [n beam breaks] |
Anxiety |
| X1956 |
12350 |
Anxiety assay, baseline untreated control (BASE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during last 5 min [n beam breaks] |
Anxiety |
| X651 |
12351 |
Anxiety assay, baseline untreated control (BASE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during 10 min [n beam breaks] |
Anxiety |
| X3226 |
12352 |
Anxiety assay, baseline untreated control (BASE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during first 5 min [beam breaks/sec] |
Anxiety |
| X3891 |
12353 |
Anxiety assay, baseline untreated control (BASE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during last 5 min [beam breaks/sec] |
Anxiety |
| X3099 |
12354 |
Anxiety assay, baseline untreated control (BASE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during 10 min [beam breaks/sec] |
Anxiety |
| X656 |
12355 |
Anxiety assay, baseline untreated control (BASE group), latency to enter an open quadrant using an elevated zero maze in 60 to 120-day-old males and females [sec] |
Anxiety |
| X3953 |
12356 |
Anxiety assay, baseline untreated control (BASE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males and females during first 5 min [percentage of time] |
Anxiety |
| X4191 |
12357 |
Anxiety assay, baseline untreated control (BASE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males and females during last 5 min [percentage of time] |
Anxiety |
| X4381 |
12358 |
Anxiety assay, baseline untreated control (BASE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males and females during 10 min [percentage of time] |
Anxiety |
| X632 |
12359 |
Anxiety assay, baseline untreated control (BASE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during first 5 min [n beam breaks] |
Anxiety |
| X1831 |
12360 |
Anxiety assay, baseline untreated control (BASE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during last 5 min [n beam breaks] |
Anxiety |
| X545 |
12361 |
Anxiety assay, baseline untreated control (BASE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during 10 min [n beam breaks] |
Anxiety |
| X1441 |
12362 |
Anxiety assay, baseline untreated control (BASE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during first 5 min [beam breaks/sec] |
Anxiety |
| X3478 |
12363 |
Anxiety assay, baseline untreated control (BASE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during last 5 min [beam breaks/sec] |
Anxiety |
| X1965 |
12364 |
Anxiety assay, baseline untreated control (BASE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during 10 min [beam breaks/sec] |
Anxiety |
| X2440 |
12365 |
Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), latency to enter an open quadrant using an elevated zero maze in 60 to 120-day-old females only [sec] |
Anxiety |
| X2847 |
12366 |
Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old females during first 5 min [% time] |
Anxiety |
| X2365 |
12367 |
Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old females only during last 5 min [percent time] |
Anxiety |
| X3961 |
12368 |
Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old females during whole 10 min test [% time] |
Anxiety |
| X1119 |
12369 |
Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during first 5 min [n beam breaks] |
Anxiety |
| X348 |
12370 |
Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during last 5 min [n beam breaks] |
Anxiety |
| X454 |
12371 |
Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during 10 min [n beam breaks] |
Anxiety |
| X5024 |
12372 |
Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during first 5 min [beam breaks/sec] |
Anxiety |
| X725 |
12373 |
Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during last 5 min [beam breaks/sec] |
Anxiety |
| X3178 |
12374 |
Anxiety assay, ethanol treated (1.8 g/kg ip) (NOE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during 10 min [beam breaks/sec] |
Anxiety |
| X3208 |
12375 |
Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), latency to enter an open quadrant using an elevated zero maze in 60 to 120-day-old males only [sec] |
Anxiety |
| X4889 |
12376 |
Anxiety assay, ethanol treated (1.8 g/kg i.p.) (NOE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males only during first 5 min [% time] |
Anxiety |
| X4352 |
12377 |
Anxiety assay, ethanol treated (1.8 g/kg i.p.) (NOE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males only during last 5 min [% time] |
Anxiety |
| X4687 |
12378 |
Anxiety assay, ethanol treated (1.8 g/kg i.p) (NOE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males only during 10 min [% time] |
Anxiety |
| X3001 |
12379 |
Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during first 5 min [n beam breaks] |
Anxiety |
| X1270 |
12380 |
Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during last 5 min [n beam breaks] |
Anxiety |
| X1592 |
12381 |
Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during 10 min [n beam breaks] |
Anxiety |
| X5091 |
12382 |
Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during first 5 min [beam breaks/sec] |
Anxiety |
| X5077 |
12383 |
Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during last 5 min [beam breaks/sec] |
Anxiety |
| X5092 |
12384 |
Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during 10 min [beam breaks/sec] |
Anxiety |
| X4030 |
12385 |
Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), latency to enter an open quadrant using an elevated zero maze in 60 to 120-day-old males and females [sec] |
Anxiety |
| X2535 |
12386 |
Anxiety assay, ethanol treated (1.8 g/kg i.p) (NOE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males and females during first 5 min [percentage of time] |
Anxiety |
| X4420 |
12387 |
Anxiety assay, ethanol treated (1.8 g/kg i.p) (NOE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males and females during last 5 min [% time] |
Anxiety |
| X4454 |
12388 |
Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males and females during 10 min [percentage of time] |
Anxiety |
| X2258 |
12389 |
Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during first 5 min [n beam breaks] |
Anxiety |
| X784 |
12390 |
Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during last 5 min [n beam breaks] |
Anxiety |
| X925 |
12391 |
Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during 10 min [n beam breaks] |
Anxiety |
| X5064 |
12392 |
Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during first 5 min [beam breaks/sec] |
Anxiety |
| X4738 |
12394 |
Anxiety assay, ethanol treated [1.8 g/kg i.p] (NOE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during 10 min (BXD102 winterized from 21.008 +-19.93 to 3.0 and BX |
Anxiety |
| X2418 |
12395 |
Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), latency to enter an open quadrant using an elevated zero maze in 60 to 120-day-old females only [sec] |
Anxiety |
| X2380 |
12396 |
Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), time in open quadrants using an elevated zero maze in 60 to 120-day-old females only during first 5 min [percentage of time] |
Anxiety |
| X4121 |
13442 |
OFA, boli produced in 8-week-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, R6/2 cases only |
Anxiety |
| X2259 |
12397 |
Anxiety assay, saline treated (0.18 ml/kg ip, NOS group), time in open quadrants only during last 5 min of test using an elevated zero maze for 60- to 120-day-old females [%] |
Anxiety |
| X3490 |
12398 |
Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), time in open quadrants using an elevated zero maze in 60 to 120-day-old females only during 10 min [percentage of time] |
Anxiety |
| X3375 |
12399 |
Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during first 5 min [n beam breaks] |
Anxiety |
| X686 |
12400 |
Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during last 5 min [n beam breaks] |
Anxiety |
| X889 |
12401 |
Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during 10 min [n beam breaks] |
Anxiety |
| X3822 |
12402 |
Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during first 5 min [beam breaks/sec] |
Anxiety |
| X3137 |
12403 |
Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during last 5 min [beam breaks/sec] |
Anxiety |
| X4520 |
12404 |
Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during 10 min [beam breaks/sec] |
Anxiety |
| X5006 |
12405 |
Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), latency to enter an open quadrant using an elevated zero maze in 60 to 120-day-old males only [sec] |
Anxiety |
| X3693 |
12406 |
Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males only during first 5 min [percentage of time] |
Anxiety |
| X3228 |
12407 |
Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males only during last 5 min [percentage of time] |
Anxiety |
| X2416 |
12408 |
Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males only during 10 min [percentage of time] |
Anxiety |
| X209 |
12409 |
Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during first 5 min [n beam breaks] |
Anxiety |
| X1796 |
12410 |
Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during last 5 min [n beam breaks] |
Anxiety |
| X462 |
12411 |
Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during 10 min [n beam breaks] |
Anxiety |
| X3197 |
12412 |
Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during first 5 min [beam breaks/sec] |
Anxiety |
| X4787 |
17546 |
number of jumps observed from 0 to 20 min for females at 11 weeks of age [n] |
Anxiety |
| X3355 |
12413 |
Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during last 5 min [beam breaks/sec] |
Anxiety |
| X2688 |
12414 |
Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during 10 min [beam breaks/sec] |
Anxiety |
| X5029 |
12415 |
Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), latency to enter an open quadrant using an elevated zero maze in 60 to 120-day-old males and females [sec] |
Anxiety |
| X4849 |
12416 |
Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males and females during first 5 min [percentage of time] |
Anxiety |
| X4256 |
12417 |
Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males and females during last 5 min [percentage of time] |
Anxiety |
| X3903 |
12418 |
Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males and females during 10 min [percentage of time] |
Anxiety |
| X457 |
12419 |
Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during first 5 min [n beam breaks] |
Anxiety |
| X332 |
12420 |
Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during last 5 min [n beam breaks] |
Anxiety |
| X228 |
12421 |
Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during 10 min [n beam breaks] |
Anxiety |
| X2490 |
12422 |
Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during first 5 min [beam breaks/sec] |
Anxiety |
| X2645 |
12423 |
Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during last 5 min [beam breaks/sec] |
Anxiety |
| X2689 |
12424 |
Anxiety assay, saline treated [0.18 ml/kg i.p.] (NOS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during 10 min [beam breaks/sec] |
Anxiety |
| X5000 |
12425 |
Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), latency to enter an open quadrant using an elevated zero maze in 60 to 120-day-old females only [sec] |
Anxiety |
| X1243 |
12426 |
Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old females only during first 5 min [% time] |
Anxiety |
| X3898 |
12427 |
Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old females only during last 5 min [% time] |
Anxiety |
| X2702 |
12428 |
Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old females only during 10 min [percentage of time] |
Anxiety |
| X4276 |
15962 |
Tuberculosis, bacterial load in lung [CFU] |
Immune |
| X3153 |
12429 |
Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during first 5 min [n beam breaks] |
Anxiety |
| X234 |
12430 |
Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during last 5 min [n beam breaks] |
Anxiety |
| X591 |
12431 |
Anxiety assay, restraint stress (15 min) followed by ethanol (1.8 g/kg ip) (RSE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during 10 min [n beam breaks] |
Anxiety |
| X5081 |
12432 |
Anxiety assay, restraint stress (15 min) followed by ethanol (1.8 g/kg ip)(RSE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during first 5 min [n beam breaks/sec] |
Anxiety |
| X4809 |
12433 |
Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during last 5 min [beam breaks/sec] |
Anxiety |
| X4765 |
12434 |
Anxiety assay, restraint stress [15 min] + ethanol treated [1.8 g/kg ip] (RSE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females over 10 min [beam breaks/sec] |
Anxiety |
| X4918 |
12435 |
Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), latency to enter an open quadrant using an elevated zero maze in 60 to 120-day-old males only [sec] |
Anxiety |
| X2557 |
12436 |
Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males only during first 5 min [% time] |
Anxiety |
| X3059 |
12437 |
Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males only during last 5 min [% time] |
Anxiety |
| X2680 |
12438 |
Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males only during 10 min [% time] |
Anxiety |
| X3056 |
12439 |
Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during first 5 min [n beam breaks] |
Anxiety |
| X691 |
12440 |
Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during last 5 min [n beam breaks] |
Anxiety |
| X959 |
12441 |
Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during 10 min [n beam breaks] |
Anxiety |
| X1485 |
12442 |
Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during first 5 min [n beam breaks/sec] |
Anxiety |
| X4658 |
12443 |
Anxiety assay, restraint stress [15 min] + ethanol treated [1.8 g/kg i.p.] (RSE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during last 5 min (data for BXD77 (4.463 +/- |
Anxiety |
| X1928 |
17547 |
number of fecal boli observed from 0 to 20 min for females at 11 weeks of age [n] |
Anxiety |
| X5083 |
12444 |
Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during 10 min [beam breaks/sec] |
Anxiety |
| X4800 |
12445 |
Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), latency to enter an open quadrant using an elevated zero maze in 60 to 120-day-old males and females [sec] |
Anxiety |
| X2373 |
12446 |
Anxiety assay, restraint stress [15 min] and ethanol (1.8 g/kg ip) (RSE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males and females during first 5 min [% time] |
Anxiety |
| X4287 |
12447 |
Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males and females during last 5 min [% time] |
Anxiety |
| X4466 |
12448 |
Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males and females during 10 min [% time] |
Anxiety |
| X1462 |
12449 |
Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during first 5 min [n beam breaks] |
Anxiety |
| X162 |
12450 |
Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during last 5 min [n beam breaks] |
Anxiety |
| X329 |
12451 |
Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during 10 min [n beam breaks] |
Anxiety |
| X5080 |
12452 |
Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during first 5 min [beam breaks/sec] |
Anxiety |
| X4021 |
12453 |
Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during last 5 min [beam breaks/sec] |
Anxiety |
| X3712 |
12454 |
Anxiety assay, restraint stress (15 min) and ethanol (1.8 g/kg ip) (RSE group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during 10 min (data for BXD11 (16.419 +/-15. |
Anxiety |
| X5075 |
12455 |
Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), latency to enter an open quadrant using an elevated zero maze in 60 to 120-day-old females only [sec] |
Anxiety |
| X2673 |
12456 |
Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), time in open quadrants using an elevated zero maze in 60 to 120-day-old females only during first 5 min [percentage of time] |
Anxiety |
| X4706 |
12457 |
Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), time in open quadrants using an elevated zero maze in 60 to 120-day-old females only during last 5 min [percentage of time] |
Anxiety |
| X4612 |
12458 |
Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), time in open quadrants using an elevated zero maze in 60 to 120-day-old females only during 10 min [percentage of time] |
Anxiety |
| X2636 |
12546 |
Transferrin saturation of 120-day-old females fed 270 ppm iron diet [%] |
Hematology |
| X1871 |
12459 |
Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during first 5 min [n beam breaks] |
Anxiety |
| X507 |
12460 |
Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during last 5 min [n beam breaks] |
Anxiety |
| X638 |
12461 |
Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during 10 min [n beam breaks] |
Anxiety |
| X3385 |
12462 |
Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during first 5 min [beam breaks/sec] |
Anxiety |
| X3017 |
12463 |
Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during last 5 min [beam breaks/sec] |
Anxiety |
| X3417 |
12464 |
Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old females only during 10 min [beam breaks/sec] |
Anxiety |
| X4464 |
12465 |
Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), latency to enter an open quadrant using an elevated zero maze in 60 to 120-day-old males only [sec] |
Anxiety |
| X4068 |
12466 |
Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males only during first 5 min [percentage of time] |
Anxiety |
| X3306 |
12467 |
Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males only during last 5 min [percentage of time] |
Anxiety |
| X3214 |
12468 |
Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males only during 10 min [percentage of time] |
Anxiety |
| X1666 |
12469 |
Anxiety assay, restraint stress (15 min) + saline treated (0.018 ml/kg ip) for RSS group, activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during first 5 min [n beam breaks] |
Anxiety |
| X2983 |
12470 |
Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during last 5 min [n beam breaks] |
Anxiety |
| X1654 |
12471 |
Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during 10 min [n beam breaks] |
Anxiety |
| X3299 |
12472 |
Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during first 5 min [beam breaks/sec] |
Anxiety |
| X3667 |
12473 |
Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during last 5 min [beam breaks/sec] |
Anxiety |
| X4544 |
12474 |
Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males only during 10 min [beam breaks/sec] |
Anxiety |
| X5061 |
12475 |
Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), latency to enter an open quadrant using an elevated zero maze in 60 to 120-day-old males and females [sec] |
Anxiety |
| X4169 |
12476 |
Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males and females during first 5 min [percentage of time] |
Anxiety |
| X3737 |
12477 |
Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males and females during last 5 min [percentage of time] |
Anxiety |
| X3941 |
12478 |
Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), time in open quadrants using an elevated zero maze in 60 to 120-day-old males and females during 10 min [percentage of time] |
Anxiety |
| X539 |
12479 |
Anxiety assay, restraint stress (15 min) + saline treated (0.018 ml/kg ip) in the RSS group, activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during first 5 min [n beam break |
Anxiety |
| X496 |
12480 |
Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during last 5 min [n beam breaks] |
Anxiety |
| X281 |
12481 |
Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during 10 min [n beam breaks] |
Anxiety |
| X3541 |
12482 |
Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during first 5 min [beam breaks/sec] |
Anxiety |
| X4129 |
12483 |
Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during last 5 min [beam breaks/sec] |
Anxiety |
| X2999 |
12484 |
Anxiety assay, restraint stress [15 min] + saline treated [.018 ml/kg i.p.] (RSS group), activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during 10 min [beam breaks/sec] |
Anxiety |
| X1326 |
12631 |
Anxiety assay (E5_PTR), restraint stress (15 min) + ethanol treated (1.8 g/kg i.p), percent time spent (sec) without locomotion in the light side of light-dark box in 8-12 week-old males during 5 min session |
Anxiety |
| X306 |
12632 |
Anxiety assay (E5_PTS), restraint stress (15 min) + ethanol treated (1.8 g/kg i.p.), percent time spent in light side (sec) using a light-dark box in 8-12 week-old males during 5 min session [%] |
Anxiety |
| X1327 |
12633 |
Anxiety assay (E5_TR), restraint stress (15 min) + ethanol treated (1.8 g/kg i.p.), time spent without locomotion in the light side of light-dark box in 8-12 week-old males during 5 min session [n sec]. |
Anxiety |
| X307 |
12634 |
Anxiety assay (E5_TS), restraint stress (15 min) + ethanol treated (1.8 g/kg i.p.), time spent in light side using a light-dark box in 8-12 week-old males during 5 min [sec] |
Anxiety |
| X3716 |
12635 |
Anxiety assay (E5_NR), restraint stress (15 min) + ethanol treated (1.8 g/kg i.p.), number of rears in the light side using a light-dark box in 8-12 week-old males during 5 min session [n beam breaks]. |
Anxiety |
| X381 |
12636 |
Anxiety assay (E10_PTS), restraint stress (15 min) + ethanol treated (1.8 g/kg i.p.), percent time spent in light side (sec) using a light-dark box in 8-12 week-old males during 10 min session [%] |
Anxiety |
| X380 |
12637 |
Anxiety assay (E10_TS), restraint stress (15 min) + ethanol treated (1.8 g/kg i.p.), time spent in light side using a light-dark box in 8-12 week-old males during 10 min [n sec] |
Anxiety |
| X1580 |
12638 |
Anxiety assay (E10_TR), restraint stress (15 min) + ethanol treated (1.8 g/kg i.p.), time spent without locomotion in the light side of light-dark box in 8-12 week-old males during 10 min session [n sec] |
Anxiety |
| X1581 |
12639 |
Anxiety assay (E10_PTR), restraint stress (15 min) + ethanol treated (1.8 g/kg i.p.), percent time spent (sec) without locomotion in the light side of light-dark box in 8-12 week-old males during 10 min sess |
Anxiety |
| X1719 |
12640 |
Anxiety assay (S5_PTR), restraint stress (15 min) + saline treated (0.018 mL/g i.p.), percent time spent (sec) without locomotion in the light side of light-dark box in 8-12 week-old males during 5 min sessi |
Anxiety |
| X888 |
12641 |
Anxiety assay (S5_PTS), restraint stress (15 min) + saline treated (0.018 mL/g i.p.), percent time spent in light side (sec) using a light-dark box in 8-12 week-old males during 5 min session [n %]. |
Anxiety |
| X1720 |
12642 |
Anxiety assay (S5_TR), restraint stress (15 min) + saline treated (0.018 mL/g i.p.), time spent without locomotion in the light side of light-dark box in 8-12 week-old males during 5 min session [n sec]. |
Anxiety |
| X887 |
12643 |
Anxiety assay (S5_TS), restraint stress (15 min) + saline treated (0.018 mL/g i.p.), time spent in light side using a light-dark box in 8-12 week-old males during 5 min [n sec]. |
Anxiety |
| X3027 |
12644 |
Anxiety assay (S10_PTR), percent time spent without locomotion in the light side of light-dark box after restraint stress (15 min) and saline control injection (0.018 ml/g ip) in 8-12 week-old males during 1 |
Anxiety |
| X1768 |
12645 |
Anxiety assay (S10_PTS), restraint stress (15 min) + saline treated (0.018 mL/g i.p.), percent time spent in light side (sec) using a light-dark box in 8-12 week-old males during 10 min session [n %]. |
Anxiety |
| X3028 |
12646 |
Anxiety assay (S10_TR), restraint stress (15 min) + saline treated (0.018 mL/g i.p.), time spent without locomotion in the light side of light-dark box in 8-12 week-old males during 10 min session [n sec] |
Anxiety |
| X1766 |
12647 |
Anxiety assay (S10_TS), restraint stress (15 min) + saline treated (0.018 mL/g i.p.), time spent in light side using a light-dark box in 8-12 week-old males during 10 min [n sec]. |
Anxiety |
| X2053 |
12760 |
Anxiety measured as center-distance:total distance ratio in the open-field (OFA) in 8-week F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, wildtype cases only [ratio] |
Anxiety |
| X1908 |
12761 |
Anxiety measured as center-distance to total distance ratio in open-field (OFA) in 8-week F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, R6/2 mutant cases only [ratio] |
Anxiety |
| X2805 |
12544 |
Iron binding capacity in plasma of 120-day-old males fed 3 ppm iron diet [ug/dL] |
Hematology |
| X2828 |
13443 |
anxiety assay, number of fecal boli produced in an open field activity (OFA) test in 8-week-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, wildtype cases only |
Anxiety |
| X4485 |
13444 |
OFA, boli produced in 8-week-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, [% WT only] |
Anxiety |
| X4460 |
13460 |
Rearing in open field test by 8-week-old F1 hybrids generated by crossing male BXDs with female C57BL/6J-R6/2 Huntington carriers [n beam breaks] |
Anxiety |
| X4911 |
13533 |
OFA, boli produced in 8-week-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, CORRECTEd R6/2 cases only |
Anxiety |
| X4340 |
13536 |
Anxiety measured as center-distance to total distance ratio in open-field (OFA) in 8-week F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, CORRECTED R6/2 mutant cases only [ratio] |
Anxiety |
| X1765 |
17528 |
locomotion, total distance traveled from 0 to 20 min for males at 11 weeks of age [cm] |
Anxiety |
| X2964 |
17529 |
thigmotaxis, distance traveled at the periphery (relative to total distance) from 0 to 20 min for males at 11 weeks of age [percent] |
Anxiety |
| X2534 |
17530 |
thigmotaxis, time spent at the periphery (relative to total time) from 0 to 20 min for males at 11 weeks of age [percent] |
Anxiety |
| X2864 |
17531 |
number of leans observed from 0 to 20 min for males at 11 weeks of age [n] |
Anxiety |
| X2906 |
17532 |
number of rears observed from 0 to 20 min for males at 11 weeks of age [n] |
Anxiety |
| X3642 |
17533 |
grooming frequency from 0 to 20 min for males at 11 weeks of age [n] |
Anxiety |
| X1421 |
17534 |
grooming duration observed from 0 to 20 min for males at 11 weeks of age [sec] |
Anxiety |
| X4097 |
17535 |
grooming bout (grooming duration divided by grooming frequency) observed from 0 to 20 min for males at 11 weeks of age [sec] |
Anxiety |
| X4354 |
17536 |
number of jumps observed from 0 to 20 min for males at 11 weeks of age [n] |
Anxiety |
| X2355 |
17537 |
number of fecal boli observed from 0 to 20 min for males at 11 weeks of age [n] |
Anxiety |
| X2642 |
17538 |
locomotion, total distance traveled from 0 to 20 min for females at 11 weeks of age [cm] |
Anxiety |
| X2482 |
17539 |
thigmotaxis, distance traveled at the periphery (relative to total distance) from 0 to 20 min for females at 11 weeks of age [percent] |
Anxiety |
| X1514 |
17540 |
thigmotaxis, time spent at the periphery (relative to total time) from 0 to 20 min for females at 11 weeks of age [percent] |
Anxiety |
| X3052 |
17541 |
number of leans observed from 0 to 20 min for females at 11 weeks of age [n] |
Anxiety |
| X4409 |
17542 |
number of rears observed from 0 to 20 min for females at 11 weeks of age [n] |
Anxiety |
| X2310 |
17543 |
grooming frequency from 0 to 20 min for females at 11 weeks of age [n] |
Anxiety |
| X4103 |
17544 |
grooming duration observed from 0 to 20 min for females at 11 weeks of age [sec] |
Anxiety |
| X4700 |
17545 |
grooming bout (grooming duration divided by grooming frequency) observed from 0 to 20 min for females at 11 weeks of age [sec] |
Anxiety |
| X964 |
12932 |
Hemoglobin of 14-week old males [g/dl] |
Hematology |
| X2638 |
10008 |
Phencyclidine response (7.5 mg/kg ip), locomotor response, difference in activity (PCP minus saline) between 1 hr test periods [cm] |
Drug response |
| X2940 |
10009 |
Phencyclidine response (7.5 mg/kg ip), locomotor activity from 0-60 min after PCP injection [cm] |
Drug response |
| X1192 |
10011 |
Amphetamine response (5 mg/kg ip), locomotor response, difference in activity (amphetamine minus saline) between 1 hr test periods [cm] |
Drug response |
| X1289 |
10012 |
Amphetamine response (5 mg/kg ip), locomotor activity from 0-60 min after injection [cm] |
Drug response |
| X955 |
10016 |
Morphine response (variable doses, ip), induced hypothermia [slope of drug-response curve] |
Drug response |
| X4936 |
10017 |
Morphine response (variable doses ip), analgesia, slope of the drug response curve [slope] |
Drug response |
| X1075 |
10018 |
Morphine response (variable doses ip), Straub tail test response, slope of the dose response curve [slope] |
Drug response |
| X835 |
10021 |
Saline control response (vehicle ip), open field activity after injection (unpublished data from Belknap and Crabbe, 1992) [units] |
Drug response |
| X3874 |
10025 |
Nitrous oxide response, withdrawal severity measured by handling-induced convulsion (HIC) area under the curve [units] |
Drug response |
| X3380 |
10026 |
Nitrous oxide response, withdrawal severity measured by handling-induced convulsion (HIC), corrected peak level [units] |
Drug response |
| X2993 |
10027 |
Nitrous oxide response, withdrawal severity measured by handling-induced convulsion (HIC), difference between treated and baseline untreated [units] |
Drug response |
| X2577 |
10028 |
Ethanol response, withdrawal severity measured as the difference in handling-induced convulsion (HIC) scores from a saline control group (unpublished supplementary data) [units] |
Drug response |
| X3523 |
10029 |
Morphine response (16 mg/kg), analgesia relative to maximum possible effect [%] |
Drug response |
| X2450 |
10040 |
Ethanol response, blood ethanol concentration (BEC) at recovery of righting reflex (retro-orbital sinus sample) [mg/ml] |
Drug response |
| X4522 |
10041 |
Ethanol response (2.5 g/kg ip), duration of loss of righting reflex [minutes] |
Drug response |
| X713 |
10042 |
Ethanol response (2.5 g/kg ip), ataxia, screen test sensitivity measured as the latency to fall, saline response minus ethanol response [seconds] |
Drug response |
| X4085 |
10046 |
Quinpirole dopaminergic D2 and D3 receptor response (1 mg/kg ip), hypothermia 60 min after injection on day 1 measured as change from baseline temperature [degrees C] |
Drug response |
| X1183 |
10047 |
Quinpirole dopaminergic D2 and D3 receptor response (1 mg/kg ip), hypothermia tolerance, day 2 compared to day 1 [degrees C] |
Drug response |
| X857 |
10048 |
Quinpirole dopaminergic D2 and D3 receptor response (1 mg/kg ip), hypothermia tolerance, day 3 compared to day 1 [degrees C] |
Drug response |
| X3101 |
10050 |
Quinpirole dopaminergic D2 and D3 receptor response (0.01 mg/kg ip), locomotion change relative to baseline [cm] |
Drug response |
| X2287 |
10051 |
Quinpirole dopaminergic D2 and D3 receptor response (0.03 mg/kg ip), locomotion change relative to baseline [cm] |
Drug response |
| X3932 |
10052 |
Quinpirole dopaminergic D2 and D3 receptor response (0.03 mg/kg ip), vertical activity (rears) change relative to baseline [n beam breaks] |
Drug response |
| X2257 |
10053 |
Quinpirole dopaminergic D2 and D3 receptor response (0.01 mg/kg ip), vertical activity (rears) change relative to baseline [n beam breaks] |
Drug response |
| X3313 |
10055 |
Ethanol withdrawal handling induced convulsions (HIC), 2-12 hours after 4 g/kg 20% v/v ethanol injection (ip), area under curve [HIC AUC] |
Drug response |
| X3738 |
10063 |
Ethanol response, withdrawal-associated handling-induced convulsions (HIC) after a 72 hr exposure to ethanol vapor (with Pyrazole injections to inhibit EtOH metabolism) (0=no effect, 1=facial grimace during |
Drug response |
| X1855 |
10064 |
Ethanol response, area under the 25-hr curve for withdrawal following 72 hr exposure to air. Pyrazole injections were given daily to inhibit EtOH metabolism. Handling-induced convulsions (HIC) were scored ho |
Drug response |
| X1763 |
10065 |
Ethanol response (1.5 g/kg ip loading dose and 68.1 mg/kg pyrazole), chronic withdrawal, handling-induced convulsion score (HIC) corrected for response to pyrazole alone (difference between strain mean value |
Drug response |
| X4960 |
10066 |
Ethanol response (1.5 g/kg), blood ethanol concentration (BEC) normalization data set (BEC was stabilized to ~1.5 mg EtOH/ml blood using daily pyrazole injections) [mg/ml] |
Drug response |
| X3608 |
10067 |
Ethanol response (2 g/kg ip), hypothermia at 30 and 60 min after injection [degrees C] |
Drug response |
| X3615 |
10068 |
Ethanol response (3 g/kg ip), hypothermia at 30 and 60 min after injection [degrees C] |
Drug response |
| X4623 |
10069 |
Ethanol response (4 g/kg ip), hypothermia at 30 and 60 min after injection [degrees C] |
Drug response |
| X2661 |
10070 |
Ethanol response (2 g/kg ip), hypothermia after injection [degrees C] |
Drug response |
| X3040 |
10071 |
Ethanol response (3 g/kg ip), hypothermia after injection [degrees C] |
Drug response |
| X3535 |
10072 |
Ethanol response (4 g/kg ip), hypothermia after injection [degrees C] |
Drug response |
| X4833 |
10073 |
Ethanol response (10% v/v in water), acceptance of ethanol under thirst motivation in a single-bottle (no choice) test following 24 hr water deprivation, total 24 hr ethanol intake relative to previous water |
Drug response |
| X2839 |
10074 |
Ethanol response (10% v/v in water), acceptance of ethanol under thirst motivation in a single-bottle (no choice) test following 24 hr water deprivation, total 24 hr ethanol intake in 20-24 week-old males [g |
Drug response |
| X1922 |
10075 |
Saline response (saline injection ip), open field activity in 20-24 week-old males (control for ethanol trait 10077) [beam crossings] |
Drug response |
| X1452 |
10076 |
Ethanol response (2.5 g/kg ip), distance run in the grid test, 10-12 min after injection in 20-24 week-old males [n beam crossings] |
Drug response |
| X4728 |
10077 |
Ethanol response (1.33 g/kg ip), open field activity in 20-24 week-old males tested under dim light, 10-13 min after injection of saline (day 1) and ethanol (day 2), difference in number of beam crossings re |
Drug response |
| X3596 |
10082 |
Ethanol response (4 g/kg ip), hypothermia tolerance (positive scores) or sensitization (negative scores), day 3 minus day 1, in young adult females (50 to 123 days) [degrees C] |
Drug response |
| X5044 |
10083 |
Ethanol response (3 g/kg ip), hypothermia tolerance (positive scores) or sensitization (negative scores), day 3 minus day 1, in young adult females (50 to 123 days) [degrees C] |
Drug response |
| X3301 |
10084 |
Ethanol response (2 g/kg), hypothermia tolerance (positive scores) or sensitization (negative scores), day 3 minus day 1, in young adult females (50 to 123 days) [degrees C] |
Drug response |
| X2154 |
10085 |
Ethanol response (4 g/kg ip), hypothermia in young adult females (50 to 123 days) relative to baseline rectal body temperature (positive scores = hypothermia) [degrees C] |
Drug response |
| X4908 |
10086 |
Ethanol response (3 g/kg ip), hypothermia in young adult females (50 to 123 days) relative to baseline rectal body temperature (positive scores = hypothermia) [degrees C] |
Drug response |
| X2850 |
10087 |
Ethanol response (2 g/kg ip), hypothermia in young adult females (50 to 123 days) relative to baseline rectal body temperature (positive scores = hypothermia) [degrees C] |
Drug response |
| X4721 |
10088 |
Ethanol response (2 g/kg ip), acute difference in locomotion between experimental ethanol-condidtioned and saline control group of males [activity counts/min] |
Drug response |
| X2276 |
10089 |
Ethanol response (2 g/kg ip), locomotor tolerance or sensitization in males, difference between activity after fourth ethanol trial and first trial [cm] |
Drug response |
| X2922 |
10090 |
Ethanol response (2 g/kg ip), conditioned place preference (CPP) for the ethanol-paired grid compartment in males in the experimental group over a 30 min trial test [% time] |
Drug response |
| X5039 |
10091 |
Saline control response (vehicle ip) of ethanol-treated (2 mg/kg ip) males, locomotion 1-5 min after saline injection, trial 4 (experimental group, prior ethanol exposure) [activity counts per min] |
Drug response |
| X2708 |
10092 |
Ethanol response (2 g/kg ip), locomotion from 1-5 min after injection, conditioning trial 1 in males [activity counts per min] |
Drug response |
| X3622 |
10094 |
Locomotion from 1-5 min after a single saline i.p. injection for the control group of males [activity/min] |
Drug response |
| X4684 |
10095 |
Saline control response (vehicle, ip), locomotion of control group from 1-5 min after injection on trial 1 [activity/min] |
Drug response |
| X4868 |
10096 |
Locomotion from 1-5 min after a saline injection for the control group of males on trial 4 [activity/min] |
Drug response |
| X4052 |
10097 |
Ethanol response (2 g/kg ip), conditioned place preference (CPP) for the ethanol-paired grid compartment in experimental group males [s/min] |
Drug response |
| X5088 |
10098 |
Ethanol response (2 g/kg ip), conditioned place preference (CPP) for the ethanol-paired hole floor in experimental group males [s/min] |
Drug response |
| X3238 |
10100 |
Locomotion from 1-5 min after a single saline ip injection of saline vehicle for the experimental group on trial 1 [activity counts per min] |
Drug response |
| X2595 |
10102 |
Ethanol response (2 g/kg ip), locomotion from 1-5 min after injection, conditioning trial 4 in males [activity counts per min] |
Drug response |
| X2333 |
10104 |
Ethanol response (2 g/kg ip), locomotor tolerance or sensitization in males, difference between experimental group (two prior exposures to ethanol) and saline control group on fourth conditioning day [activi |
Drug response |
| X2497 |
10105 |
Saline control response (0.9% ip), activity habituation in males [4th saline injection trial activity minus first saline activity trial activity] |
Drug response |
| X4368 |
10809 |
Iron binding capacity (total iron-binding capacity, TIBC, transferrin level) of males and females [ug/dL] |
Hematology |
| X2561 |
10120 |
Chlordiazepoxide response (10 mg/kg ip), acute locomotor activation, distance traveled 0 to 5 min after injection [cm] |
Drug response |
| X2942 |
10121 |
Chlordiazepoxide response (10 mg/kg ip), acute locomotor activation, distance traveled 5 to 10 min after injection [cm] |
Drug response |
| X1306 |
10122 |
Chlordiazepoxide response (10 mg/kg ip), acute locomotor activation, distance traveled 10 to 15 min after injection [cm] |
Drug response |
| X1708 |
10123 |
Chlordiazepoxide response (10 mg/kg ip), acute locomotor activation, distance traveled 15 to 20 min after injection [cm] |
Drug response |
| X1479 |
10124 |
Chlordiazepoxide response (10 mg/kg ip), acute locomotor activation, distance traveled 5 to 20 min after injection [cm] |
Drug response |
| X4210 |
10125 |
Ethanol response (1.5 mg/kg ip), acute locomotor activation, distance traveled 0 to 5 min after injection [cm] |
Drug response |
| X2550 |
10126 |
Ethanol response (1.5 mg/kg ip), acute locomotor activation, distance traveled 5 to 10 min after injection [cm] |
Drug response |
| X2253 |
10127 |
Ethanol response (1.5 mg/kg ip), acute locomotor activation, distance traveled 10 to 15 min after injection [cm] |
Drug response |
| X1234 |
10128 |
Ethanol response (1.5 mg/kg ip), acute locomotor activation, distance traveled 15-20 min after injection [cm] |
Drug response |
| X2140 |
10129 |
Ethanol response (1.5 mg/kg ip), acute locomotor activation, distance traveled 5 to 20 min after injection [cm] |
Drug response |
| X3480 |
10135 |
Ethanol acceptance (10% in tap water after 24 hr water deprivation), raw mean consumption of adult males (same data as Rodriguez et al, 1994 with outliers removed and two strains added) [g/kg body weight] |
Drug response |
| X589 |
10136 |
Ethanol acceptance (10% in tap water after 24 hr water deprivation) by young adult females (74-91 days, same data as in Rodriguez et al., 1994 with outliers removed and two strains added) [g/kg] |
Drug response |
| X4676 |
10137 |
Ethanol acceptance (10% in tap water after 24 hr water deprivation) by young adult males (53-67 days, residual values and same data as Rodriguez et al, 1994 with outliers removed and two strains added) [g/kg |
Drug response |
| X3979 |
10138 |
Ethanol acceptance (10% in tap water after 24 hr water deprivation) by young adult females (74-91 day, residuals and same data as in Rodriguez et al, 1994 with outliers removed and two strains added) [g/kg] |
Drug response |
| X3206 |
10139 |
Ethanol preference (10% in tap water), consumption using two-bottle choice in young adult males (53-67 days, same data as Rodriguez et al, 1994 with outliers removed and two strains added) [g/kg] |
Drug response |
| X1092 |
10140 |
Ethanol preference (10% in tap water), consumption using two-bottle choice in young adult females (74-91 days, and same data as Rodriguez et al, 1994 with outliers removed and two strains added) [g/kg] |
Drug response |
| X4545 |
10141 |
Ethanol preference (10% in tap water), consumption using two-bottle choice in young adult males (53-67 days, residuals and same data as Rodriguez et al, 1994 with outliers removed and two strains added) [g/ |
Drug response |
| X4744 |
10142 |
Ethanol preference (10% in tap water), consumption using two-bottle choice in young adult females (74-91 days, residuals over a two week test period and same data as Rodriguez et al, 1994 with outliers remov |
Drug response |
| X3719 |
10817 |
Iron level in plasma of males [ug/dL] |
Hematology |
| X2599 |
10144 |
Ethanol response (escalating dose given ip), initial sensitivity measured as the ataxia onset threshold following first of five injections [mg/kg] |
Drug response |
| X4836 |
10145 |
Ethanol response (escalating dose given ip), maximal threshold to ethanol induced ataxia [mg/ml] |
Drug response |
| X3913 |
10146 |
Ethanol response (escalating dose given ip), tolerance, difference between ethanol induced ataxia (maximal threshold blood ethanol concentration BEC) minus onset threshold [mg/ml] |
Drug response |
| X3289 |
10147 |
Ethanol response (escalating dose given ip), tolerance measured as the fold-increase of blood ethanol concentration (BEC) to ethanol-induced ataxia [ratio of tolerance BEC over initial BEC ataxia] |
Drug response |
| X240 |
10169 |
Methamphetamine response (4 mg/kg ip), body temperature change 48 min after injection in 10-14 week males [degree C] |
Drug response |
| X3278 |
10171 |
Methamphetamine response (16 mg/kg ip), body temperature change 48 min after injection in 10-14 week males [degree C] |
Drug response |
| X3256 |
10172 |
Methamphetamine response (8 mg/kg ip), brain concentration in brain after injection in 10-14 week males [ug/gm] |
Drug response |
| X1250 |
10174 |
Methamphetamine response (4 mg/kg ip), brain concentration after injection in 10-14 week males [ug/gm] |
Drug response |
| X3135 |
10202 |
Cocaine response (variable dose, iv), dosage required to induce tonic seizure infused via tail vein [mg/kg] |
Drug response |
| X4645 |
10203 |
Cocaine response (variable dose iv via tail vein), dose required to induce clonic seizure [mg/kg] |
Drug response |
| X877 |
10286 |
Cocaine response (5 mg/kg ip), stereotypy, repeated movements measured as difference from saline control in males [n difference] |
Drug response |
| X3212 |
10287 |
Cocaine response (5 mg/kg ip), stereotypy, repeated movements measured as difference from saline control in females [n difference] |
Drug response |
| X1105 |
10288 |
Cocaine response (5 mg/kg ip), stereotypy, repeated movements measured as difference from saline control in males and females [n difference] |
Drug response |
| X1389 |
10289 |
Cocaine response (5 mg/kg ip), locomotion activity measured as difference from saline control in males [cm difference] |
Drug response |
| X2539 |
10290 |
Cocaine response (5 mg/kg ip), locomotion measured as difference from saline control in females [cm difference] |
Drug response |
| X2854 |
10291 |
Cocaine response (5 mg/kg ip), locomotion activity measured as difference from saline control in males and females [cm difference] |
Drug response |
| X3867 |
10292 |
Cocaine response (5 mg/kg ip), exploratory activity, nose pokes in holeboard measured as difference from saline control in males [n] |
Drug response |
| X4690 |
10293 |
Cocaine response (5 mg/kg ip), exploratory activity, nose pokes in holeboard measured as difference from saline control in females [n difference |
Drug response |
| X4668 |
10294 |
Cocaine response (5 mg/kg ip), exploratory activity, nose pokes in holeboard measured as difference from saline control in males and females [n difference] |
Drug response |
| X2040 |
10295 |
Cocaine response (15 mg/kg ip), cocaine stereotypy, number of movements as difference from saline control injection in males [n] |
Drug response |
| X2407 |
10316 |
Cocaine response (45 mg/k ip), open field locomotor activity, total distance relative to saline control in males [cm] |
Drug response |
| X5084 |
10296 |
Cocaine response (15 mg/kg ip), stereotypy evaluated as the number of movements (difference from saline control) in adult females [n] |
Drug response |
| X3296 |
10297 |
Cocaine response (15 mg/kg ip), stereotypy evaluated as the number of movements (difference from saline control) in adult males and females [n] |
Drug response |
| X4736 |
10298 |
Cocaine response (15 mg/kg ip), locomotion in an open field, total distance measured as difference from saline control in males [cm] |
Drug response |
| X1348 |
10299 |
Cocaine response (15 mg/kg ip), open field activity, total distance, difference from saline control in females [cm] |
Drug response |
| X3686 |
10300 |
Cocaine response (15 mg/k ip), open field locomotor activity, total distance relative to saline control in males and females [cm] |
Drug response |
| X4212 |
10301 |
Cocaine response (15 mg/kg ip), exploratory activity (nose pokes in holeboard) difference relative to saline control, adult males [n difference] |
Drug response |
| X1101 |
10302 |
Cocaine response (15 mg/kg ip), exploratory activity (nose pokes in holeboard) difference relative to saline control, adult females [n difference] |
Drug response |
| X4480 |
10303 |
Cocaine response (15 mg/kg ip), exploratory activity (nose pokes in holeboard) difference relative to saline control, adult males and females [n difference] |
Drug response |
| X1279 |
10304 |
Cocaine response (30 mg/kg ip), stereotypy, number of movements relative to saline control injection for males [n] |
Drug response |
| X3753 |
10305 |
Cocaine response (30 mg/k ip) stereotypy, increase in numbers of movements relative to saline controls in females [n] |
Drug response |
| X2066 |
10306 |
Cocaine response (30 mg/kg ip), stereotypy, number of movements relative to saline control injection, male and female combined [n] |
Drug response |
| X1040 |
10307 |
Cocaine response (30 mg/k ip), open field locomotor activity, total distance relative to saline control in males [cm] |
Drug response |
| X2863 |
10308 |
Cocaine response (30 mg/k ip), open field locomotor activity, total distance relative to saline control in females [cm] |
Drug response |
| X2930 |
10309 |
Cocaine response (30 mg/k ip), open field locomotor activity, total distance relative to saline control in males and females [cm] |
Drug response |
| X1202 |
10310 |
Cocaine response (30 mg/kg ip), exploratory activity (nose pokes in holeboard) difference relative to saline control, adult males [n difference] |
Drug response |
| X4382 |
10311 |
Cocaine response (30 mg/kg ip), exploratory activity (nose pokes in holeboard) difference relative to saline control, adult females [n difference] |
Drug response |
| X1034 |
10312 |
Cocaine response (30 mg/kg ip), exploratory activity (nose pokes in holeboard) difference relative to saline control, adult males and females [n difference] |
Drug response |
| X2225 |
10313 |
Cocaine response (45 mg/k ip) stereotypy, increase in numbers of movements relative to saline controls in males [n] |
Drug response |
| X3075 |
10314 |
Cocaine response (45 mg/kg ip) stereotypy, increase in numbers of movements relative to saline controls in females [n] |
Drug response |
| X1026 |
10315 |
Cocaine response (45 mg/k ip) stereotypy, increase in numbers of movements relative to saline controls in males and females [n] |
Drug response |
| X4673 |
12545 |
Plasma iron of 120-day-old males fed 3 ppm iron (Fe) diet [ug/dL] |
Hematology |
| X4093 |
10317 |
Cocaine response (45 mg/k ip), open field locomotor activity, total distance relative to saline control in females [cm] |
Drug response |
| X2503 |
10318 |
Cocaine response (45 mg/k ip), open field locomotor activity, total distance relative to saline control in males and females [cm] |
Drug response |
| X4963 |
10319 |
Cocaine response (45 mg/kg ip), exploratory activity (nose pokes in holeboard) difference relative to saline control, adult males [n difference] |
Drug response |
| X1982 |
10320 |
Cocaine response (45 mg/kg ip), exploratory activity (nose pokes in holeboard) difference relative to saline control, adult females [n difference] |
Drug response |
| X4621 |
10321 |
Cocaine response (45 mg/kg ip), exploratory activity (nose pokes in holeboard) difference relative to saline control, adult males and females [n difference] |
Drug response |
| X2523 |
10322 |
Cocaine response (5 mg/k ip), open field locomotor activity relative to saline control (area under the curve with saline covariate) [cm x min] |
Drug response |
| X4017 |
10323 |
Cocaine response (15 mg/k ip), open field locomotor activity relative to saline control (area under the curve with saline covariate) [cm x min] |
Drug response |
| X3130 |
10324 |
Cocaine response (30 mg/k ip), open field locomotor activity relative to saline control (area under the curve with saline covariate) [cm x min] |
Drug response |
| X1745 |
10325 |
Cocaine response (45 mg/k ip), open field locomotor activity relative to saline control (area under the curve with saline covariate) [cm x min] |
Drug response |
| X5028 |
10326 |
Cocaine response (15 mg/kg ip), open field behavior, difference in time spent in the field center relative saline injection for females [sec] |
Drug response |
| X4112 |
10327 |
Cocaine response (30 mg/kg), open field behavior, center time (difference from saline) in males [sec] |
Drug response |
| X3532 |
10328 |
Cocaine response (30 mg/kg ip), open field behavior, center time difference from saline control in females [sec] |
Drug response |
| X3494 |
10329 |
Cocaine response (45 mg/k ip), open field center time relative to saline control in males [sec] |
Drug response |
| X2646 |
10330 |
Cocaine response (45 mg/k ip), open field center time relative to saline control in females [sec] |
Drug response |
| X528 |
10333 |
Cocaine response (5 mg/kg, ip), open field center time (difference from saline) in males [sec] |
Drug response |
| X5020 |
10334 |
Cocaine response (5 mg/kg), anxiety assay, center time in an open field test, difference from saline control in females [sec] |
Drug response |
| X4940 |
10335 |
Cocaine response (15 mg/kg ip), open field behavior, time in the field center (difference from saline control) in males [sec] |
Drug response |
| X3471 |
10347 |
Ethanol response (1.75 g/kg ip), initial sensitivity measured by blood ethanol concentration (BEC, retrobulbar bleed) at loss of balance using a dowel test (BEC time 0) [mg % ethanol] |
Drug response |
| X2604 |
10348 |
Ethanol response (1.75 g/kg ip then 2 g/kg ip), acute functional tolerance (AFT) measured as the difference in blood alcohol concentration (BEC, retrobulbar bleed) following the second recovery of balance an |
Drug response |
| X4838 |
10349 |
Ethanol response (1.75 mg/kg ip), time to ataxia measured as loss of balance using a dowel test (Loss corresponds to BEC time 0) [min] |
Drug response |
| X4927 |
10350 |
Ethanol response (1.75 mg/kg ip), duration of ataxia following the first ethanol injection using a dowel test (Regain Test 1 corresponds to BEC1) [min] |
Drug response |
| X4559 |
10351 |
Ethanol response (1.75 g/kg ip then 2 g/kg ip), duration of ataxia following the second ethanol injection using a dowel test (Regain Test 2 corresponds to BEC2) [min] |
Drug response |
| X1089 |
10352 |
cyclic AMP accumulation in cerebellum, basal level measured by liquid scintillation counting [% conversion [3H]ATP to [3H]cAMP] |
Drug response |
| X2717 |
10353 |
cyclic AMP accumulation in cerebellum, stimuated with forskolin (10 uM) measured by liquid scintillation counting [% conversion [3H]ATP to [3H]cAMP] |
Drug response |
| X3809 |
10354 |
cyclic AMP accumulation in cerebellum, stimulated with isoproterenol (1 um) measured by liquid scintillation counting [% conversion [3H]ATP to [3H]cAMP] |
Drug response |
| X3395 |
10454 |
Allopregnanolone response (10 mg/kg 3a-hydroxy-5a-pregnan-20-one, THP, in 20% 2-hydroxypropyl-beta-cyclodextrin ip), difference in locomotion between day 3 (first injection) and day 2 (vehicle |
Drug response |
| X3591 |
10455 |
Allopregnanolone response (17 mg/kg 3a-hydroxy-5a-pregnan-20-one in 20% 2-hydroxypropyl-beta-cyclodextrin ip), difference in locomotion between day 3 (first injection) and day 2 (vehicle basel |
Drug response |
| X2008 |
10469 |
Morphine response (0.3 to 0.7 mg/ml in water), consumption using two-bottle choice test [ml/test period] |
Drug response |
| X3788 |
10474 |
Ethanol response (3%, g/kg in tap water), consumption using a two-bottle choice test vs. tap water, mean of day 2 and day 4 of a 4-day 24-hr access period [g/kg/day] |
Drug response |
| X2618 |
10475 |
Ethanol response (3%, g/kg in 0.2% saccharin and tap water), consumption using a two-bottle choice test vs. tap water, mean of day 2 and day 4 of a 4-day 24-hr access period [g/kg/day] |
Drug response |
| X1678 |
10476 |
Ethanol response (10%, g/kg in tap water), consumption using a two-bottle choice test offered vs. tap water, mean of day 2 and day 4 of a 4-day 24-hr access period [g/kg/day] |
Drug response |
| X1976 |
10477 |
Ethanol response (10%, g/kg in 0.2% saccharin and tap water), consumption using a two-bottle choice test offered vs. tap water, mean of day 2 and day 4 of a 4-day 24-hr access period [g/kg/day] |
Drug response |
| X4484 |
10478 |
Ethanol response, withdrawal severity, handling-induced convulsion (HIC) score, corrected area under the HIC curve after voluntary ethanol consumption [HIC AUC] |
Drug response |
| X2304 |
10479 |
Ethanol response (10%, g/kg in tap water), preference using a two-bottle choice test offered vs. tap water, mean of day 2 and day 4 of a 4-day 24-hr access period [ratio] |
Drug response |
| X4511 |
10480 |
Water response, consumption using a two-bottle choice test offered vs. 10% ethanol [ml] |
Drug response |
| X4824 |
10481 |
Water response, consumption using a two-bottle choice test offered vs. 0.2% saccharin [ml] |
Drug response |
| X697 |
10482 |
Ethanol response (2 g/kg ip), acute locomotor activity response (horizontal distance), 1-5 min after injections, difference between day 2 saline control and day 11 ethanol injection (first and only ethanol i |
Drug response |
| X2076 |
10483 |
Ethanol response (2 g/kg ip), sensitization to ethanol, difference in locomotor activity between saline control group (CS) and ethanol treated group (CD) to final acute ethanol test on day 11 (deltaBG) [cm] |
Drug response |
| X4914 |
10484 |
Ethanol response (2 g/kg ip), sensitization to ethanol (CD group), difference in locomotor activity between fifth ethanol treatment (day 11) and first ethanol treatment (day 3), 1- 5 min after injections in |
Drug response |
| X551 |
10485 |
Ethanol response (2 g/kg ip), acute locomotor activity response (horizontal distance), 1-5 min after injection, difference between day 2 saline injection response and day 3 ethanol injection in young adult f |
Drug response |
| X1792 |
10488 |
Cocaine response (10 mg/kg ip), difference in locomotion using Accuscan activity monitor between day 3 (first cocaine treatment) and day 2 (saline ip baseline) [cm/15 min] |
Drug response |
| X1179 |
10489 |
Cocaine response (40 mg/kg ip), difference in locomotion using Accuscan activity monitor between day 3 (first cocaine treatment) and day 2 (saline ip baseline) [cm/15 min] |
Drug response |
| X4844 |
10490 |
Cocaine response (10 mg/kg ip), sensitization of locomotion following 5 daily injections, difference between day 11 (fifth treatment) and day 3 (first treatment) [cm/15 min] |
Drug response |
| X1645 |
10491 |
Cocaine response (40 mg/kg ip), sensitization of locomotion following 5 daily injections, difference between day 11 (fifth treatment) and day 3 (first treatment) [cm/15 min] |
Drug response |
| X3565 |
10492 |
Cocaine response (5 mg/kg ip), sensitization of locomotion following 5 daily injections, difference between day 11 (fifth treatment) and day 3 (first treatment) [cm/15 min] |
Drug response |
| X2919 |
10493 |
Cocaine response (5 mg/kg ip), difference in locomotion using Accuscan activity monitor between day 3 (first cocaine treatment) and day 2 (saline ip baseline) [cm/15 min] |
Drug response |
| X1304 |
10494 |
Ethanol response (2 g/kg ip), difference in locomotion using grid test (Accuscan activity monitor) following ethanol injection, day 3 (first treatment) minus day 2 (saline baseline) in the chronic ethanol gr |
Drug response |
| X2427 |
10495 |
Ethanol response (2 g/kg ip), difference in locomotion between day 11 (first and only ethanol treatment) and day 2 (saline baseline) in the chronic saline group [n beam breaks/10 min test] |
Drug response |
| X4535 |
10496 |
Ethanol response (2 g/kg ip), sensitization to ethanol measured as the difference in locomotion using grid test (Accuscan activity monitor) after repeated treatment, day 11 (fifth treatment) minus day 3 (fir |
Drug response |
| X4477 |
10497 |
Ethanol response (2 g/kg ip), acute ataxia, difference between day 3 (first ethanol treatment) and day 2 (saline baseline) in the chronic drug group [n grid test errors/10 min test] |
Drug response |
| X2109 |
10498 |
Ethanol response (2 g/kg ip), acute ataxia measured using using grid test (Accuscan activity monitor), difference between day 11 (first and only ethanol treatment) and day 2 (saline baseline) in the chronic |
Drug response |
| X4792 |
10499 |
Ethanol response (2 g/kg ip), intoxication and adaptation measured as difference in missteps using grid test (Accuscan activity monitor) after repeated treatment, day 11 (fifth treatment) minus day 3 (first |
Drug response |
| X3806 |
10500 |
Ethanol response (2 g/kg ip), difference in ataxia using grid test (Accuscan activity monitor) between acute ethanol on day 3 (first ethanol treatment) and day 2 (saline baseline) in the chronic ethanol grou |
Drug response |
| X3354 |
10589 |
Ethanol response (4.1 g/kg ip), high dose sensitivity, duration of loss of righting reflex [min] |
Drug response |
| X4657 |
10501 |
Ethanol response (2 g/kg ip), difference in ataxia using grid test (Accuscan activity monitor) between injection on day 11 (first and only ethanol treatment) and day 2 (saline baseline) in the chronic saline |
Drug response |
| X1617 |
10502 |
Ethanol response, change in ataxic effects of 2 g/kg (ip) after repeated treatment, difference between day 11 (fifth treatment) minus day 3 (first treatment) in the chronic drug (CD) group, 10 min test [grid |
Drug response |
| X3442 |
10563 |
Paraoxon organophosphate (OP) acetylcholinesterase inhibitor response (0.25 mg/kg ip), locomotor activity 16-20 min after injection [activity counts/min] |
Drug response |
| X3992 |
10564 |
Control response (10 mg/kg oil vehicle), locomotor activity 16-20 min after injection [activity counts/min] |
Drug response |
| X4773 |
10565 |
Paraoxon organophosphate (OP) acetylcholinesterase inhibitor response (0.25 mg/kg ip), locomotor activity 21-25 min after injection [activity counts/min] |
Drug response |
| X2023 |
10566 |
Control response (10 mg/kg oil vehicle), locomotor activity 21-25 min after injection [activity counts/min] |
Drug response |
| X4631 |
10567 |
Paraoxon organophosphate (OP) acetylcholinesterase inhibitor response (0.25 mg/kg ip), locomotor activity 26-30 min after injection [activity counts/min] |
Drug response |
| X2954 |
10568 |
Control response (10 mg/kg oil vehicle), locomotor activity 26-30 min after injection [activity counts/min] |
Drug response |
| X1036 |
10569 |
Paraoxon organophosphate (OP) acetylcholinesterase inhibitor response (0.25 mg/kg ip), locomotor activity from 0-15 min after injection [activity counts/min] |
Drug response |
| X3665 |
10570 |
Control response (10 mg/kg oil vehicle), locomotor activity from 0-15 min after injection [activity counts/min] |
Drug response |
| X4035 |
10571 |
Paraoxon organophosphate (OP) acetylcholinesterase inhibitor response (0.25 mg/kg ip), locomotor activity from 15-30 min after injection [activity counts/min] |
Drug response |
| X3911 |
10572 |
Control response (10 mg/kg oil vehicle), locomotor activity from 15-30 min after injection [activity counts/min] |
Drug response |
| X3929 |
10578 |
Ethanol response (4 g/kg ip), handling-induced convulsion (HIC) score 7 hr after injection [score] |
Drug response |
| X870 |
10581 |
Ethanol response (10% in water po), acceptance, total consumption over 24 hr for females [g/kg] |
Drug response |
| X3093 |
10582 |
Ethanol response (10% in water po), acceptance, total consumption over 24 hr for males [g/kg] |
Drug response |
| X933 |
10583 |
Ethanol response (10% in water po), preference for alcohol for females [g/kg] |
Drug response |
| X2055 |
10584 |
Ethanol response (10% v/v in water), preference of females using 2-bottle choice [g/kg] |
Drug response |
| X4912 |
10585 |
Ethanol response (variable dose ip), hypnotic dose sensitivity (HDS), sleep time for females [min] |
Drug response |
| X1258 |
10586 |
Ethanol response (4.1 g/kg ip), high dose sensitivity, duration of loss of righting reflex of males [min] |
Drug response |
| X1386 |
10587 |
Ethanol response (10% v/v in water), acceptance of ethanol under thirst motivation in a single-bottle (no choice) test following 24 hr water deprivation, total 24 hr ethanol intake [g/kg] |
Drug response |
| X1683 |
10588 |
Ethanol response (10% in water po), preference and consumption of 10% ethanol vs. water over 15 days [g/kg] |
Drug response |
| X1236 |
10609 |
Cocaine response (32 mg/kg ip), locomotion from 0-60 min after injections in an activity chamber [n beam breaks] |
Drug response |
| X4269 |
10610 |
Cocaine response (32 mg/kg ip), sensitization of locomotor response [% initial response] |
Drug response |
| X2603 |
10611 |
Cocaine response (32 mg/kg ip, daily), stereotypical behavior frequency after consecutive daily injections on day 8 [units] |
Drug response |
| X2921 |
10614 |
Pentylenetetrazol (PTZ, a GABA antagonists) response, dosage level (threshold) required to induce seizure [mg/kg] |
Drug response |
| X4128 |
10790 |
Ethanol response (1.5 g/kg ip), locomotion during 0 to 5 min interval (updated data PMID 9880575) [cm] |
Drug response |
| X1918 |
10791 |
Ethanol response (1.5 g/kg ip), locomotion during 5 to 10 min interval (updated data PMID 9880575) [cm] |
Drug response |
| X2174 |
10792 |
Ethanol response (1.5 g/kg ip), locomotion during 10 to 15 min interval (updated data PMID 9880575) [cm] |
Drug response |
| X1804 |
10793 |
Ethanol response (1.5 g/kg ip), locomotion during 15 to 20 min interval (updated data PMID 9880575) [cm] |
Drug response |
| X4402 |
10794 |
Ethanol response (1.5 g/kg ip), adaptation to ethanol defined as 15-20 min interval locomotion minus 0-5 min interval locomotion [cm] |
Drug response |
| X3287 |
11002 |
Ethanol response (3 g/kg ip), hypothermia (supplementary data to Brigman et al.) [deg C] |
Drug response |
| X832 |
11003 |
Ethanol response (3 g/kg ip), loss of righting reflex (LORR) sleep time (supplementary data to Brigman et al.) [min] |
Drug response |
| X724 |
11006 |
Ethanol response (1.75 g/kg ip), ataxia measured by rotarod performance, difference from saline baseline (supplementary data to Brigman et al.) |
Drug response |
| X3625 |
11303 |
Ethanol response (2 g/kg ip), motor coordination, time on dowel over a 5 min test period immediately after injection for males [sec] |
Drug response |
| X3435 |
11304 |
Ethanol response (2 g/kg ip), motor coordination, time on dowel over a 5 min test period starting 30 min after injection for males [sec] |
Drug response |
| X296 |
11312 |
Morphine response (50 mg/kg ip), locomotion from 90-105 min after injection in an activity chamber for males [n beam breaks] |
Drug response |
| X611 |
11313 |
Morphine response (50 mg/kg ip), locomotion from 105-120 min after injection in an activity chamber for males [n beam breaks] |
Drug response |
| X2283 |
11314 |
Morphine response (50 mg/kg ip), locomotion from 120-135 min after injection in an activity chamber for males [n beam breaks] |
Drug response |
| X2948 |
11315 |
Morphine response (50 mg/kg ip), locomotion from 0-15 min after injection in an activity chamber for males [n beam breaks] |
Drug response |
| X4314 |
11316 |
Morphine response (50 mg/kg ip), locomotion from 150-165 min after injection in an activity chamber for males [n beam breaks] |
Drug response |
| X2148 |
11317 |
Morphine response (50 mg/kg ip), locomotion from 165-180 min after injection in an activity chamber for males [n beam breaks] |
Drug response |
| X1659 |
11318 |
Morphine response (50 mg/kg ip), locomotion from 15-30 min after injection in an activity chamber for males [n beam breaks] |
Drug response |
| X224 |
11319 |
Morphine response (50 mg/kg ip), locomotion from 30-45 min after injection in an activity chamber for males [n beam breaks] |
Drug response |
| X99 |
11320 |
Morphine response (50 mg/kg ip), locomotion from 45-60 min after injection in an activity chamber for males [n beam breaks] |
Drug response |
| X102 |
11321 |
Morphine response (50 mg/kg ip), locomotion from 60-75 min after injection in an activity chamber for males [n beam breaks] |
Drug response |
| X172 |
11322 |
Morphine response (50 mg/kg ip), locomotion from 75-90 min after injection in an activity chamber for males [n beam breaks] |
Drug response |
| X188 |
11323 |
Morphine response (50 mg/kg ip), locomotion (open field) from 90-105 min after injection in an activity chamber for males [cm] |
Drug response |
| X375 |
11324 |
Morphine response (50 mg/kg ip), locomotion (open field) from 105-120 min after injection in an activity chamber for males |
Drug response |
| X1476 |
11325 |
Morphine response (50 mg/kg ip), locomotion (open field) from 120-135 min after injection in an activity chamber for males [cm] |
Drug response |
| X1728 |
11326 |
Morphine response (50 mg/kg ip), locomotion (open field) from 0-15 min after injection in an activity chamber for males [cm] |
Drug response |
| X3640 |
11327 |
Morphine response (50 mg/kg ip), locomotion (open field) from 150-165 min after injection in an activity chamber for males [cm] |
Drug response |
| X1526 |
11328 |
Morphine response (50 mg/kg ip), locomotion (open field) from 165-180 min after injection in an activity chamber for males [cm] |
Drug response |
| X446 |
11329 |
Morphine response (50 mg/kg ip), locomotion (open field) from 15-30 min after injection in an activity chamber for males [cm] |
Drug response |
| X117 |
11330 |
Morphine response (50 mg/kg ip), locomotion (open field) from 30-45 min after injection in an activity chamber for males [cm] |
Drug response |
| X83 |
11331 |
Morphine response (50 mg/kg ip), locomotion (open field) from 45-60 min after injection in an activity chamber for males [cm] |
Drug response |
| X87 |
11332 |
Morphine response (50 mg/kg ip), locomotion (open field) from 60-75 min after injection in an activity chamber for males [cm] |
Drug response |
| X116 |
11333 |
Morphine response (50 mg/kg ip), locomotion (open field) from 75-90 min after injection in an activity chamber for males [cm] |
Drug response |
| X4077 |
11334 |
Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), severity of abdominal contraction for males [ordinal scale, 0=no effect, 3=max] |
Drug response |
| X3987 |
11335 |
Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), defecation in an activity chamber for males [n fecal boli] |
Drug response |
| X985 |
11336 |
Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), number of jumps for males [n/15 min test] |
Drug response |
| X138 |
11337 |
Morphine response (50 mg/kg ip), locomotion from 0-180 min after injection (total open field activity over 3 hour test) for males [n beam breaks] |
Drug response |
| X114 |
11338 |
Morphine response (50 mg/kg ip), locomotion from 0-180 min (total activity over 3 hour test) after injection in an activity chamber for males [cm] |
Drug response |
| X1864 |
11339 |
Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), change in locomotion for males (last 15 min of morphine test (165-180 min) minus first 15 min after naloxone) [ |
Drug response |
| X841 |
11340 |
Morphine response (50 mg/kg ip), vertical activity (rears) from 0-180 min after injection (total vertical activity over 3 hour test) for males [n beam breaks] |
Drug response |
| X1915 |
11356 |
Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), locomotion from 0-15 min after naloxone injection for males [n beam breaks] |
Drug response |
| X1613 |
11357 |
Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), horizontal activity (distance traveled) from 0-15 min after naloxone injection for males [cm] |
Drug response |
| X2068 |
11358 |
Morphine response (50 mg/kg ip) and naloxone response (30 mg/kg ip), naloxone-induced withdrawal after morphine, vertical activity (rears) from 0-15 min for males [n beam breaks] |
Drug response |
| X3605 |
11359 |
Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), postural changes for males [ordinal scale, 0=no effect, 3=max] |
Drug response |
| X4367 |
11360 |
Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), ptosis for males [ordinal scale, 0=no effect, 3=max] |
Drug response |
| X1576 |
11361 |
Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), salivation for males [ordinal scale, 0=control level, 3=max] |
Drug response |
| X4935 |
11362 |
Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), wet dog shakes for males [ordinal scale, 0=no effect, 3=max] |
Drug response |
| X904 |
11364 |
Morphine response (50 mg/kg ip), vertical activity (rears) from 90-105 min after injection in an activity chamber for males [n beam breaks] |
Drug response |
| X2748 |
11365 |
Morphine response (50 mg/kg ip), vertical activity (rears) from 105-120 min after injection in an activity chamber for males [n beam breaks] |
Drug response |
| X4111 |
11366 |
Morphine response (50 mg/kg ip), vertical activity (rears) from 120-135 min after injection in an activity chamber for males [n beam breaks] |
Drug response |
| X3111 |
11367 |
Morphine response (50 mg/kg ip), vertical activity (rears) from 0-15 min after injection in an activity chamber for males [n beam breaks] |
Drug response |
| X2332 |
11368 |
Morphine response (50 mg/kg ip), vertical activity (rears) from 150-165 min after injection in an activity chamber for males [n beam breaks] |
Drug response |
| X1900 |
11369 |
Morphine response (50 mg/kg ip), vertical activity (rears) from 165-180 min after injection in an activity chamber for males [n beam breaks] |
Drug response |
| X314 |
11370 |
Morphine response (50 mg/kg ip), vertical activity (rears) from 15-30 min after injection in an activity chamber for males [n beam breaks] |
Drug response |
| X139 |
11371 |
Morphine response (50 mg/kg ip), vertical activity (rears) from 30-45 min after injection in an activity chamber for males [n beam breaks] |
Drug response |
| X165 |
11372 |
Morphine response (50 mg/kg ip), vertical activity (rears) from 45-60 min after injection in an activity chamber for males [n beam breaks] |
Drug response |
| X341 |
11373 |
Morphine response (50 mg/kg ip), vertical activity (rears) from 60-75 min after injection in an activity chamber for males [n beam breaks] |
Drug response |
| X4718 |
10820 |
Hematocrit (packed cell volume, erythrocyte volume fraction) in males and females [%] |
Hematology |
| X610 |
11374 |
Morphine response (50 mg/kg ip), vertical activity (rears) from 75-90 min after injection in an activity chamber for males [n beam breaks] |
Drug response |
| X2771 |
11375 |
3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) response (10 mg/kg subcutaneous), locomotion on day 2 for males [cm/90 min test] |
Drug response |
| X3386 |
11378 |
Ethanol response (4.0 g/kg ip), handling-induced convulsion (HIC) 4 hrs after injection for males [explain the score] |
Drug response |
| X3752 |
11379 |
Ethanol response (4.0 g/kg ip), handling-induced convulsions (HIC) 6 hrs after injections for males (0=no effect, 1=facial grimace during tail spin, 2=tonic convulsion during spin, 3=tonic-clonic convulsion |
Drug response |
| X1502 |
11380 |
Ethanol response (4.0 g/kg ip), handling-induced convulsion (HIC) score 7 hrs after ethanol injection for males [units] |
Drug response |
| X1344 |
11382 |
Ethanol response (4.0 g/kg ip), handling-induced convulsion (HIC) after injection for males (0=no effect, 1=facial grimace during tail spin, 2=tonic convulsion during spin, 3=tonic-clonic convulsion during s |
Drug response |
| X523 |
11440 |
Ethanol response (2.25 g/kg ip), locomotor activity after injection from 0-5 min for males [cm] |
Drug response |
| X1498 |
11441 |
Saline control response (10 ml/kg ip), locomotor activity after injection from 0-5 min for males [cm] |
Drug response |
| X573 |
11442 |
Ethanol response (2.25 g/kg ip), locomotor activity after injection from 5-10 min for males [cm] |
Drug response |
| X1098 |
11444 |
Ethanol response (2.25 g/kg ip), locomotor activity after injection from 10-15 min for males [cm] |
Drug response |
| X1230 |
11446 |
Ethanol response (2.25 g/kg ip), locomotor activity after injection from 15-20 min for males [cm] |
Drug response |
| X1676 |
11447 |
Saline control response (10 ml/kg ip) for cocaine, locomotion from 15-20 min after injection for males [cm] |
Drug response |
| X2844 |
11448 |
Ethanol response (2.25 g/kg ip), locomotor activity, difference in distance traveled (saline minus ethanol) from 0-20 min for males [cm] |
Drug response |
| X1141 |
11449 |
Ethanol response (2.25 g/kg ip), locomotor activity after injection from 0-20 min for males [cm] |
Drug response |
| X2049 |
11450 |
Saline control response (10 ml/kg ip), locomotion 0-20 min after injection for males [cm] |
Drug response |
| X1218 |
11451 |
Ethanol response (2.25 g/kg ip), locomotor activity, difference in distance traveled (saline minus ethanol) from 0-5 min for males [cm] |
Drug response |
| X1504 |
11452 |
Ethanol response (2.25 g/kg ip), locomotor activity, difference in distance traveled (saline minus ethanol) between the first 5 min and last 5 min for males [cm] |
Drug response |
| X3225 |
11453 |
Ethanol response (2.25 g/kg ip), blood ethanol concentration (BEC) for males [mg/dl XX min after injection] |
Drug response |
| X3834 |
11460 |
Ethanol response (2.25 g/kg ip), motor coordination effects, difference in time on rotarod between training session and ethanol for males and females [sec] |
Drug response |
| X2527 |
11461 |
Ethanol response (2.25 g/kg ip), duration on rotarod following injection for males [sec] |
Drug response |
| X4874 |
11462 |
Ethanol response (2.25 g/kg ip), motor coordination effects, tolerance assay, difference in time on rotarod between saline and ethanol for males [sec] |
Drug response |
| X4204 |
12934 |
Potassium of 14-week old males [mM] |
Hematology |
| X155 |
11463 |
Saline control response (10 ml/kg ip), motor coordination, rotarod performance following injection for males [sec] |
Drug response |
| X3291 |
11469 |
Cocaine response (10 mg/kg ip), locomotion from 0-15 min after first injection in an activity chamber for males [n beam breaks] |
Drug response |
| X3975 |
11470 |
Cocaine response (10 mg/kg ip), locomotion from 15-30 min after first injection in an activity chamber for males [n beam breaks] |
Drug response |
| X4548 |
11471 |
Cocaine response (10 mg/kg ip), locomotion from 30-45 min after first injection in an activity chamber for males [n beam breaks] |
Drug response |
| X3468 |
11472 |
Cocaine response (10 mg/kg ip), locomotion from 45-60 min after first injection in an activity chamber for males [n beam breaks] |
Drug response |
| X3569 |
11473 |
Cocaine response (10 mg/kg ip), locomotion from 0-15 min after first injection in an activity chamber for males [cm] |
Drug response |
| X4095 |
11474 |
Cocaine response (10 mg/kg ip), locomotion from 15-30 min after first injection in an activity chamber for males [cm] |
Drug response |
| X4456 |
11475 |
Cocaine response (10 mg/kg ip), locomotion from 30-45 min after first injection in an activity chamber for males [cm] |
Drug response |
| X2895 |
11476 |
Cocaine response (10 mg/kg ip), locomotion from 45-60 min after first injection in an activity chamber for males [cm] |
Drug response |
| X1260 |
11477 |
Cocaine response (10 mg/kg ip), vertical activity (rears) in an open field 0-15 min after injection for males [n beam breaks] |
Drug response |
| X980 |
11478 |
Cocaine response (10 mg/kg ip), vertical activity (rears) in an open field 15-30 min after injection for males [n beam breaks] |
Drug response |
| X2394 |
11479 |
Cocaine response (10 mg/kg ip), vertical activity (rears) in an open field 30-45 min after injection for males [n beam breaks] |
Drug response |
| X2114 |
11480 |
Cocaine response (10 mg/kg ip), vertical activity (rears) in an open field 45-60 min after injection for males [n beam breaks] |
Drug response |
| X2457 |
11481 |
Cocaine response (2 x 10 mg/kg ip), locomotion from 0-15 min after second injection in an activity chamber for males [n beam breaks] |
Drug response |
| X2809 |
11482 |
Cocaine response (2 x 10 mg/kg ip), locomotion from 15-30 min after second injection in an activity chamber for males [n beam breaks] |
Drug response |
| X4486 |
11484 |
Cocaine response (2 x 10 mg/kg ip), locomotion from 45-60 min after second injection in an activity chamber for males [n beam breaks] |
Drug response |
| X3173 |
11485 |
Cocaine response (2 x 10 mg/kg ip), locomotion in an open field from 0-15 min after second injection in an activity chamber for males [cm] |
Drug response |
| X3483 |
11486 |
Cocaine response (2 x 10 mg/kg ip), locomotion in an open field from 15-30 min after second injection in an activity chamber for males [cm] |
Drug response |
| X3637 |
11487 |
Cocaine response (2 x 10 mg/kg ip), locomotion in an open field from 30-45 min after second injection in an activity chamber for males [cm] |
Drug response |
| X4009 |
11488 |
Cocaine response (2 x 10 mg/kg ip), locomotion in an open field from 45-60 min after second injection in an activity chamber for males [cm] |
Drug response |
| X1107 |
11489 |
Cocaine response (2 x 10 mg/kg ip), vertical activity (rears) from 15-30 min after second injection in an activity chamber for males [n beam breaks] |
Drug response |
| X1734 |
11490 |
Cocaine response (2 x 10 mg/kg ip), vertical activity (rears) from 15-30 min after second injection in an activity chamber for males [n beam breaks] |
Drug response |
| X1044 |
11491 |
Cocaine response (2 x 10 mg/kg ip), vertical activity (rears) from 30-45 min after second injection in an activity chamber for males [n beam breaks] |
Drug response |
| X2051 |
11492 |
Cocaine response (2 x 10 mg/kg ip), vertical activity (rears) from 45-60 min after second injection in an activity chamber for males [n beam breaks] |
Drug response |
| X3881 |
11495 |
Cocaine response (3 x 3.2 mg/kg ip, Days 2,3, 4), conditioned place preference (CPP), time in drug-paired compartment on Day 5 for males [sec], |
Drug response |
| X2377 |
11496 |
Cocaine response (3 x 3.2 mg/kg ip, Days 2,3, 4), conditioned place preference (CPP), time in unconditioned saline-paired compartment on Day 5 for males [sec] |
Drug response |
| X3847 |
11498 |
Cocaine response (3 x 3.2 mg/kg ip, Days 2,3, and 4), conditioned place preference (CPP), change in time in cocaine-paired compartment relative to baseline (Day 5 minus Day 1) for males [sec] |
Drug response |
| X3765 |
11499 |
Cocaine response (3 x 3.2 mg/kg ip, Days 2,3, and 4), conditioned place preference (CPP), change in percentage of time in cocaine-paired compartment relative to baseline (Day 5 minus Day 1) for males [% cha |
Drug response |
| X3894 |
11503 |
Cocaine response (10 mg/kg ip), locomotion from 0-60 min after first cocaine injection in an activity chamber for males [n beam breaks] |
Drug response |
| X3947 |
11504 |
Cocaine response (10 mg/kg ip), locomotion in an open field from 0-60 min after first cocaine injection for males [cm] |
Drug response |
| X1814 |
11505 |
Cocaine response (10 mg/kg ip), vertical activity (rears) in open field from 0-60 min after first cocaine injection for males [n beam breaks] |
Drug response |
| X1987 |
11534 |
Saline control response (10 ml/kg ip), locomotion in an open field from 0-60 min after injection for males [n beam breaks] |
Drug response |
| X2134 |
11535 |
Saline control response (10 ml/kg ip), locomotion in an open field from 0-60 min after injection for males [cm] |
Drug response |
| X2117 |
11536 |
Saline control response (10 ml/kg), open field behavior, vertical activity (rears) 0-60 min after injection for males [n beam breaks/60 min] |
Drug response |
| X3747 |
11537 |
Cocaine response (2 x 10 mg/kg, ip), sensitization, locomotion after the second injection minus locomotion after the first injection for males [difference in cm/1 hr test, positive values indicate sensitizat |
Drug response |
| X3802 |
11538 |
Cocaine response (2 x 10 mg/kg, ip), locomotion from 0-60 min after the second injection in sensitization test for males [n beam breaks, positive values indicate sensitization] |
Drug response |
| X4366 |
11539 |
Cocaine response (2 x 10 mg/kg, ip), locomotion from 0-60 min after the second injection in sensitization test for males [cm, positive values indicate sensitization] |
Drug response |
| X996 |
11540 |
Cocaine response (2 x 10 mg/kg ip), sensitization, change in vertical activity (rears) for males between first and second injections [difference in n/1 hr test, positive values indicate sensitization] |
Drug response |
| X3087 |
11541 |
Saline control response (10 ml/kg ip), locomotion in an open field from 0-15 min after injection for males [n beam breaks/15 min] |
Drug response |
| X4158 |
10822 |
Transferrin saturation of males [%] |
Hematology |
| X2299 |
11542 |
Saline control response (10 ml/kg ip), locomotion in an open field from 15-30 min after injection for males [n beam breaks/15 min] |
Drug response |
| X3347 |
11543 |
Saline control response (10 ml/kg ip), locomotion in an open field from 30-45 min after injection for males [n beam breaks/15 min] |
Drug response |
| X1954 |
11544 |
Saline control response (10 ml/kg ip), locomotion in an open field from 45-60 min after injection for males [n beam breaks/15 min] |
Drug response |
| X2586 |
11545 |
Saline control response (10 ml/kg ip), locomotion in an open field from 0-15 min after injection for males [cm] |
Drug response |
| X2388 |
11546 |
Saline control response (10 ml/kg ip), locomotion in an open field from 15-30 min after injection for males [cm] |
Drug response |
| X3800 |
11547 |
Saline control response (10 ml/kg ip), locomotion in an open field from 30-45 min after injection for males [cm] |
Drug response |
| X2551 |
11548 |
Saline control response (10 ml/kg ip), locomotion in an open field from 45-60 min after injection for males [cm] |
Drug response |
| X1200 |
11549 |
Saline control response (10 mg/kg ip), open field behavior, vertical activity (rears) 0-15 min after injection for males [n beam breaks/15 min] |
Drug response |
| X2116 |
11550 |
Saline control response (10 mg/kg ip), open field behavior, vertical activity (rears) 15-30 min after injection for males [n beam breaks/15 min] |
Drug response |
| X2526 |
11551 |
Saline control response (10 mg/kg ip), open field behavior, vertical activity (rears) 30-45 min after injection for males [n beam breaks/15 min] |
Drug response |
| X3242 |
11552 |
Saline control response (10 mg/kg ip), open field behavior, vertical activity (rears) 45-60 min after injection for males [n beam breaks/15 min] |
Drug response |
| X4628 |
11560 |
Ethanol response (2 g/kg ip), motor coordination, time on dowel over a 5 min test period immediately after injection for females [sec] |
Drug response |
| X3948 |
11561 |
Ethanol response (2 g/kg ip), motor coordination, time on dowel over a 5 min test period starting 30 min after injection for females [sec] |
Drug response |
| X631 |
11569 |
Morphine response (50 mg/kg ip), locomotion from 90-105 min after injection in an activity chamber for females [n beam breaks] |
Drug response |
| X2504 |
11570 |
Morphine response (50 mg/kg ip), locomotion from 105-120 min after injection in an activity chamber for females [n beam breaks] |
Drug response |
| X2411 |
11571 |
Morphine response (50 mg/kg ip), locomotion from 120-135 min after injection in an activity chamber for females [n beam breaks] |
Drug response |
| X1286 |
11572 |
Morphine response (50 mg/kg ip), locomotion from 0-15 min after injection in an activity chamber for females [n beam breaks] |
Drug response |
| X940 |
11573 |
Morphine response (50 mg/kg ip), locomotion from 150-165 min after injection in an activity chamber for females [n beam breaks] |
Drug response |
| X257 |
11574 |
Morphine response (50 mg/kg ip), locomotion from 165-180 min after injection in an activity chamber for females [n beam breaks] |
Drug response |
| X1054 |
11575 |
Morphine response (50 mg/kg ip), locomotion from 15-30 min after injection in an activity chamber for females [n beam breaks] |
Drug response |
| X260 |
11576 |
Morphine response (50 mg/kg ip), locomotion from 30-45 min after injection in an activity chamber for females [n beam breaks] |
Drug response |
| X161 |
11577 |
Morphine response (50 mg/kg ip), locomotion from 45-60 min after injection in an activity chamber for females [n beam breaks] |
Drug response |
| X182 |
11578 |
Morphine response (50 mg/kg ip), locomotion from 60-75 min after injection in an activity chamber for females [n beam breaks] |
Drug response |
| X291 |
11579 |
Morphine response (50 mg/kg ip), locomotion from 75-90 min after injection in an activity chamber for females [n beam breaks] |
Drug response |
| X535 |
11580 |
Morphine response (50 mg/kg ip), locomotion (open field) from 90-105 min after injection in an activity chamber for females [cm] |
Drug response |
| X2187 |
11581 |
Morphine response (50 mg/kg ip), locomotion (open field) from 105-120 min after injection in an activity chamber for females [cm] |
Drug response |
| X1138 |
11582 |
Morphine response (50 mg/kg ip), locomotion (open field) from 120-135 min after injection in an activity chamber for females [cm] |
Drug response |
| X1401 |
11583 |
Morphine response (50 mg/kg ip), locomotion (open field) from 0-15 min after injection in an activity chamber for females [cm] |
Drug response |
| X627 |
11584 |
Morphine response (50 mg/kg ip), locomotion (open field) from 150-165 min after injection in an activity chamber for females [cm] |
Drug response |
| X249 |
11585 |
Morphine response (50 mg/kg ip), locomotion (open field) from 165-180 min after injection in an activity chamber for females [cm] |
Drug response |
| X480 |
11586 |
Morphine response (50 mg/kg ip), locomotion (open field) from 15-30 min after injection in an activity chamber for females [cm] |
Drug response |
| X158 |
11587 |
Morphine response (50 mg/kg ip), locomotion (open field) from 30-45 min after injection in an activity chamber for females [cm] |
Drug response |
| X115 |
11588 |
Morphine response (50 mg/kg ip), locomotion (open field) from 45-60 min after injection in an activity chamber for females [cm] |
Drug response |
| X143 |
11589 |
Morphine response (50 mg/kg ip), locomotion (open field) from 60-75 min after injection in an activity chamber for females [cm] |
Drug response |
| X244 |
11590 |
Morphine response (50 mg/kg ip), locomotion (open field) from 75-90 min after injection in an activity chamber for females [cm] |
Drug response |
| X4951 |
11591 |
Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), severity of abdominal contraction for females [ordinal scale, 0=no effect, 3=max] |
Drug response |
| X4187 |
11592 |
Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), defecation in an activity chamber for females [n fecal boli] |
Drug response |
| X4655 |
11593 |
Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), number of jumps for females [n/15 min test] |
Drug response |
| X289 |
11594 |
Morphine response (50 mg/kg ip), locomotion from 0-180 min (total activity over 3 hour test) after injection in an activity chamber for females [n beam breaks] |
Drug response |
| X246 |
11595 |
Morphine response (50 mg/kg ip), locomotion from 0-180 min (total activity over 3 hour test) after injection in an activity chamber for females [cm] |
Drug response |
| X896 |
11630 |
Morphine response (50 mg/kg ip), vertical activity (rears) from 60-75 min after injection in an activity chamber for females [n beam breaks] |
Drug response |
| X438 |
11596 |
Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), change in locomotion for females (last 15 min of morphine test (165-180 min) minus first 15 min after naloxone) |
Drug response |
| X2082 |
11597 |
Morphine response (50 mg/kg ip), vertical activity (rears) from 0-180 min (total activity over 3 hour test) after injection in an activity chamber for females [n beam breaks] |
Drug response |
| X1739 |
11613 |
Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), locomotion from 0-15 min after naloxone injection for females [n beam breaks] |
Drug response |
| X1528 |
11614 |
Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), horizontal activity (distance traveled) from 0-15 min after naloxone injection for females [cm] |
Drug response |
| X2782 |
11615 |
Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), vertical activity (rears) from 0-15 min after naloxone injection for females [n beam breaks] |
Drug response |
| X4326 |
11616 |
Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), postural changes for females [ordinal scale, 0=no effect, 3=max] |
Drug response |
| X3576 |
11617 |
Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), ptosis for females [ordinal scale, 0=no effect, 3=max] |
Drug response |
| X3840 |
11618 |
Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), salivation for females [ordinal scale, 0=control level, 3=max] |
Drug response |
| X2598 |
11619 |
Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), wet dog shakes for females [ordinal scale, 0=no effect, 3=max] |
Drug response |
| X3221 |
11621 |
Morphine response (50 mg/kg ip), vertical activity (rears) from 90-105 min after injection in an activity chamber for females [n beam breaks] |
Drug response |
| X2995 |
11622 |
Morphine response (50 mg/kg ip), vertical activity (rears) from 105-120 min after injection in an activity chamber for females [n beam breaks] |
Drug response |
| X2448 |
11623 |
Morphine response (50 mg/kg ip), vertical activity (rears) from 120-135 min after injection in an activity chamber for females [n beam breaks] |
Drug response |
| X1358 |
11624 |
Morphine response (50 mg/kg ip), vertical activity (rears) from 0-15 min after injection in an activity chamber for females [n beam breaks] |
Drug response |
| X1916 |
11625 |
Morphine response (50 mg/kg ip), vertical activity (rears) 150-165 min after injection in an activity chamber for females [n beam breaks] |
Drug response |
| X1497 |
11626 |
Morphine response (50 mg/kg ip), vertical activity (rears) from 165-180 min after injection in an activity chamber for females [n beam breaks] |
Drug response |
| X1491 |
11627 |
Morphine response (50 mg/kg ip), vertical activity (rears) from 15-30 min after injection in an activity chamber for females [n beam breaks] |
Drug response |
| X396 |
11628 |
Morphine response (50 mg/kg ip), vertical activity (rears) from 30-45 min after injection in an activity chamber for females [n beam breaks] |
Drug response |
| X476 |
11629 |
Morphine response (50 mg/kg ip), vertical activity (rears) from 45-60 min after injection in an activity chamber for females [n beam breaks] |
Drug response |
| X2194 |
11631 |
Morphine response (50 mg/kg ip), vertical activity (rears) from 75-90 min after injection in an activity chamber for females [n beam breaks] |
Drug response |
| X4429 |
11635 |
Ethanol response (4.0 g/kg ip), handling-induced convulsion (HIC) 4 hrs after injection for females (0=no effect, 1=facial grimace during tail spin, 2=tonic convulsion during spin, 3=tonic-clonic convulsion |
Drug response |
| X4491 |
11636 |
Ethanol response (4.0 g/kg ip), handling-induced convulsions (HIC) 6 hrs after injections for females (0=no effect, 1=facial grimace during tail spin, 2=tonic convulsion during spin, 3=tonic-clonic convulsio |
Drug response |
| X2773 |
11637 |
Ethanol response (4.0 g/kg ip), handling-induced convulsion (HIC) score 7 hrs after ethanol injection for females [units] |
Drug response |
| X3945 |
11639 |
Ethanol response (4.0 g/kg ip), handling-induced convulsion (HIC) after injection for females (0=no effect, 1=facial grimace during tail spin, 2=tonic convulsion during spin, 3=tonic-clonic convulsion during |
Drug response |
| X1374 |
11697 |
Ethanol response (2.25 g/kg ip), locomotor activity after injection from 0-5 min for females [cm] |
Drug response |
| X368 |
11699 |
Ethanol response (2.25 g/kg ip), locomotor activity after injection from 5-10 min for females [cm] |
Drug response |
| X1102 |
11701 |
Ethanol response (2.25 g/kg ip), locomotor activity after injection from 10-15 min for females [cm] |
Drug response |
| X327 |
11703 |
Ethanol response (2.25 g/kg ip), locomotor activity after injection from 15-20 min for females [cm] |
Drug response |
| X1407 |
11705 |
Ethanol response (2.25 g/kg ip), locomotor activity, difference in distance traveled (saline minus ethanol) from 0-20 min for females [cm] |
Drug response |
| X1655 |
11706 |
Ethanol response (2.25 g/kg ip), locomotor activity after injection from 0-20 min for females [cm] |
Drug response |
| X1813 |
11708 |
Ethanol response (2.25 g/kg ip), locomotor activity, difference in distance traveled (saline minus ethanol) from 0-5 min for females [cm] |
Drug response |
| X285 |
11709 |
Ethanol response (2.25 g/kg ip), locomotor activity, difference in distance traveled (saline minus ethanol) between the first 5 min and last 5 min for females [cm] |
Drug response |
| X2032 |
11717 |
Ethanol response (2.25 g/kg ip), motor coordination effects, difference in time on rotarod between training session and ethanol for females [sec] |
Drug response |
| X1955 |
11718 |
Ethanol response (2.25 g/kg ip), duration on rotarod following injection for females [sec] |
Drug response |
| X2088 |
11719 |
Ethanol response (2.25 g/kg ip), motor coordination effects, tolerance assay, difference in time on rotarod between saline and ethanol for females [sec] |
Drug response |
| X3196 |
11720 |
Saline control response (10 ml/kg ip), motor coordination, rotarod performance following injection for females [sec] |
Drug response |
| X780 |
11726 |
Cocaine response (10 mg/kg ip), locomotion from 0-15 min after first injection in an activity chamber for females [n beam breaks] |
Drug response |
| X729 |
11727 |
Cocaine response (10 mg/kg ip), locomotion from 15-30 min after first injection in an activity chamber for females [n beam breaks] |
Drug response |
| X2499 |
11728 |
Cocaine response (10 mg/kg ip), locomotion from 30-45 min after first injection in an activity chamber for females [n beam breaks] |
Drug response |
| X2378 |
11729 |
Cocaine response (10 mg/kg ip), locomotion from 45-60 min after first injection in an activity chamber for females [n beam breaks] |
Drug response |
| X506 |
11730 |
Cocaine response (10 mg/kg ip), locomotion from 0-15 min after first injection in an activity chamber for females [cm] |
Drug response |
| X986 |
11731 |
Cocaine response (10 mg/kg ip), locomotion from 15-30 min after first injection in an activity chamber for females [cm] |
Drug response |
| X2936 |
11732 |
Cocaine response (10 mg/kg ip), locomotion from 30-45 min after first injection in an activity chamber for females [cm] |
Drug response |
| X2316 |
11733 |
Cocaine response (10 mg/kg ip), locomotion from 45-60 min after first injection in an activity chamber for females [cm] |
Drug response |
| X324 |
11734 |
Cocaine response (10 mg/kg ip), vertical activity (rears) in an open field 0-15 min after injection for females [n beam breaks] |
Drug response |
| X605 |
11735 |
Cocaine response (10 mg/kg ip), vertical activity (rears) in an open field 15-30 min after injection for females [n beam breaks] |
Drug response |
| X613 |
11736 |
Cocaine response (10 mg/kg ip), vertical activity (rears) in an open field 30-45 min after injection for females [n beam breaks] |
Drug response |
| X643 |
11737 |
Cocaine response (10 mg/kg ip), vertical activity (rears) in an open field 45-60 min after injection for females [n beam breaks] |
Drug response |
| X609 |
11738 |
Cocaine response (2 x 10 mg/kg ip), locomotion from 0-15 min after second injection in an activity chamber for females [n beam breaks] |
Drug response |
| X1064 |
11739 |
Cocaine response (2 x 10 mg/kg ip), locomotion from 15-30 min after second injection in an activity chamber for females [n beam breaks] |
Drug response |
| X1704 |
11740 |
Cocaine response (2 x 10 mg/kg ip), locomotion from 30-45 min after second injection in an activity chamber for females [n beam breaks] |
Drug response |
| X3180 |
11741 |
Cocaine response (2 x 10 mg/kg ip), locomotion from 45-60 min after second injection in an activity chamber for females [n beam breaks] |
Drug response |
| X403 |
11742 |
Cocaine response (2 x 10 mg/kg ip), locomotion in an open field from 0-15 min after second injection in an activity chamber for females [cm] |
Drug response |
| X1165 |
11743 |
Cocaine response (2 x 10 mg/kg ip), locomotion in an open field from 15-30 min after second injection in an activity chamber for females [cm] |
Drug response |
| X1925 |
11744 |
Cocaine response (2 x 10 mg/kg ip), locomotion in an open field from 30-45 min after second injection in an activity chamber for females [cm] |
Drug response |
| X3211 |
11745 |
Cocaine response (2 x 10 mg/kg ip), locomotion in an open field from 45-60 min after second injection in an activity chamber for females [cm] |
Drug response |
| X1007 |
11746 |
Cocaine response (2 x 10 mg/kg ip), vertical activity (rears) from 15-30 min after second injection in an activity chamber for females [n beam breaks] |
Drug response |
| X1223 |
11747 |
Cocaine response (2 x 10 mg/kg ip), vertical activity (rears) from 15-30 min after second injection in an activity chamber for females [n beam breaks] |
Drug response |
| X542 |
11748 |
Cocaine response (2 x 10 mg/kg ip), vertical activity (rears) from 30-45 min after second injection in an activity chamber for females [n beam breaks] |
Drug response |
| X2191 |
11749 |
Cocaine response (2 x 10 mg/kg ip), vertical activity (rears) from 45-60 min after second injection in an activity chamber for females [n beam breaks] |
Drug response |
| X4399 |
11750 |
Conditioned place preference (CPP) baseline control for cocaine CPP test, time in drug-paired compartment for females [sec] |
Drug response |
| X483 |
11751 |
Conditioned place preference (CPP) baseline control for cocaine CPP test, time spent in saline-paired unconditioned side before conditioning for females [sec] |
Drug response |
| X4614 |
11752 |
Cocaine response (3 x 3.2 mg/kg ip, Days 2,3, 4), conditioned place preference (CPP), time in drug-paired compartment on Day 5 for females [sec] |
Drug response |
| X3826 |
11753 |
Cocaine response (3 x 3.2 mg/kg ip, Days 2,3, 4), conditioned place preference (CPP), time in unconditioned saline-paired compartment on Day 5 for females [sec] |
Drug response |
| X4490 |
11755 |
Cocaine response (3 x 3.2 mg/kg ip, Days 2,3, and 4), conditioned place preference (CPP), change in time in cocaine-paired compartment relative to baseline (Day 5 minus Day 1) for females [sec] |
Drug response |
| X3126 |
11756 |
Cocaine response (3 x 3.2 mg/kg ip, Days 2,3, and 4), conditioned place preference (CPP), change in percentage time in cocaine-paired compartment relative to baseline (Day 5 minus Day 1) for females [% chan |
Drug response |
| X1142 |
11760 |
Cocaine response (10 mg/kg ip), locomotion from 0-60 min after first cocaine injection in an activity chamber for females [n beam breaks] |
Drug response |
| X942 |
11761 |
Cocaine response (10 mg/kg ip), locomotion in an open field from 0-60 min after first cocaine injection for females [cm] |
Drug response |
| X361 |
11762 |
Cocaine response (10 mg/kg ip), vertical activity (rears) in open field from 0-60 min after first cocaine injection for females [n beam breaks] |
Drug response |
| X1251 |
11791 |
Saline control response (10 ml/kg ip), locomotion in an open field from 0-60 min after injection for females [n beam breaks] |
Drug response |
| X1436 |
11792 |
Saline control response (10 ml/kg ip), locomotion in an open field from 0-60 min after injection for females [cm] |
Drug response |
| X259 |
11793 |
Saline control response (10 ml/kg), open field behavior, vertical activity (rears) 0-60 min after injection for females [n beam breaks/60 min] |
Drug response |
| X4729 |
11794 |
Cocaine response (2 x 10 mg/kg, ip), sensitization, locomotion after the second injection minus locomotion after the first injection for females [difference in cm/1 hr test, positive values indicate sensitiz |
Drug response |
| X1117 |
11795 |
Cocaine response (2 x 10 mg/kg, ip), locomotion from 0-60 min after the second injection in sensitization test for females [n beam breaks, positive values indicate sensitization] |
Drug response |
| X1178 |
11796 |
Cocaine response (2 x 10 mg/kg, ip), locomotion from 0-60 min after the second injection in sensitization test for females [cm, positive values indicate sensitization] |
Drug response |
| X785 |
11797 |
Cocaine response (2 x 10 mg/kg ip), sensitization, change in vertical activity (rears) for females between first and second injections [difference in n/1 hr test, positive values indicate sensitization] |
Drug response |
| X1596 |
11798 |
Saline control response (10 ml/kg ip), locomotion in an open field from 0-15 min after injection for females [n beam breaks/15 min] |
Drug response |
| X571 |
11799 |
Saline control response (10 ml/kg ip), locomotion in an open field from 15-30 min after injection for females [n beam breaks/15 min] |
Drug response |
| X1261 |
11800 |
Saline control response (10 ml/kg ip), locomotion in an open field from 30-45 min after injection for females [n beam breaks/15 min] |
Drug response |
| X1437 |
11801 |
Saline control response (10 ml/kg ip), locomotion in an open field from 45-60 min after injection for females [n beam breaks/15 min] |
Drug response |
| X1085 |
11802 |
Saline control response (10 ml/kg ip), locomotion in an open field from 0-15 min after injection for females [cm] |
Drug response |
| X645 |
11803 |
Saline control response (10 ml/kg ip), locomotion in an open field from 15-30 min after injection for females [cm] |
Drug response |
| X1323 |
11804 |
Saline control response (10 ml/kg ip), locomotion in an open field from 30-45 min after injection for females [cm] |
Drug response |
| X1775 |
11805 |
Saline control response (10 ml/kg ip), locomotion in an open field from 45-60 min after injection for females [cm] |
Drug response |
| X226 |
11806 |
Saline control response (10 mg/kg ip), open field behavior, vertical activity (rears) 0-15 min after injection for females [n beam breaks/15 min] |
Drug response |
| X435 |
11807 |
Saline control response (10 mg/kg ip), open field behavior, vertical activity (rears) 15-30 min after injection for females [n beam breaks/15 min] |
Drug response |
| X386 |
11808 |
Saline control response (10 mg/kg ip), open field behavior, vertical activity (rears) 30-45 min after injection for females [n beam breaks/15 min] |
Drug response |
| X400 |
11809 |
Saline control response (10 mg/kg ip), open field behavior, vertical activity (rears) 45-60 min after injection for females [n beam breaks/15 min] |
Drug response |
| X2759 |
11817 |
Ethanol response (2 g/kg ip), motor coordination, time on dowel over a 5 min test period immediately after injection for males and females [sec] |
Drug response |
| X1163 |
11818 |
Ethanol response (2 g/kg ip), motor coordination, time on dowel over a 5 min test period starting 30 min after injection for males and females [sec] |
Drug response |
| X795 |
11821 |
Pain response, thermal nociception, Hargreaves' test for males and females |
Drug response |
| X2145 |
11822 |
Pain response, thermal nociception, hot plate test, average of two trials for males and females [sec] |
Drug response |
| X833 |
11823 |
Pain response, mechanical nociception, tail clip latency for males and females [sec] |
Drug response |
| X1412 |
11824 |
Pain response, thermal nociception, tail withdrawal latency for males and females [sec] |
Drug response |
| X189 |
11826 |
Morphine response (50 mg/kg ip), locomotion from 90-105 min after injection in an activity chamber for males and females [n beam breaks] |
Drug response |
| X447 |
11827 |
Morphine response (50 mg/kg ip), locomotion from 105-120 min after injection in an activity chamber for males and females [n beam breaks] |
Drug response |
| X2099 |
11828 |
Morphine response (50 mg/kg ip), locomotion from 120-135 min after injection in an activity chamber for males and females [n beam breaks] |
Drug response |
| X1511 |
11829 |
Morphine response (50 mg/kg ip), locomotion from 0-15 min after injection in an activity chamber for males and females [n beam breaks] |
Drug response |
| X505 |
11830 |
Morphine response (50 mg/kg ip), locomotion from 150-165 min after injection in an activity chamber for males and females [n beam breaks] |
Drug response |
| X243 |
11831 |
Morphine response (50 mg/kg ip), locomotion from 165-180 min after injection in an activity chamber for males and females [n beam breaks] |
Drug response |
| X845 |
11832 |
Morphine response (50 mg/kg ip), locomotion from 15-30 min after injection in an activity chamber for males and females [n beam breaks] |
Drug response |
| X169 |
11833 |
Morphine response (50 mg/kg ip), locomotion from 30-45 min after injection in an activity chamber for males and females [n beam breaks] |
Drug response |
| X101 |
11834 |
Morphine response (50 mg/kg ip), locomotion from 45-60 min after injection in an activity chamber for males and females [n beam breaks] |
Drug response |
| X100 |
11835 |
Morphine response (50 mg/kg ip), locomotion from 60-75 min after injection in an activity chamber for males and females [n beam breaks] |
Drug response |
| X134 |
11836 |
Morphine response (50 mg/kg ip), locomotion from 75-90 min after injection in an activity chamber for males and females [n beam breaks] |
Drug response |
| X163 |
11837 |
Morphine response (50 mg/kg ip), locomotion (open field) from 90-105 min after injection in an activity chamber for males and females [cm] |
Drug response |
| X342 |
11838 |
Morphine response (50 mg/kg ip), locomotion (open field) from 105-120 min after injection in an activity chamber for males and females [cm] |
Drug response |
| X1366 |
11839 |
Morphine response (50 mg/kg ip), locomotion (open field) from 120-135 min after injection in an activity chamber for males and females [cm] |
Drug response |
| X1522 |
11840 |
Morphine response (50 mg/kg ip), locomotion (open field) from 0-15 min after injection in an activity chamber for males and females [cm] |
Drug response |
| X410 |
11841 |
Morphine response (50 mg/kg ip), locomotion (open field) from 150-165 min after injections in an activity chamber for males and females [cm] |
Drug response |
| X231 |
11842 |
Morphine response (50 mg/kg ip), locomotion (open field) from 165-180 min after injection in an activity chamber for males and females [cm] |
Drug response |
| X267 |
11843 |
Morphine response (50 mg/kg ip), locomotion (open field) from 15-30 min after injection in an activity chamber for males and females [cm] |
Drug response |
| X108 |
11844 |
Morphine response (50 mg/kg ip), locomotion (open field) from 30-45 min after injection in an activity chamber for males and females [cm] |
Drug response |
| X84 |
11845 |
Morphine response (50 mg/kg ip), locomotion (open field) from 45-60 min after injection in an activity chamber for males and females [cm] |
Drug response |
| X91 |
11846 |
Morphine response (50 mg/kg ip), locomotion (open field) from 60-75 min after injection in an activity chamber for males and females [cm] |
Drug response |
| X112 |
11847 |
Morphine response (50 mg/kg ip), locomotion (open field) from 75-90 min after injection in an activity chamber for males and females [cm] |
Drug response |
| X3998 |
11848 |
Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), severity of abdominal contraction for males and females [ordinal scale, 0=no effect, 3=max] |
Drug response |
| X2412 |
10749 |
HDL cholesterol level following 16-week high-fat diet [mg/dL] |
Hematology |
| X3804 |
11849 |
Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), defecation in an activity chamber for males and females [n fecal boli] |
Drug response |
| X3666 |
11850 |
Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), number of jumps for males and females [n/15 min test] |
Drug response |
| X132 |
11851 |
Morphine response (50 mg/kg ip), locomotion from 0-180 min (total activity over 3 hour test) after injection in an activity chamber for males and females [n beam breaks] |
Drug response |
| X118 |
11852 |
Morphine response (50 mg/kg ip), locomotion from 0-180 min (total activity over 3 hour test) after injection in an activity chamber for males and females [cm] |
Drug response |
| X333 |
11853 |
Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), change in locomotion for males and females (last 15 min of morphine test (165-180 min) minus first 15 min after |
Drug response |
| X987 |
11854 |
Morphine response (50 mg/kg ip), vertical activity (rears) from 0-180 min (total activity over 3 hour test) after injection in an activity chamber for males and females [n beam breaks] |
Drug response |
| X1184 |
11870 |
Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), locomotion from 0-15 min after naloxone injection for males and females [n beam breaks] |
Drug response |
| X916 |
11871 |
Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), horizontal activity (distance traveled) from 0-15 min after naloxone injection for males and females [cm] |
Drug response |
| X3833 |
11872 |
Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), vertical activity (rears) from 0-15 min after naloxone injection for males and females [n beam breaks] |
Drug response |
| X3198 |
11873 |
Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), postural changes for males and females [ordinal scale, 0=no effect, 3=max] |
Drug response |
| X2492 |
11874 |
Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), ptosis for males and females [ordinal scale, 0=no effect, 3=max] |
Drug response |
| X3983 |
11875 |
Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), salivation for males and females [ordinal scale, 0=control level, 3=max] |
Drug response |
| X2937 |
11876 |
Naloxone-induced morphine withdrawal, naloxone (30 mg/kg ip) after morphine (50 mg/kg dose ip), wet dog shakes for males [ordinal scale, 0=no effect, 3=max] |
Drug response |
| X1203 |
11878 |
Morphine response (50 mg/kg ip), vertical activity (rears) from 90-105 min after injection in an activity chamber for males and females [n beam breaks] |
Drug response |
| X2004 |
11879 |
Morphine response (50 mg/kg ip), vertical activity (rears) from 105-120 min after injection in an activity chamber for males and females [n beam breaks] |
Drug response |
| X2718 |
11880 |
Morphine response (50 mg/kg ip), vertical activity (rears) from 120-135 min after injection in an activity chamber for males and females [n beam breaks] |
Drug response |
| X1394 |
11881 |
Morphine response (50 mg/kg ip), vertical activity (rears) from 0-15 min after injection in an activity chamber for males and females [n beam breaks] |
Drug response |
| X1577 |
11882 |
Morphine response (50 mg/kg ip), vertical activity (rears) from 150-165 min after injection in an activity chamber for males and females [n beam breaks] |
Drug response |
| X650 |
11883 |
Morphine response (50 mg/kg ip), vertical activity (rears) from 165-180 min after injection in an activity chamber for males and females [n beam breaks] |
Drug response |
| X825 |
11884 |
Morphine response (50 mg/kg ip), vertical activity (rears) from 15-30 min after injection in an activity chamber for males and females [n beam breaks] |
Drug response |
| X142 |
11885 |
Morphine response (50 mg/kg ip), vertical activity (rears) from 30-45 min after injection in an activity chamber for males and females [n beam breaks] |
Drug response |
| X171 |
11886 |
Morphine response (50 mg/kg ip), vertical activity (rears) from 45-60 min after injection in an activity chamber for males and females [n beam breaks] |
Drug response |
| X382 |
11887 |
Morphine response (50 mg/kg ip), vertical activity (rears) from 60-75 min after injection in an activity chamber for males and females [n beam breaks] |
Drug response |
| X801 |
11888 |
Morphine response (50 mg/kg ip), vertical activity (rears) from 75-90 min after injection in an activity chamber for males and females [n beam breaks] |
Drug response |
| X2371 |
11889 |
3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) response (10 mg/kg subcutaneous), locomotion on day 2 for males and females [cm/90 min test] |
Drug response |
| X4034 |
11892 |
Ethanol response (4.0 g/kg ip), handling-induced convulsion (HIC) 4 hrs after injection for males and females [ordinal scale] |
Drug response |
| X2348 |
11894 |
Ethanol response (4.0 g/kg ip), handling-induced convulsion (HIC) score 7 hrs after ethanol injection for males and females [ordinal scale] |
Drug response |
| X3368 |
11896 |
Ethanol response (4.0 g/kg ip), handling-induced convulsion (HIC) after injection for males and females [ordinal scale] |
Drug response |
| X4221 |
11954 |
Ethanol response (2.25 g/kg ip), locomotor activity after injection from 0-5 min for males and females [cm] |
Drug response |
| X2931 |
11955 |
Saline control response (10 ml/kg ip), locomotor activity after injection from 0-5 min for males and females [cm] |
Drug response |
| X4184 |
11956 |
Ethanol response (2.25 g/kg ip), locomotor activity after injection from 5-10 min for males and females [cm] |
Drug response |
| X1143 |
11957 |
Saline control response (10 ml/kg ip), locomotor activity after injection from 5-10 min after injection for males and females [cm] |
Drug response |
| X1492 |
11958 |
Ethanol response (2.25 g/kg ip), locomotor activity after injection from 10-15 min for males and females [cm] |
Drug response |
| X683 |
11959 |
Saline control response (10 ml/kg ip), locomotor activity after injection from 10-15 min for males and females [cm] |
Drug response |
| X796 |
11960 |
Ethanol response (2.25 g/kg ip), locomotor activity after injection from 15-20 min for males and females [cm] |
Drug response |
| X602 |
11961 |
Saline control response (10 ml/kg ip), locomotion from 15-20 min after injection for males and females [cm] |
Drug response |
| X4154 |
11962 |
Ethanol response (2.25 g/kg ip), locomotor activity, difference in distance traveled (saline minus ethanol) from 0-20 min for males and females [cm] |
Drug response |
| X2150 |
10750 |
HDL cholesterol levels following 16-week chow diet (control group) [mg/dL] |
Hematology |
| X3369 |
11963 |
Ethanol response (2.25 g/kg ip), locomotor activity after injection from 0-20 min for males and females [cm] |
Drug response |
| X851 |
11964 |
Saline control response (10 ml/kg ip), locomotion 0-20 min after injection for males and females [cm] |
Drug response |
| X4961 |
11965 |
Ethanol response (2.25 g/kg ip), locomotor activity, difference in distance traveled (saline minus ethanol) from 0-5 min for males and females [cm] |
Drug response |
| X1692 |
11966 |
Ethanol response (2.25 g/kg ip), locomotor activity, difference in distance traveled (saline minus ethanol) between the first 5 min and last 5 min for males and females [cm] |
Drug response |
| X1859 |
11967 |
Ethanol response (2.25 g/kg ip), blood ethanol concentration (BEC) for males and females [mg/dl XX min after injection] |
Drug response |
| X2169 |
11974 |
Ethanol response (2.25 g/kg ip), motor coordination effects, difference in time on rotarod between training session and ethanol for males females [sec] |
Drug response |
| X1030 |
11975 |
Ethanol response (2.25 g/kg ip), duration on rotarod following injection for males and females [sec] |
Drug response |
| X4910 |
11976 |
Ethanol response (2.25 g/kg ip), time on rotarod after saline minus time on rotarod after ethanol for males and females [sec] |
Drug response |
| X1373 |
11977 |
Saline control response (10 ml/kg ip), motor coordination, rotarod performance following injection for males and females [sec] |
Drug response |
| X2781 |
11978 |
Saline control response (dose ip), motor coordination effects, difference in time on rotarod between training session and saline for males and females [sec] |
Drug response |
| X2152 |
11983 |
Cocaine response (10 mg/kg ip), locomotion from 0-15 min after first injection in an activity chamber for males and females [n beam breaks] |
Drug response |
| X2136 |
11984 |
Cocaine response (10 mg/kg ip), locomotion from 15-30 min after first injection in an activity chamber for males and females [n beam breaks] |
Drug response |
| X2741 |
11985 |
Cocaine response (10 mg/kg ip), locomotion from 30-45 min after first injection in an activity chamber for males and females [n beam breaks] |
Drug response |
| X2529 |
11986 |
Cocaine response (10 mg/kg ip), locomotion from 45-60 min after first injection in an activity chamber for males and females [n beam breaks] |
Drug response |
| X1537 |
11987 |
Cocaine response (10 mg/kg ip), locomotion from 0-15 min after first injection in an activity chamber for males and females [cm] |
Drug response |
| X2009 |
11988 |
Cocaine response (10 mg/kg ip), locomotion from 15-30 min after first injection in an activity chamber for males and females [cm] |
Drug response |
| X3097 |
11989 |
Cocaine response (10 mg/kg ip), locomotion from 30-45 min after first injection in an activity chamber for males and females [cm] |
Drug response |
| X2399 |
11990 |
Cocaine response (10 mg/kg ip), locomotion from 45-60 min after first injection in an activity chamber for males and females [cm] |
Drug response |
| X429 |
11991 |
Cocaine response (10 mg/kg ip), vertical activity (rears) in an open field 0-15 min after injection for males and females [n beam breaks] |
Drug response |
| X719 |
11992 |
Cocaine response (10 mg/kg ip), vertical activity (rears) in an open field 15-30 min after injection for males and females [n beam breaks] |
Drug response |
| X2213 |
10823 |
Transferrin saturation of males and females [%] |
Hematology |
| X912 |
11993 |
Cocaine response (10 mg/kg ip), vertical activity (rears) in an open field 30-45 min after injection for males and females [n beam breaks] |
Drug response |
| X737 |
11994 |
Cocaine response (10 mg/kg ip), vertical activity (rears) in an open field 45-60 min after injection for males and females [n beam breaks] |
Drug response |
| X2368 |
11995 |
Cocaine response (2 x 10 mg/kg ip), locomotion from 0-15 min after second injection in an activity chamber for males and females [n beam breaks] |
Drug response |
| X1722 |
11996 |
Cocaine response (2 x 10 mg/kg ip), locomotion from 15-30 min after second injection in an activity chamber for males and females [n beam breaks] |
Drug response |
| X2081 |
11997 |
Cocaine response (2 x 10 mg/kg ip), locomotion from 30-45 min after second injection in an activity chamber for males and females [n beam breaks] |
Drug response |
| X3651 |
11998 |
Cocaine response (2 x 10 mg/kg ip), locomotion from 45-60 min after second injection in an activity chamber for males and females [n beam breaks] |
Drug response |
| X1658 |
11999 |
Cocaine response (2 x 10 mg/kg ip), locomotion in an open field from 0-15 min after second injection in an activity chamber for males and females [cm] |
Drug response |
| X1628 |
12000 |
Cocaine response (2 x 10 mg/kg ip), locomotion in an open field from 15-30 min after second injection in an activity chamber for males and females [cm] |
Drug response |
| X2345 |
12001 |
Cocaine response (2 x 10 mg/kg ip), locomotion in an open field from 30-45 min after second injection in an activity chamber for males and females [cm] |
Drug response |
| X4172 |
12002 |
Cocaine response (2 x 10 mg/kg ip), locomotion in an open field from 45-60 min after second injection in an activity chamber for males and females [cm] |
Drug response |
| X715 |
12003 |
Cocaine response (2 x 10 mg/kg ip), vertical activity (rears) from 15-30 min after second injection in an activity chamber for males and females [n beam breaks] |
Drug response |
| X930 |
12004 |
Cocaine response (2 x 10 mg/kg ip), vertical activity (rears) from 15-30 min after second injection in an activity chamber for males and females [n beam breaks] |
Drug response |
| X504 |
12005 |
Cocaine response (2 x 10 mg/kg ip), vertical activity (rears) from 30-45 min after second injection in an activity chamber for males and females [n beam breaks] |
Drug response |
| X2033 |
12006 |
Cocaine response (2 x 10 mg/kg ip), vertical activity (rears) from 45-60 min after second injection in an activity chamber for males and females [n beam breaks] |
Drug response |
| X4407 |
12007 |
Conditioned place preference (CPP) baseline control for cocaine CPP test, time in drug-paired compartment for males and females [sec] |
Drug response |
| X3083 |
12008 |
Conditioned place preference (CPP) baseline control for cocaine CPP test, time spent in saline-paired unconditioned side before conditioning for males and females [sec] |
Drug response |
| X4136 |
12009 |
Cocaine response (3 x 3.2 mg/kg ip, days 2,3, 4), conditioned place preference (CPP), time in drug-paired compartment on day 5 for males and females [sec] |
Drug response |
| X2620 |
12010 |
Cocaine response (3 x 3.2 mg/kg ip, days 2,3, 4), conditioned place preference (CPP), time in unconditioned saline-paired compartment on day 5 for males and females [sec] |
Drug response |
| X4928 |
10825 |
Hemoglobin in males [g/dL] |
Hematology |
| X4297 |
12011 |
Conditioned place preference (CPP) baseline control for cocaine CPP test, percentage of time spent in conditioned side before conditioning for males and females [%] |
Drug response |
| X3997 |
12012 |
Cocaine response (3 x 3.2 mg/kg ip, days 2,3, and 4), conditioned place preference (CPP), change in time in cocaine-paired compartment relative to baseline (day 5 minus day 1) for males |
Drug response |
| X4145 |
12013 |
Cocaine response (3 x 3.2 mg/kg ip, days 2,3, and 4), conditioned place preference (CPP), change in percentage time in cocaine-paired compartment relative to baseline (day 5 minus day 1 |
Drug response |
| X2327 |
12017 |
Cocaine response (10 mg/kg ip), locomotion from 0-60 min after first cocaine injection in an activity chamber for males and females [n beam breaks] |
Drug response |
| X2312 |
12018 |
Cocaine response (10 mg/kg ip), locomotion in an open field from 0-60 min after first cocaine injection for males and females [cm] |
Drug response |
| X1255 |
12019 |
Cocaine response (10 mg/kg ip), vertical activity (rears) in the open field from 0-60 min after first cocaine injection for males and females [n beam breaks] |
Drug response |
| X1913 |
12048 |
Saline control response (10 ml/kg ip), locomotion in an open field from 0-60 min after injection for males and females [n beam breaks] |
Drug response |
| X1582 |
12049 |
Saline control response (10 ml/kg ip), locomotion in an open field from 0-60 min after injection for males and females [cm] |
Drug response |
| X512 |
12050 |
Saline control response (10 ml/kg), open field behavior, vertical activity (rears) 0-60 min after injection for males and females [n beam breaks/60 min] |
Drug response |
| X3914 |
12051 |
Cocaine response (2 x 10 mg/kg ip), sensitization, locomotion after the second injection minus locomotion after the first injection for males and females [difference in cm/1 hr test, positive values indicate |
Drug response |
| X1951 |
12052 |
Cocaine response (2 x 10 mg/kg, ip), locomotion from 0-60 min after the second injection in sensitization test for males and females [n beam breaks, positive values indicate sensitization] |
Drug response |
| X1998 |
12053 |
Cocaine response (2 x 10 mg/kg, ip), locomotion from 0-60 min after the second injection in sensitization test for males and females [cm, positive values indicate sensitization] |
Drug response |
| X642 |
12054 |
Cocaine response (2 x 10 mg/kg ip), sensitization, change in vertical activity (rears) for males and females between first and second injections [difference in n/1 hr test, positive values indicate sensitiza |
Drug response |
| X2239 |
12055 |
Saline control response (10 ml/kg ip), locomotion in an open field from 0-15 min after injection for males and females [n beam breaks/15 min] |
Drug response |
| X1185 |
12056 |
Saline control response (10 ml/kg ip), locomotion in an open field from 15-30 min after injection for males and females [n beam breaks/15 min] |
Drug response |
| X2067 |
12057 |
Saline control response (10 ml/kg ip), locomotion in an open field from 30-45 min after injection for males and females [n beam breaks/15 min] |
Drug response |
| X2391 |
12058 |
Saline control response (10 ml/kg ip), locomotion in an open field from 45-60 min after injection for males and females [n beam breaks/15 min] |
Drug response |
| X1843 |
12059 |
Saline control response (10 ml/kg ip), locomotion in an open field from 0-15 min after injection for males and females [cm] |
Drug response |
| X1282 |
12060 |
Saline control response (10 ml/kg ip), locomotion in an open field from 15-30 min after injection for males and females [cm] |
Drug response |
| X1878 |
12061 |
Saline control response (10 ml/kg ip), locomotion in an open field from 30-45 min after injection for males and females [cm] |
Drug response |
| X2375 |
12062 |
Saline control response (10 ml/kg ip), locomotion in an open field from 45-60 min after injection for males and females [cm] |
Drug response |
| X413 |
12063 |
Saline control response (10 mg/kg ip), open field behavior, vertical activity (rears) 0-15 min after injection for males and females [n beam breaks/15 min] |
Drug response |
| X680 |
12064 |
Saline control response (10 mg/kg ip), open field behavior, vertical activity (rears) 15-30 min after injection for males and females [n beam breaks/15 min] |
Drug response |
| X649 |
12065 |
Saline control response (10 mg/kg ip), open field behavior, vertical activity (rears) 30-45 min after injection for males and females [n beam breaks/15 min] |
Drug response |
| X793 |
12066 |
Saline control response (10 mg/kg ip), open field behavior, vertical activity (rears) 45-60 min after injection for males and females [n beam breaks/15 min] |
Drug response |
| X5071 |
12393 |
Ethanol response (1.8 g/kg ip), anxiety assay in ethanol-treated (NOE) group, activity in closed quadrants using an elevated zero maze in 60 to 120-day-old males and females during last 5 min [n beam breaks/ |
Drug response |
| X4883 |
12565 |
Ethanol response (10% in tap water), average daily preference ratio, two-bottle choice in males and females [EtOH/water ratio] |
Drug response |
| X4263 |
12574 |
Ethanol response, consumption of 15% ethanol (v/v) using two-bottle choice system (ethanol vs water), 2-hour access, 6th week average, young adult male or female (Dec 2009 Cohort 1) [log g/kg/2h] |
Drug response |
| X4117 |
12575 |
Ethanol response, consumption of 15% ethanol (v/v) using two-bottle choice system (ethanol vs water), 2-hour access, 5th week average, young adult male or female (Dec 2009 Cohort 1) [log g/kg/2h] |
Drug response |
| X4697 |
12576 |
Ethanol response, consumption of 15% ethanol (v/v) using two-bottle choice system (ethanol vs water), 2-hour access, 4th week average, young adult male or female (Dec 2009 Cohort 1) [log g/kg/2h] |
Drug response |
| X3012 |
12577 |
Ethanol response, consumption of 15% ethanol (v/v) using two-bottle choice system (ethanol vs water), 2-hour access, 3rd week average, young adult male or female (Dec 2009 Cohort 1) [log g/kg/2h] |
Drug response |
| X2364 |
12578 |
Ethanol response, consumption of 15% ethanol (v/v) using two-bottle choice system (ethanol vs water), 2-hour access, 2nd week average, young adult male or female (Dec 2009 Cohort 1) [log g/kg/2h] |
Drug response |
| X4059 |
12579 |
Ethanol response, consumption of 15% ethanol (v/v) using two-bottle choice system (ethanol vs water), 2-hour access, 1st week average, young adult male or female (Dec 2009 Cohort 1) [log g/kg/2h] |
Drug response |
| X3920 |
12580 |
Ethanol response, consumption of 15% ethanol using a two-bottle choice systems (ethanol vs water), 2 h access, principal component 1 eigentrait (similar to residuals) based on weeks 1 through 6 data (Dec 200 |
Drug response |
| X2627 |
12586 |
Ethanol response (10% in tap water), average daily consumption, two-bottle choice, males and females [g/kg] |
Drug response |
| X4346 |
12623 |
Ethanol response (10% EtOH in tap water) average daily consumption, two bottle choice [g/kg], males |
Drug response |
| X2807 |
12624 |
Ethanol response (10% EtOH in tap water), average daily consumption using two-bottle choice method in females [g/kg] |
Drug response |
| X4043 |
12733 |
Ethanol response (10% v/v ethanol), average daily consumption at 2 hr, males and females combined [g/kg] |
Drug response |
| X2711 |
12741 |
Ethanol response (chronic intermittent ethanol CIE cycles), consumption of 15% ethanol (v/v) using two-bottle choice system (ethanol vs water) and 2-hour access from day 3 to day 8 after the 4th cycle of eth |
Drug response |
| X775 |
12742 |
Ethanol response (chronic intermittent ethanol CIE cycles), consumption of 15% ethanol (v/v) using two-bottle choice system (ethanol vs water) and 2-hour access from day 3 to day 8 after the 3rd cycle of eth |
Drug response |
| X2229 |
12743 |
Ethanol response (chronic intermittent ethanol CIE cycles), consumption of 15% ethanol (v/v) using two-bottle choice system (ethanol vs water) and 2-hour access from day 3 to day 8 after the 2nd cycle of eth |
Drug response |
| X4091 |
12744 |
Ethanol response (chronic intermittent ethanol CIE cycles), consumption of 15% ethanol (v/v) using two-bottle choice system (ethanol vs water) and 2-hour access from day 3 to day 8 after the 1st cycle of eth |
Drug response |
| X4703 |
12745 |
Ethanol response (chronic intermittent ethanol CIE cycles), baseline consumption of 15% ethanol (v/v) using two-bottle choice system (ethanol vs water) and 2-hour access from day 3 to day 8 before any ethano |
Drug response |
| X2903 |
12780 |
Ethanol response (chronic intermittent ethanol CIE cycles),3,4-dihydroxyphenylacetic acid (DOPAC) level in the striatum (caudate putamen) 72 h after the 5th cycle of ethanol vapor chamber treatment, 16 to 18 week-old |
Drug response |
| X4898 |
12781 |
Ethanol response (chronic intermittent ethanol CIE cycles), norepinephrine (NE) level in the striatum (caudate putamen) 72 h after the 5th cycle of ethanol vapor chamber treatment, 16 to 18 week-old males or females ( |
Drug response |
| X4617 |
12782 |
Ethanol response (chronic intermittent ethanol CIE cycles), dopamine (DA) level in the striatum (caudate putamen) 72 h after the 5th cycle of ethanol vapor chamber treatment, 16 to 18 week-old males or females (Dec 20 |
Drug response |
| X4174 |
12783 |
Ethanol response (chronic intermittent ethanol CIE cycles), 5-hydroxyindoleacetic acid (5-HIAA) level in the striatum (caudate putamen) 72 h after the 5th cycle of ethanol vapor chamber treatment, 16 to 18 week-old ma |
Drug response |
| X3606 |
12784 |
Ethanol response (chronic intermittent ethanol CIE cycles), homovanillic acid (HVA) level in the striatum (caudate putamen) 72 h after the 5th cycle of ethanol vapor chamber treatment, 16 to 18 week-old males or femal |
Drug response |
| X3774 |
12785 |
Ethanol response (chronic intermittent ethanol CIE cycles), 5-hydroxytryptamine (5-HT, serotonin) level in the striatum (caudate putamen) 72 h after the 5th cycle of ethanol vapor chamber treatment, 16 to 18 week-old |
Drug response |
| X4510 |
12786 |
Control for ethanol response, norepinephrine (NE) level in striatum (caudate putamen) tissue 72 h after the 5th air control cycle of vapor chamber treatment, 16 to 18 week-old males or females (Dec 2009 Cohort 1) [ng/ |
Drug response |
| X5050 |
12787 |
Control for ethanol response,3,4-dihydroxyphenylacetic acid (DOPAC) level in striatum (caudate putamen) tissue 72 h after the 5th air control cycle of vapor chamber treatment, 16 to 18 week-old males or females (Dec |
Drug response |
| X3026 |
10826 |
Hemoglobin in males and females [g/dL] |
Hematology |
| X4948 |
12788 |
Control for ethanol response, 5-hydroxyindoleacetic acid (5-HIAA) level in striatum (caudate putamen) tissue 72 h after the 5th air control cycle of vapor chamber treatment, 16 to 18 week-old males or females (Dec 200 |
Drug response |
| X3207 |
12789 |
Control for ethanol response, homovanilic acid (HVA) level in striatum (caudate putamen) tissue 72 h after the 5th air control cycle of vapor chamber treatment, 16 to 18 week-old males or females (Dec 2009 Cohort 1) [ |
Drug response |
| X4527 |
12790 |
Control for ethanol response, 5-hydroxytryptamine (5-HT, serotonin) level in striatum (caudate putamen) tissue 72 h after the 5th air control cycle of vapor chamber treatment, 16 to 18 week-old males or females (Dec 2 |
Drug response |
| X4534 |
12791 |
Ethanol response (chronic intermittent ethanol CIE cycles), norepinephrine levels (NE) in the medial septal nucleus 72 h after the 5th cycle of ethanol vapor chamber treatment, 16 to 18 week-old males or females (Dec |
Drug response |
| X2897 |
12792 |
Ethanol response (chronic intermittent ethanol CIE cycles),3,4-dihydroxyphenylacetic acid levels (DOPAC) in the medial septal nucleus 72 h after the 5th cycle of ethanol vapor chamber treatment, 16 to 18 week-old mal |
Drug response |
| X3725 |
12793 |
Ethanol response (chronic intermittent ethanol CIE cycles), dopamine (DA) level in the medial septal nucleus 72 h after the 5th cycle of ethanol vapor chamber treatment, 16 to 18 week-old males or females (Dec 2009 Co |
Drug response |
| X2211 |
12794 |
Ethanol response (chronic intermittent ethanol CIE cycles), 5-hydroxyindoleacetic acid levels (5-HIAA) in the medial septal nucleus 72 h after the 5th cycle of ethanol vapor chamber treatment, 16 to 18 week-old males |
Drug response |
| X1340 |
12795 |
Ethanol response (chronic intermittent ethanol CIE cycles), homovanillic acid (HVA) in the medial septal nucleus 72 h after the 5th cycle of ethanol vapor chamber treatment, 16 to 18 week-old males or females (Dec 200 |
Drug response |
| X3713 |
12796 |
Ethanol response (chronic intermittent ethanol CIE cycles), 5-hydroxytryptamine (5-HT, serotonin) in the medial septal nucleus 72 h after the 5th cycle of ethanol vapor chamber treatment, 16 to 18 week-old males or f |
Drug response |
| X4292 |
12797 |
Control for ethanol response, norepinephrine (NE) level in the medial septal nucleus 72 h after the 5th cycle of ethanol vapor chamber treatment, 16 to 18 week-old males or females (Dec 2009 Cohort 1) [ng/mg] |
Drug response |
| X2264 |
12798 |
Ethanol response,3,4-dihydroxyphenylacetic acid levels (DOPAC, a dopamine metabolite) in the medial septal nucleus 72 h after the 5th cycle of chronic intermittent ethanol (CIE) vapor chamber treatment, 15 to 17 week |
Drug response |
| X2204 |
12799 |
Control for ethanol response, dopamine (DA) level in the medial septal nucleus 72 h after the 5th cycle of ethanol vapor chamber treatment, 16 to 18 week-old males or females (Dec 2009 Cohort 1) [ng/mg] |
Drug response |
| X4450 |
12800 |
Control for ethanol response, 5-hydroxyindoleacetic acid levels (5-HIAA, a serotonin metabolite) in the medial septal nucleus 72h after the 5th air control cycle of vapor chamber treatment, 16 to 18 weeks males or fem |
Drug response |
| X2727 |
12801 |
Control for ethanol response, homovanillic acid (HVA) level in the medial septal nucleus 72 h after the 5th air control cycle of vapor chamber treatment, 16 to 18 week-old males or females (Dec 2009 Cohort 1) [ng/mg] |
Drug response |
| X2705 |
10751 |
LDL cholesterol levels following 16-week chow diet (control group) [mg/dL] |
Hematology |
| X3967 |
12802 |
Control for ethanol response, 5-hydroxytryptamine (5-HT, serotonin) level in the medial septal nucleus 72 h after the 5th air control cycle of vapor chamber treatment, 16 to 18 week-old males or females (Dec 2009 Coho |
Drug response |
| X3399 |
12803 |
Ethanol response (chronic intermittent vapor exposure CIE), norepinephrine (NE) level in hindbrain tissue 72 h after the 5th cycle of treatment, 16 to 18 week-old males or females (Dec 2009 Cohort 1) [ng/mg] |
Drug response |
| X2845 |
12804 |
Control for ethanol response,3,4-dihydroxyphenylacetic acid (DOPAC) level in hindbrain tissue 72 h after the 5th air control cycle of vapor chamber treatment, 16 to 18 week-old males or females (Dec 2009 Cohort 1) [n |
Drug response |
| X3324 |
12805 |
Ethanol response (5 cycles of chronic intermittent vapor exposure CIE), dopamine level in hindbrain tissue 72h after the 5th cycle of treatment, 16 to 18 week-old males or females (Dec 2009 Cohort 1) [ng/mg] |
Drug response |
| X2382 |
12806 |
Ethanol response, 5-hydroxyindoleacetic acid levels (5-HIAA, a serotonin metabolite) in hindbrain tissue 72h after the 5th cycle of chronic intermittent ethanol (CIE) vapor chamber treatment, 16 to 18 weeks males or f |
Drug response |
| X1432 |
12807 |
Ethanol response (5 cycles of chronic intermittent vapor exposure CIE), homovanillic (HVA) level in hindbrain tissue 72 h after the 5th cycle of treatment, 16 to 18 week-old males or females (Dec 2009 Cohort 1) [ng/mg |
Drug response |
| X805 |
12808 |
Ethanol response, 5-hydroxytrptamine levels (5-HT, serotonin) in hindbrain tissue 72h after the 5th cycle of chronic intermittent ethanol (CIE) vapor chamber treatment, 16 to 18 weeks males or females (Dec 2009 Cohort |
Drug response |
| X3990 |
12809 |
Control for ethanol response, norepinephrine (NE) level in hindbrain tissue 72 h after the 5th air control cycle of vapor chamber treatment, 16 to 18 week-old males or females (Dec 2009 Cohort 1) [ng/mg] |
Drug response |
| X4854 |
12810 |
Control for ethanol response,3,4-dihydroxyphenylacetic acid levels (DOPAC) in hindbrain tissue 72 h after the 5th air control cycle of vapor chamber treatment, 16 to 18 week-old males or females (Dec 2009 Cohort 1) [ |
Drug response |
| X1872 |
12811 |
Control for ethanol response, dopamine levels (DA) in hindbrain tissue 72 h after the 5th air control cycle of vapor chamber treatment, 16 to 18 week-old males or females (Dec 2009 Cohort 1) [ng/mg] |
Drug response |
| X3294 |
12812 |
Control for ethanol response, 5-hydroxyindoleacetic acid levels (5-HIAA, a serotonin metabolite) in hindbrain tissue 72h after the 5th air control cycle of vapor chamber treatment, 16 to 18 weeks males or females (Dec |
Drug response |
| X2105 |
12813 |
Control for ethanol response, homovanillic acid (HVA, a dopamine metabolite) level in hindbrain tissue 72 h after the 5th air control cycle of vapor chamber treatment, 16 to 18 week-old males or females (Dec 2009 Coho |
Drug response |
| X3230 |
12814 |
Control for ethanol response, 5-hydroxytryptamine levels (5-HT, serotonin) in hindbrain tissue 72h after the 5th air control cycle of vapor chamber treatment, 16 to 18 weeks males or females (Dec 2009 Cohort 1) [ng/mg |
Drug response |
| X4114 |
12815 |
Control for ethanol response, dopamine (DA) level in hindbrain tissue 72 h after the 5th air control cycle of vapor chamber treatment, 16 to 18 week-old males or females (Dec 2009 Cohort 1) [ng/mg] |
Drug response |
| X4701 |
10752 |
Cholesterol levels following 16-week high-fat diet [natural log of cholesterol levels] |
Hematology |
| X4452 |
12940 |
Mean corpuscular hemoglobin of 14-week old males [pg] |
Hematology |
| X3161 |
12816 |
Ethanol response (chronic intermittent ethanol CIE cycles), consumption of 15% ethanol (v/v) using two-bottle choice system (ethanol vs water) and 2-hour access, 3 days after 1st cycle of ethanol vapor chamber treatme |
Drug response |
| X229 |
12817 |
Ethanol response, ethanol consumption using a 2-bottle choice with 2 h access/day from day 3 to day 8 after the fourth cycle of treatment in a chronic intermittent ethanol vapor chamber (CIE) [g/kg/2h/day] |
Drug response |
| X1919 |
12961 |
Ethanol response, ethanol intake using a 2-bottle choice test, 2h access after cycle 4 of air exposure only (control for CIE) in vapor chambers (average of 5 days ethanol intake [g/kg/2h] |
Drug response |
| X661 |
12963 |
Ethanol response, ethanol intake using a 2-bottle choice test, 2 h access after the second cycle of air exposure (control for CIE) in vapor chamber (average of 5 days ethanol intake, young adult males or females [g/kg |
Drug response |
| X1000 |
12964 |
Ethanol response, ethanol intake using a 2-bottle choice test, 2 hr access after cycle 1 of air exposure only (control for CIE) in vapor chambers (average of 5 days ethanol intake, 16 to 18 weeks males or females [g/ |
Drug response |
| X4247 |
12965 |
Ethanol response (ethanol vapor inhalation chronic intermittent ethanol (CIE) inhalation chamber), two-bottle choice consumption, 2 hr access after first cycle of exposure, intake over 5 days [g/kg/2h] |
Drug response |
| X1759 |
12967 |
Ethanol response (ethanol vapor inhalation chronic intermittent ethanol (CIE) inhalation chamber), two-bottle choice consumption, 2 hr access after third cycle of exposure, intake over 5 days [g/kg/2h] |
Drug response |
| X3110 |
13018 |
Ethanol response (3 day exposure to 8-11 g/kg ethanol in vapor chamber with pyrazole 1 mM/kg/day),handling-induced convulsion (HIC) withdrawal severity score (15x 1 hour measurements) in 24-28 week-old males |
Drug response |
| X1309 |
13565 |
Ethanol response (20% v/v), consumption using drinking in the dark (DID) method (4 hr access on day 4 of DID) in females, baseline in normally housed group, control for chronic mild stress (CMS) group (Phas |
Drug response |
| X1959 |
13566 |
Ethanol response (20% v/v), consumption using drinking in the dark (DID) method (4 hr access on day 4 of DID) in females, baseline in chronic mild (CMS) stress group 1 week before start of 7 weeks of CMS (Ph |
Drug response |
| X2774 |
13567 |
Ethanol response (20% v/v), consumption using drinking in the dark (DID) method (4 hr access on day 4 of DID, first DID), difference between chronic mild stress (CMS) and control groups one week before the s |
Drug response |
| X623 |
13568 |
Ethanol response (20% v/v), consumption using drinking in the dark (DID) method (4 hr access on day 4 of DID, second DID phase) in females, control group for chronic mild stress (CMS) group (Phase 2) [g/kg] |
Drug response |
| X3062 |
13569 |
Ethanol response (20% v/v), consumption using drinking in the dark (DID) method (4 hr access on day 4 of DID, second DID) in females, chronic mild stress (CMS) group (Phase 2) [g/kg] |
Drug response |
| X1015 |
13570 |
Ethanol response (20% v/v), consumption using drinking in the dark (DID) method (4 hr access on day 4 of DID, second DID) in females, difference between chronic mild stress (CMS) group and control group (Pha |
Drug response |
| X5015 |
13571 |
Ethanol response (20% v/v), consumption using drinking in the dark (DID) method (4 hr access on day 4 of DID, third DID)in females, in the control group for the chronic mild stress (CMS) group (Phase 3) [g/k |
Drug response |
| X2785 |
13572 |
Ethanol response (20% v/v), consumption using drinking in the dark (DID) method (4 hr access on day 4 of DID, third DID) in females, chronic mild stress (CMS) group following CMS (Phase 3) [g/kg] |
Drug response |
| X4300 |
13573 |
Ethanol response (20% v/v), consumption using drinking in the dark (DID) method (4 hr access on day 4 of DID, third DID) in females, difference between chronic mild stress (CMS) group and control group follo |
Drug response |
| X2509 |
13574 |
Ethanol response (20% v/v), consumption using drinking in the dark (DID) method (4 hr access on day 4 of DID) in females, within-group change (phase 3 minus phase 2) in the control group [g/kg] |
Drug response |
| X2494 |
13575 |
Ethanol response (20% v/v), consumption using drinking in the dark (DID) method (4 hr access on day 4 of DID) in females, within-group change (phase 3 minus phase 2) in the chronic mild stress (CMS) group [g |
Drug response |
| X701 |
13576 |
Ethanol response (20% v/v), consumption using drinking in the dark (DID) method (4 hr access on day 4 of DID) in females, within-group change (phase 2 minus phase 1) in the control group for chronic mild str |
Drug response |
| X4637 |
13577 |
Ethanol response (20% v/v), consumption using drinking in the dark (DID) method (4 hr access on day 4 of DID) in females, within-group change (phase 2 minus phase 1) for the chronic mild stress (CMS) group [ |
Drug response |
| X1048 |
13578 |
Ethanol response (20% v/v), consumption using drinking in the dark (DID) method (4 hr access on day 4 of DID) in females, within-group change (phase 3 minus phase 1) for the control group for chronic mild st |
Drug response |
| X3652 |
13579 |
Ethanol response (20% v/v), consumption using drinking in the dark (DID) method (4 hr access on day 4 of DID) in females, within-group change (phase 3 minus phase 1) for the chronic mild stress (CMS) group [ |
Drug response |
| X4536 |
14803 |
Nicotine response (0.5mg/kg, s.c., b.i.d., on days 2-4), conditioned place preference (CPP) on day 5 in 7-8-week old males (upper panel, Fig 1, dark bars) [sec] |
Drug response |
| X2975 |
14804 |
Saline control response (0.9%, s.c., b.i.d., on days 2-4) for nicotine experiment, conditioned place preference (CPP) on day 5 in 7-8-week old males (upper panel, Fig 1, light bars) [sec] |
Drug response |
| X2868 |
14805 |
Nicotine response (0.5mg/kg, sc, twice a day on days 2-4), post-conditioning scores on day 5 in 7-8-week old males (supplementary data) [sec] |
Drug response |
| X4211 |
14806 |
Saline control response (0.9%, s.c., b.i.d., on days 2-4) for nicotine experiment, post-conditioning score on day 5 of CPP in 7-8-week old males (supplementary data) [score] |
Drug response |
| X418 |
15572 |
Withdrawal anxiety assay, 7-day nicotine-treated (24 mg/kg/day, s.c. minipump) + day 8 mecamylamine (2.0 mg/kg, s.c.), number of somatic signs observed in 8- to 12-week-old males during 20 min session [n] |
Drug response |
| X4150 |
15573 |
withdrawal anxiety assay (Nic_Sal_Som), 7-day nicotine-treated (24mg/kg/day, s.c. minipump) + day 8 saline (0.01mL/g, s.c.), number of somatic signs observedin 8-12 week old males during 20 minute session [ |
Drug response |
| X1076 |
15574 |
Withdrawal anxiety assay, 7-day nicotine-treated (24 mg/kg/day, s.c. minipump) + day 8 mecamylamine (2 mg/kg, s.c.), percent time spent in open arms of the elevated plus maze in 8-12 week old males during 5 |
Drug response |
| X4607 |
10753 |
LDL cholesterol levels following 16-week high-fat diet [natural log of cholesterol levels] |
Hematology |
| X1653 |
15575 |
Nicotine response (nicotine at 24 mg/kg/day for 7 days, s.c. by minipump followed by s.c. saline injection on day 8), withdrawal anxiety, percentage of time spent in open arms of an elevated plus maze in 8-1 |
Drug response |
| X662 |
16180 |
Alcohol response (4 mg/kg in saline, IP), blood alcohol concentration (BAC) 1 hr after injection of young adult males and females (strain average associated with GenEx EtOH cerebellum gene expression) [mg/dl] |
Drug response |
| X707 |
16184 |
Alcohol response (4 mg/kg in saline, IP), blood alcohol concentration (BAC) maximum after injection of young adult males and females (strain average associated with GenEx EtOH cerebellum gene expression) [mg/dl] |
Drug response |
| X4500 |
16197 |
Difference in nicotine response (0.5mg/kg, s.c., b.i.d., on days 2-4) and saline response (0.9%, s.c., b.i.d., on days 2-4), conditioned place preference (CPP) on day 5 in 7-8-week old males (lower panel, Fi |
Drug response |
| X625 |
16375 |
Ethanol response, blood ethanol concentration (BEC) during 4th cycle of ethanol exposure in vapor chamber (not associated with voluntary consumption) for male or female (Dec 2009 Cohort 1) [mg%] |
Drug response |
| X2907 |
17329 |
Saline control response (0.9%, s.c., b.i.d., on days 1) for nicotine experiment, basal movement on day 1 in CPP box in 7-8-week old males |
Drug response |
| X1934 |
17330 |
Saline control response (0.9%, s.c., b.i.d., on days 2-4) for nicotine experiment, locomotor activity on day 5 in CPP box in 7-8-week old males |
Drug response |
| X4882 |
17331 |
Saline control response (0.9%, s.c., b.i.d., on days 2-4) for nicotine experiment, change in movement (post - basal movement) on day 5 of CPP in 7-8-week old males |
Drug response |
| X4038 |
17332 |
Nicotine response (0.5 mg/kg, s.c., b.i.d., on day 1), locomotor activity prior to conditioning (pre-drug paired side) in CPP box in 7-8-week old males |
Drug response |
| X1823 |
17333 |
Nicotine response (0.5 mg/kg, s.c., b.i.d., on days 2-4), locomotor activity on test day (day 5) in CPP boxes in 7-8-week old males |
Drug response |
| X3668 |
17334 |
Nicotine response (0.5 mg/kg, s.c., b.i.d., on days 2-4), change in movement (pre - post-drug paired side) on day 5 of CPP in 7-8-week old males |
Drug response |
| X3744 |
17335 |
Withdrawal nociception assay, 7-day nicotine treatment (24 mg/kg/day, s.c. minipump) + day 8 mecamylamine (2.0 mg/kg, s.c.), hot plate latency (sec) |
Drug response |
| X3445 |
17336 |
Withdrawal hyperlocomotion assay, 7-day nicotine treatment (24 mg/kg/day, s.c. minipump) + day 8 mecamylamine (2.0 mg/kg, s.c.), hot plate activity (sec) |
Drug response |
| X2917 |
17337 |
Withdrawal nociception assay, 7-day nicotine treatment (24 mg/kg/day, s.c. minipump) + day 8 saline (0.01mL/g, s.c.), hot plate latency (sec) |
Drug response |
| X3403 |
17338 |
Withdrawal hyperlocomotion assay, 7-day nicotine treatment (24 mg/kg/day, s.c. minipump) + day 8 saline (0.01mL/g, s.c.), hot plate activity (sec) |
Drug response |
| X928 |
18103 |
Ethanol response (20% v/v) using the drinking in the dark (DID) method (4 hr access on day 4 of DID) to measure average baseline drinking under 5 weeks of normal housing [g/kg] |
Drug response |
| X1235 |
18104 |
Ethanol response (20% v/v), using the drinking in the dark (DID) method (4 hr access on day 4 of DID) in females to measure average consumption over 7 weeks (control for chronic mild stress (CMS) group) [g/k |
Drug response |
| X1500 |
18105 |
Ethanol response (20% v/v), using the drinking in the dark (DID) method (4 hr access on day 4 of DID) in females to measure average consumption over 4 weeks (control for chronic mild stress (CMS) group) [g/k |
Drug response |
| X3986 |
18106 |
Ethanol response (20% v/v), consumption using drinking in the dark (DID) method (4 hr access on day 4 of DID) in females, difference between average baseline alcohol consumption for normally housed mice over |
Drug response |
| X2752 |
18107 |
Ethanol response (20% v/v), consumption using drinking in the dark (DID) method (4 hr access on day 4 of DID) in females, difference between average alcohol consumption during last 4 weeks and 7 weeks follow |
Drug response |
| X4151 |
18108 |
Ethanol response (20% v/v), consumption using drinking in the dark (DID) method (4 hr access on day 4 of DID) in females, difference between average alcohol consumption during first 5 weeks and last 4 weeks |
Drug response |
| X464 |
18114 |
Ethanol response (20% v/v) using the drinking in the dark (DID) method (4 hr access on day 4 of DID) to measure average baseline drinking under 5 weeks of normal housing [g/kg] |
Drug response |
| X2232 |
18115 |
Ethanol response (20% v/v), using the drinking in the dark (DID) method (4 hr access on day 4 of DID) in females to measure average consumption over 7 weeks of chronic mild stress (CMS) [g/kg] |
Drug response |
| X2084 |
18116 |
Ethanol response (20% v/v), using the drinking in the dark (DID) method (4 hr access on day 4 of DID) in females to measure average consumption over 4 weeks following 7 weeks of chronic mild stress (CMS) [g/ |
Drug response |
| X2403 |
18117 |
Ethanol response (20% v/v), consumption using drinking in the dark (DID) method (4 hr access on day 4 of DID) in females, difference between average baseline alcohol consumption for normally housed mice over |
Drug response |
| X2528 |
18118 |
Ethanol response (20% v/v), consumption using drinking in the dark (DID) method (4 hr access on day 4 of DID) in females, difference between average alcohol consumption for normally housed mice 4 weeks after |
Drug response |
| X869 |
18119 |
Ethanol response (20% v/v), consumption using drinking in the dark (DID) method (4 hr access on day 4 of DID) in females, difference between average baseline alcohol consumption for normally housed mice over |
Drug response |
| X81 |
10429 |
Serum amyloid P component level (APCS protein, endogenous SAP maps to Chr 1 at 174,8 Mb) [ug/ml] |
Hematology |
| X4139 |
10440 |
Red blood cell osmotic fragility, following treatment with 0.425% NaCl [% lysis] |
Hematology |
| X3707 |
10511 |
Blood glucose levels before 4 g/kg ip ethanol injection in females [mg/dl] |
Hematology |
| X4915 |
10512 |
Blood glucose levels before 4 g/kg ip ethanol injection in males [mg/dl] |
Hematology |
| X1551 |
10513 |
Ethanol response (4 g/kg ip), blood glucose levels 120 min after injection in females [mg/dl] |
Hematology |
| X4457 |
10514 |
Ethanol response (4 g/kg ip), blood glucose levels 120 min after injection in males [mg/dl] |
Hematology |
| X4632 |
10515 |
Blood glucose levels before saline ip control injection in females [mg/dl] |
Hematology |
| X4667 |
10516 |
Blood glucose levels before saline ip control injection in males [mg/dl] |
Hematology |
| X3348 |
10517 |
Blood glucose levels 120 min after saline control injection in females [mg/dl] |
Hematology |
| X4761 |
10518 |
Blood glucose levels 120 min after saline control injection in males [mg/dl] |
Hematology |
| X4451 |
10827 |
Iron binding capacity (systemic, total iron-binding capacity, TIBC, transferrin level) of males [ug/dL] |
Hematology |
| X3202 |
10828 |
Iron level in plasma of females [g/dL] |
Hematology |
| X1910 |
10829 |
Iron level in plasma of males and females [ug/dL] |
Hematology |
| X3601 |
10830 |
Transferrin saturation of females [%] |
Hematology |
| X4357 |
10831 |
Iron binding capacity (total iron-binding capacity, TIBC, transferrin level) of females [ug/dL] |
Hematology |
| X1790 |
10832 |
Hemoglobin in females [g/dL] |
Hematology |
| X4776 |
10833 |
Hematocrit (packed cell volume, erythrocyte volume fraction) in males [%] |
Hematology |
| X3750 |
10834 |
Hematocrit (packed cell volume, erythrocyte volume fraction) in females [%] |
Hematology |
| X3105 |
12073 |
Metabolism, Albumin-to-creatinine ratio (ABR) baseline control in males at 10-12 weeks of age [ratio of ug/mg] |
Hematology |
| X2530 |
12491 |
Hemoglobin of 120-day-old females fed 3 ppm iron (Fe) diet [ug/dl] |
Hematology |
| X2092 |
12492 |
Hematocrit of 120-day-old females fed 3 parts per million iron (ppm Fe) diet [% packed red blood cells] |
Hematology |
| X4540 |
12499 |
Hemoglobin of 120-day-old males fed 3 ppm Fe diet [ug/dl] |
Hematology |
| X4186 |
12500 |
Hematocrit of 120-day-old males fed 3 parts per million iron (ppm Fe) diet [% packed red blood cells] |
Hematology |
| X1319 |
12507 |
Hemoglobin of 120-day-old females fed 270 ppm Fe diet [ug/dl] |
Hematology |
| X3620 |
12508 |
Hematocrit of 120-day-old females fed 270 parts per million iron (ppm Fe) diet [% packed red blood cells] |
Hematology |
| X78 |
12515 |
Hemoglobin of 120-day-old males fed 270 ppm Fe diet [ug/dl] |
Hematology |
| X352 |
12516 |
Hematocrit of 120-day-old males fed 270 parts per million iron (ppm Fe) diet [% packed red blood cells] |
Hematology |
| X4166 |
12523 |
Transferrin saturation in plasma of 120-day-old males and females fed 3 ppm Fe diet [%] |
Hematology |
| X4175 |
12524 |
Iron binding capacity (total) in plasma of 120-day-old males and females fed 3 ppm Fe diet [ug/dl] |
Hematology |
| X1571 |
12525 |
Iron level of plasma of 120-day-old males and females fed 3 ppm Fe diet [ug/dl] |
Hematology |
| X1204 |
12526 |
Hemoglobin of 120-day-old males and females fed 3 ppm Fe diet [ug/dl] |
Hematology |
| X2024 |
12527 |
Hematocrit of 120-day-old males and females fed 3 ppm iron (Fe) diet [% packed red blood cells] |
Hematology |
| X2579 |
12534 |
Transferrin saturation in plasma of 120-day-old males and females fed 270 ppm Fe diet [%] |
Hematology |
| X4939 |
12535 |
Iron binding capacity (total) in plasma of 120-day-old males and females fed 270 ppm Fe diet [ug/dl] |
Hematology |
| X4696 |
12536 |
Iron level of plasma of 120-day-old males and females fed 270 ppm Fe diet [ug/dl] |
Hematology |
| X97 |
12537 |
Hemoglobin of 120-day-old males and females fed 270 ppm Fe diet [ug/dl] |
Hematology |
| X654 |
12538 |
Hematocrit of 120-day-old males and females fed 270 parts per million iron (ppm Fe) diet [% packed red blood cells] |
Hematology |
| X2295 |
12540 |
Transferrin saturation of 120-day-old females fed 3 ppm iron diet [%] |
Hematology |
| X4547 |
12541 |
Iron binding capacity in plasma of 120-day-old females fed 3 ppm iron diet [ug/dL] |
Hematology |
| X4901 |
12547 |
Iron binding capacity in plasma of 120-day-old females fed 270 ppm iron diet [ug/dL] |
Hematology |
| X4585 |
12548 |
Plasma iron of 120-day-old females fed 270 ppm iron diet [ug/dL] |
Hematology |
| X2622 |
12549 |
Transferrin saturation of 120-day-old males fed 270 ppm iron diet [%] |
Hematology |
| X3853 |
12550 |
Iron binding capacity in plasma of 120-day-old males fed 270 ppm iron diet [ug/dL] |
Hematology |
| X5035 |
12551 |
Plasma iron of 120-day-old males fed 270 ppm iron diet [ug/dL] |
Hematology |
| X2324 |
12821 |
Alpha-amylase of 14-week old females [U/l] |
Hematology |
| X853 |
12822 |
Alanine transaminase (ALT, ALAT, SGPT) level in serum of 14-week old females [U/L] |
Hematology |
| X979 |
12823 |
Albumin of 14-week old females [g/l] |
Hematology |
| X154 |
12824 |
Alkaline phosphatase of 14-week old females, (ALPL gene product) [U/l] |
Hematology |
| X3357 |
12825 |
Aspartate transaminase of 14-week old females [U/l] |
Hematology |
| X3551 |
12844 |
Calcium of 14-week old females [mM] |
Hematology |
| X4922 |
12845 |
Chloride of 14-week old females [mM] |
Hematology |
| X1272 |
12846 |
Creatinine of 14-week old females [uM] |
Hematology |
| X489 |
12855 |
Glucose after 4 hour fast of 14-week old females [mMl] |
Hematology |
| X3994 |
12861 |
Hematocrit of 14-week old females [%] |
Hematology |
| X3919 |
12862 |
Hemoglobin of 14-week old females [g/dl] |
Hematology |
| X3123 |
12864 |
Potassium of 14-week old females [mM] |
Hematology |
| X3746 |
12870 |
Mean corpuscular hemoglobin of 14-week old females [pg] |
Hematology |
| X628 |
12871 |
Mean cell hemoglobin concentration of 14-week old females [g/dl] |
Hematology |
| X198 |
12872 |
Mean red blood cell volume (MCV of standard complete blood count) of 14-week old females [fL] |
Hematology |
| X1936 |
12873 |
Sodium of 14-week old females [mM] |
Hematology |
| X992 |
12874 |
Phosphorus of 14-week old females [mM] |
Hematology |
| X692 |
12875 |
Platelet count of 14-week old females [x10^3/ul] |
Hematology |
| X4462 |
12877 |
Red blood cell count of 14-week old females [x10^6/ul] |
Hematology |
| X1675 |
12881 |
Cholesterol (total) of 14-week old females [mM] |
Hematology |
| X4049 |
12882 |
Triglyceride of 14-week old females [mM] |
Hematology |
| X3426 |
12883 |
Blood proteins (total) of 14-week old females [g/l] |
Hematology |
| X1988 |
12884 |
Urea of 14-week old females [mM] |
Hematology |
| X199 |
12888 |
White blood cell count of 14-week old females [x10^3/ul] |
Hematology |
| X4995 |
12891 |
Alpha-amylase of 14-week old males [U/l] |
Hematology |
| X1147 |
12892 |
Alanine transaminase (ALT, ALAT, SGPT) level in serum of 14-week old males [U/L] |
Hematology |
| X1623 |
12893 |
Albumin of 14-week old males [g/l] |
Hematology |
| X122 |
12894 |
Alkaline phosphatase of 14-week old males (ALPL gene product) [U/l] |
Hematology |
| X3817 |
12895 |
Aspartate transaminase of 14-week old males [U/l] |
Hematology |
| X4695 |
12914 |
Calcium of 14-week old males [mM] |
Hematology |
| X4682 |
12915 |
Chloride of 14-week old males [mM] |
Hematology |
| X3865 |
12916 |
Creatinine of 14-week old males [uM] |
Hematology |
| X3598 |
12925 |
Glucose after 4 hour fast of 14-week old males [mMl] |
Hematology |
| X323 |
12931 |
Hematocrit of 14-week old males [%] |
Hematology |
| X248 |
12941 |
Mean cell hemoglobin concentration of 14-week old males [g/dl] |
Hematology |
| X151 |
12942 |
Mean cell volume of 14-week old males [fl] |
Hematology |
| X4494 |
12943 |
Sodium of 14-week old males [mM] |
Hematology |
| X633 |
12944 |
Phosphorus of 14-week old males [mM] |
Hematology |
| X2582 |
12945 |
Platelet count of 14-week old males [x10^3/ul] |
Hematology |
| X3730 |
12947 |
Red blood cell count of 14-week old males [x10^6/ul] |
Hematology |
| X2477 |
12951 |
Cholesterol (total) in serum of 14-week old males [mM] |
Hematology |
| X967 |
12952 |
Triglyceride of 14-week old males [mM] |
Hematology |
| X1933 |
12953 |
Blood proteins (total) of 14-week old males [g/l] |
Hematology |
| X2178 |
12954 |
Urea of 14-week old males [mM] |
Hematology |
| X569 |
12958 |
White blood cell count of 14-week old males [x10^3/ul] |
Hematology |
| X4275 |
12979 |
Alanine transaminase (ALT, ALAT, SGPT) level in serum following alcohol (6 gm ethanol/kg via gastric gavage) at 24 hours after gavage in young adult males and females ( DBA/2J winsorized from 89.37 +/- 10.96 to 8 |
Hematology |
| X3721 |
12984 |
Alanine transaminase (ALT, ALAT, SGPT) level in serum following alcohol (6 gm ethanol/kg via gastric gavage) at 24 hours after gavage in young adult females (associated with GenEx EtOH liver gene expression) [U/L |
Hematology |
| X3171 |
12985 |
Alanine transaminase (ALT, ALAT, SGPT) level in serum following alcohol (6 gm ethanol/kg via gastric gavage) at 24 hours after gavage in young adult males (BXD16 winsorized from 158 +/- 32 to 92 and DBA/2J from 1 |
Hematology |
| X61 |
13034 |
Transthyretin protein serum band (prealbumin, Pre locus) detected by acylamide electrophoresis in adult males [a-genotype of DBA/2J with band is coded as 1, o-genotype without band is coded as -1] |
Hematology |
| X4803 |
15798 |
Bilirubin, fasted state, chow diet, males [umol/L] |
Hematology |
| X2552 |
15816 |
Bilirubin, fasted state, high fat diet, males [umol/L] |
Hematology |
| X46 |
15868 |
Nucleated red blood cells, chow diet, males [%] |
Hematology |
| X2444 |
15875 |
Nucleated red blood cells, chow diet, males [10^3/uL] |
Hematology |
| X47 |
15912 |
Nucleated red blood cells, high fat diet, males [%] |
Hematology |
| X48 |
15919 |
Nucleated red blood cells, high fat diet, males [10^3/uL] |
Hematology |
| X1553 |
16659 |
C16:1-carnitine_HFD for 20 weeks [nmol/ml] |
Hematology |
| X2158 |
16794 |
Ratio of C14:2-carnitine/C14:1-carnitine_HFD for 20 weeks |
Hematology |
| X4552 |
17799 |
Basal glucose in plasma, fasted state at 29 weeks of age_CD, males [mmol/L] |
Hematology |
| X2472 |
17800 |
Basal glucose in plasma, fasted state at 29 weeks of age_HFD, males [mmol/L] |
Hematology |
| X3124 |
17801 |
Cholesterol in plasma, fasted state at 29 weeks of age_CD, males [mmol/L] |
Hematology |
| X3636 |
17802 |
Cholesterol in plasma, fasted state at 29 weeks of age_HFD, males [mmol/L] |
Hematology |
| X1566 |
17803 |
HDL in plasma, fasted state at 29 weeks of age_CD, males [mmol/L] |
Hematology |
| X1530 |
17804 |
HDL in plasma, fasted state at 29 weeks of age_HFD, males [mmol/L] |
Hematology |
| X4924 |
17805 |
HDL in plasma, fasted state at 29 weeks of age_CD, males [batch-corrected z-score] |
Hematology |
| X1350 |
17806 |
HDL in plasma, fasted state at 29 weeks of age_HFD, males [batch-corrected z-score] |
Hematology |
| X3700 |
17807 |
LDL in plasma, fasted state at 29 weeks of age_CD, males [mmol/L] |
Hematology |
| X4742 |
17808 |
LDL in plasma, fasted state at 29 weeks of age_HFD, males [mmol/L] |
Hematology |
| X4306 |
17809 |
Triglycerides in plasma, fasted state at 29 weeks of age_CD, males [mmol/L] |
Hematology |
| X2719 |
17810 |
Triglycerides in plasma, fasted state at 29 weeks of age_HFD, males [mmol/L] |
Hematology |
| X3441 |
17811 |
Free fatty acids (FFA) in plasma, fasted state at 29 weeks of age_CD, males [mmol/L] |
Hematology |
| X3145 |
17812 |
Free fatty acids (FFA) in plasma, fasted state at 29 weeks of age_HFD, males [mmol/L] |
Hematology |
| X3379 |
17813 |
Free fatty acids (FFA) in plasma, fasted state at 29 weeks of age_CD, males [batch-corrected z-score] |
Hematology |
| X4980 |
17814 |
Free fatty acids (FFA) in plasma, fasted state at 29 weeks of age_HFD, males [batch-corrected z-score] |
Hematology |
| X2679 |
17815 |
Lactic acid in plasma, fasted state at 29 weeks of age_CD, males [mmol/L] |
Hematology |
| X1239 |
17816 |
Lactic acid in plasma, fasted state at 29 weeks of age_HFD, males [mmol/L] |
Hematology |
| X4422 |
17817 |
Total protein in plasma, fasted state at 29 weeks of age_CD, males [g/L] |
Hematology |
| X2810 |
17818 |
Total protein in plasma, fasted state at 29 weeks of age_HFD, males [g/L] |
Hematology |
| X3702 |
17819 |
Alanine transaminase (ALAT) in plasma, fasted state at 29 weeks of age_CD, males [U/L] |
Hematology |
| X4565 |
17820 |
Alanine transaminase (ALAT) in plasma, fasted state at 29 weeks of age_HFD, males [U/L] |
Hematology |
| X4286 |
17821 |
Aspartate transaminase (ASAT) in plasma, fasted state at 29 weeks of age_CD, males [U/L] |
Hematology |
| X4232 |
17822 |
Aspartate transaminase (ASAT) in plasma, fasted state at 29 weeks of age_HFD, males [U/L] |
Hematology |
| X917 |
17823 |
Aspartate transaminase (ASAT) in plasma, fasted state at 29 weeks of age_CD, males [batch-corrected z-score] |
Hematology |
| X4278 |
17824 |
Aspartate transaminase (ASAT) in plasma, fasted state at 29 weeks of age_HFD, males [batch-corrected z-score] |
Hematology |
| X1280 |
17825 |
Lactate dehydrogenase (LDH) in plasma, fasted state at 29 weeks of age_CD, males [U/L] |
Hematology |
| X3621 |
17826 |
Lactate dehydrogenase (LDH) in plasma, fasted state at 29 weeks of age_HFD, males [U/L] |
Hematology |
| X2056 |
17827 |
Lactate dehydrogenase (LDH) in plasma, fasted state at 29 weeks of age_CD, males [batch-corrected z-score] |
Hematology |
| X543 |
17828 |
Lactate dehydrogenase (LDH) in plasma, fasted state at 29 weeks of age_HFD, males [batch-corrected z-score] |
Hematology |
| X179 |
17829 |
Alkaline phosphatase (ALPL) in plasma, fasted state at 29 weeks of age_CD, males [U/L] |
Hematology |
| X181 |
17830 |
Alkaline phosphatase (ALPL) in plasma, fasted state at 29 weeks of age_HFD, males [U/L] |
Hematology |
| X740 |
17831 |
Amylase in plasma, fasted state at 29 weeks of age_CD, males [U/L] |
Hematology |
| X808 |
17832 |
Amylase in plasma, fasted state at 29 weeks of age_HFD, males [U/L] |
Hematology |
| X2342 |
17833 |
Creatine kinase (CPK) in plasma, fasted state at 29 weeks of age_CD, males [U/L] |
Hematology |
| X2614 |
17834 |
Creatine kinase (CPK) in plasma, fasted state at 29 weeks of age_HFD, males [U/L] |
Hematology |
| X2884 |
17835 |
Creatinine in plasma, fasted state at 29 weeks of age_CD, males [umol/L] |
Hematology |
| X153 |
17836 |
Creatinine in plasma, fasted state at 29 weeks of age_HFD, males [umol/L] |
Hematology |
| X2675 |
17837 |
Creatinine in plasma, fasted state at 29 weeks of age_CD, males [batch-corrected z-score] |
Hematology |
| X3501 |
17838 |
Creatinine in plasma, fasted state at 29 weeks of age_HFD, males [batch-corrected z-score] |
Hematology |
| X3935 |
17839 |
Iron (Fe) in plasma, fasted state at 29 weeks of age_CD, males [umol/L] |
Hematology |
| X4421 |
17840 |
Iron (Fe) in plasma, fasted state at 29 weeks of age_HFD, males [umol/L] |
Hematology |
| X1821 |
17841 |
Interferon-gamma (IFN-g) cytokine level in plasma after 12 h fast at 29 weeks of age, Luminex assay_HFD, males [pg/mL] |
Hematology |
| X455 |
17842 |
Tumor necrosis factor-alpha (TNF, cachexin) cytokine level in plasma after 12 h fast at 29 weeks of age, Luminex assay_HFD, males [pg/mL] |
Hematology |
| X1517 |
17843 |
Interleukin 15 (IL15) cytokine level in plasma after 12 h fast at 29 weeks of age, Luminex assay_HFD, males [pg/mL] |
Hematology |
| X3151 |
17844 |
Monocyte chemotactic protein 1 (MCP1, CCL2) cytokine level in plasma after 12 h fast at 29 weeks of age, Luminex assay_HFD, males [pg/mL] |
Hematology |
| X3491 |
17845 |
Interleukin 10 (IL10) cytokine level in plasma after 12 h fast at 29 weeks of age, Luminex assay_HFD, males [pg/mL] |
Hematology |
| X2466 |
17846 |
Macrophage inflammatory protein 1-beta (MIP1B, CCL4) cytokine level in plasma after 12 h fast at 29 weeks of age, Luminex assay_HFD, males [pg/mL] |
Hematology |
| X3777 |
17847 |
Macrophage inflammatory protein 1-alpha (MIP1A, CCL3) cytokine level in plasma after 12 h fast at 29 weeks of age, Luminex assay_HFD, males [pg/mL] |
Hematology |
| X741 |
17848 |
Interleukin 6 (IL6) cytokine level in plasma after 12 h fast at 29 weeks of age, Luminex assay_HFD, males [pg/mL] |
Hematology |
| X351 |
17849 |
Interleukin 18 (IL18) cytokine level in plasma after 12 h fast at 29 weeks of age, Luminex assay_HFD, males [pg/mL] |
Hematology |
| X1781 |
17878 |
Mean corpuscular volume reticulocytes at 29 weeks of age_HFD, males [fL/RTC] |
Hematology |
| X404 |
17850 |
Regulated and normal T cell expressed and secreted (RANTES, CCL5) cytokine level in plasma after 12 h fast at 29 weeks of age, Luminex assay_HFD, males [pg/mL] |
Hematology |
| X872 |
17851 |
Red blood cells at 29 weeks of age_CD, males [10^6/uL] |
Hematology |
| X4616 |
17852 |
Red blood cells at 29 weeks of age_HFD, males [10^6/uL] |
Hematology |
| X1128 |
17853 |
Mature red blood cells at 29 weeks of age_CD, males [%] |
Hematology |
| X3936 |
17854 |
Mature red blood cells at 29 weeks of age_HFD, males [%] |
Hematology |
| X1100 |
17855 |
Mature red blood cells at 29 weeks of age_CD, males [10^9/L] |
Hematology |
| X3925 |
17856 |
Mature red blood cells at 29 weeks of age_HFD, males [10^9/L] |
Hematology |
| X3628 |
17857 |
Hemoglobin at 29 weeks of age_CD, males [g/dL] |
Hematology |
| X3592 |
17858 |
Hemoglobin at 29 weeks of age_HFD, males [g/dL] |
Hematology |
| X3638 |
17859 |
Hematocrit at 29 weeks of age_CD, males [%] |
Hematology |
| X5058 |
17860 |
Hematocrit at 29 weeks of age_HFD, males [%] |
Hematology |
| X783 |
17861 |
Mean corpuscular volume (MCV) at 29 weeks of age_CD, males [fL/RBC] |
Hematology |
| X1402 |
17862 |
Mean corpuscular volume (MCV) at 29 weeks of age_HFD, males [fL/RBC] |
Hematology |
| X2366 |
17863 |
Mean corpuscular hemoglobin (MCH) at 29 weeks of age_CD, males [pg/RBC] |
Hematology |
| X4071 |
17864 |
Mean corpuscular hemoglobin (MCH) at 29 weeks of age_HFD, males [pg/RBC] |
Hematology |
| X2754 |
17865 |
Mean corpuscular hemoglobin concentration (MCHC) at 29 weeks of age_CD, males [g/dL] |
Hematology |
| X2245 |
17866 |
Mean corpuscular hemoglobin concentration (MCHC) at 29 weeks of age_HFD, males [g/dL] |
Hematology |
| X3258 |
17867 |
Red blood cell hemoglobin content at 29 weeks of age_CD, males [pg/RBC] |
Hematology |
| X863 |
17868 |
Red blood cell hemoglobin content at 29 weeks of age_HFD, males [pg/RBC] |
Hematology |
| X3694 |
17869 |
Red blood cell distribution width at 29 weeks of age_CD, males [%] |
Hematology |
| X1921 |
17870 |
Red blood cell distribution width at 29 weeks of age_HFD, males [%] |
Hematology |
| X1808 |
17871 |
Hemoglobin concentration distribution width at 29 weeks of age_CD, males [g/dL] |
Hematology |
| X4200 |
17872 |
Hemoglobin concentration distribution width at 29 weeks of age_HFD, males [g/dL] |
Hematology |
| X2246 |
17873 |
Reticulocytes at 29 weeks of age_CD, males [%] |
Hematology |
| X3420 |
17874 |
Reticulocytes at 29 weeks of age_HFD, males [%] |
Hematology |
| X1256 |
17875 |
Reticulocytes at 29 weeks of age_CD, males [10^9/L] |
Hematology |
| X3755 |
17876 |
Reticulocytes at 29 weeks of age_HFD, males [10^9/L] |
Hematology |
| X4415 |
17877 |
Mean corpuscular volume reticulocytes at 29 weeks of age_CD, males [fL/RTC] |
Hematology |
| X1399 |
17908 |
Mean platelet mass at 29 weeks of age_HFD, males [pg/PLT] |
Hematology |
| X2779 |
17879 |
Mean corpuscular hemoglobin concentration reticulocytes at 29 weeks of age_CD, males [g/dL] |
Hematology |
| X4659 |
17880 |
Mean corpuscular hemoglobin concentration reticulocytes at 29 weeks of age_HFD, males [g/dL] |
Hematology |
| X1276 |
17881 |
Red cell hemoglobin content reticulocytes at 29 weeks of age_CD, males [pg/RTC] |
Hematology |
| X3879 |
17882 |
Red cell hemoglobin content reticulocytes at 29 weeks of age_HFD, males [pg/RTC] |
Hematology |
| X3789 |
17883 |
Mature reticulocytes at 29 weeks of age_CD, males [%] |
Hematology |
| X1398 |
17884 |
Mature reticulocytes at 29 weeks of age_HFD, males [%] |
Hematology |
| X773 |
17885 |
Mature reticulocytes at 29 weeks of age_CD, males [10^9/L] |
Hematology |
| X4959 |
17886 |
Mature reticulocytes at 29 weeks of age_HFD, males [10^9/L] |
Hematology |
| X1816 |
17887 |
Medium maturity reticulocytes at 29 weeks of age_CD, males [%] |
Hematology |
| X3125 |
17888 |
Medium maturity reticulocytes at 29 weeks of age_HFD, males [%] |
Hematology |
| X2238 |
17889 |
Medium maturity reticulocytes at 29 weeks of age_CD, males [10^9/L] |
Hematology |
| X1220 |
17890 |
Medium maturity reticulocytes at 29 weeks of age_HFD, males [10^9/L] |
Hematology |
| X2928 |
17891 |
Immature reticulocytes at 29 weeks of age_CD, males [%] |
Hematology |
| X437 |
17892 |
Immature reticulocytes at 29 weeks of age_HFD, males [%] |
Hematology |
| X4578 |
17893 |
Immature reticulocytes at 29 weeks of age_CD, males [10^9/L] |
Hematology |
| X4231 |
17894 |
Immature reticulocytes at 29 weeks of age_HFD, males [10^9/L] |
Hematology |
| X1464 |
17895 |
Platelets at 29 weeks of age_CD, males [10^3/uL] |
Hematology |
| X2359 |
17896 |
Platelets at 29 weeks of age_HFD, males [10^3/uL] |
Hematology |
| X4864 |
17897 |
Mean platelet volume at 29 weeks of age_CD, males [fL/PLT] |
Hematology |
| X3233 |
17898 |
Platelet volume at 29 weeks of age_HFD, males [fL/PLT] |
Hematology |
| X577 |
17899 |
Platelet distribution width at 29 weeks of age_CD, males [%] |
Hematology |
| X2454 |
17900 |
Platelet distribution width at 29 weeks of age_HFD, males [%] |
Hematology |
| X4165 |
17901 |
Plateletcrit at 29 weeks of age_CD, males [%] |
Hematology |
| X3604 |
17902 |
Plateletcrit at 29 weeks of age_HFD, males [%] |
Hematology |
| X4253 |
17903 |
Platelet component concentration at 29 weeks of age_CD, males [g/dL] |
Hematology |
| X3433 |
17904 |
Platelet component concentration at 29 weeks of age_HFD, males [g/dL] |
Hematology |
| X4941 |
17905 |
Platelet component distribution width at 29 weeks of age_CD, males [g/dL] |
Hematology |
| X4266 |
17906 |
Platelet component distribution width at 29 weeks of age_HFD, males [g/dL] |
Hematology |
| X4360 |
17907 |
Platelet mass at 29 weeks of age_CD, males [pg/PLT] |
Hematology |
| X4028 |
10186 |
Syngeneic breast cancer tumor growth, day 20 [mm3] |
Immune |
| X4743 |
17909 |
White blood cells at 29 weeks of age_CD, males [10^3/uL] |
Hematology |
| X4432 |
17910 |
White blood cells at 29 weeks of age_HFD, males [10^3/uL] |
Hematology |
| X4280 |
17911 |
Neutrophils at 29 weeks of age_CD, males [%] |
Hematology |
| X4242 |
17912 |
Neutrophils at 29 weeks of age_HFD, males [%] |
Hematology |
| X4954 |
17913 |
Lymphocytes at 29 weeks of age_CD, males [%] |
Hematology |
| X4737 |
17914 |
Lymphocytes at 29 weeks of age_HFD, males [%] |
Hematology |
| X3679 |
17915 |
Monocytes at 29 weeks of age_CD, males [%] |
Hematology |
| X4245 |
17916 |
Monocytes at 29 weeks of age_HFD, males [%] |
Hematology |
| X4839 |
17917 |
Eosinophils at 29 weeks of age_CD, males [%] |
Hematology |
| X5078 |
17918 |
Eosinophils at 29 weeks of age_HFD, males [%] |
Hematology |
| X2142 |
17919 |
Basophils at 29 weeks of age_CD, males [%] |
Hematology |
| X2849 |
17920 |
Basophils at 29 weeks of age_HFD, males [%] |
Hematology |
| X4909 |
17921 |
Large unknown cells at 29 weeks of age_CD, males [%] |
Hematology |
| X4317 |
17922 |
Large unknown cells at 29 weeks of age_HFD, males [%] |
Hematology |
| X3757 |
17923 |
Neutrophils at 29 weeks of age_CD, males [10^3/uL] |
Hematology |
| X4734 |
17924 |
Neutrophils at 29 weeks of age_HFD, males [10^3/uL] |
Hematology |
| X4921 |
17925 |
Lymphocytes at 29 weeks of age_CD, males [10^3/uL] |
Hematology |
| X4322 |
17926 |
Lymphocytes at 29 weeks of age_HFD, males [10^3/uL] |
Hematology |
| X2841 |
17927 |
Monocytes at 29 weeks of age_CD, males [10^3/uL] |
Hematology |
| X481 |
17928 |
Monocytes at 29 weeks of age_HFD, males [10^3/uL] |
Hematology |
| X4694 |
17929 |
Eosinophils at 29 weeks of age_CD, males [10^3/uL] |
Hematology |
| X5079 |
17930 |
Eosinophils at 29 weeks of age_HFD, males [10^3/uL] |
Hematology |
| X4344 |
17931 |
Basophils at 29 weeks of age_CD, males [10^3/uL] |
Hematology |
| X5055 |
17932 |
Basophils at 29 weeks of age_HFD, males [10^3/uL] |
Hematology |
| X3928 |
17933 |
Large unknown cells at 29 weeks of age_CD, males [10^3/uL] |
Hematology |
| X3950 |
17934 |
Large unknown cells at 29 weeks of age_HFD, males [10^3/uL] |
Hematology |
| X4257 |
17968 |
Blood 5-hydroxyindoleacetic acid (5-HIAA) level in adult males [pg/ul] |
Hematology |
| X2763 |
17970 |
Blood 5-hydroxytryptamine (5-HT, serotonin) level in adult females [pg/ul] |
Hematology |
| X2790 |
17972 |
Blood 5-hydroxytryptamine turnover rates (5-HIAA/5-HT) in adult females [units] |
Hematology |
| X4033 |
17973 |
Blood 5-hydroxytryptamine (5-HT, serotonin) level in adult males and females [pg/ul] |
Hematology |
| X2761 |
17974 |
Blood 5-hydroxyindoleacetic acid (5-HIAA) level in adult males and females [pg/ul] |
Hematology |
| X3579 |
17975 |
Blood 5-hydroxytryptamine turnover rates (5-HIAA/5-HT) in adult males and females [units] |
Hematology |
| X1273 |
10187 |
Growth of syngeneic breast cancer tumors day 25 [mm3] |
Immune |
| X1540 |
10034 |
Salmonella typhimurium bacterial strain LT2-Z growth from livers and spleens 6 days post inoculation with 10^2 CFU (figure 3, filled circles) [log10 CFU] |
Immune |
| X844 |
10035 |
Salmonella typhimurium bacterial strain WB500 from livers and spleens 6 days post inoculation with 10^2 CFU (figure 3 open circles) [log10 CFU] |
Immune |
| X79 |
10036 |
Salmonella typhimurium bacterial strain SR-11, net growth in livers and spleens 6 days after inoculation with 10^2 CFU (figure 5, triangles, Itk/Nramp1/Slc11a1-associated) [log10 CFU] |
Immune |
| X1298 |
10043 |
Ectromelia virus-induced mortality in males [3 = resistant, 2 = intermediate, 1 = susceptible, table 1 column 1, ordinal scale] |
Immune |
| X3912 |
10044 |
Ectromelia virus-induced mortality [3 = resistant, 1 = both intermediate and susceptible, ordinal scale] |
Immune |
| X321 |
10056 |
Hematopoietic stem cell pool size, cobblestone area-forming cells per 100,000 bone marrow cells [n] |
Immune |
| X746 |
10058 |
Peripheral blood lymphocytes, percentage of B cells [B220 %] |
Immune |
| X3210 |
10059 |
Peripheral blood lymphocytes, percentage of CD4+ T cells [%] |
Immune |
| X3868 |
10060 |
Peripheral blood lymphocytes, percentage of CD8+ T cells [%] |
Immune |
| X4584 |
10061 |
Polymorphonuclear leukocyte number (PMN) after aerosolized LPS exposure [PMN/ml (x103)] |
Immune |
| X1795 |
10062 |
Tumor necrosis factor (TNF)-alpha level in lung after aerosolized lipopolysaccharide (LPS) exposure [pg/ml] |
Immune |
| X4950 |
10113 |
Proliferative activity of hematopoietic stem cells, quiescent stem cells in aged mice, cobblestone area forming cells (CAFC) at day 35 in culture, frequency in bone marrow [CAFC per 10e5 bone marrow cells] |
Immune |
| X1762 |
10114 |
Proliferative activity of hematopoietic stem cells, quiescent HSCs in aged mice, cobblestone area forming cells (CAFC) on day 35, frequency in bone marrow [CAFC per 10e5 bone marrow cells] |
Immune |
| X4880 |
10115 |
Stem cell cycling, change in day 7 cobblestone area forming cell (CAFC) frequency during aging [%CAFC] |
Immune |
| X4430 |
10116 |
Proliferative activity of hematopoietic stem cells, day 21 cobblestone area forming cell (CAFC) frequency change [% CAFC] |
Immune |
| X3793 |
10117 |
Proliferative activity of hematopoietic stem cells, change in quiescent HSC percentage (cobblestone area-forming cells day 35 of culture) at 20 months [% CAFC] |
Immune |
| X4858 |
10118 |
Stem cell frequency, cobblestone area-forming cell assay count (CAFC) on day 35 [CAFC per 10e5 bone marrow cells] |
Immune |
| X2228 |
10119 |
Proliferative activity of hematopoietic stem cells on day 7 in culture [% CAFC] |
Immune |
| X312 |
10150 |
Thymic T-cell proliferative unresponsiveness (anergy) to anti-CD3-induced proliferation (chemokine-associated) [units] |
Immune |
| X3509 |
10179 |
Metastasis of implanted breast tumor in lymph node, cases with tumor metastasis [n] |
Immune |
| X3453 |
10180 |
Metastasis of implanted breast tumor in pancreas, cases with tumor metastasis [n] |
Immune |
| X3317 |
10181 |
Necrosis of implanted breast tumor [n] |
Immune |
| X2542 |
10182 |
Syngeneic breast tumor growth, number of cases with tumor metastasis [n] |
Immune |
| X2935 |
10183 |
Syngeneic breast cancer tumor growth, day 5 [mm3] |
Immune |
| X3791 |
10184 |
Growth of syngeneic breast cancer tumors day 10 [mm3] |
Immune |
| X3813 |
10185 |
Growth of syngeneic breast cancer tumors day 15 [mm3] |
Immune |
| X4364 |
10206 |
Granulocyte colony stimulating factor (G-CSF) induced progenitor cell mobilization from bone marrow to blood [PB-CFC/ul] |
Immune |
| X655 |
10207 |
Hematopoietic stem cell and progenitor cell proliferative capacity (Lin-Sca1++ cells from femur bone marrow), in vitro assay of cells from 2-3 month old females in response to KL, flt3L, and TPO (Figure 3A of paper) [n |
Immune |
| X790 |
10208 |
Hematopoietic stem cells and progenitor cells, numbers of Lin-Sca1++ cells at 2 months of age in females (Figure 3B of paper) [n] |
Immune |
| X2019 |
10209 |
Relative fraction of hematopoietic stem cells and progenitor cells (Lin-Sca1++) from bone marrow in 2-3 month old females (Figure 3C of paper) [%] |
Immune |
| X4558 |
10210 |
Hematopoietic stem cells and progenitor cells in femur bone marrow, percentage of c-kit-postiive cells to c-kit-ngative cells among Lin-Sca1++ cells in 2-month old femaies (Figure 3d of paper) [%] |
Immune |
| X4648 |
10211 |
Hematopoietic stem cells and progenitor cells (lin-Sca1++ c-kit+ cells) at 18 months of age taken from femur bone marrow (Fig 2A of paper) [n per well] |
Immune |
| X4896 |
10212 |
Percentage of hematopoietic stem cells and progenitor cells in femur bone marrow (lin-Sca1++ c-kit+) at 18 months of age (Figure 2B of paper) [%] |
Immune |
| X1887 |
10213 |
Proliferative capacity in vitro of bone marrow stem and progenitor cells (lin-Sca1++ c-kit+ cells) at 18 months of age in response to KL, flt3L and TPO (figure 2C of paper) [n cells] |
Immune |
| X1493 |
10214 |
Hematopoietic stem cells and progenitor cells (lin-Sca1++ c-kit+ cells) at 18 months of age taken from femur bone marrow (additional data not included in paper) [n cells total] |
Immune |
| X1644 |
10215 |
Hematopoietic stem cell and progenitor cell number (lin-Sca1++ c-kit+ cells) from femur bone marrow of females a 18 months (confirm) (unpublished additional data) [n cells] |
Immune |
| X4249 |
10216 |
Proliferative capacity, number of hematopoietic stem cells and progenitor cells (lin-Sca1++ c-kit+ cells) after treatment with transforming growth factor beta 2 (TGFB2, 0.01 ng/ml) at 18 months of age (confirm) (unpublished additiona |
Immune |
| X3015 |
10217 |
Proliferative capacity, effect of TGF-beta2 stimulation (0.1 ng/ml) on numbers of lin-Sca1++ c-kit+ cells (unpublished additional data) [% increase] |
Immune |
| X3046 |
10218 |
Proliferative capacity change, difference between old (18 months) and young (2 months) on number of hematopoietic stem cells and progenitor cells (lin-Sca1++ c-kit+ cells) after treatment with transforming growth factor beta 2 (TGFB2 |
Immune |
| X2592 |
10219 |
Percentage of hematopoietic stem cells and progenitor cells (lin-Sca1++ c-kit+ cells) at 18 months of age taken from femur bone marrow [%] |
Immune |
| X145 |
10225 |
T-cell proliferative response (age-related decline), concavalin-A induced thymic T-cell response at 22-month-old in females (average of days 2 and 4)[unit] |
Immune |
| X4835 |
10226 |
Age-related T-cell decline, percentage of CD4-negative CD8-negative DN cells in thymus [%] |
Immune |
| X4876 |
10227 |
Age-related T-cell decline, percent of CD4-CD8 double positive cells in thymus [%] |
Immune |
| X3539 |
10228 |
T-cell decline during aging, percentage of CD25-negative/CD44-positive double negative (CD4(-)CD8(-)) cells in thymus at 22 months [%] |
Immune |
| X4788 |
10229 |
Age-related T-cell decline, percentage of CD25-positive CD44-negative DN cells in thymus [%] |
Immune |
| X1950 |
12907 |
Body weight at echocardiography of 17-week old males [g] |
Morphology |
| X4228 |
10230 |
Age-related T-cell decline, percentage of CD25-CD44 double negative thymocytes at 22 months in females [%] |
Immune |
| X4821 |
10231 |
Thymus involution, age-related rate of decline measured as involution slope (-beta 1x10^4) |
Immune |
| X2962 |
10232 |
Thymocyte count in young adult mice, initial [Beta 0] |
Immune |
| X3160 |
10233 |
Thymocyte count, projected at 60 days [units] |
Immune |
| X86 |
10235 |
Proliferation of T cell clone (JTL-G12 clone) without 50 ug/ml GAT (Glu60, Ala30, Tyr10) [cpm] |
Immune |
| X223 |
10236 |
Proliferation of T cell clone (JTL-G12 clone) with 50 ug/ml GAT (Glu60, Ala30, Tyr10) [cpm] |
Immune |
| X75 |
10237 |
Proliferation of T cell clone (JTL-G12.8 clone) without 50 ug/ml GAT (Glu60, Ala30, Tyr10) [cpm] |
Immune |
| X175 |
10238 |
Proliferation of T cell clone (JTL-G12.8 clone) with 50 ug/ml GAT (Glu60, Ala30, Tyr10) [cpm] |
Immune |
| X4042 |
10355 |
Airway inflammatory response to ozone (2 ppm for 3 h) measured as lavageable bronchoalveolar polymorphonuclear leukocytes 6 h after acute exposure [number of PMNs x10^3] |
Immune |
| X2028 |
10356 |
Airway inflammatory response to ozone (0.30 ppm for 48 h) measured as lavageable bronchoalveolar polymorphonuclear leukocytes 6 h after exposure [n PMNs x10^3] |
Immune |
| X1150 |
10361 |
Progenitor cell proliferation in young mice (2 months of age), effect of TGFB2 (0.1 ng/ml) on the proliferation of lin-Sca1++kit+ cells relative to control without TGFB2 [%] |
Immune |
| X4983 |
10370 |
Hepatocellular carcinoma tumor multiplicities induced by N,N-diethylnitrosamine (DEN 0.01 ml/g, ip at postnatal day 12), mean tumor multiplicity in liver at 32 weeks in male [n] |
Immune |
| X1897 |
10372 |
Tumor necrosis factor (TNF)-induced hypothermia [degree C] |
Immune |
| X339 |
10373 |
Tumor necrosis factor (TNF) lethal shock, induction of serum interleukin 6 (IL-6) cytokine after injection [ng/ml] |
Immune |
| X937 |
10374 |
Tumor necrosis factor (TNF) lethality after injection [%] |
Immune |
| X2851 |
10403 |
Theiler's murine encephalomyelitis virus (TMEV) spinal cored demyelination susceptibility (excludes strains with B allele at H2 locus) [% affected] |
Immune |
| X2352 |
10404 |
Theiler's murine encephalomyelitis virus (TMEV, dermal injection), delayed-type hypersensitivity (DTH) response measured as ear swelling [inch x 1E-3] |
Immune |
| X3980 |
10427 |
xenotropic MuLV envelope-related cell-surface antigens (XenCSA) levels on thymus cells measured as mean fluorescence value (sum of products of each channel number times n cells in that channel divided by n cells counted) |
Immune |
| X856 |
10428 |
lymphocyte major glycoprotein (gp70) xenotropic leukemia virus envelope-related cell-surface antigen (XenCSA) level measured as mean fluorescence value (sum of products of each channel number times the number of spleen cells in that channel |
Immune |
| X4925 |
10433 |
;Immune complex deposits in kidney immunized with the 16/6 Id [0=no immune complexes;; 1=1-5 immune complex deposits;; 2=5-20 immune complex deposits;; 3=20-50 immune complex deposits;; 4=50 immune complex deposits]; |
Immune |
| X2469 |
10439 |
Lung, Airway bronchial constrictor response after exposure to atracurium, airway pressure time index [cmH2O/s] |
Immune |
| X487 |
10463 |
Thymus to body size ratio [x10^3] |
Immune |
| X1868 |
13008 |
H1N1 (PR8) influenza A virus (2x10E3 FFU), median body weight loss day 4 after infection in 9-14 week-old females [%] |
Immune |
| X212 |
10464 |
Intestinal intraepithelial gamma-delta type T lymphocytes (i-IELs) in 2-6 month old adults based on receptor expression (V-gamma-1 positive, Vgamma-4 positive T cells) [%] |
Immune |
| X149 |
10465 |
Intestinal intraepithelial gamma-delta type T lymphocytes (i-IELs) in 2-6 month old adults based on receptor expression (V-gamma-7 positive, Vgamma-4 positive T cells) [%] |
Immune |
| X109 |
10466 |
Intestinal intraepithelial gamma-delta type T lymphocytes (i-IELs) in 2-6 month old adults based on receptor expression (V-gamma-7 positive, Vgamma-4 negative T cells) from Fig 4 y-axis [%] |
Immune |
| X3349 |
10467 |
Intestinal intraepithelial gamma-delta type T lymphocytes (i-IELs) in 2-6 month old adults based on receptor expression (V-gamma-1 positive, Vgamma-4 negative T cells) from Fig 4 x-axis [%] |
Immune |
| X1539 |
10508 |
V beta 3+ T cells in lymph nodes [%] |
Immune |
| X94 |
10591 |
Murine cytomegalovirus (MCMV) titer in spleen 4 days after infection with 5X10^4 PFU (KLRA complex) [log10 burden] |
Immune |
| X2650 |
10592 |
Anergy measured by footpad thickness resulting from BCG injection [mm] |
Immune |
| X3710 |
10656 |
LacZ expression 7 days post 5x109 PFU i.v injection of AdLacZ [counts/mg protein/minx10-4] |
Immune |
| X4993 |
10657 |
LacZ expression 21 days post 5x109 PFU i.v injection of AdLacZ [counts/mg protein/minx10-4] |
Immune |
| X5037 |
10658 |
LacZ expression 30 days post 5x109 PFU i.v injection of AdLacZ [counts/mg protein/minx10-4] |
Immune |
| X4994 |
10659 |
LacZ expression 50 days post 5x109 PFU i.v injection of AdLacZ [counts/mg protein/minx10-4] |
Immune |
| X4857 |
10660 |
Cytotoxicity in spleen T cells 7 days after 5x109 PFU AdLacZ i.v injection [%] |
Immune |
| X5041 |
10661 |
Cytotoxicity in spleen T cells 21 days post 5x109 PFU AdLacZ i.v injection [%] |
Immune |
| X4726 |
10662 |
Cytotoxicity in spleen T cells 30 days post 5x109 PFU AdLacZ i.v injection [%] |
Immune |
| X2826 |
10663 |
Cytotoxicity in spleen T cells 50 days post 5x109 PFU AdLacZ i.v injection [%] |
Immune |
| X608 |
10664 |
Cytotoxic T-cell (CTL) response (5 x 10^9 PFU AdLacZ iv), measured as interferon gamma (IFNG) cytokine expression [ng/ml/] |
Immune |
| X3720 |
10665 |
Cytotoxic T-cell (CTL) response (5 x 10^9 PFU AdLacZ iv), measured as tumor necrosis factor alpha (TNFa) cytokine expression [pg/ml] |
Immune |
| X1543 |
10666 |
Cytotoxic T-cell (CTL) response (5 x 10^9 PFU AdLacZ iv), measured as interleukin 6 (IL-6) cytokine expression [pg/ml] |
Immune |
| X2216 |
10687 |
Mycoplasmosis susceptibility (M. pulmonis, intranasal 10^4 CFU), fraction dead 21 days after infection [ratio] |
Immune |
| X4467 |
10688 |
Myoplasmosis susceptibility (M. pulmonis, intranasal 10^4 CFU) 21 days post-infection gross pulmonary lesions [burden] |
Immune |
| X3249 |
10689 |
Mycoplasmosis susceptibility (M. pulmonis, intranasal 10^4 CFU) 21 days post-infection, airway exudate [units] |
Immune |
| X3388 |
10690 |
Mycoplasmosis susceptibility (M. pulmonis, intranasal 10^4 CFU) 21 days post-infection, airway epithelial hyperplasia |
Immune |
| X3962 |
10691 |
Mycoplasmosis susceptibility (M. pulmonis, intranasal 10^4 CFU) 21 days post-infection, airway lymphoid hyperplasia |
Immune |
| X1345 |
10692 |
Mycoplasmosis susceptibility (M. pulmonis, intranasal 10^4 CFU) 21 days post-infection, alveolar exudate [units] |
Immune |
| X4618 |
10695 |
Lung inflammatory response, pulmonary granulomatous inflammation induced by Bacillus Calmette___Guê©rin tuberculosis vaccine (BCG) [units] |
Immune |
| X4144 |
10696 |
Spleen weight, splenomegaly induced by Bacillus Calmette___Guê©rin tuberculosis vaccine (iv injection in oil and saline) (BCG) [mg] |
Immune |
| X584 |
10697 |
Autoimmune disease, spontaneous development of immune response, anti-DNA antibodies sera titers, 13 month females (Fig 7 from Mountz et al., 2005) [natural log of the average sum of IgG1, IgG2a, IgG2b, IgM x10^4, ln of 0 |
Immune |
| X3558 |
10698 |
Autoimmune disease, rheumatoid factor sera titers, 13 month females (natural log of the average sum of IgG1, IgG2a, IgG2b, IgM x10^4) |
Immune |
| X442 |
10711 |
Phenyloxazolone hapten-induced Igh-Ox antibody marker level (public idiotype)[units] |
Immune |
| X4252 |
10712 |
Skin tumors after initiation with N-methyl-N'-nitro-N-nitrosoguanidine and promotion with phorbol ester, 12-o-tetradecanoylphorbol-13-acetate [n per case] |
Immune |
| X3436 |
10715 |
Sendai virus lethality with 1.0 TCID50 [% mortality] |
Immune |
| X3362 |
10716 |
Resistance to lymphoma tumors induced by ESb DBA/2 (H-2d) cell transplant [%] |
Immune |
| X3175 |
10736 |
Skin tumor incidence following initiation with N-Methyl-N'-nitro-N-nitrosoguanidine and promotion with phorbol ester, 12-o-tetradecanoylphorbol-13-acetate [% mice] |
Immune |
| X5072 |
10766 |
Autoimmune disease, spontaneous development of immune response, IgG1-specific anti-DNA serum levels in 13-month-old mice [ELISA OD 450 (x 10^4)] |
Immune |
| X5038 |
10767 |
Autoimmune disease, spontaneous development of immune response, IgG2a-specific anti-DNA serum levels in 13-month-old mice [ELISA OD 450 (x 10^4)] |
Immune |
| X5082 |
10768 |
Autoimmune disease, spontaneous development of immune response, IgG2b-specific anti-DNA serum levels in 13-month-old mice [ELISA OD 450 (x 10^4)] |
Immune |
| X3065 |
10769 |
Autoimmune disease, spontaneous development of IgM-specific anti-DNA serum levels in 13-month-old mice [ELISA OD 450 (x 10^4)] |
Immune |
| X4666 |
10770 |
Autoimmune disease, spontaneous development of immune response, IgG1-specific rheumatoid factor (RF) serum levels in 13-month-old mice [ELISA OD 450 (x 10^4)] |
Immune |
| X4481 |
10771 |
Autoimmune disease, spontaneous development of immune response, IgG2a-specific rheumatoid factor (RF) serum levels in 13-month-old mice [ELISA OD 450 (x 10^4)] |
Immune |
| X5070 |
10772 |
Autoimmune disease, spontaneous development of immune response, IgG2b-specific rheumatoid factor (RF) serum levels in 13-month-old mice [ELISA OD 450 (x 10^4)] |
Immune |
| X2010 |
10773 |
Autoimmune disease, spontaneous development of immune response, IgM-specific rheumatoid factor (RF) serum levels in 13-month-old mice [ELISA OD 450 (x 10^4)] |
Immune |
| X5076 |
10774 |
IgG2b anti-AAV2 (adeno-associated virus type 2) response following injection of 3e11 vg/mouse AAV2-(ApoE)4/hAAT-cF.IX, day 0 baseline [ELISA OD 450] |
Immune |
| X941 |
10775 |
IgG2b anti-AAV2 (adeno-associated virus type 2) response following injection of 3e11 vg/mouse AAV2-(ApoE)4/hAAT-cF.IX - Day 14 [ELISA OD 450] |
Immune |
| X891 |
10776 |
IgG2b anti-AAV2 (adeno-associated virus type 2) immune response following injection of 3xE11 vector genomes vg/mouse AAV2-(ApoE)4/hAAT-cF.IX, on day 42 [ELISA OD 450] |
Immune |
| X2804 |
12908 |
Body weight of 18-week old males [g] |
Morphology |
| X585 |
10777 |
IgG2b anti-AAV2 (adeno-associated virus type 2) response following injection of 3e11 vg/mouse AAV2-(ApoE)4/hAAT-cF.IX - Day 120 [ELISA OD 450] |
Immune |
| X412 |
10778 |
IgG2b anti-AAV2 (adeno-associated virus type 2) response following injection of 3xE11 vector genomes (vg) /mouse AAV2-(ApoE)4/hAAT-cF.IX on day 180 [ELISA OD 450] |
Immune |
| X1867 |
10779 |
IgG1 isotype-specific anti-cF.IX (coagulation Factor IX) response following injection of 3e11 vg/mouse AAV2-cF.IX [ELISA OD 450 (x 10^4)] |
Immune |
| X4140 |
10780 |
Antibody IgG1 response following iv injection of canine coagulation factor IX (cF.IX, 3E11 vg/mouse) [ng/ml] |
Immune |
| X2361 |
10784 |
Autoimmune disease, spontaneous development of generalized Ig to anti-DNA in 13-month-old mice [natural log of total Ig to anti-DNA (ELISA OD 450 x 10^4)] |
Immune |
| X3580 |
10785 |
Autoimmune disease, spontaneous development of generalized autoimmunity measured as ratio of Ig to rheumatoid factor (RF) in 13-month-old mice [ratio, natural log of total Ig to RF (ELISA OD 450 x 10^4)] |
Immune |
| X157 |
10801 |
Streptococcus pyogenes disease severity, corrected relative survival index (Fig 1A, residuals after correction for age, sex, body weight and log inoculum, with added strains BXD76 and BXD80) [-1 = high susceptible, +1 is |
Immune |
| X77 |
10806 |
Chlamydia psittaci (6BC) infection response (10^4 IFU ip), survival index at 11 days in 2-4 month males [mean score, 0=resistant, 1=weight loss and all survive, 2=weight loss some survive, 3=no survival] |
Immune |
| X2838 |
10811 |
Iron level in spleen of males and females [ug/g] |
Immune |
| X4606 |
10813 |
Iron level in spleen of females [ug/g] |
Immune |
| X4830 |
10818 |
Iron level in spleen of males [ug/g] |
Immune |
| X136 |
10836 |
Streptococcus pyogenes disease severity, corrected relative survival index (differs from Fig 1A slightly, residuals after correction for age, sex, body weight and log inoculum, with added strain BXD80) where -1 means hig |
Immune |
| X388 |
10855 |
Chlamydia psittaci (6BC) infection response (10^4 IFU ip), weight loss ratio at 11 days compared to baseline in 2-4 month males [ratio] |
Immune |
| X657 |
10865 |
H5N1 influenza A virus mortality rate 30 days after infection (10^4 EID-50 of HK213 virus in 30 microliters saline) [% death] |
Immune |
| X893 |
10866 |
H5N1 influenza A virus survival time (10^4 EID-50 of HK213 virus in 30 microliters saline) [days, max to 30] |
Immune |
| X2409 |
10890 |
Hematopoietic stem cell number (cobblestone-area-forming cells per femur at 35 days of age from 3 females, also previously published) [n] |
Immune |
| X4258 |
10954 |
Hepatocellular carcinoma tumor multiplicity in liver of males after infection with 0.01 ml/g body wt N,N-diethylnitrosamine [n] |
Immune |
| X4055 |
11001 |
Immune response to bacterial LPS, polymorphonuclear macrophage after 4 hr acute, bronchial lavage [1000/ml] |
Immune |
| X1980 |
11021 |
Streptococcus pyogenes (Group A streptococcal infection) dissemination to spleens, 24 h post-infection (Fig 1C) [CFU/ml] |
Immune |
| X236 |
11022 |
Streptococcus pyogenes (Group A streptococcal infection) sepsis bacteremia 24 h post-infection corrected for age, sex, body weight, log inoculum (Fig 1B) [corrected log CFU/ml] |
Immune |
| X107 |
11025 |
Chlamydia psittaci (6BC) infection response (10^4 IFU ip), pathogen load in peritoneal cavity at 30 days among surviving 3-5 month males (subset of cases) [log ng of DNA] |
Immune |
| X803 |
11026 |
Chlamydia psittaci (6BC) infection response (10^4 IFU ip), spleen weight at 30 days among surviving animals, 2-4 months males (subset of cases from Miyiari 2007) [gm] |
Immune |
| X2932 |
12488 |
Spleen weight of 120-day-old females fed 3 ppm Fe diet [g] |
Immune |
| X3943 |
12489 |
Iron level in spleen of 120-day-old females fed 3 ppm Fe diet [ug/g] |
Immune |
| X2947 |
12496 |
Spleen weight of 120-day-old males fed 3 ppm Fe diet [g] |
Immune |
| X5016 |
12497 |
Iron level in spleen of 120 day old males fed 3 ppm Fe diet [ug/g] |
Immune |
| X4371 |
12504 |
Spleen weight of 120-day-old females fed 270 ppm iron (Fe) diet [g] |
Immune |
| X5073 |
12505 |
Iron level in spleen of 120-day-old females fed 270 ppm Fe diet [ug/g] |
Immune |
| X1995 |
12512 |
Spleen weight of 120-day-old males fed 270 ppm Fe diet [g] |
Immune |
| X3520 |
12513 |
Iron level in spleen of 120 day old males fed 270 ppm Fe diet [ug/g] |
Immune |
| X3588 |
12520 |
Spleen weight of 120-day-old males and females fed 3 ppm Fe diet [g] |
Immune |
| X2896 |
12521 |
Iron level in spleen of 120 day old males and females fed 3 ppm Fe diet [ug/g] |
Immune |
| X2789 |
12531 |
Spleen weight of 120-day-old males and females fed 270 ppm Fe diet [g] |
Immune |
| X5065 |
12532 |
Iron level in spleen of 120 day old males and females fed 270 ppm Fe diet [ug/g] |
Immune |
| X4013 |
12603 |
Peripheral blood lymphocytes, CD4+/CD8+ T cell ratio, males at 3-5 month [ratio] |
Immune |
| X587 |
12667 |
Ectromelia virus survival over two weeks after a 90 pfu injection into the footpad, males and females between 40 and 150 days of age, residuals corrected for sex, age, and body weight [~2.7 days/unit] |
Immune |
| X884 |
12668 |
Ectromelia virus formation of secondary dermal lesions over two weeks after 90 pfu injection into the footpad, males and females between 40 and 150 days of age, residuals corrected for sex, age and body weight [presence |
Immune |
| X1274 |
12669 |
Ectromelia virus euthanasia scale over two weeks after a 90 pfu injection into the footpad, males and females between 40 and 150 days of age, residuals corrected for sex, age and body weight [-1 is survival, +2 is rapid |
Immune |
| X693 |
12670 |
Ectromelia virus measure of disease onset, day of maximum clinical score over two weeks after a 90 pfu injection into the footpad, males and females between 40 and 150 days of age, residuals corrected for sex, age, and |
Immune |
| X378 |
12671 |
Ectromelia virus measure of severity of disease measured by the maximum clinical score over two weeks after a 90 pfu injection into the footpad, males and females between 40 and 150 days of age, residuals corrected for s |
Immune |
| X521 |
12672 |
Ectromelia virus survival over two weeks after a 90 pfu intranasal inoculation, males and females between 40 and 150 days of age, residuals corrected for sex, age, and body weight [~2.33 days/unit] |
Immune |
| X4331 |
12673 |
Ectromelia virus formation of secondary dermal lesions over two weeks after 90 pfu intranasal inoculation, males and females between 40 and 150 days of age, residuals corrected for sex, age and body weight [presence of l |
Immune |
| X1139 |
12674 |
Ectromelia virus measure of severity of disease measured by the maximum clinical score over two weeks after a 90 pfu intranasal inoculation, males and females between 40 and 150 days of age, residuals corrected for sex, |
Immune |
| X2346 |
12675 |
Ectromelia virus measure of disease onset measured by the day of maximum clinical score over two weeks after a 90 pfu intranasal inoculation, males and females between 40 and 150 days of age, residuals corrected for sex, |
Immune |
| X2730 |
12676 |
Cowpox virus survival over two weeks after 10^6 pfu intranasal inoculation, males and females between 40 and 152 days of age, residuals corrected for sex, age and body weight [~2.67/unit] |
Immune |
| X1307 |
12677 |
Cowpox virus severity of disease measured by the maximum clinical score over two weeks after a 10^6 pfu intranasal inoculation, males and females between 40 and 152 days of age, residuals corrected for sex, age, and body |
Immune |
| X3687 |
12678 |
Cowpox virus measure of disease onset measured by the day of maximum clinical score over two weeks after 10^6 pfu intranasal inoculation, males and females between 40 and 152 days of age, residuals corrected for sex, age |
Immune |
| X4349 |
12679 |
Cowpox virus maximum body temperature over two weeks after 10^6 pfu intranasal inoculation, males and females between 40 and 152 days of age, residuals corrected for sex, age and body weight [scaled deg C where -0.5 is > |
Immune |
| X3431 |
12680 |
Cowpox virus measure of disease onset measured by the day of maximum body temperature over two weeks after 10^6 pfu intranasal inoculation, males and females between 40 and 152 days of age, residuals corrected for sex, a |
Immune |
| X2133 |
12681 |
Cowpox virus maximum weight loss over two weeks after 10^6 pfu intranasal inoculation, males and females between 40 and 152 days of age, residuals corrected for sex, age and body weight at time of inoculation [scaled % l |
Immune |
| X4991 |
12682 |
Cowpox virus measure of disease onset measured by the day of maximum weight loss over two weeks after 10^6 pfu intranasal inoculation, males and females between 40 and 152 days of age, residuals corrected for sex, age an |
Immune |
| X387 |
12683 |
Ectromelia virus mortality score (combined data from Brownstein 1999 and Rice et al. 2010) [3 = resistant, 2 = intermediate, 1 = susceptible, table 1 column 1, ordinal scale] |
Immune |
| X2505 |
12702 |
Leishmania major (footpad injection, 5 million promastigotes at 7 weeks) footpad swelling, 3 weeks post infection in females (BXD80 winsorized from 196 to 120) [% of C57BL/6 control] |
Immune |
| X477 |
12703 |
Leishmania major (footpad injection, 5 million promastigotes at 7 weeks), parasite burden in feet 3 weeks post infection in females [% of C57BL/6 control] |
Immune |
| X2739 |
12704 |
Leishmania major (footpad injection, 5 million promastigotes at 7 weeks) Interferon-gamma from draining lymph node, 3 weeks post infection in females [% of C57BL/6 control] |
Immune |
| X1375 |
12705 |
Leishmania major (footpad injection, 5 million promastigotes at 7 weeks), granulocyte colony-stimulating factor (G-CSF, CSF3, Chr 11 at 98.6 Mb) from draining lymph node 3 weeks post infection in females [%of C57BL/6 con |
Immune |
| X2087 |
12706 |
Leishmania major (footpad injection of 5 million promastigotes at 7 weeks) granulocyte macrophage colony-stimulating factor (GM-CSF) level from draining lymph node, 3 weeks after infection in females (Luminex assay) [% |
Immune |
| X3112 |
12707 |
Leishmania major (footpad injection, 5 million promastigotes at 7 weeks) interleukin-1 alpha from draining lymph node, 3 weeks post infection in females [% of C57BL/6 control] |
Immune |
| X593 |
13009 |
H1N1 (PR8) influenza A virus (2x10E3 FFU), median body weight loss day 5 after infection in 9-14 week-old females [%] |
Immune |
| X894 |
12708 |
Leishmania major (footpad injection, 5 million promastigotes at 7 weeks), interleukin-1 beta level (IL1B, Chr 2 at 129 Mb) from draining lymph node 3 weeks post infection in females [%of C57BL/6 control] |
Immune |
| X5027 |
12709 |
Leishmania major (footpad injection, 5 million promastigotes at 7 weeks) interleukin-2 from draining lymph node, 3 weeks post infection in females [% of C57BL/6 control] |
Immune |
| X3459 |
12710 |
Leishmania major (footpad injection, 5 million promastigotes at 7 weeks) interleukin-3 from draining lymph node, 3 weeks post infection in females [% of C57BL/6 control] |
Immune |
| X2946 |
12711 |
Leishmania major (footpad injection, 5 million promastigotes at 7 weeks) interleukin-4 from draining lymph node, 3 weeks post infection in females [% of C57BL/6 control] |
Immune |
| X4926 |
12712 |
Leishmania major (footpad injection, 5 million promastigotes at 7 weeks) interleukin-5 from draining lymph node, 3 weeks post infection in females [% of C57BL/6 control] |
Immune |
| X2887 |
12713 |
Leishmania major (footpad injection, 5 million promastigotes at 7 weeks) interleukin-6 from draining lymph node, 3 weeks post infection in females [% of C57BL/6 control] |
Immune |
| X3496 |
12714 |
Leishmania major (footpad injection, 5 million promastigotes at 7 weeks) interleukin-10 from draining lymph node, 3 weeks post infection in females [% of C57BL/6 control] |
Immune |
| X3507 |
12715 |
Leishmania major (footpad injection, 5 million promastigotes at 7 weeks) interleukin-13 from draining lymph node, 3 weeks post infection in females [% of C57BL/6 control] |
Immune |
| X1631 |
12716 |
Leishmania major (footpad injection, 5 million promastigotes at 7 weeks) interleukin-17 from draining lymph node, 3 weeks post infection in females [% of C57BL/6 control] |
Immune |
| X1917 |
12717 |
Leishmania major (footpad injection, 5 million promastigotes at 7 weeks) IP-10 from draining lymph node, 3 weeks post infection in females [% of C57BL/6 control] |
Immune |
| X2532 |
12718 |
Leishmania major (footpad injection, 5 million promastigotes at 7 weeks) macrophage inflammatory protein-2 from draining lymph node, 3 weeks post infection in females [% of C57BL/6 control] |
Immune |
| X927 |
12719 |
Leishmania major (footpad injection, 5 million promastigotes at 7 weeks), chemokine (C-X-C motif) ligand 1 level (CXCL1, KC, Chr 5 at 91 Mb) from draining lymph node 3 weeks post infection in females [% of C57BL/6 contro |
Immune |
| X2339 |
12720 |
Leishmania major (footpad injection, 5 million promastigotes at 7 weeks) LIF from draining lymph node, 3 weeks post infection in females [% of C57BL/6 control] |
Immune |
| X4118 |
12721 |
Leishmania major response (footpad injection, 5 million promastigotes at 7 weeks), monocyte chemoattractant protein-1 (MCP1) level from draining lymph nodes 3 weeks after infection in females [% of C57BL/6 control] |
Immune |
| X1819 |
12723 |
Leishmania major (footpad injection, 5 million promastigotes at 7 weeks) macrophage inflammatory protein-1 alpha from draining lymph node, 3 weeks post infection in females [% of C57BL/6 control] |
Immune |
| X4260 |
12724 |
Leishmania major response (footpad injection, 5 million promastigotes at 7 weeks), macrophage inflammatory protein-1 beta (MIP1B) from draining lymph nodes 3 weeks after infection in females [% of C57BL/6 control] |
Immune |
| X544 |
13010 |
H1N1 (PR8) influenza A virus (2x10E3 FFU), median body weight loss day 6 after infection in 9-14 week-old females [%] |
Immune |
| X1770 |
12725 |
Leishmania major (footpad injection, 5 million promastigotes at 7 weeks) MIG alpha from draining lymph node, 3 weeks post infection in females [% of C57BL/6 control] |
Immune |
| X2431 |
12726 |
Leishmania major (footpad injection, 5 million promastigotes at 7 weeks) RANTES from draining lymph node, 3 weeks post infection in females [% of C57BL/6 control] |
Immune |
| X815 |
12727 |
Leishmania major (footpad injection, 5 million promastigotes at 7 weeks), tumor necrosis factor alpha level (TNFA, Chr 17 at 35 Mb) from draining lymph node 3 weeks post infection in females using Luminex assay |
Immune |
| X1045 |
12728 |
Leishmania major (footpad injection, 5 million promastigotes at 7 weeks), vascular endothelial growth factor (VEGF) level from draining lymph node, 3 weeks post infection in females [% of C57BL/6 control] |
Immune |
| X3733 |
12968 |
Malaria lethality, Plasmodium yoelii (PY17X subclone, 10^6 PRBC) in 7-12 week-old males (1 = 100% susceptible and 0 = 100% resistant) [fraction of cohort that survives] |
Immune |
| X670 |
12969 |
Malaria lethality, Plasmodium yoelii (PY17X subclone, 10^6 PRBC i.p.) in 7-12 week-old females (1 = 100% susceptible and 0 = 100% resistant) [fraction of cohort that survives] |
Immune |
| X216 |
12971 |
TNFa cytokine expression level two days after infection with H5N1 influenza A virus (10^4 EID-50 of HK213 virus in 30 microliters saline) [pg/mL] |
Immune |
| X1144 |
12972 |
MCP1 cytokine expression level two days after infection with H5N1 influenza A virus (10^4 EID-50 of HK213 virus in 30 microliters saline) [pg/mL] |
Immune |
| X194 |
12973 |
Interferon alpha (IFNa) cytokine expression level two days after infection with H5N1 influenza A virus (10^4 EID-50 of HK213 virus in 30 microliters saline) [pg/mL] |
Immune |
| X4722 |
12994 |
Malaria lethality, Plasmodium yoelii (PY17XL subclone, 10^6 PRBC i.p.) in 7-10 week old males (1=resistant and 0= susceptible)[survival fraction] |
Immune |
| X2266 |
12995 |
Malaria lethality, Plasmodium yoelii (PY17XL subclone, 10^6 PRBC i.p.) in 7-10 week old females (1=resistant and 0= susceptible)[survival fraction] |
Immune |
| X419 |
12996 |
H1N1 (PR8) influenza A virus (2x10E3 FFU), mean time to death after infection in 9-14 week-old females [days] |
Immune |
| X1797 |
13000 |
H1N1 (PR8) influenza A virus (2x10E3 FFU), percent survival day 11 after infection in 9-14 week-old females [%] |
Immune |
| X217 |
13001 |
H1N1 (PR8) influenza A virus (2x10E3 FFU), percent survival day 7 after infection in 9-14 week-old females [%] |
Immune |
| X511 |
13002 |
H1N1 (PR8) influenza A virus (2x10E3 FFU), percent survival day 8 after infection in 9-14 week-old females [%] |
Immune |
| X1071 |
13003 |
H1N1 (PR8) influenza A virus (2x10E3 FFU), percent survival day 9 after infection in 9-14 week-old females [%] |
Immune |
| X1618 |
13004 |
H1N1 (PR8) influenza A virus (2x10E3 FFU), percent survival day 10 after infection in 9-14 week-old females [%] |
Immune |
| X1832 |
13005 |
H1N1 (PR8) influenza A virus (2x10E3 FFU), median body weight loss day 1 after infection in 9-14 week-old females [%] |
Immune |
| X2637 |
13006 |
H1N1 (PR8) influenza A virus (2x10E3 FFU), median body weight loss day 2 after infection in 9-14 week-old females [%] |
Immune |
| X2468 |
13007 |
H1N1 (PR8) influenza A virus (2x10E3 FFU), median body weight loss day 3 after infection in 9-14 week-old females [%] |
Immune |
| X1481 |
13011 |
H1N1 (PR8) influenza A virus (2x10E3 FFU), median body weight loss day 7 after infection in 9-14 week-old females [%] |
Immune |
| X2558 |
13012 |
H1N1 (PR8) influenza A virus (2x10E3 FFU), median body weight loss day 8 after infection in 9-14 week-old females [%] |
Immune |
| X2275 |
13013 |
H1N1 (PR8) influenza A virus (2x10E3 FFU), median body weight loss day 9 after infection in 9-14 week-old females [%] |
Immune |
| X1586 |
13014 |
H1N1 (PR8) influenza A virus (2x10E3 FFU), median body weight loss day 10 after infection in 9-14 week-old females [%] |
Immune |
| X2030 |
13015 |
H1N1 (PR8) influenza A virus (2x10E3 FFU), median body weight loss day 11 after infection in 9-14 week-old females [%] |
Immune |
| X1288 |
13016 |
H1N1 (PR8) influenza A virus (2x10E3 FFU), median body weight loss day 12 after infection in 9-14 week-old females [%] |
Immune |
| X1573 |
13017 |
H1N1 (PR8) influenza A virus (2x10E3 FFU), median body weight loss day 13 after infection in 9-14 week-old females [%] |
Immune |
| X999 |
13043 |
Coccidioides immitis (Valley fever, San Joaquin California disease fungus, Coccidioidomycosis) susceptibility after an IP injection (500 - 800 CFU of the RS strain) in 7 to 12-week-old females, 10 per |
Immune |
| X674 |
13507 |
Burkholderia pseudomallei (126b) infection response (50 CFU intranasal), survival in males, [1=resistant, 0=sensitive] |
Immune |
| X600 |
14309 |
Serum glucose (unfasted) at 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [mg/dL serum) |
Immune |
| X4075 |
14310 |
Candida albicans titer in brain at 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [CFU x 10^4 per gram tissue] |
Immune |
| X706 |
14312 |
Candida albicans titer in kidney (log) at 72 h after inoculation with 1 x 10^6 cfu (ATCC 10231) IV via retroorbital sinus immediately after light onset [CFU x 10^4 per gram tissue] |
Immune |
| X4057 |
14316 |
lipocalin-2 (LCN-2) at 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [pg/mg protein, kidney] |
Immune |
| X4281 |
14317 |
Interleukin-6 (IL-6) protein level in kidney 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [pg/mg protein] |
Immune |
| X1717 |
14318 |
G-CSF (granulocyte colony stimulating factor) at 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [pg/mg protein, kidney] |
Immune |
| X2668 |
14319 |
IP-10 (Interferon gamma-induced protein 10 or CXLC10) at 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinusimmediately after light onset [pg/mg protein, kidney] |
Immune |
| X4965 |
14320 |
MIP-2 (macrophage inflammatory protein 2-alpha or CXCL2) at 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [pg/mg protein, kidney] |
Immune |
| X1829 |
14321 |
;\KC (CXCL1;; keratinocyte-derived chemokine at 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [pg/mg protein, kidney] |
Immune |
| X1769 |
10175 |
Ethanol response (2 g/kg ip), rate of ethanol clearance [mg/ml/hr] |
Metabolism |
| X3772 |
14322 |
MCP-1 (CCL2 or monocyte chemotactic protein-1) at 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [pg/mg protein, kidney] |
Immune |
| X2894 |
14323 |
TNF-a at 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [pg/mg protein, kidney] |
Immune |
| X2654 |
14324 |
temperature during h 0-12 after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset (difference from baseline, C) |
Immune |
| X3321 |
14326 |
Temperature during h 24-36 after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [difference from baseline, C] |
Immune |
| X4463 |
14328 |
Temperature during h 48-60 after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [difference from baseline, C] |
Immune |
| X4428 |
14330 |
locomotor activity during h 0-12 after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus performed immediately after light onset [ratio to baseline] |
Immune |
| X3848 |
14331 |
locomotor activity during h 12-24 after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus performed immediately after light onset [ratio to baseline] |
Immune |
| X4793 |
14332 |
locomotor activity during h 24-36 after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [ratio to baseline] |
Immune |
| X2806 |
14333 |
locomotor activity during h 36-48 after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [ratio to baseline] |
Immune |
| X1353 |
14334 |
locomotor activity during h 48-60 after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [ratio to baseline] |
Immune |
| X1094 |
14335 |
Locomotor activity 60-72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [ratio to baseline] |
Immune |
| X2674 |
14338 |
G-CSF (granulocyte colony stimulating factor) (log) at 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [pg/mg protein, log, kidney] |
Immune |
| X2035 |
14339 |
IL-6 (interleukin-6) protein level in kidney 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [log pg/mg protein] |
Immune |
| X2179 |
14340 |
;\KC (CXCL1;; keratinocyte-derived chemokine) (log) at 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [pg/mg protein, log, kidney]\ |
Immune |
| X3406 |
14341 |
IP-10 (Interferon gamma-induced protein 10 or CXLC10) (log) at 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinusimmediately after light onset [pg/mg protein, log, kidney] |
Immune |
| X491 |
14342 |
Lipocalin-2 (LCN-2) level in kidney 72 h after inoculation with 1 x 10^6 CFU Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [log pg/mg protein] |
Immune |
| X2951 |
10176 |
Ethanol response (3 g/kg ip), rate of clearance, beta [mg/ml/hr] |
Metabolism |
| X1422 |
14343 |
MCP-1 (CCL2 or monocyte chemotactic protein-1) (log) at 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [pg/mg protein, log, kidney] |
Immune |
| X2308 |
14344 |
MIP-2 (macrophage inflammatory protein 2-alpha or CXCL2) (log) at 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [pg/mg protein, log, kidn |
Immune |
| X634 |
14345 |
TNF-a (log) at 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [pg/mg protein, log, kidney] |
Immune |
| X4984 |
14349 |
locomotor activity (log) during h 12-24 after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus performed immediately after light onset [ratio to baseline. log] |
Immune |
| X4711 |
14350 |
locomotor activity (log) during h 24-36 after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [ratio to baseline, log] |
Immune |
| X4816 |
14351 |
locomotor activity (log) during h 36-48 after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [ratio to baseline, log] |
Immune |
| X2284 |
14352 |
locomotor activity (log) during h 48-60 after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [ratio to baseline, log] |
Immune |
| X1588 |
14353 |
Locomotor activity (log) during h 60-72 after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [ratio to baseline, log] |
Immune |
| X2920 |
14401 |
Acinetobacter baumannii infection, bronchoalveolar lavage (BAL) lung lymphocyte cell number following (BXD65 winsorized from 47.5 to 26.0) [units/ul] |
Immune |
| X1639 |
14402 |
Bronchoalveolar lavage (BAL) lung lymphocyte cell number following infection with Acinetobacter baumannii [units/ul] |
Immune |
| X264 |
14783 |
Chlamydia muridarum upper genital tract disease severity (endometrium, uterine horn) after primary and secondary intravaginal infection by with 5x10^3 C. muridarum [ordinal scale 0 = no disease, 4 = severe] |
Immune |
| X414 |
14785 |
Chlamydia muridarum upper genital tract disease severity (oviduct) after primary and secondary intravaginal infection by with 5x10^3 C. muridarum [ordinal scale 0 = no disease, 4 = severe disease] |
Immune |
| X3266 |
14807 |
Susceptibility to Staphylococcus aureus, colony forming units (CFU) in blood 48h after infection of 10E5 CFU per mouse in 10-14 old females [CFU (log10)] |
Immune |
| X2350 |
14808 |
Susceptibility to Staphylococcus aureus, colony forming units (CFU) in kidney 48 h after infection of 10E5 CFU in 10-14 old females [CFU (log10)] |
Immune |
| X4506 |
14809 |
Susceptibility to Staphylococcus aureus, colony forming units (CFU) in liver 48 h after infection of 10E5 CFU in 10-14 old females [CFU (log10)] |
Immune |
| X1663 |
14810 |
Susceptibility to Staphylococcus aureus, colony forming units (CFU) in heart 48h after infection of 10E5 CFU per mouse in 10-14 old females [CFU (log10)] |
Immune |
| X3981 |
14811 |
Susceptibility to Staphylococcus aureus, mean time of death in days of mice infected with 10E5 colony forming units (CFU) per mouse in 10-14 old females [days] |
Immune |
| X1194 |
14812 |
Susceptibility to Staphylococcus aureus, survival 10 days after infection with 10E5 colony forming units (CFU) in 10 to 14 day-old females [%] |
Immune |
| X1970 |
14813 |
Susceptibility to Staphylococcus aureus, % survival after 4 days of mice infected with 10E5 colony forming units (CFU) per mouse in 10-14 old females [%] |
Immune |
| X1891 |
14814 |
Mycobacterium tuberculosis (H37Rv, 100 colony forming units (CFU)) response, bacterial load in lung 21 days after aerosol infection in 12-23 week-old females [linear CFU/lung/1000] |
Immune |
| X575 |
14815 |
Linear bacterial load in lung 90 days after aerosol infection with 100 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 18-30 week-old females [linear CFU / lung / 10000] |
Immune |
| X4934 |
14816 |
Linear bacterial load in spleen 21 days after aerosol infection with 100 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 12-23 week-old females [linear CFU / spleen / 100] |
Immune |
| X3526 |
14817 |
Linear bacterial load in spleen 90 days after aerosol infection with 100 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 18-30 week-old females [linear CFU / spleen / 1000] |
Immune |
| X1834 |
14818 |
Linear bacterial load in liver 21 days after aerosol infection with 100 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 12-23 week-old females [linear CFU / liver / 10] |
Immune |
| X5053 |
14819 |
Linear bacterial load in liver 90 days after aerosol infection with 100 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 18-30 week-old females [linear CFU / liver / 100] |
Immune |
| X3128 |
14820 |
Quantity of lung pathology 21 days after aerosol infection with 100 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 12-23 week-old females [quantitative score (10 lowest - 70 highest)] |
Immune |
| X3989 |
14821 |
Quantity of lung pathology 90 days after aerosol infection with 100 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 18-30 week-old females [quantitative score (10 lowest - 70 highest)] |
Immune |
| X1642 |
14822 |
Lung weight/body weight 21 days after aerosol infection with 100 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 12-23 week-old females [lung weight/body weight * 10000] |
Immune |
| X4891 |
14823 |
Lung weight/body weight 90 days after aerosol infection with 100 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 18-30 week-old females [lung weight/body weight * 10000] |
Immune |
| X2495 |
14824 |
Linear median survival time after aerosol infection with 1000 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 12-48 week-old females [days] |
Immune |
| X3416 |
14825 |
Bacterial load in lungs 21 days after aerosol infection with 100 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 12-23 week-old females [log10 CFU / lung * 100] |
Immune |
| X2967 |
14826 |
Bacterial load in lungs 90 days after aerosol infection with 100 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 18-30 week-old females [log10 CFU / lung * 100] |
Immune |
| X4933 |
14827 |
Normalized bacterial load in lungs 90 days after aerosol infection with 100 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 18-30 week-old females [ratio CFU BXD / CFU C57BL/6J * 100] |
Immune |
| X2343 |
15120 |
CD44+ Ly6C+ cells as a percentage of CD3+ CD8+ cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%] |
Immune |
| X4086 |
14828 |
Quality of lung pathology 90 days after aerosol infection with 100 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 18-30 week-old females [ordinal scale (10 = normal, 20 = intermediate, 30 = severe)] |
Immune |
| X4997 |
14829 |
Body weight 13 weeks after aerosol infection with 1000 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 13-30 week-old females [g] |
Immune |
| X2402 |
14830 |
Mean moribund body weight after aerosol infection with 1000 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 12-48 week-old females [g * 10] |
Immune |
| X4427 |
14831 |
Mean temperature 13 weeks after aerosol infection with 1000 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 13-30 week-old females [deg C * 10] |
Immune |
| X4923 |
14832 |
Mean moribund temperature after aerosol infection with 1000 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 12-48 week-old females [deg C * 10] |
Immune |
| X3195 |
14833 |
Normalized median survival time after aerosol infection with 1000 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 12-48 week-old females [ratio survival time BXD / survival time C57BL/6J * 100] |
Immune |
| X4194 |
14834 |
Median survival time in log10 after aerosol infection with 1000 colony forming units (CFU) Mycobacterium tuberculosis H37Rv in 12-48 week-old females [days in log10 * 100] |
Immune |
| X1198 |
15107 |
CD3+ cells as a percentage of CD45+ cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%] |
Immune |
| X1041 |
15108 |
CD3+CD4+ cells as a percentage of CD45+ cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%] |
Immune |
| X2992 |
15109 |
CD3+CD8a+ cells as a percentage of CD45+ cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%] |
Immune |
| X2508 |
15110 |
CD25+ cells as a percentage of CD3+ CD4+ in peripheral blood measured by fluorescence activated cell sorting (FACS) [%] |
Immune |
| X2020 |
15111 |
CD3+ gamma/delta TCR+ cells as a percentage of CD45+ cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%] |
Immune |
| X2325 |
15112 |
Ly6C+ cells as a percentage of CD3+ CD4+ cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%] |
Immune |
| X1895 |
15113 |
CD62L+ cells as a percentage of CD3+ CD4+ cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%] |
Immune |
| X126 |
15114 |
CD44+ effector-memory T cells as a percentage of CD3+ CD4+ T cells in peripheral blood measured by fluorescence activated cell sorting (this trait maps to CD44 locus) (FACS) [%] |
Immune |
| X1945 |
15115 |
CD44+ cells as a percentage of CD3+ CD4+ without CD62L cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%] |
Immune |
| X991 |
15116 |
CD62L+ T cells without CD44 cells as a percentage of CD3+ CD4+ T cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%] |
Immune |
| X2891 |
15117 |
Ly6C+ cells as a percentage of CD3+ CD8+ cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%] |
Immune |
| X2986 |
15118 |
CD62L+ cells as a percentage of CD3+ CD8+ cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%] |
Immune |
| X4376 |
15119 |
CD44+ cells as a percentage of CD3+ CD8+ cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%] |
Immune |
| X1997 |
15121 |
CD44+ cells excluding CD62L cells as a percentage of CD8+ CD3+ cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%] |
Immune |
| X660 |
15122 |
CD62L+ cells excluding CD44 cells as a percentage of CD3+CD8+ cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%] |
Immune |
| X3451 |
15123 |
GR-1+ CD11b+ cells as a percentage of CD45 cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%] |
Immune |
| X3969 |
15124 |
Gr-1-NKp46- CD11b+ as a percentage of CD45+ cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%] |
Immune |
| X4986 |
15125 |
Nkp46+ cells as a percentage of CD45 cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%] |
Immune |
| X4000 |
15126 |
B cells (CD19 or B220 and IgD) as a percentage of CD45+ cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%] |
Immune |
| X4459 |
15127 |
CD5+ cells as a percentage of B cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%] |
Immune |
| X4680 |
15128 |
IgD+ cells as a percentage of B cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%] |
Immune |
| X1043 |
15129 |
B cells as a percentage of MHC class II (I/A-E) cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%] |
Immune |
| X1909 |
15130 |
Immune system, CD11b+ NKp46+ cells as a percentage of CD5-cells in peripheral blood measured by fluorescence activated cell sorting (FACS) [%] |
Immune |
| X3655 |
15133 |
Malaria infection lethality, Plasmodium yoelii (PY17X subclone, 10^6 PRBC i.p.) in 7-12 week-old males and females (0 = 100% resistant, 1 = 100% susceptible) [fraction of cohort that survives] |
Immune |
| X1550 |
15167 |
Ectromelia virus formation of secondary dermal lesions over two weeks after 90 pfu injection into the footpad, females between 40 and 150 days of age, residuals corrected for age and body weight [presence of lesions wh |
Immune |
| X3149 |
15168 |
Ectromelia virus formation of secondary dermal lesions over two weeks after 90 pfu injection into the footpad, males only between 40 and 150 days of age, residuals corrected for age and body weight [presence of lesions |
Immune |
| X475 |
15555 |
Kramer RM, Lamkin T, and colleagues TAFI1 |
Immune |
| X823 |
15556 |
Kramer RM, Lamkin T, and colleagues TAFI3 |
Immune |
| X278 |
15557 |
Kramer RM, Lamkin T, and colleagues TAFI2 |
Immune |
| X347 |
15558 |
Kramer RM, Lamkin T, and colleagues TAFI4 |
Immune |
| X552 |
15559 |
Kramer RM, Lamkin T, and colleagues TAFI5 |
Immune |
| X525 |
15560 |
Kramer RM, Lamkin T, and colleagues TAFI6 |
Immune |
| X406 |
15561 |
Kramer RM, Lamkin T, and colleagues TAFI7 |
Immune |
| X1572 |
15562 |
Kramer RM, Lamkin T, and colleagues TAFI8 |
Immune |
| X1650 |
15563 |
Kramer RM, Lamkin T, and colleagues TAFI9 |
Immune |
| X782 |
15564 |
Kramer RM, Lamkin T, and colleagues TAFI10 |
Immune |
| X2684 |
15565 |
Kramer RM, Lamkin T, and colleagues TAFI11 |
Immune |
| X4530 |
15566 |
Kramer RM, Lamkin T, and colleagues TAFI12 |
Immune |
| X3561 |
15568 |
Kramer RM, Lamkin T, and colleagues, TAFI13 |
Immune |
| X2166 |
15569 |
Kramer RM, Lamkin T, and colleagues TAFI14 |
Immune |
| X331 |
15963 |
Tuberculosis, bacterial load in lung (BXD71 winsorized from 4.18 to 4.98) [log CFU] |
Immune |
| X4135 |
15964 |
Malaria susceptibility, murine Plasmodium yoelli 17 (PY17X-L) [0=resistant, 1= susceptible] |
Immune |
| X531 |
16185 |
Herpes simplex virus type 1, virulence following corneal infection, young adult male and female (combined) [percent mortality] |
Immune |
| X1506 |
16186 |
Herpes simplex virus type 1, stromal keratitis severity following corneal infection, young adult male and female (combined) [ordinal 1 t0 5 scale, 0=none, 5 = penetrating lesions] |
Immune |
| X4083 |
16191 |
Herpes simplex virus type 1, spleen weight following corneal infection, young adult female [g] |
Immune |
| X4851 |
16192 |
Herpes simplex virus type 1, spleen weight following corneal infection, young adult male [g] |
Immune |
| X5018 |
16193 |
Herpes simplex virus type 1, spleen weight following corneal infection, young adult male and female (combined) [g] |
Immune |
| X310 |
16194 |
Herpes simplex virus type 1, percent maximum weight loss following corneal infection, young adult female (combined) [max weight loss %] |
Immune |
| X203 |
16195 |
Herpes simplex virus type 1, percent weight loss following corneal infection, young adult male [max weight loss %] |
Immune |
| X133 |
16196 |
Herpes simplex virus type 1, percent weight loss following corneal infection, young adult female and male [max weight loss %] |
Immune |
| X2001 |
16228 |
Herpes simplex virus 1 (HSV-1) ocular pathogenesis, please add details on sex, innoculum, age, etc here [units] |
Immune |
| X2370 |
16242 |
Cowpox virus disease onset measured by day of max clinical score over three weeks after 10^5pfu intranasal infection, males and females between XX and XXX days of age, residuals corrected for age, sex and body weight [ |
Immune |
| X3884 |
16304 |
Herpes simplex virus type 1, serum neutralizing antibody titer in young adult males [unit] |
Immune |
| X749 |
16305 |
Herpes simplex virus type 1, serum neutralizing antibody titer in young adult females [unit] |
Immune |
| X3828 |
16314 |
serum inhibition of TSH binding to the TSHR before immunization [% inhibition] |
Immune |
| X98 |
16315 |
TBI-2x, serum inhibition of TSH binding to the TSHR 1 week after 2 immunizations with TSHR A-subunit adenovirus [% inhibition] |
Immune |
| X74 |
16316 |
Serum inhibition of TSH binding to the TSHR 4 weeks after 3 immunizations with TSHR A-subunit adenovirus in young adult females [% inhibition] |
Immune |
| X2102 |
16320 |
ELISA-2x, IgG class antibody binding to TSHR A-subunit protein in ELISA 1 week after 2 immunizations of female mice with TSHR A-subunit adenovirus [OD 490 nm] |
Immune |
| X1687 |
16321 |
ELISA-3x, IgG class antibody binding to TSHR A-subunit protein in ELISA 4 weeks after 3 immunizations with TSHR A-subunit adenovirus [OD490 nm] |
Immune |
| X215 |
16330 |
Burkholderia pseudomallei (1026b) infection response (50-100 CFU intranasal), survival in males, [1=resistant, 0=sensitive] |
Immune |
| X254 |
16331 |
Burkholderia pseudomallei (1026b) infection response (50-100 CFU intranasal), survival in males, day of death [days] |
Immune |
| X1317 |
16332 |
Burkholderia pseudomallei (1026b) infection response (50-100 CFU intranasal), survival in males, weight loss Day 1 [% change in body weight] |
Immune |
| X1963 |
15733 |
Body temperature after 6 hours in 4 deg C chamber, high fat diet / chow diet, males [ratio] |
Metabolism |
| X1778 |
16333 |
Burkholderia pseudomallei (1026b) infection response (50-100 CFU intranasal), survival in males, weight loss Day 2 [% change in body weight] |
Immune |
| X1308 |
16334 |
Burkholderia pseudomallei (1026b) infection response (50-100 CFU intranasal), survival in males, weight loss Day 3 [% change in body weight] |
Immune |
| X745 |
16335 |
Burkholderia pseudomallei (1026b) infection response (50-100 CFU intranasal), survival in males, weight loss Day 4 [% change in body weight] |
Immune |
| X1427 |
16343 |
H1N1 (PR8) influenza A virus (2x10E3 FFU), body weight loss day 3 after infection in 9-14 week-old females [%] - individual mice from RNAseq experiment (HZI PR8M-Infected Lungs Females RNAseq (Nov13) RPKM) |
Immune |
| X1489 |
16346 |
Herpes simplex virus type 1, serum neutralization titer following corneal infection, young adult male and female (combined) [unit] |
Immune |
| X1010 |
16350 |
Burkholderia pseudomallei (1026b) infection response (50-100 CFU intranasal), survival in males, weight loss, first principal component, days 1-4 [% change in body weight] |
Immune |
| X798 |
16376 |
Please enter the full trait description here even BEFORE publication. Only you will see these descriptions. |
Immune |
| X3506 |
16377 |
EOMES coefficient (Malak Kotb and colleagues 2014) Please provide a full description of the trait now here with information on sex, age range, innoculum, route of infection etc. [units] |
Immune |
| X2731 |
16607 |
Please put in a full description of the phenotype here with sex, age, innoculum, dose, route and at the end in square brackets the [units] 3_colo_Russo |
Immune |
| X3143 |
16608 |
Please put in a full description of the phenotype here with sex, age, innoculum, dose, route and at the end in square brackets the [units]deltaD2-D1_colo_Russo |
Immune |
| X743 |
17081 |
Staphloccocus pyogenes (sq injection of 1.0x10x8 CFU) survival index in males and females injected at 10___16 weeks of age (scored as follows: death before day 3 = 1, death from 3 to 7 = 2, death after day 7 =3) [index] |
Immune |
| X4894 |
17319 |
H1N1 (PR8) influenza A virus (2x10E3 FFU), viral HA gene expression in lung of individual mice used in companion RNAseq experiment (see HZI PR8M-Infected Lungs Females RNAseq (Nov13) RPKM) [log2 RPKM] |
Immune |
| X4802 |
17320 |
H1N1 (PR8) influenza A virus (2x10E3 FFU), viral M gene expression in lung of individual mice used in companion RNAseq experiment (see HZI PR8M-Infected Lungs Females RNAseq (Nov13) RPKM) [log2 RPKM] |
Immune |
| X3699 |
17321 |
H1N1 (PR8) influenza A virus (2x10E3 FFU), viral NA gene expression in lung of individual mice used in companion RNAseq experiment (see HZI PR8M-Infected Lungs Females RNAseq (Nov13) RPKM) [log2 RPKM] |
Immune |
| X3830 |
17322 |
H1N1 (PR8) influenza A virus (2x10E3 FFU), viral NP gene expression in lung of individual mice used in companion RNAseq experiment (see HZI PR8M-Infected Lungs Females RNAseq (Nov13) RPKM) [log2 RPKM] |
Immune |
| X3263 |
17323 |
H1N1 (PR8) influenza A virus (2x10E3 FFU), viral NS gene expression in lung of individual mice used in companion RNAseq experiment (see HZI PR8M-Infected Lungs Females RNAseq (Nov13) RPKM) [log2 RPKM] |
Immune |
| X1939 |
17324 |
H1N1 (PR8) influenza A virus (2x10E3 FFU), viral PB1 gene expression in lung of individual mice used in companion RNAseq experiment (see HZI PR8M-Infected Lungs Females RNAseq (Nov13) RPKM) [log2 RPKM |
Immune |
| X3584 |
17325 |
H1N1 (PR8) influenza A virus (2x10E3 FFU), viral PB2 gene expression in lung of individual mice used in companion RNAseq experiment (see HZI PR8M-Infected Lungs Females RNAseq (Nov13) RPKM) [log2 RPKM |
Immune |
| X4315 |
17326 |
H1N1 (PR8) influenza A virus (2x10E3 FFU), viral PA gene expression in lung of individual mice used in companion RNAseq experiment (see HZI PR8M-Infected Lungs Females RNAseq (Nov13) RPKM) [log2 RPKM] |
Immune |
| X59 |
17439 |
Rickettsiu tsutsugamushi susceptibility (strain Gilliam, ip 100 50% mouse infectious doses, two treatments) of both sexes at 6-12 weeks-of-age (ordinal scale 0 = resistant, 1=susceptible, also see BXH RI set), maps to Gb |
Immune |
| X443 |
17467 |
Log Day 1 of counts of E coli colonization in BXD strains colon after infection with 109 cfu of E. coli strain O157:H7, isolate Tuv 86-2 (Stx2-), intra-gastric gavage, female mice, 5___7 weeks old [CFU/g feces] |
Immune |
| X958 |
17520 |
Streptococcus pyogenes (Group A streptococcal infection), Necrotizing soft tissue infections body weight change after infection corrected for strain, sex, age and body weight, day 4 [%] |
Immune |
| X449 |
17521 |
Streptococcus pyogenes (Group A streptococcal infection), Necrotizing soft tissue infections body weight change after infection corrected for strain, sex, age and body weight, day 3 [%] |
Immune |
| X989 |
17522 |
Streptococcus pyogenes (Group A streptococcal infection), Necrotizing soft tissue infections body weight change after infection corrected for strain, sex, age and body weight, day 2 [%] |
Immune |
| X871 |
17523 |
Streptococcus pyogenes (Group A streptococcal infection), Necrotizing soft tissue infections body weight change after infection corrected for strain, sex, age and body weight, day 1 [%] |
Immune |
| X106 |
17524 |
Streptococcus pyogenes (Group A streptococcal infection), Necrotizing soft tissue infections survival after infection corrected for strain, sex, age and body weight given as corrected relative survival index [-1.5 = high |
Immune |
| X1541 |
17525 |
Streptococcus pyogenes (Group A streptococcal infection), Necrotizing soft tissue infections lesion size after infection corrected for strain, sex, age and body weight given as maximum lesion area [Sq.mm] |
Immune |
| X284 |
17527 |
Streptococcus pyogenes (Group A streptococcal infection), Necrotizing soft tissue infections body weight change after infection corrected for strain, sex, age and body weight given as principal component 1 of day 1 to da |
Immune |
| X4233 |
18440 |
Malaria susceptibility, murine Plasmodium yoelli 17X-lethal (PY17X-L) [0=100% resistant, 1= 100% susceptible] |
Immune |
| X1700 |
10019 |
Body temperature following saline injection, control for morphine response [degree C] |
Metabolism |
| X3400 |
10045 |
Body temperature (baseline control for quinpirole study) [degrees C] |
Metabolism |
| X687 |
10112 |
Life span, longevity of females (RWW winsorized outliers BXD2, BXD14, and DBA2J from 400,500, and 175 days, respectively, data originally from Gelman et al. 1988, except parental strains) [days] |
Metabolism |
| X536 |
10148 |
Life span, longevity of females (mean age) at the Dana-Faber Cancer Institute (Redstone Animal Facility, Boston MA) from Jackson Laboratory between Nov 1982 and Mar 1983 on Purina chow (all data reinstated, authors initially excluded BXD13 due to s |
Metabolism |
| X3076 |
10149 |
Hepatic lipid peroxidation (LPO) levels in 2-month-old males [malondialdehyde (MDA)/mg] |
Metabolism |
| X261 |
17731 |
Body weight in home cage_CD, males [g] |
Morphology |
| X4553 |
10177 |
Pharmacology. Ethanol response (2 g/kg ip), blood ethanol concentration (BEC) 60 min after injection [mg/ml] |
Metabolism |
| X3138 |
10178 |
Ethanol response (3 g/kg ip), blood ethanol concentration (BEC) 60 min after injection [mg/ml] |
Metabolism |
| X3824 |
10247 |
Iron level in liver of males [ug/g] |
Metabolism |
| X2462 |
10248 |
Iron level in liver of females [ug/g] |
Metabolism |
| X90 |
10371 |
Cytosolic aryl-hydrocarbon receptor (AHR) protein levels in liver (fmol/mg cytosolic protein) |
Metabolism |
| X1214 |
10380 |
B-mannosidase activity in liver of females, p-nitrophenl liberated per tissue wet weight per hour at 37 deg C (Manba gene on Chr 3 at 135 Mb) [mg/gm/hr] |
Metabolism |
| X3132 |
10510 |
Ethanol response (4 g/kg ip), body temperature 120 min after injection in males [degrees C] |
Metabolism |
| X3177 |
10519 |
Body temperature baseline control before injection with ethanol (4 g/kg ip) in females [degrees C] |
Metabolism |
| X4040 |
10520 |
Body temperature baseline control before injection with ethanol (4 g/kg ip) in males [degrees C] |
Metabolism |
| X1649 |
10521 |
Ethanol response (4 g/kg ip), body temperature 120 min after injection in females [degrees C] |
Metabolism |
| X1875 |
10522 |
Body temperature baseline control before saline injection in females [degrees C] |
Metabolism |
| X4372 |
10812 |
Iron level in liver of males [ug/g] |
Metabolism |
| X4392 |
10821 |
Iron level in liver of males and females [ug/g] |
Metabolism |
| X4763 |
10835 |
Iron level in liver of females [ug/g] |
Metabolism |
| X4167 |
11710 |
Ethanol response (2.25 g/kg ip), blood ethanol concentration (BEC) for females [mg/dl XX min after injection] |
Metabolism |
| X5045 |
12490 |
Iron level of liver of 120-day-old females fed 3 ppm Fe diet [ug/g] |
Metabolism |
| X4310 |
12498 |
Iron level of liver of 120-day-old males fed 3 ppm Fe diet [ug/g] |
Metabolism |
| X2319 |
12506 |
Iron level in liver of 120-day-old females fed 270 ppm Fe diet [ug/g] |
Metabolism |
| X1854 |
12514 |
Iron level of liver of 120-day-old males fed 270 ppm Fe diet [ug/g] |
Metabolism |
| X5034 |
12522 |
Iron level of liver of 120-day-old males and females fed 3 ppm Fe diet [ug/g] |
Metabolism |
| X2127 |
12533 |
Iron level of liver of 120-day-old males and females fed 270 ppm Fe diet [ug/g] |
Metabolism |
| X3332 |
12563 |
Life span, longevity of males on ad libitum diet, 12 hr light cycle [median of 12 animals in days] (BXD13=116 days and BXD31=434 days are deleted outliers) |
Metabolism |
| X3309 |
12564 |
Life span, longevity of females on ad libitum diet, 12 hr light cycle [median of 12 animals in days] (BXD13=158 days and BXD31=264 days are deleted outliers) |
Metabolism |
| X4495 |
12684 |
High-dose total body gamma-irradiation survival for 12-week-old females, mean survival time (MST) after a 137-Cesium 6 Gy single exposure (LD80/30) evaluated over a 30 day post-exposure, no supportive care [resid |
Metabolism |
| X1518 |
12826 |
Blood glucose level (intraperitoneal glucose tolerance test), area under curve (AUC) of 18-week old females [mg/dl] |
Metabolism |
| X1731 |
12852 |
Food intake of 13-week old females [g/mouse] |
Metabolism |
| X3365 |
12856 |
Blood glucose level (intraperitoneal glucose tolerance test) at time=0 min of 18-week old females [mg/dl] |
Metabolism |
| X3340 |
12857 |
Blood glucose level (intraperitoneal glucose tolerance test) at time=120 min of 18-week old females [mg/dl] |
Metabolism |
| X3528 |
12858 |
Blood glucose level (intraperitoneal glucose tolerance test) at time=15 min of 18-week old females [mg/dl] |
Metabolism |
| X3358 |
12859 |
Blood glucose level (intraperitoneal glucose tolerance test) at time=30 min of 18-week old females [mg/dl] |
Metabolism |
| X2713 |
12860 |
Blood glucose level (intraperitoneal glucose tolerance test) at time=60 min of 18-week old females [mg/dl] |
Metabolism |
| X4264 |
12867 |
Liver mass of 20-week old females [g] |
Metabolism |
| X508 |
12878 |
Respiratory exchange ratio (RER) of 13-week old females [ratio] |
Metabolism |
| X3446 |
12879 |
Body temperature (rectal) of 13-week old females [deg C] |
Metabolism |
| X2846 |
12885 |
Volume of CO2 production of 13-week old females [ml/kg/h] |
Metabolism |
| X3053 |
12886 |
Volume oxygen consumption of 13-week old females [ml/kg/h] |
Metabolism |
| X1210 |
12889 |
Water intake of 13-week old females [ml/mouse/unit time] |
Metabolism |
| X913 |
12896 |
Blood glucose level (intraperitoneal glucose tolerance test), area under curve (AUC) of 18-week old males [mg/dl] |
Metabolism |
| X4872 |
12922 |
Food intake of 13-week old males [g/mouse] |
Metabolism |
| X1475 |
12926 |
Blood glucose level (intraperitoneal glucose tolerance test) at time=0 min of 18-week old males [mg/dl] |
Metabolism |
| X1863 |
12927 |
Blood glucose level (intraperitoneal glucose tolerance test) at time=120 min of 18-week old males [mg/dl] |
Metabolism |
| X2159 |
12928 |
Blood glucose level (intraperitoneal glucose tolerance test) at time=15 min of 18-week old males [mg/dl] |
Metabolism |
| X1078 |
12929 |
Blood glucose level (intraperitoneal glucose tolerance test) at time=30 min of 18-week old males [mg/dl] |
Metabolism |
| X2941 |
12930 |
Blood glucose level (intraperitoneal glucose tolerance test) at time=60 min of 18-week old males [mg/dl] |
Metabolism |
| X4956 |
12937 |
Liver mass of 20-week old males [g] |
Metabolism |
| X993 |
12948 |
Respiratory exchange ratio (RER) of 13-week old males [ratio] |
Metabolism |
| X4758 |
12949 |
Body temperature (rectal) of 13-week old males [deg C] |
Metabolism |
| X309 |
12955 |
Volume of CO2 production of 13-week old males [ml/kg/h] |
Metabolism |
| X966 |
12956 |
Volume oxygen consumption of 13-week old males [ml/kg/h] |
Metabolism |
| X3600 |
12959 |
Water intake of 13-week old males [ml/mouse/unit time] |
Metabolism |
| X4023 |
12977 |
Alcohol response (6 mg/kg in saline, gastric gavage), blood alcohol concentration (BAC) 1-3 hr after gavage of young adult males and females (strain average associated with GenEx EtOH liver gene expression) [mg/dl] |
Metabolism |
| X3630 |
12978 |
Alcohol response (6 mg/kg in saline, gastric gavage), blood alcohol concentration (BAC) 24 hr after gavage of young adult males and females (strain average associated with GenEx EtOH liver gene expression) [mg/dl] |
Metabolism |
| X3764 |
12980 |
Alcohol response (6 mg/kg in saline, gastric gavage), blood alcohol concentration (BAC) 1-3 hr after gavage of young adult males (associated with GenEx EtOH liver gene expression) [mg/dl] |
Metabolism |
| X2338 |
12981 |
Alcohol response (6 mg/kg in saline, gastric gavage), blood alcohol concentration (BAC) 1-3 hr after gavage of young adult females (associated with GenEx EtOH liver gene expression) [mg/dl] |
Metabolism |
| X3008 |
12983 |
Alcohol response (6 mg/kg in saline, gastric gavage), blood alcohol concentration (BAC) 24 hr after gavage of young adult females (associated with GenEx EtOH liver gene expression) [mg/dl] |
Metabolism |
| X3645 |
16924 |
Ratio of acid beta-glucosidase/hexosaminidase A activity in liver _CD |
Metabolism |
| X2619 |
13030 |
Vials of hepatocyte obtained per strain from first run of spring 2011 by Piedmont and Varigenix, one vial of approximately 1 million cells (the error term is 2 times the percentage of non-viable cells) [n] |
Metabolism |
| X2749 |
13037 |
Hepatocyte phase I (CYP1A) metabolic activity measured by 7-ethoxycoumarin-o-deethylase (ECOD, 7EC) consumption at 0 and 30 minutes (25 uM/sample) using cryorederived hepatocytes from young adult male liver (BXD31 winsorize |
Metabolism |
| X1694 |
13038 |
Hepatocyte phase II metabolic activity (7HC, glucuronidation and sulfation) measured by production of 7-hydroxycoumarin glucouronide at 30 minutes (100 uM 7-EC/sample) using cryorederived hepatocytes from young adult male li |
Metabolism |
| X3854 |
13040 |
Hepatocyte viability, fraction of viable cells after rederivation relative to viable cells immediately after isolation in suspension (data from first run of spring 2011 by Piedmont and Varigenix) [ratio] |
Metabolism |
| X3780 |
13042 |
Hepatocyte phase II metabolic activity measured by 7-HCS sulfation assay at 30 minutes (100 uM 7-EC/sample) using cryorederived hepatocytes from young adult male liver [7-HCS pmol/million cells/min] |
Metabolism |
| X3663 |
13542 |
Hepatocyte general viability at 0 hr post-thaw in suspension, young adult male pool, Promega CellTiter-Blue fluorometric assay (5 replicates) [RFU/20000 cells/well] |
Metabolism |
| X1682 |
13543 |
Hepatocyte general viability at 4 hr post-thaw on plates, young adult male pool, Promega CellTiter-Blue fluorometric assay (5 replicates) [RFU/20000 cells/well] |
Metabolism |
| X3610 |
13552 |
Hepatocyte injury assay, lactate dehydrogenase (LDH) release in culture medium from control wells corrected for DNA content 31.5 hr after seeding with 20,000 cells, young adult male liver (BXD15 winsorized from 223 to 160) [ |
Metabolism |
| X1513 |
13553 |
Hepatocyte plating efficiency, cells per control wells (DNA assay) 31.5 hr after seeding with 20,000 cells/well, young adult male liver [ng/ml] |
Metabolism |
| X714 |
13554 |
Hepatocyte injury assay, lactate dehydrogenase (LDH) release in culture medium from control wells (uncorrected for viable cell number) 33 hours after seeding with 20,000 cells, young adult male liver (BXD29 and BXD15 winsori |
Metabolism |
| X366 |
13555 |
Acetaminophen hepatocyte viability response 9 hr after treatment (0.5 mM in vehicle), lactate dehydrogenase (LDH) release assay adjusted for DNA content, young adult male liver (BXD31 winsorized from 243 to 200) [LDH/DNA rat |
Metabolism |
| X4516 |
13556 |
Ethanol hepatocyte cytotoxicity response 9 hr after treatment (2.0 M), lactate dehydrogenase (LDH) release assay adjusted for DNA content, young adult male liver (BXD15 deleted due to bad LDH control, BXD21 winsorized from 1 |
Metabolism |
| X3408 |
13557 |
Maximal hepatocyte cytotoxicity response 9 hr after treatment with lysis buffer, lactate dehydrogenase (LDH) release assay, young adult male liver [LDH] |
Metabolism |
| X903 |
13558 |
Acetaminophen hepatocyte viability response 9 hr after treatment (0.5 mM in vehicle), lactate dehydrogenase (LDH) assay adjusted for DNA content minus Control LDH/DNA background ratio, young adult male liver (BXD15 deleted d |
Metabolism |
| X4443 |
13559 |
Ethanol hepatocyte cytotoxicity response 9 hr after treatment (2.0 M), lactate dehydrogenase (LDH) assay adjusted for DNA content minus Control LDH/DNA background ratio, young adult male liver (BXD15 deleted due to bad LDH c |
Metabolism |
| X3045 |
16925 |
Sphingomyelin (d16:1) _HFD for 20 weeks [nmol/mg] |
Metabolism |
| X2564 |
13560 |
Ethanol hepatocyte cytotoxicity response 9 hr after treatment (2.0 M), lactate dehydrogenase (LDH) release assay (relative fluorescent units), young adult male liver [RFU] |
Metabolism |
| X4845 |
13561 |
Ethanol hepatocyte cytotoxicity response 9 hr after treatment (2.0 M), ratio of ethanol-induced release to maximal (lysis) lactate dehydrogenase (LDH) release, young adult male liver (BXD15 deleted due to bad LDH control, BX |
Metabolism |
| X4238 |
14355 |
Fibrosis susceptibility in adult males after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), mean hepatic collagen, data trimmed [ug hydroxyproline/g liver] |
Metabolism |
| X4512 |
14356 |
Fibrosis susceptibility in adult males after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), median hepatic collagen, data trimmed [ug hydroxyproline/g liver] |
Metabolism |
| X1807 |
14357 |
Fibrosis susceptibility in adult females after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), mean hepatic collagen, trimmed [ug hydroxyproline/g liver] |
Metabolism |
| X2734 |
14358 |
Fibrosis susceptibility in adult females after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), median hepatic collagen, data trimmed [ug hydroxyproline/g liver] |
Metabolism |
| X3033 |
14359 |
Fibrosis susceptibility in adult males and females after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), mean hepatic collagen, data, trimmed [ug hydroxyproline/g liver] |
Metabolism |
| X3795 |
14360 |
Fibrosis susceptibility in adult males and females after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), median hepatic collagen data, trimmed [ug hydroxyproline/g liver] |
Metabolism |
| X2064 |
14361 |
Fibrosis susceptibility in adult males after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), mean liver to body weight ratio, trimmed [g] |
Metabolism |
| X2737 |
14362 |
Fibrosis susceptibility in adult males after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), median liver to body weight ratio, data trimmed [g] |
Metabolism |
| X4829 |
14363 |
Fibrosis susceptibility in adult females after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), mean liver to body weight ratio, data trimmed [g] |
Metabolism |
| X4602 |
14364 |
Fibrosis susceptibility in adult females after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, Days 1 and 4), median liver to body weight ratio, data trimmed [g] |
Metabolism |
| X4045 |
14365 |
Fibrosis susceptibility in adult males and females after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), mean liver to body weight ratio, data trimmed [g] |
Metabolism |
| X4234 |
14366 |
Fibrosis susceptibility in adult males and females after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), median liver to body weight ratio, data trimmed [g] |
Metabolism |
| X4132 |
14367 |
Liver injury day 0 in adult males before carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), mean alanine aminotransferase (ALT) aktivity, trimmed [U/l] |
Metabolism |
| X3544 |
14368 |
Liver injury day 0 in adult males before carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), median of alanine aminotransferase (ALT) aktivity, trimmed [U/l] |
Metabolism |
| X2496 |
14369 |
Liver injury day 0 in adult females before carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), mean alanine aminotransferase (ALT) aktivity, trimmed [U/l] |
Metabolism |
| X2511 |
14370 |
Liver injury day 0 in adult females before carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), median of alanine aminotransferase (ALT) aktivity, trimmed [U/l] |
Metabolism |
| X4759 |
14371 |
Liver injury day 0 in adult males and females before carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), mean alanine aminotransferase (ALT) aktivity, trimmed [U/l] |
Metabolism |
| X4853 |
14372 |
Liver injury day 0 in adult males and females before carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), median of alanine aminotransferase (ALT) aktivity, trimmed [U/l] |
Metabolism |
| X3684 |
14373 |
Liver injury in adult males after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), mean alanine aminotransferase (ALT) aktivity, trimmed [U/l] |
Metabolism |
| X3581 |
14374 |
Liver injury in adult males after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), median alanine aminotransferase (ALT) aktivity, trimmed [U/l] |
Metabolism |
| X2026 |
14375 |
Liver injury in adult females after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), mean alanine aminotransferase (ALT) activity, trimmed [U/l] |
Metabolism |
| X2057 |
14376 |
Liver injury in adult females after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), median alanine aminotransferase (ALT) activity, trimmed [U/l] |
Metabolism |
| X3807 |
14377 |
Liver injury in adult males and females after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), mean alanine aminotransferase (ALT) aktivity, trimmed [U/l] |
Metabolism |
| X4475 |
14378 |
Liver injury in adult males and females after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), median alanine aminotransferase (ALT) aktivity, trimmed [U/l] |
Metabolism |
| X4108 |
14379 |
Fibrosis susceptibility in adult females after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), mean fibrosis score, semi-quantitative ordinal histology score, 1=mild, 4=severe [severity] |
Metabolism |
| X1211 |
14380 |
Fibrosis susceptibility in adult females after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), median fibrosis score, semi-quantitative ordinal histology score, 1=mild, 4=severe [severity] |
Metabolism |
| X3612 |
14381 |
Fibrosis susceptibility in males after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), mean fibrosis score, semi-quantitative ordinal histology score, 1=mild, 4=severe [severity] |
Metabolism |
| X3515 |
14382 |
Fibrosis susceptibility in adult males after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), median fibrosis score, semi-quantitative ordinal histology score, 1=mild, 4=severe [severity] |
Metabolism |
| X3916 |
14383 |
Fibrosis susceptibility in adult males and females after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), mean fibrosis score, semi-quantitative ordinal histology score, 1=mild, 4=severe [severity] |
Metabolism |
| X4391 |
14384 |
Fibrosis susceptibility in adult males and females after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), median fibrosis score, semi-quantitative ordinal histology score, 1=mild, 4=severe [severety] |
Metabolism |
| X3649 |
14385 |
Fibrosis susceptibility in adult males after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), mean area of Sirius red stained collagen (100x magnification, pathology Bonn) [%] |
Metabolism |
| X3298 |
14386 |
Fibrosis susceptibility in adult males after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), median area of Sirius red stained collagen (100x magnification, pathology Bonn) [%] |
Metabolism |
| X3968 |
14387 |
Fibrosis susceptibility in adult females after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), mean area of Sirius red stained collagen (100x magnification, pathology Bonn) [%] |
Metabolism |
| X4801 |
14388 |
Fibrosis susceptibility in females after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), median area of Sirius red stained collagen (100x magnification, pathology Bonn) [%] |
Metabolism |
| X4982 |
14389 |
Fibrosis susceptibility in adult males and females after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), mean area of Sirius red stained collagen (100x magnification, pathology Bonn) [%] |
Metabolism |
| X4769 |
14390 |
Fibrosis susceptibility in adult males and females after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), median area of Sirius red stained collagen (100x magnification, pathology Bonn) [%] |
Metabolism |
| X2237 |
14391 |
Fibrosis susceptibility in adult males after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), mean area of Sirius red stained collagen (100x magnification, laboratory at Homburg), data trimmed [%] |
Metabolism |
| X2215 |
14392 |
Fibrosis susceptibility in adult males after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), median area of Sirius red stained collagen (100x magnification, Homburg Laboratory), trimmed [%] |
Metabolism |
| X4161 |
14393 |
Fibrosis susceptibility in adult females after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), mean area of Sirius red stained collagen (100x magnification, laboratory homburg), data trimmed [%] |
Metabolism |
| X3696 |
14394 |
Fibrosis susceptibility in adult males and females after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), median area of Sirius red stained collagen (100x magnification, laboratory homburg), data trimmed [%] |
Metabolism |
| X4840 |
14395 |
Fibrosis susceptibility in adult males and females after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), mean area of Sirius red stained collagen (100x magnification, laboratory homburg), data trimmed [%] |
Metabolism |
| X4137 |
14396 |
fibrosis susceptibility in adult males and females after carbon tetrachloride challenge (12 x 0.7 mg/kg ip, days 1 and 4), median area of Sirius red stained collagen (100x magnification, laboratory homburg), data trimmed [%] |
Metabolism |
| X335 |
14796 |
Acetaminophen (APAP) hepatocyte viability response 9 hr after treatment (0.5 mM in vehicle), lactate dehydrogenase (LDH) release assay adjusted for DNA content, young adult male liver [log2 LDH/DNA ratio treated/control] |
Metabolism |
| X4343 |
14975 |
Lung, morphology, Lung weight at 20 weeks in females and males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Metabolism |
| X2696 |
15048 |
Food intake between 17 and 20 weeks in males on a high fat diet (45% energy from fat, Ssniff(R) diet S8074-E010, Germany) initiated at 4 weeks [g/day] |
Metabolism |
| X1969 |
15091 |
Saturated fat content measured by Fourier Transform Infrared Spectroscopy (FTIR) in liver at 140 days in males on high fat diet (45% energy from fat) feeding from 4 weeks on [arbitrary unit] |
Metabolism |
| X990 |
15092 |
Total fat content measured by Fourier Transform Infrared Spectroscopy (FTIR) in liver at 140 days in males on high fat diet (45% energy from fat) feeding from 4 weeks on [arbitrary unit] |
Metabolism |
| X530 |
15094 |
Ratio of lipid to protein content measured by Fourier Transform Infrared Spectroscopy (FTIR) in liver at 140 days in males on high fat diet (45% energy from fat) feeding from 4 weeks on [arbitrary unit] |
Metabolism |
| X532 |
15095 |
Ratio of total lipid to total protein content measured by Fourier Transform Infrared Spectroscopy (FTIR) in liver at 140 days in males on high fat diet (45% energy from fat) feeding from 4 weeks on [ratio] |
Metabolism |
| X4403 |
16181 |
Alcohol response (4 mg/kg in saline, IP), blood alcohol concentration (BAC) 2 hr after injection of young adult males and females (strain average associated with GenEx EtOH cerebellum gene expression) [mg/dl] |
Metabolism |
| X3374 |
16182 |
Alcohol response (4 mg/kg in saline, IP), blood alcohol concentration (BAC) 3 hr after injection of young adult males and females (strain average associated with GenEx EtOH cerebellum gene expression) [mg/dl] |
Metabolism |
| X2991 |
16183 |
Alcohol response (4 mg/kg in saline, IP), blood alcohol concentration (BAC) 7 hr after injection of young adult males and females (strain average associated with GenEx EtOH cerebellum gene expression) [mg/dl] |
Metabolism |
| X4704 |
16229 |
Hepatocyte damage in vitro measured as lactate dehydrogenase (LDH) release after 24 hrs attachment (no treatment) median in males and females [% LDH supernatant of total LDH] |
Metabolism |
| X4162 |
16230 |
Hepatocyte damage in vitro measured as difference in lactate dehydrogenase (LDH) release relative to untreated hepatocytes, after 48 hrs 0.6% alcohol, median in males and females [% LDH increase] |
Metabolism |
| X1510 |
16231 |
Hepatocyte damage in vitro measured as difference in lactate dehydrogenase (LDH) release relative to untreated hepatocytes, after 48 hrs 5 ng/ml TGF-beta median in males and females [% LDH increase] |
Metabolism |
| X3215 |
16232 |
Hepatocyte damage in vitro measured as difference in lactate dehydrogenase (LDH) release relative to untreated hepatocytes, after 48 hrs 5 ng/ml TGF-beta + 0.6% ethanol, median in males and females [% LDH increase] |
Metabolism |
| X4725 |
16233 |
Hepatocyte damage in vitro measured as lactate dehydrogenase (LDH) release after 24 hrs attachment (no treatment) median in males [% LDH supernatant of total LDH] |
Metabolism |
| X2575 |
16234 |
Hepatocyte damage in vitro measured as difference in lactate dehydrogenase (LDH) release relative to untreated hepatocytes, after 48 hrs 0.6% alcohol median in males [% LDH increase] |
Metabolism |
| X1635 |
16235 |
Hepatocyte damage in vitro measured as difference in lactate dehydrogenase (LDH) release relative to untreated hepatocytes, after 48 hrs 5 ng/ml TGF-beta, median in males [% LDH increase] |
Metabolism |
| X3662 |
16236 |
Hepatocyte damage in vitro measured as difference in lactate dehydrogenase (LDH) release relative to untreated hepatocytes, after 48 hrs 5 ng/ml TGF-beta + 0.6% ethanol, median in males [% LDH increase] |
Metabolism |
| X3841 |
16237 |
Hepatocyte damage in vitro measured as lactate dehydrogenase (LDH) release after 24 hrs attachment (no treatment), median in females [% LDH supernatant of total LDH] |
Metabolism |
| X4149 |
16238 |
Hepatocyte damage in vitro measured as difference in lactate dehydrogenase (LDH) release relative to untreated hepatocytes, after 48 hrs 0.6% alcohol, median in females [% LDH increase] |
Metabolism |
| X2297 |
16239 |
Hepatocyte damage in vitro measured as difference in lactate dehydrogenase (LDH) release relative to untreated hepatocytes, after 48 hrs 5 ng/ml TGF-beta, median in females [% LDH increase] |
Metabolism |
| X444 |
16240 |
Hepatocyte damage in vitro measured as difference in lactate dehydrogenase (LDH) release relative to untreated hepatocytes, after 48 hrs 5 ng/ml TGF-beta + 0.6% ethanol median in females [% LDH increase vs. untreated cells] |
Metabolism |
| X96 |
16604 |
Induction of CYP1B1 mRNA after treatment with beta-Naphthoflavone (BNF, 15 uM for 24 h), measured by rtPCR in cryorederived primary hepatocytes (Varigenix CRL Panel, three technical replicates/strain/treatment) [fold-incre |
Metabolism |
| X4449 |
10108 |
Striatum cholinergic neurons in section 17 [n/section] |
Nervous system |
| X635 |
16605 |
Basal CYP1B1 mRNA expression measured by rtPCR in cryorederived primary hepatocytes in DMSO (Varigenix CRL Panel, three technical replicates/strain/treatment, higher numbers = lower endogenous expression, the Cyp1b1 gene i |
Metabolism |
| X3118 |
16874 |
Total sphingomyelin_CDHFD [nmol/ml] |
Metabolism |
| X1961 |
16875 |
Total sphingomyelin_HFD for 20 weeks [nmol/ml] |
Metabolism |
| X2089 |
16876 |
Total sphingomyelin_CD [nmol/ml] |
Metabolism |
| X4647 |
16905 |
Sphingomyelin (d16:1) _CD [nmol/mg] |
Metabolism |
| X1604 |
16906 |
Sphingomyelin (d18:2) _CD [nmol/mg] |
Metabolism |
| X4834 |
16907 |
Sphingomyelin (d16:0) _CD [nmol/mg] |
Metabolism |
| X1463 |
16908 |
Sphingomyelin (d18:1) _CD [nmol/mg] |
Metabolism |
| X1439 |
16909 |
Total sphingomyelin _CD [nmol/mg] |
Metabolism |
| X4930 |
16910 |
Gluco(galacto)sylsphingosine levels measured by LC-MS/MS in liver _CD [pmol/mg] |
Metabolism |
| X1352 |
16911 |
Globotriaosylsphingosine levels measured by LC-MS/MS in liver _CD [AU/mg] |
Metabolism |
| X1755 |
16912 |
N-glycolyl GM2 (ganglioside) _CD [nmol/mg] |
Metabolism |
| X1599 |
16913 |
Gluco(galacto)sylceramide _CD [nmol/mg] |
Metabolism |
| X1824 |
16914 |
Ceramide (d18:1) _CD [nmol/mg] |
Metabolism |
| X3658 |
16915 |
Acid beta-glucosidase activity _CD [nmol/(hour*mg)] |
Metabolism |
| X4903 |
16916 |
Hexosaminidase activity _CD [nmol/(hour*mg)] |
Metabolism |
| X4062 |
16917 |
Ratio of Gluco(galacto)sylceramide/Ceramide levels in liver _CD |
Metabolism |
| X4350 |
16918 |
Ratio of Total sphingomyelin/Ceramide levels in liver _CD |
Metabolism |
| X836 |
16919 |
Ratio of N-glycolyl GM2 (ganglioside)/Ceramide levels in liver _CD |
Metabolism |
| X2768 |
16920 |
Ratio of N-glycolyl GM2 (ganglioside)/Gluco(galacto)sylceramide levels in liver _CD |
Metabolism |
| X2628 |
16921 |
Ratio of Globotriaosylsphingosine/Ceramide levels in liver _CD |
Metabolism |
| X1018 |
16922 |
Ratio of Globotriaosylsphingosine/Gluco(galacto)sylceramide levels in liver _CD |
Metabolism |
| X5001 |
16923 |
Ratio of Gluco(galacto)sylsphingosine/Gluco(galacto)sylceramide levels in liver _CD |
Metabolism |
| X1894 |
10363 |
Hippocampus mossy fiber pathway volume, CA4 (dentate gyrus) component [volume units] |
Morphology |
| X2243 |
16926 |
Sphingomyelin (d18:2) _HFD for 20 weeks [nmol/mg] |
Metabolism |
| X1986 |
16927 |
Sphingomyelin (d16:0) _HFD for 20 weeks [nmol/mg] |
Metabolism |
| X4384 |
16928 |
Sphingomyelin (d18:1) _HFD for 20 weeks [nmol/mg] |
Metabolism |
| X4050 |
16929 |
Total sphingomyelin _HFD for 20 weeks [nmol/mg] |
Metabolism |
| X2872 |
16930 |
Gluco(galacto)sylsphingosine levels measured by LC-MS/MS in liver _HFD for 20 weeks [pmol/mg] |
Metabolism |
| X3709 |
16931 |
Globotriaosylsphingosine levels measured by LC-MS/MS in liver _HFD for 20 weeks [AU/mg] |
Metabolism |
| X3328 |
16932 |
N-glycolyl GM2 (ganglioside) _HFD for 20 weeks [nmol/mg] |
Metabolism |
| X1227 |
16933 |
Gluco(galacto)sylceramide _HFD for 20 weeks [nmol/mg] |
Metabolism |
| X1826 |
16934 |
Ceramide (d18:1) _HFD for 20 weeks [nmol/mg] |
Metabolism |
| X3982 |
16935 |
Acid beta-glucosidase activity _HFD for 20 weeks [nmol/(min*mg)] |
Metabolism |
| X2796 |
16936 |
Hexosaminidase activity _HFD for 20 weeks [nmol/(min*mg)] |
Metabolism |
| X2569 |
16937 |
Ratio of Gluco(galacto)sylceramide/Ceramide levels in liver after overnight fasting in males at 29 weeks of age_HFD for 20 weeks |
Metabolism |
| X2054 |
16938 |
Ratio of Total sphingomyelin/Ceramide levels in liver _HFD for 20 weeks |
Metabolism |
| X2079 |
16939 |
Ratio of N-glycolyl GM2 (ganglioside)/Ceramide levels in liver _HFD for 20 weeks |
Metabolism |
| X2965 |
16940 |
Ratio of N-glycolyl GM2 (ganglioside)/Gluco(galacto)sylceramide levels in liver _HFD for 20 weeks |
Metabolism |
| X2770 |
16941 |
Ratio of Globotriaosylsphingosine/Ceramide levels in liver _HFD for 20 weeks |
Metabolism |
| X3646 |
16942 |
Ratio of Globotriaosylsphingosine/Gluco(galacto)sylceramide levels in liver _HFD for 20 weeks |
Metabolism |
| X2760 |
16943 |
Ratio of Gluco(galacto)sylsphingosine/Gluco(galacto)sylceramide levels in liver _HFD for 20 weeks |
Metabolism |
| X1842 |
16944 |
Ratio of acid beta-glucosidase/hexosaminidase A activity in liver _HFD for 20 weeks |
Metabolism |
| X2570 |
16945 |
Sphingomyelin (d16:1) _CDHFD [nmol/mg] |
Metabolism |
| X2631 |
16946 |
Sphingomyelin (d18:2) _CDHFD [nmol/mg] |
Metabolism |
| X4104 |
16947 |
Sphingomyelin (d16:0) _CDHFD [nmol/mg] |
Metabolism |
| X1621 |
16948 |
Sphingomyelin (d18:1) _CDHFD [nmol/mg] |
Metabolism |
| X1725 |
16949 |
Total sphingomyelin _CDHFD [nmol/mg] |
Metabolism |
| X1360 |
16950 |
Gluco(galacto)sylsphingosine levels measured by LC-MS/MS in liver _CDHFD [pmol/mg] |
Metabolism |
| X1145 |
16951 |
Globotriaosylsphingosine levels measured by LC-MS/MS in liver _CDHFD [AU/mg] |
Metabolism |
| X702 |
16952 |
N-glycolyl GM2 (ganglioside) _CDHFD [nmol/mg] |
Metabolism |
| X3201 |
16953 |
Gluco(galacto)sylceramide _CDHFD [nmol/mg] |
Metabolism |
| X2571 |
16954 |
Ceramide (d18:1) _CDHFD [nmol/mg] |
Metabolism |
| X932 |
16955 |
Acid beta-glucosidase activity _CDHFD [nmol/(min*mg)] |
Metabolism |
| X4290 |
16956 |
Hexosaminidase activity _CDHFD [nmol/(min*mg)] |
Metabolism |
| X2963 |
16957 |
Ratio of Gluco(galacto)sylceramide/Ceramide levels in liverafter overnight fasting in males at 29 weeks of age_CDHFD [units] |
Metabolism |
| X2792 |
16958 |
Ratio of Total sphingomyelin/Ceramide levels in liver _CDHFD [units] |
Metabolism |
| X166 |
16959 |
Ratio of N-glycolyl GM2 (ganglioside)/Ceramide levels in liver _CDHFD [units] |
Metabolism |
| X1648 |
16960 |
Ratio of N-glycolyl GM2 (ganglioside)/Gluco(galacto)sylceramide levels in liver _CDHFD [units] |
Metabolism |
| X607 |
16961 |
Ratio of Globotriaosylsphingosine/Ceramide levels in liver _CDHFD [units] |
Metabolism |
| X826 |
16962 |
Ratio of Globotriaosylsphingosine/Gluco(galacto)sylceramide levels in liver _CDHFD [units] |
Metabolism |
| X2793 |
16963 |
Ratio of Gluco(galacto)sylsphingosine/Gluco(galacto)sylceramide levels in liver _CDHFD [units] |
Metabolism |
| X2036 |
16964 |
Ratio of acid beta-glucosidase/hexosaminidase A activity in liver _CDHFD [units] |
Metabolism |
| X5074 |
17020 |
Diabetes model, response to alloxan (80 mg/kg iv to induce diabetes by killing pancretic beta cells), kidney weight 7 days after treatment as a percentage of body weight in adult males and females without statistical adjust |
Metabolism |
| X975 |
17023 |
Diabetes model, alloxan response (80 mg/kg iv to induce diabetes by killing pancretic beta cells), eye weight 7 days after treatment as a percentage of body weight in adult males and females without statistical |
Metabolism |
| X4353 |
17466 |
Life span, longevity of females (mean age) at UTHSC, Memphis TN, on standard low fat diet (Harlan Teklad 2018 chow diet, 18.6% protein, 6.2% fat, 3.1 kcal/g of which 18% are from fat), 12 hr light cycle in polypropylene cages (145 sq-in with up to |
Metabolism |
| X1318 |
17468 |
Life span, longevity of females (mean age) at UTHSC, Memphis TN, on high fat diet (Harlan Teklad 06414, 18.4% protein, 60.3% calories from fat, 5.1 kcal/g), 12 hr light cycle in polypropylene cages (145 sq-in with up to 10 animals/cage, Harlan Tekl |
Metabolism |
| X3229 |
12589 |
Hippocampus mossy fiber pathway volume, suprapyramidal (SMF) [mm^3] |
Morphology |
| X4321 |
17469 |
Life span, longevity difference of females at UTHSC on either a normal low fat chow diet or a high fat diet (60% calories from fat), 12 hr light cycle (only computed if more than 4 cases per diet) [days] |
Metabolism |
| X173 |
17475 |
Life span, longevity of females (median age) at the Dana-Faber Cancer Institute (Redstone Animal Facility, Boston MA) from Jackson Laboratory between Nov 1982 and Mar 1983 on Purina chow (all data reinstated, authors initially excluded BXD13 due to |
Metabolism |
| X373 |
17548 |
Lrp6 mRNA expression in liver after carbon tetrachloride treatment, first principal component generated using SNP-free exon probe sets (exons 14, 17 and 18) and SUH_Liv_RMAEx_0611 data [relative residual concentration] |
Metabolism |
| X1332 |
17549 |
Lrp6 mRNA expression in untreated rederived hepatocytes, first principal component eigengene (loads heavily on almost all central exons, from exon 4 to exon 21, 40% of variance) with correct polarity generated using 18 SNP-free exo |
Metabolism |
| X4395 |
17550 |
Lrp6 mRNA expression in untreated rederived hepatocytes, second principal component eigengene (loads mainly on most proximal and most distal exons, exon 1, 22 and 23, 17% of total variance) with correct polarity generated using 18 |
Metabolism |
| X2656 |
17551 |
Metabolism, Diabetes model, Streptozotocin-induced albumin-to-creatinine ratio (ABR, Streptozocin, STZ, Zanosar), in males at 10-12 weeks of age (BXD32 winsorised from 5047 to 1100) [ratio of ug/mg] |
Metabolism |
| X3740 |
17552 |
Metabolism, Diabetes model, Streptozotocin-induced albumin-to-creatinine log ratio (ABR, Streptozocin, STZ, Zanosar), in males at 10-12 weeks of age (BXD32 winsorised from 5047 to 1100) [log ratio of ug/mg] |
Metabolism |
| X4783 |
17611 |
Respiratory exchange ratio (RER) light phase (day) _CD, males [ratio] |
Metabolism |
| X5014 |
17612 |
Respiratory exchange ratio (RER) light phase (day) _HFD, males [ratio] |
Metabolism |
| X4962 |
17613 |
Respiratory exchange ratio (RER) dark phase (night) _CD, males [ratio] |
Metabolism |
| X4992 |
17614 |
Respiratory exchange ratio (RER) dark phase (night) _HFD, males [ratio] |
Metabolism |
| X4945 |
17615 |
Respiratory exchange ratio (RER) over 24 hours _CD, males [ratio] |
Metabolism |
| X5003 |
17616 |
Respiratory exchange ratio (RER) over 24 hours _HFD, males [ratio] |
Metabolism |
| X4320 |
17617 |
VO2 light phase (day) average _CD, males [mL/kg/h] |
Metabolism |
| X1563 |
17618 |
VO2 light phase (day) average _HFD, males [mL/kg/h] |
Metabolism |
| X4318 |
17619 |
VO2 dark phase (night) average _CD, males [mL/kg/h] |
Metabolism |
| X1443 |
17620 |
VO2 dark phase (night) average _HFD, males [mL/kg/h] |
Metabolism |
| X4468 |
17621 |
VO2 over 24 hours _CD, males [mL/kg/h] |
Metabolism |
| X1558 |
17622 |
VO2 over 24 hours _HFD, males [mL/kg/h] |
Metabolism |
| X3623 |
17623 |
VCO2 light phase (day) average _CD, males [mL/kg/h] |
Metabolism |
| X1672 |
17624 |
VCO2 light phase (day) average _HFD, males [mL/kg/h] |
Metabolism |
| X3897 |
17625 |
VCO2 dark phase (night) average _CD, males [mL/kg/h] |
Metabolism |
| X1321 |
17626 |
VCO2 dark phase (night) average _HFD, males [mL/kg/h] |
Metabolism |
| X4022 |
17627 |
VCO2 over 24 hours _CD, males [mL/kg/h] |
Metabolism |
| X1470 |
17628 |
VCO2 over 24 hours _HFD, males [mL/kg/h] |
Metabolism |
| X1365 |
17633 |
Food intake in 24 h _CD, males [g] |
Metabolism |
| X3078 |
17634 |
Food intake in 24 h _HFD, males [g] |
Metabolism |
| X1364 |
17635 |
Food intake in 24 h _CD, males [kCal] |
Metabolism |
| X3079 |
17636 |
Food intake in 24 h _HFD, males [kCal] |
Metabolism |
| X4487 |
17637 |
Water intake in 24 h _CD, males [mL] |
Metabolism |
| X2987 |
17638 |
Water intake in 24 h _HFD, males [mL] |
Metabolism |
| X1148 |
17639 |
VO2 light phase (day) average, lean mass corrected _CD, males [mL/kg/h] |
Metabolism |
| X2207 |
17640 |
VO2 light phase (day) average, lean mass corrected _HFD, males [mL/kg/h] |
Metabolism |
| X1411 |
17641 |
VO2 dark phase (night) average, lean mass corrected _CD, males [mL/kg/h] |
Metabolism |
| X821 |
17642 |
VO2 dark phase (night) average, lean mass corrected _HFD, males [mL/kg/h] |
Metabolism |
| X2958 |
17643 |
Glycemia after overnight fast_CD, males [mg/mL] |
Metabolism |
| X1983 |
17644 |
Glycemia after overnight fast_HFD, males [mg/mL] |
Metabolism |
| X2585 |
17645 |
OGTT_ 15min, at 17 weeks of age_CD, males [mg/mL] |
Metabolism |
| X1718 |
17646 |
OGTT_ 15min, at 17 weeks of age_HFD, males [mg/mL] |
Metabolism |
| X1271 |
17647 |
OGTT_ 30 min, at 17 weeks of age_CD, males [mg/mL] |
Metabolism |
| X2893 |
17648 |
OGTT_ 30 min, at 17 weeks of age_HFD, males [mg/mL] |
Metabolism |
| X931 |
17649 |
OGTT_ 45min, at 17 weeks of age_CD, males [mg/mL] |
Metabolism |
| X3597 |
17650 |
OGTT_ 45min, at 17 weeks of age_HFD, males [mg/mL] |
Metabolism |
| X858 |
17651 |
OGTT_ 60 min, at 17 weeks of age_CD, males [mg/mL] |
Metabolism |
| X3220 |
17652 |
OGTT_ 60 min, at 17 weeks of age_HFD, males [mg/mL] |
Metabolism |
| X1419 |
17653 |
OGTT_ 90 min, at 17 weeks of age_CD, males [mg/mL] |
Metabolism |
| X599 |
17654 |
OGTT_ 90 min, at 17 weeks of age_HFD, males [mg/mL] |
Metabolism |
| X3164 |
17655 |
OGTT_ 120 min, at 17 weeks of age_CD, males [mg/mL] |
Metabolism |
| X3312 |
17656 |
OGTT_ 120 min, at 17 weeks of age_HFD, males [mg/mL] |
Metabolism |
| X4608 |
17657 |
OGTT_ 150 min, at 17 weeks of age_CD, males [mg/mL] |
Metabolism |
| X4588 |
17658 |
OGTT_ 150 min, at 17 weeks of age_HFD, males [mg/mL] |
Metabolism |
| X4791 |
17659 |
OGTT_ 180 min, at 17 weeks of age_CD, males [mg/mL] |
Metabolism |
| X4046 |
17660 |
OGTT_ 180 min, at 17 weeks of age_HFD, males [mg/mL] |
Metabolism |
| X1259 |
17661 |
OGTT_ overall_CD, males [AUC] |
Metabolism |
| X2751 |
17662 |
OGTT_ overall_HFD, males [AUC] |
Metabolism |
| X2075 |
17663 |
Insulin response from oral glucose tolerance test (OGTT), at 17 weeks of age_CD, males [AUC] |
Metabolism |
| X1862 |
17664 |
Insulin response from oral glucose tolerance test (OGTT), at 17 weeks of age_HFD, males [AUC] |
Metabolism |
| X3518 |
17665 |
Insulin during oral glucose tolerance test (OGTT), 0min, at 17 weeks of age, (after overnight fast)_CD, males [ug/mL] |
Metabolism |
| X4609 |
17666 |
Insulin during oral glucose tolerance test (OGTT), 0min, at 17 weeks of age, (after overnight fast)_HFD, males [ug/mL] |
Metabolism |
| X2203 |
17667 |
Insulin during oral glucose tolerance test (OGTT), 15min, at 17 weeks of age_CD, males [ug/mL] |
Metabolism |
| X1106 |
17668 |
Insulin during oral glucose tolerance test (OGTT), 15min, at 17 weeks of age_HFD, males [ug/mL] |
Metabolism |
| X837 |
17669 |
Insulin during oral glucose tolerance test (OGTT), 30min, at 17 weeks of age_CD, males [ug/mL] |
Metabolism |
| X1536 |
17670 |
Insulin during oral glucose tolerance test (OGTT), 30min, at 17 weeks of age_HFD, males [ug/mL] |
Metabolism |
| X1971 |
17671 |
Glucose / insulin ratio in plasma after overnight fast, at 17 weeks of age_CD, males [ratio] |
Metabolism |
| X5043 |
17672 |
Glucose / insulin ratio in plasma after overnight fast, at 17 weeks of age_HFD, males [ratio] |
Metabolism |
| X5011 |
17673 |
Glucose / insulin ratio in plasma 15 minutes after start of oral glucose tolerance test (OGTT), at 17 weeks of age_CD, males [ratio] |
Metabolism |
| X1773 |
17674 |
Glucose / insulin ratio in plasma 15 minutes after start of oral glucose tolerance test (OGTT), at 17 weeks of age_HFD, males [ratio] |
Metabolism |
| X4437 |
17675 |
Glucose / insulin ratio in plasma 30 minutes after start of oral glucose tolerance test (OGTT), at 17 weeks of age_CD, males [ratio] |
Metabolism |
| X2104 |
17676 |
Glucose / insulin ratio in plasma 30 minutes after start of oral glucose tolerance test (OGTT), at 17 weeks of age_HFD, males [ratio] |
Metabolism |
| X4182 |
17677 |
Glucose * insulin in plasma after overnight fast, at 17 weeks of age_CD, males [(ug*mg)/(mL*mL)] |
Metabolism |
| X4164 |
17678 |
Glucose * insulin in plasma after overnight fast, at 17 weeks of age_HFD, males [(ug*mg)/(mL*mL)] |
Metabolism |
| X3432 |
17679 |
McAuley fasted insulin ratio in plasma after overnight fast, at 17 weeks of age_CD, males. This phenotype is part of the EPFL LISP3 Study. |
Metabolism |
| X4574 |
17680 |
McAuley fasted insulin ratio in plasma after overnight fast, at 17 weeks of age_HFD, males. This phenotype is part of the EPFL LISP3 Study. |
Metabolism |
| X3424 |
17681 |
HOMA-IR after overnight fast, at 17 weeks of age_CD, males [index] |
Metabolism |
| X3676 |
17682 |
HOMA-IR after overnight fast, at 17 weeks of age_HFD, males [index] |
Metabolism |
| X4656 |
17683 |
HOMA-B after overnight fast, at 17 weeks of age_CD, males [index] |
Metabolism |
| X4225 |
17684 |
HOMA-B after overnight fast, at 17 weeks of age_HFD, males [index] |
Metabolism |
| X374 |
17685 |
Diastolic blood pressure measured using a tail cuff system at 19 weeks of age_CD, males [mmHg] |
Metabolism |
| X2426 |
17686 |
Diastolic blood pressure measured using a tail cuff system at 19 weeks of age_HFD, males [mmHg] |
Metabolism |
| X1787 |
17687 |
Systolic blood pressure measured using a tail cuff system at 19 weeks of age_CD, males [mmHg] |
Metabolism |
| X3593 |
17688 |
Systolic blood pressure measured using a tail cuff system at 19 weeks of age_HFD, males [mmHg] |
Metabolism |
| X1833 |
17689 |
Heart rate measured using a tail cuff system at 19 weeks of age_CD, males [bpm] |
Metabolism |
| X1384 |
17690 |
Heart rate measured using a tail cuff system at 19 weeks of age_HFD, males [bpm] |
Metabolism |
| X860 |
17691 |
Body temperature, basal, at 21 weeks of age_CD, males [Celsius] |
Metabolism |
| X2428 |
17692 |
Body temperature, basal, at 21 weeks of age_HFD, males [deg C] |
Metabolism |
| X1109 |
17693 |
Body temperature after 1 hour in 4 deg C chamber at 21 weeks of age_CD, males [deg C] |
Metabolism |
| X4785 |
17694 |
Body temperature after 1 hour in 4 deg C chamber at 21 weeks of age_HFD, males [deg C] |
Metabolism |
| X1299 |
17695 |
Body temperature after 2 hours in 4 deg C chamber at 21 weeks of age_CD, males [deg C] |
Metabolism |
| X3688 |
17696 |
Body temperature after 2 hours in 4 deg C chamber at 21 weeks of age_HFD, males [deg C] |
Metabolism |
| X2567 |
17697 |
Body temperature after 3 hours in 4 deg C chamber at 21 weeks of age_CD, males [deg C] |
Metabolism |
| X2413 |
17698 |
Body temperature after 3 hours in 4 deg C chamber at 21 weeks of age_HFD, males [deg C] |
Metabolism |
| X3310 |
17699 |
Body temperature after 4 hours in 4 deg C chamber at 21 weeks of age_CD, males [deg C] |
Metabolism |
| X1458 |
17700 |
Body temperature after 4 hours in 4 deg C chamber at 21 weeks of age_HFD, males [deg C] |
Metabolism |
| X865 |
17701 |
Body temperature after 5 hours in 4 deg C chamber at 21 weeks of age_CD, males [deg C] |
Metabolism |
| X648 |
17702 |
Body temperature after 5 hours in 4 deg C chamber at 21 weeks of age_HFD, males [deg C] |
Metabolism |
| X2874 |
17703 |
Body temperature after 6 hours in 4 deg C chamber at 21 weeks of age_CD, males [deg C] |
Metabolism |
| X756 |
17704 |
Body temperature after 6 hours in 4 deg C chamber at 21 weeks of age_HFD, males [deg C] |
Metabolism |
| X1595 |
17705 |
Body temperature loss after 3 hours in 4 deg C chamber at 21 weeks of age_CD, males [%] |
Metabolism |
| X1881 |
17706 |
Body temperature loss after 3 hours in 4 deg C chamber at 21 weeks of age_HFD, males [%] |
Metabolism |
| X3677 |
17707 |
Body temperature loss after 6 hours in 4 deg C chamber at 21 weeks of age_CD, males [%] |
Metabolism |
| X1749 |
17708 |
Body temperature loss after 6 hours in 4 deg C chamber at 21 weeks of age_HFD, males [%] |
Metabolism |
| X4179 |
17709 |
Body temperature loss between 3 to 6 hours after being placed in 4 deg C chamber at 21 weeks of age_CD, males [%] |
Metabolism |
| X1665 |
17710 |
Body temperature loss between 3 to 6 hours after being placed in 4 deg C chamber at 21 weeks of age_HFD, males [%] |
Metabolism |
| X3209 |
17711 |
Body temperature, basal, diet ratio, at 21 weeks of age_HFD / chow diet (6% kCal/fat Harlan.2918), males [ratio] |
Metabolism |
| X1973 |
17712 |
Body temperature, after 6 hours in 4 deg C chamber at 21 weeks of age, diet ratio_HFD / chow diet (6% kCal/fat Harlan.2918), males [ratio] |
Metabolism |
| X4197 |
17725 |
Food intake in 24 h, standard housing cage at 23 weeks of age_CD, males [g] |
Metabolism |
| X732 |
17726 |
Food intake in 24 h, standard housing cage at 23 weeks of age_HFD, males [g] |
Metabolism |
| X3690 |
17727 |
Food intake in 24 h, standard housing cage at 23 weeks of age_CD, males [kCal] |
Metabolism |
| X907 |
17728 |
Food intake in 24 h, standard housing cage at 23 weeks of age_HFD, males [kCal] |
Metabolism |
| X275 |
17729 |
Food intake/body weight g, standard housing cage at 23 weeks of age_CD, males [g/g] |
Metabolism |
| X4886 |
17730 |
Food intake/body weight g, standard housing cage at 23 weeks of age_HFD, males [g/g] |
Metabolism |
| X1208 |
17739 |
VO2 basal untrained, treadmill at 10 degree incline at 23 weeks of age_CD, males [mL/kg/min] |
Metabolism |
| X2052 |
17740 |
VO2 basal untrained, treadmill at 0 degree incline at 23 weeks of age_HFD, males [mL/kg/min] |
Metabolism |
| X595 |
17741 |
VO2 max untrained, treadmill at 10 degree incline at 23 weeks of age_CD, males [mL/kg/min] |
Metabolism |
| X2141 |
17742 |
VO2 max untrained, treadmill at 0 degree incline at 23 weeks of age_HFD, males [mL/kg/min] |
Metabolism |
| X4461 |
17743 |
Respiratory exchange ratio (RER) basal untrained, treadmill at 10 degree incline at 23 weeks of age_CD, males [ratio] |
Metabolism |
| X4957 |
17744 |
Respiratory exchange ratio (RER) basal untrained, treadmill at 0 degree incline at 23 weeks of age_HFD, males [ratio] |
Metabolism |
| X3698 |
10364 |
Hippocampus mossy fiber pathway volume, suprapyramidal component (SPMF) [units] |
Morphology |
| X5085 |
17745 |
Respiratory exchange ratio (RER) max untrained, treadmill at 10 degree incline at 23 weeks of age_CD, males [ratio] |
Metabolism |
| X2489 |
17746 |
Respiratory exchange ratio (RER) max untrained, treadmill at 0 degree incline at 23 weeks of age_HFD, males [ratio] |
Metabolism |
| X2262 |
17747 |
VO2 basal trained, treadmill at 10 degree incline at 25 weeks of age_CD, males [mL/kg/min] |
Metabolism |
| X2252 |
17748 |
VO2 basal trained, treadmill at 0 degree incline at 25 weeks of age_HFD, males [mL/kg/min] |
Metabolism |
| X3825 |
17749 |
VO2 max trained, treadmill at 10 degree incline at 25 weeks of age_CD, males [mL/kg/min] |
Metabolism |
| X1730 |
17750 |
VO2 max trained, treadmill at 0 degree incline at 25 weeks of age_HFD, males [mL/kg/min] |
Metabolism |
| X4465 |
17751 |
Respiratory exchange ratio (RER) basal trained, treadmill at 10 degree incline at 25 weeks of age_CD, males [ratio] |
Metabolism |
| X2755 |
17752 |
Respiratory exchange ratio (RER) basal trained, treadmill at 0 degree incline at 25 weeks of age_HFD, males [ratio] |
Metabolism |
| X1886 |
17753 |
Respiratory exchange ratio (RER) max trained, treadmill at 10 degree incline at 25 weeks of age_CD, males [ratio] |
Metabolism |
| X883 |
17754 |
Respiratory exchange ratio (RER) max trained, treadmill at 0 degree incline at 25 weeks of age_HFD, males [ratio] |
Metabolism |
| X3084 |
17755 |
VO2 basal improvement after 10 days of voluntary exercise, treadmill at 10 degree incline_CD, males [mL/kg/min] |
Metabolism |
| X4312 |
17756 |
VO2 basal improvement after 10 days of voluntary exercise, treadmill at 0 degree incline_HFD, males [mL/kg/min] |
Metabolism |
| X1196 |
17757 |
VO2 max improvement after 10 days of voluntary exercise, treadmill at 10 degree incline_CD, males [mL/kg/min] |
Metabolism |
| X3624 |
17758 |
VO2 max improvement after 10 days of voluntary exercise, treadmill at 0 degree incline_HFD, males [mL/kg/min] |
Metabolism |
| X4122 |
17759 |
Respiratory exchange ratio (RER) improvement after 10 days of voluntary exercise, treadmill at 10 degree incline_CD, males [ratio] |
Metabolism |
| X3627 |
17760 |
Respiratory exchange ratio (RER) improvement after 10 days of voluntary exercise, treadmill at 0 degree incline_HFD, males [ratio] |
Metabolism |
| X5047 |
18404 |
Urinary albumin/creatinin ratio (ACR microgram/milligram) in following longterm diabetes induced by streptozotocin (STZ) treatment [ug/mg] |
Metabolism |
| X3098 |
18430 |
Ejection fraction by echocardiography of 17-week old females and males [%] |
Metabolism |
| X1830 |
18431 |
Shortening fraction by echocardiography of 17-week old females and males [%] |
Metabolism |
| X4222 |
18432 |
Ejection fraction by echocardiography of 17-week old paired females and males [%] |
Metabolism |
| X1390 |
18433 |
Shortening fraction by echocardiography of 17-week old paired females and males [%] |
Metabolism |
| X2379 |
16641 |
C12-carnitine_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X2478 |
18435 |
Life span, longevity of females at UTHSC on high fat diet (Harlan Teklad 06414, 60.3% calories from fat), 12 hr light cycle with up to 10 animals/cage, updated March 2016 (n=382) [days] |
Metabolism |
| X4730 |
18441 |
Life span, longevity of females at UTHSC on standard chow diet (Harlan Teklad 2018 chow diet, 6.2% fat), 12 hr light cycle with up to 10 animals/cage, updated March 2016 (n=357) [days] |
Metabolism |
| X4007 |
14308 |
Blood chemistry, infectious disease, Blood [serum] urea nitrogen (BUN) at 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinusimmediately after light onset [mg/dl serum] |
Metabolites |
| X1641 |
14337 |
Blood chemistry, infectious disease, Blood [serum] urea nitrogen (BUN) (log) at 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinusimmediately after light onset [mg/dl serum, log] |
Metabolites |
| X2658 |
16622 |
Alanine levels_CDHFD [nmol/ml] |
Metabolites |
| X4328 |
16623 |
Alanine levels_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X2006 |
16624 |
Alanine levels_CD [nmol/ml] |
Metabolites |
| X170 |
16625 |
Alpha-aminoadipate levels_CDHFD [nmol/ml] |
Metabolites |
| X319 |
16626 |
Alpha-aminoadipate levels_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X164 |
16627 |
Alpha-aminoadipate levels_CD [nmol/ml] |
Metabolites |
| X4356 |
16628 |
Asparagine levels_CDHFD [nmol/ml] |
Metabolites |
| X3179 |
16629 |
Asparagine levels_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X1879 |
16630 |
Asparagine levels_CD [nmol/ml] |
Metabolites |
| X1195 |
16631 |
C0-carnitine_CDHFD [nmol/ml] |
Metabolites |
| X3715 |
16632 |
C0-carnitine_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X1578 |
16633 |
C0-carnitine_CD [nmol/ml] |
Metabolites |
| X3670 |
16634 |
C10-carnitine_CDHFD [nmol/ml] |
Metabolites |
| X2692 |
16635 |
C10-carnitine_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X4669 |
16636 |
C10-carnitine_CD [nmol/ml] |
Metabolites |
| X1262 |
16637 |
C12:1-carnitine_CDHFD [nmol/ml] |
Metabolites |
| X3378 |
16638 |
C12:1-carnitine_CD [nmol/ml] |
Metabolites |
| X2395 |
16639 |
C12:1-carnitine_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X3767 |
16640 |
C12-carnitine_CDHFD [nmol/ml] |
Metabolites |
| X4274 |
16642 |
C12-carnitine_CD [nmol/ml] |
Metabolites |
| X3074 |
16643 |
C12-hydroxy-carnitine_CDHFD [nmol/ml] |
Metabolites |
| X2113 |
16644 |
C12-hydroxy-carnitine_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X4842 |
16645 |
C12-hydroxy-carnitine_CD [nmol/ml] |
Metabolites |
| X4605 |
16646 |
C14:1-carnitine_CDHFD [nmol/ml] |
Metabolites |
| X3339 |
16647 |
C14:1-carnitine_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X3372 |
16648 |
C14:1-carnitine_CD [nmol/ml] |
Metabolites |
| X3508 |
16649 |
C14:1-hydroxy-carnitine_CDHFD [nmol/ml] |
Metabolites |
| X3959 |
16650 |
C14:1-hydroxy-carnitine_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X2873 |
16651 |
C14:1-hydroxy-carnitine_CD [nmol/ml] |
Metabolites |
| X4370 |
16652 |
C14:2-carnitine_CDHFD [nmol/ml] |
Metabolites |
| X3181 |
16653 |
C14:2-carnitine_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X4205 |
16654 |
C14:2-carnitine_CD [nmol/ml] |
Metabolites |
| X4750 |
16655 |
C14-carnitine_CDHFD [nmol/ml] |
Metabolites |
| X2740 |
16656 |
C14-carnitine_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X4817 |
16657 |
C14-carnitine_CD [nmol/ml] |
Metabolites |
| X4670 |
16658 |
C16:1-carnitine_CDHFD [nmol/ml] |
Metabolites |
| X3297 |
16660 |
C16:1-carnitine_CD [nmol/ml] |
Metabolites |
| X1453 |
16661 |
C16:1-hydroxy-carnitine_CDHFD [nmol/ml] |
Metabolites |
| X1199 |
16662 |
C16:1-hydroxy-carnitine_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X3038 |
16663 |
C16:1-hydroxy-carnitine_CD [nmol/ml] |
Metabolites |
| X4865 |
16664 |
C16:2-carnitine_CDHFD [nmol/ml] |
Metabolites |
| X4561 |
16665 |
C16:2-carnitine_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X4813 |
16666 |
C16:2-carnitine_CD [nmol/ml] |
Metabolites |
| X4503 |
12590 |
Hippocampus mossy fiber pathway volume, hilus [mm^3] |
Morphology |
| X4488 |
16667 |
C16-carnitine_CDHFD [nmol/ml] |
Metabolites |
| X1924 |
16668 |
C16-carnitine_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X4906 |
16669 |
C16-carnitine_CD [nmol/ml] |
Metabolites |
| X484 |
16670 |
C16-hydroxy-carnitine_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X3944 |
16671 |
C16-hydroxy-carnitine_CDHFD [nmol/ml] |
Metabolites |
| X4302 |
16672 |
C16-hydroxy-carnitine_CD [nmol/ml] |
Metabolites |
| X4056 |
16673 |
C18:1-carnitine_CDHFD [nmol/ml] |
Metabolites |
| X2072 |
16674 |
C18:1-carnitine_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X3781 |
16675 |
C18:1-carnitine_CD [nmol/ml] |
Metabolites |
| X1544 |
16676 |
C18:1-hydroxy-carnitine_CDHFD [nmol/ml] |
Metabolites |
| X3664 |
16677 |
C18:1-hydroxy-carnitine_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X4309 |
16678 |
C18:1-hydroxy-carnitine_CD [nmol/ml] |
Metabolites |
| X4195 |
16679 |
C18:2-carnitine_CDHFD [nmol/ml] |
Metabolites |
| X3675 |
16680 |
C18:2-carnitine_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X3761 |
16681 |
C18:2-carnitine_CD [nmol/ml] |
Metabolites |
| X2094 |
16682 |
C18-carnitine_CDHFD [nmol/ml] |
Metabolites |
| X2121 |
16683 |
C18-carnitine_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X4955 |
16684 |
C18-carnitine_CD [nmol/ml] |
Metabolites |
| X4764 |
16685 |
C2-carnitine-acetylcarnitine_CDHFD [nmol/ml] |
Metabolites |
| X4146 |
16686 |
C2-carnitine-acetylcarnitine_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X4550 |
16687 |
C2-carnitine-acetylcarnitine_CD [nmol/ml] |
Metabolites |
| X3271 |
16688 |
C4-hydroxy-carnitine_CDHFD [nmol/ml] |
Metabolites |
| X4720 |
16689 |
C4-hydroxy-carnitine_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X2860 |
16690 |
C4-hydroxy-carnitine_CD [nmol/ml] |
Metabolites |
| X4987 |
12906 |
Body weight of 17-week old males [g] |
Morphology |
| X286 |
16691 |
C5 dicarboxylylcarnitine_CDHFD [nmol/ml] |
Metabolites |
| X2827 |
16692 |
C5 dicarboxylylcarnitine_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X1914 |
16693 |
C5 dicarboxylylcarnitine_CD [nmol/ml] |
Metabolites |
| X2780 |
16694 |
C6-carnitine_CDHFD [nmol/ml] |
Metabolites |
| X4643 |
16695 |
C6-carnitine_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X2221 |
16696 |
C6-carnitine_CD [nmol/ml] |
Metabolites |
| X4261 |
16697 |
C8-carnitine_CDHFD [nmol/ml] |
Metabolites |
| X1482 |
16698 |
C8-carnitine_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X4843 |
16699 |
C8-carnitine_CD [nmol/ml] |
Metabolites |
| X2733 |
16700 |
Ceramide (d18:1)_CDHFD [nmol/ml] |
Metabolites |
| X2703 |
16701 |
Ceramide (d18:1)_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X322 |
16702 |
Ceramide (d18:1)_CD [nmol/ml] |
Metabolites |
| X3718 |
16703 |
Citrulline levels_CDHFD [nmol/ml] |
Metabolites |
| X2801 |
16704 |
Citrulline levels_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X4027 |
16705 |
Citrulline levels_CD [nmol/ml] |
Metabolites |
| X758 |
16706 |
Globotriaosylsphingosine levels (without sphingomyelinase)_CDHFD [nmol/ml] |
Metabolites |
| X855 |
16707 |
Globotriaosylsphingosine levels (without sphingomyelinase)_HFD for 20 weeks [nmol/ml |
Metabolites |
| X2802 |
16708 |
Globotriaosylsphingosine levels (without sphingomyelinase)_CD [nmol/ml] |
Metabolites |
| X1124 |
16709 |
Gluco(galacto)sylceramide_CDHFD [nmol/ml] |
Metabolites |
| X3926 |
16710 |
Gluco(galacto)sylceramide_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X2398 |
16711 |
Gluco(galacto)sylceramide_CD [nmol/ml] |
Metabolites |
| X4408 |
16712 |
Glutamate levels_CDHFD [nmol/ml] |
Metabolites |
| X1339 |
16713 |
Glutamate levels_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X3163 |
16714 |
Glutamate levels_CD [nmol/ml] |
Metabolites |
| X3475 |
16715 |
Glutamine levels_CDHFD [nmol/ml] |
Metabolites |
| X2833 |
16716 |
Glutamine levels_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X3674 |
16717 |
Glutamine levels_CD [nmol/ml] |
Metabolites |
| X241 |
16718 |
Glycine levels_CDHFD [nmol/ml] |
Metabolites |
| X308 |
16719 |
Glycine levels_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X540 |
16720 |
Glycine levels_CD [nmol/ml] |
Metabolites |
| X3364 |
16721 |
Isoleucine levels_CDHFD [nmol/ml] |
Metabolites |
| X4971 |
16722 |
Isoleucine levels_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X1269 |
16723 |
Isoleucine levels_CD [nmol/ml] |
Metabolites |
| X2294 |
16724 |
Kynurenine levels_CDHFD [nmol/ml] |
Metabolites |
| X2693 |
16725 |
Kynurenine levels_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X1568 |
16726 |
Kynurenine levels_CD [nmol/ml] |
Metabolites |
| X2555 |
16727 |
Leucine levels_CDHFD [nmol/ml] |
Metabolites |
| X2423 |
16728 |
Leucine levels_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X2602 |
16729 |
Leucine levels_CD [nmol/ml] |
Metabolites |
| X3191 |
16730 |
Lysine levels_CDHFD [nmol/ml] |
Metabolites |
| X4810 |
16731 |
Lysine levels_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X1794 |
16732 |
Lysine levels_CD [nmol/ml] |
Metabolites |
| X2981 |
16733 |
Methionine levels_CDHFD [nmol/ml] |
Metabolites |
| X4784 |
16734 |
Methionine levels_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X1113 |
16735 |
Methionine levels_CD [nmol/ml] |
Metabolites |
| X2892 |
16736 |
Natural logarithm of Arginine levels_CDHFD [nmol/ml] |
Metabolites |
| X2151 |
16737 |
Arginine levels (LogN)_HFD for 20 weeks [logN nmol/ml] |
Metabolites |
| X4438 |
16738 |
Natural logarithm of Arginine levels_CD [nmol/ml] |
Metabolites |
| X516 |
16831 |
Ratio of ornithine/citrulline_CD |
Metabolites |
| X1112 |
16739 |
Natural logarithm of Aspartate levels_CDHFD [nmol/ml] |
Metabolites |
| X1758 |
16740 |
Natural logarithm of Aspartate levels_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X2349 |
16741 |
Natural logarithm of Aspartate levels_CD [nmol/ml] |
Metabolites |
| X104 |
16742 |
Natural logarithm of C3 dicarboxylylcarnitine_CDHFD [nmol/ml] |
Metabolites |
| X103 |
16743 |
C3 dicarboxylylcarnitine_HFD for 20 weeks [logN nmol/ml] |
Metabolites |
| X119 |
16744 |
Natural logarithm of C3 dicarboxylylcarnitine_CD [nmol/ml] |
Metabolites |
| X1247 |
16745 |
Natural logarithm of C3-carnitine_propionylcarnitine_CDHFD [nmol/ml] |
Metabolites |
| X774 |
16746 |
Natural logarithm of C3-carnitine_propionylcarnitine_HFD for 20 weeks [nmol/ |
Metabolites |
| X1542 |
16747 |
Natural logarithm of C3-carnitine_propionylcarnitine_CD [nmol/ml] |
Metabolites |
| X3560 |
16748 |
Natural logarithm of C4-carnitine_CDHFD [nmol/ml] |
Metabolites |
| X4100 |
16749 |
Natural logarithm of C4-carnitine_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X3061 |
16750 |
Natural logarithm of C4-carnitine_CD [nmol/ml] |
Metabolites |
| X675 |
16751 |
Natural logarithm of C5-carnitine_CDHFD [nmol/ml] |
Metabolites |
| X3281 |
16752 |
Natural logarithm of C5-carnitine_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X346 |
16753 |
Natural logarithm of C5-carnitine_CD [nmol/ml] |
Metabolites |
| X590 |
16754 |
Natural logarithm of Fasting glucose_CDHFD [mg/ml] |
Metabolites |
| X1714 |
16755 |
Natural logarithm of Fasting glucose_HFD for 20 weeks [mg/ml] |
Metabolites |
| X1589 |
16756 |
Natural logarithm of Fasting glucose_CD [mg/ml] |
Metabolites |
| X4641 |
16757 |
Natural logarithm of N-glycolyl GM2 (ganglioside)_CDHFD [nmol/ml] |
Metabolites |
| X3169 |
16758 |
Natural logarithm of N-glycolyl GM2 (ganglioside)_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X3466 |
16759 |
Natural logarithm of N-glycolyl GM2 (ganglioside)_CD [nmol/ml] |
Metabolites |
| X304 |
16760 |
Natural logarithm of Phenylalanine levels_CDHFD [nmol/ml] |
Metabolites |
| X583 |
16761 |
Natural logarithm of Phenylalanine levels_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X637 |
16762 |
Natural logarithm of Phenylalanine levels_CD [nmol/ml] |
Metabolites |
| X3701 |
16763 |
Natural logarithm of Proline levels_CDHFD [nmol/ml] |
Metabolites |
| X4324 |
16764 |
Natural logarithm of Proline levels_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X3882 |
16765 |
Natural logarithm of Proline levels_CD [nmol/ml] |
Metabolites |
| X252 |
16766 |
Ornithine levels_CDHFD [nmol/ml] |
Metabolites |
| X1691 |
16767 |
Ornithine levels_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X178 |
16768 |
Ornithine levels_CD [nmol/ml] |
Metabolites |
| X265 |
16769 |
Alpha-aminoadipate to lysine ratio_CDHFD [ratio] |
Metabolites |
| X700 |
16770 |
Alpha-aminoadipate to lysine ratio_HFD for 20 weeks [ratio] |
Metabolites |
| X222 |
16771 |
Alpha-aminoadipate to lysine ratio_CD [ratio] |
Metabolites |
| X728 |
16772 |
Ratio of total branched-chain amino acid/Alanine_CDHFD [units] |
Metabolites |
| X1609 |
16773 |
Ratio of total branched-chain amino acid/Alanine_HFD for 20 weeks |
Metabolites |
| X1328 |
16774 |
Ratio of total branched-chain amino acid/Alanine_CD |
Metabolites |
| X1598 |
16775 |
Ratio of total branched-chain amino acid/C3-carnitine_CDHFD [units] |
Metabolites |
| X3121 |
16776 |
Ratio of total branched-chain amino acid/C3-carnitine_HFD for 20 weeks |
Metabolites |
| X2949 |
16777 |
Ratio of total branched-chain amino acid/C3-carnitine_CD |
Metabolites |
| X3051 |
16778 |
Ratio of total branched-chain amino acid/Glutamine_CDHFD [units] |
Metabolites |
| X2128 |
16779 |
Ratio of total branched-chain amino acid/Glutamine_HFD for 20 weeks |
Metabolites |
| X4823 |
16780 |
Ratio of total branched-chain amino acid/Glutamine_CD |
Metabolites |
| X2315 |
16781 |
Ratio of total branched-chain amino acid/total amino acid_HFD for 20 weeks |
Metabolites |
| X1388 |
16782 |
Ratio of total branched-chain amino acid/total amino acid_CDHFD [units] |
Metabolites |
| X4005 |
16832 |
Ratio of phenylalanine/tyrosine_CDHFD [units] |
Metabolites |
| X1224 |
16783 |
Ratio of total branched-chain amino acid/total amino acid_CD |
Metabolites |
| X1707 |
16784 |
Ratio of C0-carnitine/C2-carnitine_CDHFD [units] |
Metabolites |
| X4163 |
16785 |
Ratio of C0-carnitine/C2-carnitine_HFD for 20 weeks |
Metabolites |
| X3661 |
16786 |
Ratio of C0-carnitine/C2-carnitine_CD |
Metabolites |
| X2329 |
16787 |
Ratio of C14:1-carnitine/C14-carnitine_CDHFD [units] |
Metabolites |
| X2017 |
16788 |
Ratio of C14:1-carnitine/C14-carnitine_HFD for 20 weeks |
Metabolites |
| X2476 |
16789 |
Ratio of C14:1-carnitine/C14-carnitine_CD |
Metabolites |
| X3286 |
16790 |
Ratio of C14:1-carnitine/C2-carnitine_CDHFD [units] |
Metabolites |
| X4289 |
16791 |
Ratio of C14:1-carnitine/C2-carnitine_HFD for 20 weeks |
Metabolites |
| X3320 |
16792 |
Ratio of C14:1-carnitine/C2-carnitine_CD |
Metabolites |
| X1565 |
16793 |
Ratio of C14:2-carnitine/C14:1-carnitine_CDHFD [units] |
Metabolites |
| X3422 |
16795 |
Ratio of C14:2-carnitine/C14:1-carnitine_CD |
Metabolites |
| X1294 |
16796 |
Ratio of C16:1-carnitine/C16-carnitine_CDHFD [units] |
Metabolites |
| X2424 |
16797 |
Ratio of C16:1-carnitine/C16-carnitine_HFD for 20 weeks |
Metabolites |
| X1397 |
16798 |
Ratio of C16:1-carnitine/C16-carnitine_CD |
Metabolites |
| X1825 |
16799 |
Ratio of C16:2-carnitine/C16:1-carnitine_CDHFD [units] |
Metabolites |
| X3734 |
16800 |
Ratio of C16:2-carnitine/C16:1-carnitine_HFD for 20 weeks |
Metabolites |
| X2306 |
16801 |
Ratio of C16:2-carnitine/C16:1-carnitine_CD |
Metabolites |
| X3042 |
16802 |
Ratio of C18:1-carnitine/C18-carnitine_CDHFD [units] |
Metabolites |
| X4595 |
16803 |
Ratio of C18:1-carnitine/C18-carnitine_HFD for 20 weeks |
Metabolites |
| X4638 |
16804 |
Ratio of C18:1-carnitine/C18-carnitine_CD |
Metabolites |
| X1164 |
16805 |
Ratio of C18:2-carnitine/C18:1-carnitine_CDHFD [units] |
Metabolites |
| X771 |
16806 |
Ratio of C18:2-carnitine/C18:1-carnitine_HFD for 20 weeks |
Metabolites |
| X629 |
16807 |
Ratio of C18:2-carnitine/C18:1-carnitine_CD |
Metabolites |
| X4509 |
16808 |
Ratio of Gluco(galacto)sylceramide/Ceramide_CDHFD [units] |
Metabolites |
| X761 |
16809 |
Ratio of Gluco(galacto)sylceramide/Ceramide_HFD for 20 weeks |
Metabolites |
| X2464 |
16810 |
Ratio of Gluco(galacto)sylceramide/Ceramide_CD |
Metabolites |
| X1395 |
16811 |
Ratio of N-glycolyl GM2 (ganglioside)/Ceramide_CDHFD [units] |
Metabolites |
| X1297 |
16812 |
Ratio of N-glycolyl GM2 (ganglioside)/Ceramide_HFD for 20 weeks |
Metabolites |
| X852 |
16813 |
Ratio of N-glycolyl GM2 (ganglioside)/Ceramide_CD |
Metabolites |
| X3394 |
16814 |
Ratio of N-glycolyl GM2 (ganglioside)/Gluco(galacto)sylceramide_CDHFD [units] |
Metabolites |
| X4070 |
16815 |
Ratio of N-glycolyl GM2 (ganglioside)/Gluco(galacto)sylceramide_HFD for 20 weeks |
Metabolites |
| X3810 |
16816 |
Ratio of N-glycolyl GM2 (ganglioside)/Gluco(galacto)sylceramide_CD |
Metabolites |
| X3421 |
16817 |
Ratio of Isoleucine/C3-carnitine_CDHFD [units] |
Metabolites |
| X1705 |
16818 |
Ratio of Isoleucine/C3-carnitine_HFD for 20 weeks |
Metabolites |
| X2797 |
16819 |
Ratio of Isoleucine/C3-carnitine_CD |
Metabolites |
| X1219 |
16820 |
Ratio of Kynurenine/Tryptophan_CDHFD [units] |
Metabolites |
| X1420 |
16821 |
Ratio of Kynurenine/Tryptophan_HFD for 20 weeks |
Metabolites |
| X1004 |
16822 |
Ratio of Kynurenine/Tryptophan_CD |
Metabolites |
| X2463 |
16823 |
Ratio of Globotriaosylsphingosine/Ceramide_CDHFD [units] |
Metabolites |
| X2565 |
16824 |
Ratio of Globotriaosylsphingosine/Ceramide_HFD for 20 weeks |
Metabolites |
| X2282 |
16825 |
Ratio of Globotriaosylsphingosine/Ceramide_CD |
Metabolites |
| X2817 |
16826 |
Ratio of Globotriaosylsphingosine/Gluco(galacto)sylceramide_CDHFD [units] |
Metabolites |
| X1456 |
16827 |
Ratio of Globotriaosylsphingosine/Gluco(galacto)sylceramide_HFD for 20 weeks |
Metabolites |
| X3681 |
16828 |
Ratio of Globotriaosylsphingosine/Gluco(galacto)sylceramide_CD |
Metabolites |
| X533 |
16829 |
Ratio of ornithine/citrulline_CDHFD [units] |
Metabolites |
| X1974 |
16830 |
Ratio of ornithine/citrulline_HFD for 20 weeks |
Metabolites |
| X4818 |
16833 |
Ratio of phenylalanine/tyrosine_HFD for 20 weeks |
Metabolites |
| X4053 |
16834 |
Ratio of phenylalanine/tyrosine_CD |
Metabolites |
| X2977 |
16835 |
Ratio of total long chain acylcarnitine/C0-carnitine_CDHFD [units] |
Metabolites |
| X3683 |
16836 |
Ratio of total long chain acylcarnitine/C0-carnitine_HFD for 20 weeks |
Metabolites |
| X4998 |
16837 |
Ratio of total long chain acylcarnitine/C0-carnitine_CD |
Metabolites |
| X2219 |
16838 |
Ratio of total long chain acylcarnitine/C2-carnitine_CDHFD [units] |
Metabolites |
| X2296 |
16839 |
Ratio of total long chain acylcarnitine/C2-carnitine_HFD for 20 weeks |
Metabolites |
| X2924 |
16840 |
Ratio of total long chain acylcarnitine/C2-carnitine_CD |
Metabolites |
| X1416 |
16841 |
Ratio of total sphingomyelin/ceramide_CDHFD [units] |
Metabolites |
| X1848 |
16842 |
Ratio of total sphingomyelin/ceramide_HFD for 20 weeks |
Metabolites |
| X1698 |
16843 |
Ratio of total sphingomyelin/ceramide_CD |
Metabolites |
| X1445 |
16844 |
Ratio of Valine/C3-carnitine_CDHFD [units] |
Metabolites |
| X3319 |
16845 |
Ratio of Valine/C3-carnitine_HFD for 20 weeks |
Metabolites |
| X1907 |
16846 |
Ratio of Valine/C3-carnitine_CD |
Metabolites |
| X3521 |
16847 |
Serine levels_CDHFD [nmol/ml] |
Metabolites |
| X3691 |
16848 |
Serine levels_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X4058 |
16849 |
Serine levels_CD [nmol/ml] |
Metabolites |
| X4786 |
16850 |
Sphingomyelin (d16:0)_CDHFD [nmol/ml] |
Metabolites |
| X3454 |
16851 |
Sphingomyelin (d16:0)_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X4474 |
16852 |
Sphingomyelin (d16:0)_CD [nmol/ml] |
Metabolites |
| X2710 |
16853 |
Sphingomyelin (d16:1)_CDHFD [nmol/ml] |
Metabolites |
| X2456 |
16854 |
Sphingomyelin (d16:1)_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X4237 |
16855 |
Sphingomyelin (d16:1)_CD [nmol/ml] |
Metabolites |
| X2853 |
16856 |
Sphingomyelin (d18:1)_CDHFD [nmol/ml] |
Metabolites |
| X1557 |
16857 |
Sphingomyelin (d18:1)_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X1673 |
16858 |
Sphingomyelin (d18:1)_CD [nmol/ml] |
Metabolites |
| X2812 |
16859 |
Sphingomyelin (d18:2)_CDHFD [nmol/ml] |
Metabolites |
| X2085 |
16860 |
Sphingomyelin (d18:2)_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X4479 |
16861 |
Sphingomyelin (d18:2)_CD [nmol/ml] |
Metabolites |
| X2112 |
16862 |
Spingosine-1-phosphate levels_CDHFD [pmol/ml] |
Metabolites |
| X3954 |
16863 |
Spingosine-1-phosphate levels_HFD for 20 weeks [pmol/ml] |
Metabolites |
| X300 |
16864 |
Spingosine-1-phosphate levels_CD [pmol/ml] |
Metabolites |
| X2701 |
16865 |
Total amino acid levels_CDHFD [nmol/ml] |
Metabolites |
| X4741 |
16866 |
Total amino acid levels_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X1603 |
16867 |
Total amino acid levels_CD [nmol/ml] |
Metabolites |
| X2175 |
16868 |
Total branched-chain amino acid levels_CDHFD [nmol/ml] |
Metabolites |
| X3489 |
16869 |
Total branched-chain amino acid levels_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X2513 |
16870 |
Total branched-chain amino acid levels_CD [nmol/ml] |
Metabolites |
| X4424 |
16871 |
Total long-chain acylcarnitine_CDHFD [nmol/ml] |
Metabolites |
| X1801 |
16872 |
Total long-chain acylcarnitine_HFD for 20 weeks |
Metabolites |
| X4047 |
16873 |
Total long-chain acylcarnitine_CD [nmol/ml] |
Metabolites |
| X3006 |
16877 |
Tryptophan levels_CDHFD [nmol/ml] |
Metabolites |
| X4999 |
16878 |
Tryptophan levels_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X1293 |
16879 |
Tryptophan levels_CD [nmol/ml] |
Metabolites |
| X3695 |
16880 |
Tyrosine levels_CDHFD [nmol/ml] |
Metabolites |
| X4492 |
16881 |
Tyrosine levels_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X3556 |
16882 |
Tyrosine levels_CD [nmol/ml] |
Metabolites |
| X4273 |
10358 |
Body weight [g] |
Morphology |
| X3154 |
16883 |
Unknown lipid (16minRT)_CDHFD [nmol/ml] |
Metabolites |
| X3457 |
16884 |
Unknown lipid (16minRT)_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X2587 |
16885 |
Unknown lipid (16minRT)_CD [nmol/ml] |
Metabolites |
| X3669 |
16886 |
Valine levels_CDHFD [nmol/ml] |
Metabolites |
| X4942 |
16887 |
Valine levels_HFD for 20 weeks [nmol/ml] |
Metabolites |
| X962 |
16888 |
Valine levels_CD [nmol/ml] |
Metabolites |
| X3786 |
16889 |
Free fatty acid (FFA)_CDHFD [z scores of umol/ml] |
Metabolites |
| X3705 |
16890 |
Free fatty acid (FFA)_HFD for 20 weeks [z scores of umol/ml] |
Metabolites |
| X4850 |
16891 |
Free fatty acid (FFA)_CD for 20 weeks [z scores of umol/ml] |
Metabolites |
| X2184 |
16892 |
Z score normalized HDL_CDHFD [umol/ml] |
Metabolites |
| X1300 |
16893 |
Z score normalized HDL_HFD for 20 weeks [umol/ml] |
Metabolites |
| X4869 |
16894 |
Z score normalized HDL_CD [umol/ml] |
Metabolites |
| X2479 |
16895 |
Weighted metabolite coexpression network, Blue module eigengene on a chow diet (Harlan 2918, 6% kCal/fat) |
Metabolites |
| X1835 |
16896 |
Weighted metabolite coexpression network, Brown module eigengene on a chow diet (Harlan 2918, 6% kCal/fat) |
Metabolites |
| X2086 |
16897 |
Weighted metabolite coexpression network, Green module eigengene on a chow diet (Harlan 2918, 6% kCal/fat) |
Metabolites |
| X4878 |
16898 |
Weighted metabolite coexpression network, Turquoise module eigengene on a chow diet (Harlan 2918, 6% kCal/fat) |
Metabolites |
| X515 |
16899 |
Weighted metabolite coexpression network, Yellow module eigengene on a chow diet (Harlan 2918, 6% kCal/fat) |
Metabolites |
| X1023 |
16900 |
Weighted metabolite coexpression network, Blue module eigengene_HFD for 20 weeks |
Metabolites |
| X3609 |
16901 |
Weighted metabolite coexpression network, Brown module eigengene_HFD for 20 weeks |
Metabolites |
| X3439 |
16902 |
Weighted metabolite coexpression network, Green module eigengene_HFD for 20 weeks |
Metabolites |
| X4119 |
16903 |
Weighted metabolite coexpression network, Turquoise module eigengene_HFD for 20 weeks |
Metabolites |
| X2808 |
16904 |
Weighted metabolite coexpression network, Yellow module eigengene_HFD for 20 weeks |
Metabolites |
| X2786 |
16247 |
Microbiome, Actinobacteria (class) frequency assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X2787 |
16248 |
Microbiome, Actinobacteria (phylum) frequency assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X1877 |
16249 |
Microbiome, Actinobacteridae (subclass) frequency assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X1989 |
16250 |
Microbiome, Actinomycetales (order) frequency assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X4920 |
16251 |
Microbiome, Aerococcaceae (family) frequency assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X4919 |
16252 |
Microbiome, Aerococcus (genus) frequency assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X1966 |
16253 |
Microbiome, Alistipes (genus) frequency assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X2794 |
16254 |
Microbiome, Bacilli (class) frequency assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X1495 |
16255 |
Microbiome, Bacteroidales (order) frequency assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X1496 |
16256 |
Microbiome, Bacteroidetes (class) frequency assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X2591 |
16257 |
Microbiome, Bacteroidetes (phylum) frequency assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X3314 |
16258 |
Microbiome, Clostridia (class) frequency assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X3334 |
16259 |
Microbiome, Clostridiales (order) frequency assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X4860 |
16260 |
Microbiome, Coriobacteriaceae (family) frequency assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X4861 |
16261 |
Microbiome, Coriobacteriales (order) frequency assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X4862 |
16262 |
Microbiome, Coriobacteridaesub (class) frequency assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X4863 |
16263 |
Microbiome, Coriobacterineae (suborder) proportionassessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X3273 |
16264 |
Microbiome, Corynebacteriaceae (family) proportionassessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X4613 |
10362 |
Hippocampus mossy fiber pathway volume, total [units] |
Morphology |
| X2814 |
16265 |
Microbiome, Corynebacterineae (suborder) proportion assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X3274 |
16266 |
Microbiome, Corynebacterium (genus) proportion assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X3448 |
16267 |
Microbiome, Erysipelotrichaceae (family) proportion assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X3449 |
16268 |
Microbiome, Erysipelotrichales (order) proportion assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X3450 |
16269 |
Microbiome, Erysipelotrichi (class) proportion assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X2108 |
16270 |
Microbiome, Firmicutes (phylum) proportion assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X1661 |
16271 |
Microbiome, Lachnospiraceae Incertae Sedis (genus) proportion assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X2902 |
16272 |
Microbiome, Lachnospiraceae (family) proportion assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X4217 |
16273 |
Microbiome, Lactobacillaceae (family) proportion assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X3946 |
16274 |
Microbiome, Lactobacillales (order) proportion assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X4208 |
16275 |
Microbiome, Lactobacillus (genus) proportion assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X1096 |
16276 |
Microbiome, Marinilabilia (genus) proportion assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X213 |
16277 |
Microbiome, Prevotellaceae (family) proportion assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X555 |
16278 |
Microbiome, Rikenellaceae (family) proportion assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X3657 |
16279 |
Microbiome, Ruminococcaceae (family) proportion assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X251 |
16280 |
Microbiome, TM7 genera incertae sedis (genus) proportion assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X250 |
16281 |
Microbiome, TM7 (phylum) proportion assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X2300 |
16282 |
Microbiome, Turicibacter (genus) proportion assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X509 |
16283 |
Microbiome, Bacillales (order) proportion assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X574 |
16284 |
Microbiome, Staphylococcaceae (family) proportion assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X554 |
16285 |
Microbiome, Staphylococcus (genus) proportion assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X4756 |
16286 |
Microbiome, Jeotgalicoccus (genus) proportion assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X723 |
16287 |
Microbiome, Bacteroidaceae (family) proportion assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X722 |
16288 |
Microbiome, Bacteroides (genus) proportion assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X4171 |
16289 |
Microbiome, Proteobacteria (phylum) proportion assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X2442 |
16290 |
Microbiome, Lactobacillus johnsonii (OTU) proportion assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X1417 |
16291 |
Microbiome, Lactobacillus murinus (OTU) proportion assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X4380 |
16292 |
Microbiome, Lactobacillus intestinalis (OTU) proportion assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X3999 |
16293 |
Microbiome, Staphylococcus xylosus (OTU) proportion assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X3779 |
16294 |
Microbiome, Staphylococcus lentus (OTU) proportion assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X3860 |
16295 |
Microbiome, Barnsiella (OTU) proportion assessed by 16S rRNA sequencing of fecal pellets from young adult males and females [residuals, log10 of fraction] |
Microbiome |
| X2097 |
10001 |
Cerebellum weight, whole, bilateral in adults of both sexes [mg] |
Morphology |
| X313 |
10002 |
Cerebellum weight after adjustment for covariance with brain size [mg] |
Morphology |
| X1320 |
10003 |
Brain weight, male and female adult average, unadjusted for body weight, age, sex [mg] |
Morphology |
| X3064 |
10004 |
Cerebellum volume [mm3] |
Morphology |
| X255 |
10005 |
Cerebellum volume, adjusted for covariance with brain size [mm3] |
Morphology |
| X423 |
10006 |
Cerebellum internal granule layer (IGL) volume without adjustment [mm3] |
Morphology |
| X1747 |
10007 |
Internal granule layer (IGL) of the cerebellum volume, adjusted for sex, age, body and brain weight [mm3] |
Morphology |
| X3567 |
10031 |
Body weight of adult males [g] |
Morphology |
| X4203 |
10032 |
Brain weight in young adult males [mg] |
Morphology |
| X2493 |
10033 |
Brain to body weight ratio [ratio] |
Morphology |
| X3272 |
10365 |
Hippocampus mossy fiber pathway volume, intra- and infrapyramidal component (IIPMF) [units] |
Morphology |
| X2353 |
10366 |
Hippocampus mossy fiber pathway, ratio of volume of CA4 to total MF [%] |
Morphology |
| X4664 |
10367 |
Hippocampus mossy fiber pathway volume, fraction of suprapyramidal component relative to total volume [%] |
Morphology |
| X3091 |
10368 |
Hippocampus mossy fiber pathway volume, fraction of IIPMT relative to total volume [%] |
Morphology |
| X1501 |
10369 |
Androgenetic blastocysts (embryos) percentage induced by sperm-mediated egg cytoplasmic epigenetic imprinting effects [%] |
Morphology |
| X738 |
10375 |
Hippocampus weight, bilateral, fixed and hand-dissected tissue, unadjusted for differences in age, sex, or body weight [mg] |
Morphology |
| X1736 |
10376 |
Hippocampus bilateral weight with adjustment only for age and sex (no adjustment for brain weight) [mg] |
Morphology |
| X2778 |
10377 |
Hippocampus granule cell density [n x10^3] |
Morphology |
| X1170 |
10378 |
Hippocampus granule cell number, unilateral [n x10^3] |
Morphology |
| X4003 |
10379 |
Brain weight [mg] |
Morphology |
| X500 |
10381 |
B-mannosidase activity in kidney of females measured as the release of p-nitrophenl per gram tissue wet weight per hour at 37 deg C [mg/g/hr] |
Morphology |
| X2317 |
10436 |
Cerebellum fissure number (vermis, midsagittal section, intraculminate fissure variation) [n] |
Morphology |
| X3069 |
10456 |
Hippocampus volume, total [mm^3] |
Morphology |
| X3647 |
10457 |
Hippocampus proper volume [mm^3] |
Morphology |
| X1981 |
10458 |
Hippocampus pyramidal cell layer volume, unilateral [mm^3] |
Morphology |
| X4041 |
10459 |
Hippocampus dentate gyrus granule cell layer volume, unilateral [mm^3] |
Morphology |
| X556 |
10460 |
Hippocampus dentate gyrus volume [mm^3] |
Morphology |
| X3070 |
10461 |
Body weight, average males and females [g] |
Morphology |
| X3940 |
10462 |
Brain weight [mg] |
Morphology |
| X2664 |
10573 |
Ethanol response (4/g/kg ip), plasma corticosterone concentration 1 hr after injection [ug/dl] |
Morphology |
| X1616 |
10574 |
Corticosterone plasma concentration 1 hr after saline injection [ug/dl] |
Morphology |
| X3963 |
10575 |
Ethanol response (4 g/kg ip), plasma corticosterone concentration 6 hr after injection [ug/dl] |
Morphology |
| X2031 |
10576 |
Plasma corticosterone concentration 6 hr after saline control injection (ip) [ug/dl] |
Morphology |
| X3964 |
10577 |
Ethanol response (4 g/kg ip), corticosterone plasma level 7 hr after injection [ug/dl] |
Morphology |
| X2923 |
10579 |
Ethanol response (4 g/kg ip), corticosterone plasma level 6 hr after injection in females (unpublished means from Roberts et al. 1995, Behav Neurosci 109:1199) [ug/dl] |
Morphology |
| X4651 |
10580 |
Ethanol response [4/g/kg ip], plasma corticosterone concentration 6 hr after injection in males (unpublished data from Roberts, Phillips, Belknap, Finn, Keith 1995, Behavioral Neurosci 109:1199-1208) [ug/dl] |
Morphology |
| X3741 |
10590 |
Vascular endothelial growth factor (VEGF)-induced angiogenesis measured using corneal micropocket neovascularization assay [mm2] |
Morphology |
| X4751 |
10594 |
Brain weight [mg] |
Morphology |
| X2198 |
10991 |
Kidney weight (unilateral) in adult males and females without statistical adjustments [mg] |
Morphology |
| X4483 |
10612 |
Endogenous mouse mammary tumor virus (MMTV)-specific RNA in mammary glands, dot blot assay, primiparous lactating female [% total RNA] |
Morphology |
| X1660 |
10613 |
Endogenous mouse mammary tumor virus (MMTV)-specific RNA in mammary glands, dot blot assay, multiparous lactating female [% total RNA] |
Morphology |
| X4295 |
10640 |
Hindbrain weight, unadjusted [mg] |
Morphology |
| X2824 |
10646 |
Brain weight [mg] |
Morphology |
| X2460 |
10647 |
Body weight, adult sex average [g] |
Morphology |
| X3796 |
10648 |
Brain weight [mg] |
Morphology |
| X146 |
10667 |
Eye weight corrected for age, sex, body and brain weight (BXD38 added) [mg] |
Morphology |
| X448 |
10668 |
Lens weight [mg] |
Morphology |
| X167 |
10671 |
Eye weight, regression corrected for age, sex, body and brain weight [mg] |
Morphology |
| X1805 |
10672 |
Brain weight [mg] |
Morphology |
| X1359 |
10673 |
Testis weight [g] |
Morphology |
| X64 |
10678 |
Hair coat color, ordinal scale version 1 black=4, brown=3, grey=2, dba dilute=1 [color intensity] |
Morphology |
| X951 |
10710 |
Striatum volume, dorsal striatum of young adults, bilateral and shrinkage corrected [mm^3] |
Morphology |
| X201 |
10713 |
Hydronephrosis induced by gestational tetrachlorodibenzofuran exposure, AHR-dependent (TCDBF, 0.6 mg/kg ip at E12) [%] |
Morphology |
| X144 |
10714 |
Cleft palate frequency induced by gestational tetrachlorodibenzofuran exposure, AHR-dependent (TCDBF, 0.6 mg/kg ip at E12) [%] |
Morphology |
| X3044 |
10737 |
Cerebral cortex grey matter volume residuals after adjustment for age [mm^3 residuals] |
Morphology |
| X3844 |
10738 |
Dorsal thalamus volume of young adults, shrinkage corrected [mm^3] |
Morphology |
| X828 |
10748 |
Aortic atherosclerotic lesions following 16-week atherogenic diet in 16-month females [n] |
Morphology |
| X4026 |
10754 |
Cortical grey matter volume, residual volume adjusting for volume of thalamus [mm3] |
Morphology |
| X1406 |
10755 |
Hippocampus, dorsal hippocampus volume, age-adjusted residuals [mm3] |
Morphology |
| X2420 |
10756 |
Hippocampus, ventral hippocampus volume, age-adjusted residuals (V2 Table 2A) [mm3] |
Morphology |
| X1845 |
10757 |
Hippocampus, ventral hippocampus volume residuals, adjusted for differences in age and brain weight (from V3 Table 2A) [mm3] |
Morphology |
| X2147 |
10799 |
Eye weight, fresh unfixed, corrected for age [mg] |
Morphology |
| X239 |
10803 |
Heart weight without statistical adjustment (C57BL/6J data looks anomalous) [mg] |
Morphology |
| X1110 |
10856 |
Kidney weight, males and females (unilateral, uncorrected, 2006) [mg] |
Morphology |
| X3839 |
10858 |
Kidney weight (unilateral, regressed to eliminate variance due to age, body weight, and sex in 2006) [mg] |
Morphology |
| X4385 |
10859 |
Kidney weight of adult females, unilateral, without any adjustments [mg] |
Morphology |
| X4663 |
10861 |
Kidney weight of females (unilateral, corrected for age and body weight)[mg] |
Morphology |
| X425 |
10862 |
Kidney weight of males (unilateral) [mg] |
Morphology |
| X2732 |
10863 |
Kidney weight of males (unilateral, adjusted for age and body size) [mg] |
Morphology |
| X4115 |
10888 |
Brain weight, fixed tissue without statistical adjustments [mg] |
Morphology |
| X3599 |
10992 |
Cerebral cortex volume, shrinkage corrected [mm^3] |
Morphology |
| X2123 |
10993 |
Cerebral cortex volume, regression adjusted for age and body weight, shrinkage corrected [mm^3] |
Morphology |
| X567 |
10994 |
Kidney weight (unilateral, corrected for age, sex, and body weight) [mg] |
Morphology |
| X2201 |
10995 |
Cerebral cortex volume, bilateral, shrinkage corrected [mm^3] |
Morphology |
| X1693 |
10997 |
Cerebral cortex volume, adjusted for shrinkage, age, sex, plane of section, and BXD group/epoch) [mm^3] |
Morphology |
| X494 |
10998 |
Striatum volume, dorsal striatum, bilateral and adjusted for shrinkage, age, sex, plane of section, and BXD group/epoch (mm^3) |
Morphology |
| X820 |
11016 |
Brain weight, statistically adjusted for variation in sex, age, body weight, litter size, and parity [mg] |
Morphology |
| X2164 |
11018 |
Forebrain weight, adjusted by age, sex, body weight and BXD epoch [mg] |
Morphology |
| X3188 |
11020 |
Wilms tumor 1 negative (WT1-neg) cells per glomerular cross section in males (8 - 20 weeks of age) [n/section] |
Morphology |
| X3239 |
11262 |
Adrenal medulla width for females [um] |
Morphology |
| X957 |
11263 |
Adrenal medulla width for males [um] |
Morphology |
| X848 |
11266 |
Adrenal width (total) for males [um] |
Morphology |
| X3537 |
11267 |
Adrenal width (total) for females [um] |
Morphology |
| X4579 |
11268 |
Adrenal zona glomerulosa width for males [um] |
Morphology |
| X3568 |
11269 |
Adrenal zona glomerulosa width for females [um] |
Morphology |
| X1430 |
11270 |
Adrenal zona fasciculata width in young adult males [um] |
Morphology |
| X3148 |
11271 |
Adrenal zona fasciculata width for females [um] |
Morphology |
| X2037 |
11272 |
Adrenal X-zone width for males [um] |
Morphology |
| X4601 |
11273 |
Adrenal X-zone width for females [um] |
Morphology |
| X62 |
11280 |
Hair coat color, ordinal scale version 2 where black=4, grey=3, brown=2, dba dilute=1 [color intensity] |
Morphology |
| X2690 |
11288 |
Adrenal zona intermedia width for females [um] |
Morphology |
| X2706 |
11291 |
Adrenal zona reticularis width for females [um] |
Morphology |
| X4499 |
11293 |
Adrenal zona intermedia width for males [um] |
Morphology |
| X4089 |
11295 |
Adrenal zona reticularis width for males [um] |
Morphology |
| X499 |
11298 |
Adrenal total weight for females [mg] |
Morphology |
| X658 |
11299 |
Adrenal total weight for males [mg] |
Morphology |
| X720 |
11557 |
Adrenal weight (left) of males [mg] |
Morphology |
| X804 |
11558 |
Adrenal weight (right) of males [mg] |
Morphology |
| X751 |
11814 |
Adrenal weight (left) of females [mg] |
Morphology |
| X293 |
11815 |
Adrenal weight (right) of females [mg] |
Morphology |
| X1049 |
12071 |
Adrenal weight (left) of males and females [mg] |
Morphology |
| X372 |
12072 |
Adrenal weight (right) of males and females [mg] |
Morphology |
| X2784 |
12226 |
Wilms tumor 1 homolog positive cell density in glomerular sections in males (8-20 wks of age) [WT1-positive cell number per 1000 um2 glomerular area] |
Morphology |
| X1383 |
12227 |
Podocytes per glomerulus in males (8-20 wks) [number per glomerulus in cross sectioned material] |
Morphology |
| X4325 |
12588 |
Hippocampus mossy fiber pathway volume, infrapyramidal (IMF) [mm^3] |
Morphology |
| X4551 |
12228 |
Glomerular section area (GSA) in glomeruli of males (8-20 wks of age) [um^2] |
Morphology |
| X972 |
12229 |
Kidney weight of males at 8-20 wk [mg] |
Morphology |
| X1888 |
12230 |
Wilms tumor 1 homolog positive cells per glomerular section in males (8-20 wks of age) [WT1-positive cells/glomerular section] |
Morphology |
| X2584 |
12231 |
Kidney weight/body weight ratio in males (8 - 20 wks) [mg/g] |
Morphology |
| X2925 |
12232 |
Glomerular cells per glomerular section in males (8 to 20 weeks of age) [cell density] |
Morphology |
| X2062 |
12300 |
Intraocular pressure (IOP), 1 to 2 months old, both sexes, average of left and right eyes [mmHg] |
Morphology |
| X4615 |
12303 |
Intraocular pressure (IOP), 3 to 5 months old, both sexes, average of left and right eyes [mmHg] |
Morphology |
| X3423 |
12306 |
Intraocular pressure (IOP), 6 to 9 months old, both sexes, average of left and right eyes [mmHg] |
Morphology |
| X622 |
12309 |
Intraocular pressure (IOP), 10 to 13 months old, both sexes, average of left and right eyes [mmHg] |
Morphology |
| X4215 |
12312 |
Intraocular pressure (IOP), more than 13 months old, both sexes, average of left and right eyes [mmHg] |
Morphology |
| X3085 |
12315 |
Intraocular pressure (IOP), all ages (1 to 30 months old), both sexes, average of left and right eyes [mmHg] |
Morphology |
| X67 |
12318 |
Iris pigmentation at 1-2 months in males and females [ordinal scale, 0=full pigmentation, 4=light] |
Morphology |
| X69 |
12321 |
Iris pigmentation at 3-5 months in males and females [ordinal scale, 0=full pigmentation, 4=light, dispersed] |
Morphology |
| X66 |
12324 |
Iris pigmentation at 6-9 months, males and females [ordinal score, 0=normal, 4=light, dispersed] |
Morphology |
| X70 |
12327 |
Iris pigmentation score at 10-13 months in males and females [ordinal scale, 0=full pigmentation, 4=light, dispersed] |
Morphology |
| X88 |
12330 |
Iris pigmentation score in old males and females (>13 months) [ordinal scale, 0=full pigmentation, 4=light, dispersed] |
Morphology |
| X65 |
12333 |
Iris pigmentation (all ages) [ordinal scale, 0=pigmented, 4=light, dispersed] |
Morphology |
| X2559 |
12485 |
Cerebellar Purkinje cell number, with Abercrombie correction, for male and females between 30 and 150-days-of-age [n x1000] |
Morphology |
| X4825 |
12493 |
Body weight of 120-day-old females fed 3 ppm Fe diet [g] |
Morphology |
| X3685 |
12501 |
Body weight of 120-day-old males fed 3 ppm Fe diet [g] |
Morphology |
| X4671 |
12509 |
Body weight of 120-day-old females fed 270 ppm Fe diet [g] |
Morphology |
| X3763 |
12517 |
Body weight of 120-day-old males fed 270 ppm Fe diet [g] |
Morphology |
| X4296 |
12528 |
Body weight of 120-day-old males and females fed 3 ppm Fe diet [g] |
Morphology |
| X3939 |
12539 |
Body weight of 120-day-old males and females fed 270 ppm Fe diet [g] |
Morphology |
| X1291 |
12555 |
Adrenal medulla width [um] |
Morphology |
| X2831 |
12556 |
Adrenal zona fasciculata width [um] |
Morphology |
| X1392 |
12584 |
Thyroxine (T4), free level in serum, control pre-immunization in females 5-8 weeks old, by radioimmunoassay [ng/dL] |
Morphology |
| X1701 |
12585 |
Thyroxine (T4), total level in serum, control pre-immunization in females 5-8 weeks old, by radioimmunoassay [ug/dL] |
Morphology |
| X4404 |
12587 |
Hippocampus mossy fiber pathway volume, total without IMF (hilus + SMF) [mm^3] |
Morphology |
| X4291 |
12591 |
Hippocampus mossy fiber pathway volume, total (hilus + IMF + SMF) [mm^3] |
Morphology |
| X1716 |
12592 |
Kidney morphology, number of podocytes per unit glomerular surface area following longterm diabetes (streptozotocin treatment) [n/1000 um2] |
Morphology |
| X2976 |
12593 |
Kidney morphology, total glomerular cell count per glomerular surface area following longterm diabetes (streptozotocin treatment) [n/1000 um2] |
Morphology |
| X3014 |
12594 |
Kidney morphology, podocyte (WT1-positive cells) count per glomerular section following longterm diabetes (streptozotocin treatment) [n] |
Morphology |
| X1788 |
12595 |
Kidney morphology, glomerular surface area following longterm diabetes (streptozotocin treatment) [1000 um2] |
Morphology |
| X764 |
12596 |
WT1-negative cell count per glomerular section following longterm diabetes (streptozotocin treatment) [units] |
Morphology |
| X1487 |
12597 |
Kidney, total glomerular cell count per glomerular section following longterm diabetes (streptozotocin treatment) [units] |
Morphology |
| X2572 |
12598 |
Wilm's tumor 1 (WT1) -negative cells per glomerular surface area in longterm diabetes [n/1000 um2] |
Morphology |
| X4099 |
12599 |
Kidney morphology, number of podocytes per 1000 um2 [units] |
Morphology |
| X4248 |
12600 |
Kidney morphology, podocytes (WT1-positive cells) per glomerular section, 6 months after induction of type I diabetes by streptozotocin treatment [n/section] |
Morphology |
| X1002 |
12659 |
Brain weight, corrected only for dissection error (modified Feb2015 with new data for BXD79, from 374.017 to 432.7+/-10 ) [mg] |
Morphology |
| X328 |
12660 |
Brain weight, repeat measurement prior to dissection, corrected only for initial dissection errors [mg] |
Morphology |
| X218 |
12661 |
Brain weight, repeat measurement prior to dissection, statistically adjusted for variation in sex, age, body weight and for dissection error (Hager et al., 2012) [mg] |
Morphology |
| X416 |
12662 |
Brain weight, statistically adjusted for variation in sex, age, body weight, and dissection error [mg] |
Morphology |
| X1431 |
12663 |
Small intestine length, statistically adjusted for variation in sex and age [cm] |
Morphology |
| X1073 |
12664 |
small intestine length, without statistical adjustment [cm] |
Morphology |
| X1302 |
12685 |
Body weight, statistically adjusted for variation in sex and age, and corrected for pregnancy (Hager et al., 2012) [g] |
Morphology |
| X699 |
12686 |
Body weight (no statistical adjustment) [g] |
Morphology |
| X4152 |
12738 |
Pregnenolone levels X hrs after saline injection, XX sample collection (preliminary) [pg/g] |
Morphology |
| X696 |
12747 |
Uterus and ovary weight at maturity, bilateral, unadjusted for body weight, age, or parity [mg] |
Morphology |
| X900 |
12748 |
Uterus weight at maturity, bilateral, unadjusted for body weight, age, or parity [mg] |
Morphology |
| X685 |
12749 |
Uterus horn length at maturity (average of right and left sides), unadjusted for body weight, age, or parity [mg] |
Morphology |
| X436 |
12750 |
Uterus body length, unadjusted for body weight, age, or parity [cm] |
Morphology |
| X3629 |
12751 |
Uterus body width at maturity, unadjusted for body weight, age, or parity [cm] |
Morphology |
| X4873 |
12752 |
Ovary weight at maturity, unilateral (average of right and left), unadjusted for body weight, age, or parity [mg] |
Morphology |
| X3603 |
12765 |
Body weight in 8-week F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, wildtype cases only [gm] |
Morphology |
| X3361 |
12766 |
Body weight in 8-week F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington mode, R6/2 cases only [gm] |
Morphology |
| X4633 |
12767 |
Body weight in 8-week F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model [% wildtype] |
Morphology |
| X2077 |
12827 |
Brown adipose tissue mass of 20-week old females [g] |
Morphology |
| X4593 |
12831 |
Systolic blood pressure by tail cuff system of 16-week old females [mmHg] |
Morphology |
| X2226 |
12832 |
Body weight of 13-week old females [g] |
Morphology |
| X2016 |
12833 |
Body weight of 14-week old females [g] |
Morphology |
| X3602 |
12834 |
Body weight of 15-week old females [g] |
Morphology |
| X2744 |
12835 |
Body weight of 16-week old females [g] |
Morphology |
| X1357 |
12836 |
Body weight of 17-week old females [g] |
Morphology |
| X978 |
12837 |
Body weight at echocardiography of 17-week old females [g] |
Morphology |
| X676 |
12838 |
Body weight of 18-week old females [g] |
Morphology |
| X742 |
12839 |
Body weight for glucose tolerance test (ip) test of 18-week old females [g] |
Morphology |
| X2093 |
12840 |
Body weight of 19-week old females [g] |
Morphology |
| X2616 |
12841 |
Body weight at bone densitometry assay (peripheral dual energy X-ray absorptiometer (PDEXA)) of 19-week old females [g] |
Morphology |
| X1585 |
12842 |
Body weight of 20-week old females [g] |
Morphology |
| X1099 |
12843 |
Body weight of 20-week old females at necropsy [g] |
Morphology |
| X4084 |
12847 |
End-diastolic diameter by echocardiography of 17-week old females [mm] |
Morphology |
| X3482 |
12848 |
End-systolic diameter by echocardiography of 17-week old females [mm] |
Morphology |
| X3888 |
12849 |
Body fat mass percentage of 19-week old females [%] |
Morphology |
| X3815 |
12850 |
Body fat mass of 19-week old females [g] |
Morphology |
| X3338 |
12851 |
Ejection fraction by echocardiography of 17-week old females [%] |
Morphology |
| X4305 |
12853 |
Shortening fraction by echocardiography of 17-week old females [%] |
Morphology |
| X394 |
12863 |
Heart rate during echocardiography of 17-week old females [beat/min] |
Morphology |
| X1670 |
12865 |
Body lean mass of 19-week old females [g] |
Morphology |
| X4250 |
12866 |
Body lean mass percentage of 19-week old females [%] |
Morphology |
| X659 |
12868 |
Left ventricular mass by echocardiography of 17-week old females [mg] |
Morphology |
| X2480 |
12869 |
Left ventricular mass/body weight ratio by echocardiography of 17-week old females [ratio] |
Morphology |
| X3371 |
12876 |
Posterior wall thickness by echocardiography of 17-week old females [mm] |
Morphology |
| X2470 |
12880 |
Septum thickness by echocardiography of 17-week old females [mm] |
Morphology |
| X2912 |
12887 |
White adipose tissue mass of 20-week old females [g] |
Morphology |
| X4113 |
12897 |
Brown adipose tissue mass of 20-week old males [g] |
Morphology |
| X4563 |
12901 |
Systolic blood pressure by tail cuff system of 16-week old males [mmHg] |
Morphology |
| X4359 |
12902 |
Body weight of 13-week old males [g] |
Morphology |
| X2662 |
12903 |
Body weight of 14-week old males [g] |
Morphology |
| X3861 |
12904 |
Body weight of 15-week old males [g] |
Morphology |
| X1283 |
12909 |
Body weight for glucose tolerance test (ip) test of 18-week old males [g] |
Morphology |
| X4316 |
12910 |
Body weight of 19-week old males [g] |
Morphology |
| X4081 |
12911 |
Body weight at bone densitometry assay (peripheral dual energy X-ray absorptiometer (PDEXA)) of 19-week old males [g] |
Morphology |
| X4080 |
12912 |
Body weight of 20-week old males [g] |
Morphology |
| X2025 |
12913 |
Body weight of 20-week old males at necropsy [g] |
Morphology |
| X3974 |
12917 |
End-diastolic diameter by echocardiography of 17-week old males [mm] |
Morphology |
| X5062 |
12918 |
End-systolic diameter by echocardiography of 17-week old males [mm] |
Morphology |
| X3429 |
12919 |
Body fat mass percentage of 19-week old males [%] |
Morphology |
| X3583 |
12920 |
Body fat mass of 19-week old males [g] |
Morphology |
| X2417 |
12921 |
Ejection fraction by echocardiography of 17-week old males [%] |
Morphology |
| X1237 |
12923 |
Shortening fraction by echocardiography of 17-week old males [%] |
Morphology |
| X1334 |
12933 |
Heart rate during echocardiography of 17-week old males [beat/min] |
Morphology |
| X3227 |
12935 |
Body lean mass of 19-week old males [g] |
Morphology |
| X1474 |
12936 |
Body lean mass percentage of 19-week old males [%] |
Morphology |
| X4189 |
12938 |
Left ventricular mass by echocardiography of 17-week old males [mg] |
Morphology |
| X3170 |
12939 |
Left ventricular mass/body weight ratio by echocardiography of 17-week old males [ratio] |
Morphology |
| X4336 |
12946 |
Posterior wall thickness by echocardiography of 17-week old males [mm] |
Morphology |
| X1937 |
12950 |
Septum thickness by echocardiography of 17-week old males [mm] |
Morphology |
| X3724 |
12957 |
White adipose tissue mass of 20-week old males [g] |
Morphology |
| X4441 |
12970 |
Ethanol response (chronic intermittent ethanol CIE cycles), 3a,5a-tetrahydroprogesterone (THP, allopregnanolone) in plasma 72 h after the 5th cycle of ethanol vapor chamber treatment, 16 to 18 week-old males o |
Morphology |
| X2301 |
13019 |
Ethanol response (CIE), 3a,5b-THP in blood plasma 3 days after cycle 5 of chronic intermittent ethanol (CIE) vapor treatment [pg/g] |
Morphology |
| X4362 |
13020 |
Ethanol response (CIE), 3a,5a-tetrahydrodeoxycorticosterone (THDOC) in blood plasma 3 days after cycle 5 of chronic intermittent ethanol (CIE) vapor treatment [pg/g] |
Morphology |
| X2544 |
13022 |
Ethanol response (CIE), 3a,5a-androsterone in blood plasma 3 days after cycle 5 of chronic intermittent ethanol vapor [pg/g] |
Morphology |
| X4760 |
13023 |
Ethanol response (CIE), corticosterone in blood plasma 3 days after cycle 5 of chronic intermittent ethanol (CIE) vapor chamber treatment [ng/g] |
Morphology |
| X4173 |
13024 |
Control for ethanol response, corticosterone in blood plasma 3 days after cycle 5 of chronic intermittent air vapor [ng/g] |
Morphology |
| X2231 |
13025 |
Air control response, 3a,5a-tetrahydroprogesterone (THP, allopregnanolone) in plasma 72 h after the 5th cycle of chronic intermittent air control in 16 to 18 week-old males or females (Dec 2009 Cohort 1) [pg/g] |
Morphology |
| X1614 |
13026 |
Control for ethanol response, 3a,5b-THP in blood plasma 3 days after cycle 5 of chronic intermittent air vapor [pg/g] |
Morphology |
| X137 |
13027 |
Ethanol response control, 3a,5a-tetrahydrodeoxycorticosterone (THDOC) in blood plasma 3 days after cycle 5 of chronic intermittent air vapor (CIE air control) [pg/g] |
Morphology |
| X2101 |
13029 |
Air control response, 3a,5a-androsterone in blood plasma 72 h after 5th air control cycle of vapor chamber treatment, 16 to 18 week-old males or females (Dec 2009 Cohort 1) [pg/g] |
Morphology |
| X708 |
13031 |
Hippocampus bilateral weight [mg] with adjustment for age, sex, body weight, and brain minus hippocampus weight. |
Morphology |
| X60 |
13032 |
electrophoretic band variant of Lap-1 protein (ANPEP) that maps to proximal Chr 9 (this is not the Anpep locus, but is a possible trans-effect) [-1 band present, 1 band absent] |
Morphology |
| X195 |
13035 |
Cadmium response (0.03 mM/kg CdCl2 subcutaneous in 0.1 ml), susceptibility to cadmium-induced testicular necrosis at 48 hrs, recessive cadmium resistance locus Cdm (Slc39a8) [-1= resistant, 1 = susceptible] |
Morphology |
| X58 |
13036 |
Cadmium toxicity (0.03 mM/kg CdCl2 subcutaneous in 0.1 ml), susceptibility to cadmium-induced testicular necrosis at 48 hrs, recessive cadmium resistance locus cdm (Slc39a8) [-1= resistant, 1 = susceptible] |
Morphology |
| X3918 |
13057 |
Kidney weight of females (raw data) [mg] |
Morphology |
| X468 |
13058 |
Kidney weight of males (raw data, unadjusted) [mg] |
Morphology |
| X4762 |
13062 |
Total cell number in cerebral neocortex of adults (neurons, glial cells, endothelial cells), bilateral (direct 3D counting method) [millions] |
Morphology |
| X482 |
13384 |
Lateral septum volume, adult both sexes (MBL samples), morphometric point counting estimate from serial sections (without corrections) [mm3] |
Morphology |
| X2230 |
13385 |
Midsagittal area of the corpus callosum, corrected for shrinkage, age, sex, brain weight, epoch [mm2] |
Morphology |
| X4753 |
13466 |
Body weight in 8-week F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington mode, female R6/2 cases only [gm] |
Morphology |
| X1806 |
13467 |
Body weight in 8-week F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington mode, male R6/2 cases only [gm] |
Morphology |
| X4885 |
13468 |
Body weight in 8-week F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model female only [% wildtype] |
Morphology |
| X4224 |
13469 |
Body weight in 8-week F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model male only [% wildtype] |
Morphology |
| X2630 |
13470 |
Body weight in 8-week F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington mode, female wildtype cases only [gm] |
Morphology |
| X1174 |
13471 |
Body weight in 8-week F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington mode, male wildtype cases only [gm] |
Morphology |
| X3066 |
13514 |
Brain:body weight ratio in 8-week-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, wildtype cases only [ratio, left hemisphere:brain weight] |
Morphology |
| X3094 |
13515 |
Brain:body weight ratio in 8-week-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, R6/2 cases only [ratio, left hemisphere:brain weight] |
Morphology |
| X2483 |
13516 |
Brain:body weight ratio in 8-week-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, [% WT] [ratio, left hemisphere:brain weight] |
Morphology |
| X4504 |
13518 |
Body weight in 8-week F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington mode, corrected female R6/2 cases only [gm] |
Morphology |
| X1268 |
13519 |
Body weight in 8-week F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington mode, CORRECTED female R6/2 cases [gm] |
Morphology |
| X1315 |
13546 |
Cerebellum residual weight, repeat measurement prior to dissection, statistically adjusted for variation in sex, age, and body weight [residual mg] |
Morphology |
| X792 |
13548 |
Dorsal striatum (caudate putamen) residual volume, statistically adjusted for variation in sex, age, body weight, and epoch (Hager et al., 2012) [residual mm^3] |
Morphology |
| X1017 |
13550 |
Cerebral cortex (neocortex) residual volume, statistically adjusted for variation in sex, age, body weight, and epoch (Hager et al., 2012) [residual mm^3] |
Morphology |
| X1166 |
13551 |
Hippocampus residual weight, repeat measurement prior to dissection, statistically adjusted for variation in sex, age, body weight, and epoch (Hager et al., 2012) [residual mg] |
Morphology |
| X3887 |
13562 |
Corticosterone in serum 15 min following 15 min restraint in females (6-8 months) for normally housed control group for chronic mild stress (CMS) [ng/ml] |
Morphology |
| X2408 |
13563 |
Corticosterone in serum 15 min following 15 min of restraint in adult females (6-8 months) following 7 weeks of chronic mild stress (CMS) [ng/ml] |
Morphology |
| X934 |
13564 |
Corticosterone difference in serum 15 min following 15 min of restraint in adult females (6-8 months) following 7 weeks of chronic mild stress (CMS), CMS group minus control [ng/ml] |
Morphology |
| X4953 |
13580 |
Adrenal gland weight in normally housed females (6___8 months) [mg x 10] |
Morphology |
| X2155 |
13581 |
Adrenal gland weights in chronic mild stress (CMS) cases following CMS in adult females (6-8 months) [mg x 10] |
Morphology |
| X4766 |
13582 |
Adrenal weight difference in adult females (6-8 months) between chronic mild stress group (CMS for 7 weeks) and control group [mg x 10] |
Morphology |
| X560 |
13583 |
Endocrine system, Thymus weight in normally housed adult female controls (6___8 months) for chronic mild stress (CMS) [mg x 10] |
Morphology |
| X2562 |
13584 |
Endocrine system, Thymus weight in adult females (6___8 months) following 7 weeks of chronic mild stress (CMS) [mg x 10] |
Morphology |
| X2274 |
13585 |
Thymus gland weight difference in adult females (6-8 months), chronic mild stress (CMS) group minus control group [mg x 10] |
Morphology |
| X1711 |
13587 |
Cerebellum residual weight, repeat measurement prior to dissection, statistically adjusted for variation in sex, age, body weight, and epoch (Hager et al., 2012) [residual mg] |
Morphology |
| X1561 |
13588 |
Lateral geniculate nucleus residual volume, repeat measurement prior to dissection, statistically adjusted for variation in sex, age, and body weight (Hager et al.,2012, data from Seecharan et al., 2003) [mm^3] |
Morphology |
| X4387 |
14397 |
Corneal neovascular response to FGF2 (10 ng in corneal micro pocket assay), vessel length five days postoperatively measured by slit lamp (from Fig 1) [mm] |
Morphology |
| X4890 |
14398 |
Corneal neovascular response to FGF2 (10 ng, corneal micro pocket assay), vessel area five days postoperatively measured by slit lamp (from Fig 2) [mm2] |
Morphology |
| X2242 |
14399 |
Central corneal thickness measured by ocular coherence tomography (OCT) in 60 to 100-day-old males and females [um] |
Morphology |
| X2818 |
14781 |
Breeding performance at the Regional Biocontainment Facility, Memphis (UTHSC 2010-2011) [ordinal scale, 0=poor, 1=fair, 2=good] |
Morphology |
| X1233 |
14835 |
Total fat weight measured by Magnetic Resonance Interference (MRI) at 42 days in females on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X1435 |
14836 |
Total fat weight measured by Magnetic Resonance Interference (MRI) at 56 days in females on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X586 |
14837 |
Total fat weight measured by Magnetic Resonance Interference (MRI) at 70 days in females on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X1186 |
14838 |
Total fat weight measured by Magnetic Resonance Interference (MRI) at 84 days in females on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X1362 |
14839 |
Total fat weight measured by Magnetic Resonance Interference (MRI) at 112 days in females on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X2069 |
14840 |
Total fat weight measured by Magnetic Resonance Interference (MRI) at 140 days in females on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X4044 |
14841 |
Fat gain between 7 and 10 weeks in females on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X4757 |
14842 |
Fat gain between 17 and 20 weeks in females on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X3470 |
14843 |
Total lean weight measured by Magnetic Resonance Interference (MRI) at 42 days in females on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X3292 |
14844 |
Total lean weight measured by Magnetic Resonance Interference (MRI) at 56 days in females on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X2697 |
14845 |
Total lean weight measured by Magnetic Resonance Interference (MRI) at 70 days in females on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X2272 |
14846 |
Total lean weight measured by magnetic resonance interference analysis at 84 days in females on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X2640 |
14847 |
Total lean weight measured by Magnetic Resonance Interference (MRI) at 112 days in females on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X2952 |
14848 |
Total lean weight measured by magnetic resonance interference analysis at 140 days in females on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X2330 |
14849 |
Lean gain between 7 and 10 weeks in females on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X2188 |
14850 |
Lean gain between 17 and 20 weeks in females on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X2153 |
14851 |
Body weight at 28 days (4 weeks) in females on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X3381 |
14852 |
Body weight at 35 days (5 weeks) in females on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X3020 |
14853 |
Body weight at 42 days (6 weeks) in females on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X3578 |
14854 |
Body weight at 49 days (7 weeks) in females on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X3303 |
14855 |
Body weight at 56 days (8 weeks) in females on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X3639 |
14856 |
Body weight at 63 days (9 weeks) in females on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X2029 |
17732 |
Body weight in home cage_HFD, males [g] |
Morphology |
| X3275 |
14857 |
Body weight at 70 days (10 weeks) in females on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X1284 |
14858 |
Body weight at 77 days (11 weeks) in females on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X1534 |
14859 |
Body weight at 84 days (12 weeks) in females on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X663 |
14860 |
Body weight at 91 days (13 weeks) in females on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X566 |
14861 |
Body weight at 98 days (14 weeks) in females on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X763 |
14862 |
Body weight at 105 days (15 weeks) in females on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X580 |
14863 |
Body weight at 112 days (16 weeks) in females on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X1774 |
14864 |
Body weight at 119 days (17 weeks) in females on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X1264 |
14865 |
Body weight at 126 days (18 weeks) in females on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X831 |
14866 |
Body weight at 133 days (19 weeks) in females on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X1625 |
14867 |
Body weight at 140 days (20 weeks) in females on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X2578 |
14868 |
Body weight gain between 4 and 5 weeks in females on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X3497 |
14869 |
Body weight gain between 5 and 6 weeks in females on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X2459 |
14870 |
Body weight gain between 6 and 7 weeks in females on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X4188 |
14871 |
Body weight gain between 7 and 8 weeks in females on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X4453 |
14872 |
Body weight gain between 8 and 9 weeks in females on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X3283 |
14873 |
Body weight gain between 9 and 10 weeks in females on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X4990 |
14874 |
Body weight gain between 10 and 11 weeks in females on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X2869 |
14875 |
Body weight gain between 11 and 12 weeks in females on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X2538 |
14876 |
Body weight gain between 12 and 13 weeks in females on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X2149 |
14877 |
Body weight gain between 13 and 14 weeks in females on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X2984 |
14878 |
Body weight gain between 14 and 15 weeks in females on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X1158 |
14879 |
Body weight gain between 15 and 16 weeks in females on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X2871 |
14880 |
Body weight gain between 16 and 17 weeks in females on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X1782 |
14881 |
Body weight gain between 17 and 18 weeks in females on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X3058 |
14882 |
Body weight gain between 18 and 19 weeks in females on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X2799 |
14883 |
Body weight gain between 19 and 20 weeks in females on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X1177 |
14884 |
Body length from the nose until the tail at 42 days in females on high fat diet (45% energy from fat) feeding from 4 weeks on [cm] |
Morphology |
| X3219 |
14885 |
Body length from the nose until the tail at 70 days in females on high fat diet (45% energy from fat) feeding from 4 weeks on [cm] |
Morphology |
| X1940 |
14886 |
Body length from the nose until the tail at 140 days in females on high fat diet (45% energy from fat) feeding from 4 weeks on [cm] |
Morphology |
| X1447 |
14887 |
Serum glucose level at 70 days in females on high fat diet (45% energy from fat) feeding from 4 weeks on [mmol/l] |
Morphology |
| X1022 |
14888 |
Serum glucose level at 140 days in females on high fat diet (45% energy from fat) feeding from 4 weeks on [mmol/l] |
Morphology |
| X4020 |
14889 |
Food Intake between 7 and 10 weeks in females on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X3545 |
14890 |
Food Intake between 17 and 20 weeks in females on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X3632 |
14891 |
Brain weight at 20 weeks in females fed a high fat diet (45% energy from fat) from weaning (4 weeks) [g] |
Morphology |
| X2960 |
14892 |
Liver weight at 20 weeks in females on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X2163 |
14893 |
Kidney weight at 20 weeks in females on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X1668 |
14894 |
Spleen weight at 20 weeks in females on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X2387 |
14895 |
Heart weight at 20 weeks in females on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X1532 |
14896 |
Lung weight at 20 weeks in females on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X4170 |
14897 |
Pancreas weight at 20 weeks in females on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X2722 |
14898 |
Quadriceps (musculus rectus femulus, musculus vastus intermedius, musculus vastus lateralis, musculus vastus medialis) weight at 20 weeks in females on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X3327 |
14899 |
Muscle, Longissmus dorsi weight at 20 weeks in females on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X2126 |
14900 |
Reproductive adipose tissue weight at 20 weeks (epididymal adipose tissue in males and the periuterine and the periovarian adipose tissues in females) in females on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X735 |
14901 |
Retroperitoneal adipose tissue weight at 20 weeks in females on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X3043 |
14902 |
Peritoneal adipose tissue weight at 20 weeks in females on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X4662 |
15008 |
Lean gain between 17 and 20 weeks in males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X919 |
14903 |
Total retroperitoneal and peritneal adipose tissue weight at 20 weeks in females on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X3010 |
14904 |
Adipose tissue hanging at the intestine in females on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X2318 |
14905 |
Inguinal adipose tissue weight at 20 weeks in females on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X3562 |
14906 |
Subcutaneous adipose tissue upon the gluteal Mucsculus maximus between the legs, left and right of the tail in females on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X3270 |
14907 |
Total subcutaneous adipose tissue weight at 20 weeks in females on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X1624 |
14908 |
Total white adipose weight at 20 weeks in the whole body in females on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X988 |
14909 |
Brown adipose tissue located on the back, along the upper half of the spine and toward the shoulders in females on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X2904 |
14910 |
Skeleton with muscle (excluding the Longissmus dorsi and femoral muscle) weight at 20 weeks in females on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X318 |
14911 |
Fat weight around the neck at 20 weeks in females on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X3575 |
14912 |
Fat weight in the visceral organs (liver, lung) at 20 weeks in females on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X3250 |
14913 |
Residual subcutaneous fat weight at 20 weeks in females on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X2045 |
14914 |
Total fat weight measured by Magnetic Resonance Interference (MRI) at 42 days in females + males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X1175 |
14915 |
Total fat weight measured by Magnetic Resonance Interference (MRI) at 56 days in females + males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X677 |
14916 |
Total fat weight measured by Magnetic Resonance Interference (MRI) at 70 days in females + males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X1363 |
14917 |
Total fat weight measured by magnetic resonance interference analysis at 84 days in females and males on a high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X1690 |
14918 |
Total fat weight measured by magnetic resonance interference analysis (EchoMRI-100 system) at 112 days in females and males on a high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X1975 |
14919 |
Total fat weight measured by Magnetic Resonance Interference (MRI) at 140 days in females + males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X704 |
14920 |
Fat gain between 7 and 10 weeks in females + males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X4661 |
14921 |
Fat gain between 17 and 20 weeks in females + males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X1601 |
14922 |
Total lean weight measured by Magnetic Resonance Interference (MRI) at 42 days in females + males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X3039 |
14923 |
Total lean weight measured by Magnetic Resonance Interference (MRI) at 56 days in females + males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X3237 |
14924 |
Total lean weight measured by Magnetic Resonance Interference (MRI) at 70 days in females + males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X3607 |
14925 |
Total lean weight measured by Magnetic Resonance Interference (MRI) at 84 days in females + males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X2436 |
14926 |
Total lean weight measured by Magnetic Resonance Interference (MRI) at 112 days in females + males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X3002 |
14927 |
Total lean weight measured by Magnetic Resonance Interference (MRI) at 140 days in females + males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X4192 |
14928 |
Lean gain between 7 and 10 weeks in females + males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X2611 |
14929 |
Lean gain between 17 and 20 weeks in females + males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X1715 |
14930 |
Body weight at 28 days (4 weeks) in females + males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X1949 |
14931 |
Body weight at 35 days (5 weeks) in females + males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X2071 |
14932 |
Body weight at 42 days (6 weeks) in females + males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X943 |
14933 |
Body weight at 49 days (7 weeks) in females + males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X840 |
14934 |
Body weight at 56 days (8 weeks) in females + males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X1033 |
14935 |
Body weight at 63 days (9 weeks) in females + males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X2389 |
14936 |
Body weight at 70 days (10 weeks) in females + males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X3018 |
14937 |
Body weight at 77 days (11 weeks) in females + males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X3899 |
14938 |
Body weight at 84 days (12 weeks) in females + males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X4583 |
14939 |
Body weight at 91 days (13 weeks) in females + males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X4243 |
14940 |
Body weight at 98 days (14 weeks) in females + males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X4532 |
14941 |
Body weight at 105 days (15 weeks) in females + males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X4699 |
14942 |
Body weight at 112 days (16 weeks) in females + males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X4820 |
14943 |
Body weight at 119 days (17 weeks) in females + males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X4732 |
14944 |
Body weight at 126 days (18 weeks) in females + males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X4342 |
14945 |
Body weight at 133 days (19 weeks) in females + males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X4796 |
14946 |
Body weight at 140 days (20 weeks) in females + males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X3223 |
14947 |
Body weight gain between 4 and 5 weeks in females + males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X2626 |
14948 |
Body weight gain between 5 and 6 weeks in females + males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X3232 |
14949 |
Body weight gain between 6 and 7 weeks in females + males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X1082 |
14950 |
Body weight gain between 7 and 8 weeks in females + males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X847 |
14951 |
Body weight gain between 8 and 9 weeks in females + males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X4193 |
14952 |
Body weight gain between 9 and 10 weeks in females + males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X1583 |
14953 |
Body weight gain between 10 and 11 weeks in females + males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X527 |
14954 |
Body weight gain between 11 and 12 weeks in females + males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X4567 |
14955 |
Body weight gain between 12 and 13 weeks in females + males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X2248 |
14956 |
Body weight gain between 13 and 14 weeks in females + males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X2728 |
14957 |
Body weight gain between 14 and 15 weeks in females + males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X2644 |
14958 |
Body weight gain between 15 and 16 weeks in females + males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X4542 |
14959 |
Body weight gain between 16 and 17 weeks in females + males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X3586 |
14960 |
Body weight gain between 17 and 18 weeks in females + males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X3659 |
14961 |
Body weight gain between 18 and 19 weeks in females + males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X4642 |
14962 |
Body weight gain between 19 and 20 weeks in females + males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X3564 |
14963 |
Body length from the nose until the tail at 42 days in females + males on high fat diet (45% energy from fat) feeding from 4 weeks on [cm] |
Morphology |
| X3590 |
14964 |
Body length from the nose until the tail at 70 days in females + males on high fat diet (45% energy from fat) feeding from 4 weeks on [cm] |
Morphology |
| X3167 |
14965 |
Body length from the nose until the tail at 140 days in females + males on high fat diet (45% energy from fat) feeding from 4 weeks on [cm] |
Morphology |
| X1737 |
14966 |
Serum glucose level at 70 days in females + males on high fat diet (45% energy from fat) feeding from 4 weeks on [mmol/l] |
Morphology |
| X3090 |
10359 |
Femur bone cross-sectional area, weight corrected, in males [mm^2] |
Musculoskeletal |
| X3392 |
14967 |
Serum glucose level at 140 days in females + males on high fat diet (45% energy from fat) feeding from 4 weeks on [mmol/l] |
Morphology |
| X1213 |
14968 |
Food Intake between 7 and 10 weeks in females + males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X2601 |
14969 |
Food Intake between 17 and 20 weeks in females + males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X4283 |
14970 |
Brain weight at 20 weeks (males and females combined) fed a high fat diet (45% energy from fat) from weaning (4 weeks) [g] |
Morphology |
| X3116 |
14971 |
Liver weight at 20 weeks in females + males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X1173 |
14972 |
Kidney weight at 20 weeks in females + males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X1129 |
14973 |
Spleen weight at 20 weeks in females + males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X3168 |
14974 |
Heart weight at 20 weeks in females + males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X495 |
14976 |
Pancreas weight at 20 weeks in females + males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X1809 |
14977 |
The quadriceps (musculus rectus femulus, musculus vastus intermedius, musculus vastus lateralis, musculus vastus medialis) weight at 20 weeks in females + males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X3635 |
14978 |
Muscle, Longissmus dorsi weight at 20 weeks in females + males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X2957 |
14979 |
Reproductive adipose tissue weight at 20 weeks (epididymal adipose tissue in males and the periuterine and the periovarian adipose tissues in females) in females + males on high fat diet (45% energy from fat) feeding from 4 weeks o |
Morphology |
| X1629 |
14980 |
Retroperitoneal adipose tissue weight at 20 weeks in females + males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X3985 |
14981 |
Peritoneal adipose tissue weight at 20 weeks in females + males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X1870 |
14982 |
Total retroperitoneal and peritneal adipose tissue weight at 20 weeks in females + males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X4051 |
14983 |
Adipose tissue hanging at the intestine in females + males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X2406 |
14984 |
Inguinal adipose tissue weight at 20 weeks in females + males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X2160 |
14985 |
Subcutaneous adipose tissue upon the gluteal Mucsculus maximus between the legs, left and right of the tail in females + males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X2501 |
14986 |
Total subcutaneous adipose tissue weight at 20 weeks in females + males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X3194 |
14987 |
Total white adipose weight at 20 weeks in the whole body in females + males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X1484 |
15009 |
Body weight at 28 days (4 weeks) in males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X4048 |
14988 |
Brown adipose tissue located on the back, along the upper half of the spine and toward the shoulders in females + males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X1538 |
14989 |
Skeleton with muscle (excluding the Longissmus dorsi and femoral muscle) weight at 20 weeks in females + males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X2167 |
14990 |
Fat weight around the neck at 20 weeks in females + males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X292 |
14991 |
Fat weight in the visceral organs (liver, lung) at 20 weeks in females + males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X2900 |
14992 |
Residual subcutaneous fat weight at 20 weeks in females + males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X2414 |
14993 |
Total fat weight measured by Magnetic Resonance Interference (MRI) at 42 days in males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X1735 |
14994 |
Total fat weight measured by Magnetic Resonance Interference (MRI) at 56 days in males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X781 |
14995 |
Total fat weight measured by Magnetic Resonance Interference (MRI) at 70 days in males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X953 |
14996 |
Total fat weight measured by Magnetic Resonance Interference (MRI) at 84 days in males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X2856 |
14997 |
Total fat weight measured by Magnetic Resonance Interference (MRI) at 112 days in males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X2876 |
14998 |
Total fat weight measured by Magnetic Resonance Interference (MRI) at 140 days in males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X594 |
14999 |
Fat gain between 7 and 10 weeks in males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X4975 |
15000 |
Fat gain between 17 and 20 weeks in males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X4497 |
15001 |
Total lean weight measured by Magnetic Resonance Interference (MRI) at 42 days in males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X4414 |
15002 |
Total lean weight measured by Magnetic Resonance Interference (MRI) at 56 days in males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X4078 |
15003 |
Total lean weight measured by Magnetic Resonance Interference (MRI) at 70 days in males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X4185 |
15004 |
Total lean weight measured by Magnetic Resonance Interference (MRI) at 84 days in males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X2415 |
15005 |
Total lean weight measured by Magnetic Resonance Interference (MRI) at 112 days in males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X3905 |
15006 |
Total lean weight measured by Magnetic Resonance Interference (MRI) at 140 days in males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X4774 |
15007 |
Lean gain between 7 and 10 weeks in males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X3035 |
15010 |
Body weight at 35 days (5 weeks) in males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X918 |
15011 |
Body weight at 42 days (6 weeks) in males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X369 |
15012 |
Body weight at 49 days (7 weeks) in males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X176 |
15013 |
Body weight at 56 days (8 weeks) in males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X214 |
15014 |
Body weight at 63 days (9 weeks) in males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X363 |
15015 |
Body weight at 70 days (10 weeks) in males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X639 |
15016 |
Body weight at 77 days (11 weeks) in males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X981 |
15017 |
Body weight at 84 days (12 weeks) in males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X2046 |
15018 |
Body weight at 91 days (13 weeks) in males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X3548 |
15019 |
Body weight at 98 days (14 weeks) in males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X3653 |
15020 |
Body weight at 105 days (15 weeks) in males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X3484 |
15021 |
Body weight at 112 days (16 weeks) in males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X4001 |
15022 |
Body weight at 119 days (17 weeks) in males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X4338 |
15023 |
Body weight at 126 days (18 weeks) in males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X4386 |
15024 |
Body weight at 133 days (19 weeks) in males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X4393 |
15025 |
Body weight at 140 days (20 weeks) in males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X4654 |
15026 |
Body weight gain between 4 and 5 weeks in males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X1029 |
15027 |
Body weight gain between 5 and 6 weeks in males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X3634 |
15028 |
Body weight gain between 6 and 7 weeks in males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X1524 |
15029 |
Body weight gain between 7 and 8 weeks in males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X954 |
15030 |
Body weight gain between 8 and 9 weeks in males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X3330 |
15031 |
Body weight gain between 9 and 10 weeks in males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X3996 |
15032 |
Body weight gain between 10 and 11 weeks in males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X290 |
15033 |
Body weight gain between 11 and 12 weeks in males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X1190 |
17578 |
Body weight before activity wheel_HFD, males [g] |
Morphology |
| X1547 |
15034 |
Body weight gain between 12 and 13 weeks in males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X4529 |
15035 |
Body weight gain between 13 and 14 weeks in males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X3933 |
15036 |
Body weight gain between 14 and 15 weeks in males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X4229 |
15037 |
Body weight gain between 15 and 16 weeks in males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X4531 |
15038 |
Body weight gain between 16 and 17 weeks in males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X921 |
15039 |
Body weight gain between 17 and 18 weeks in males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X3878 |
15040 |
Body weight gain between 18 and 19 weeks in males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X789 |
15041 |
Body weight gain between 19 and 20 weeks in males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X3244 |
15042 |
Body length from the nose until the tail at 42 days in males on high fat diet (45% energy from fat) feeding from 4 weeks on [cm] |
Morphology |
| X3384 |
15043 |
Body length from the nose until the tail at 70 days in males on high fat diet (45% energy from fat) feeding from 4 weeks on [cm] |
Morphology |
| X2588 |
15044 |
Body length from the nose until the tail at 140 days in males on high fat diet (45% energy from fat) feeding from 4 weeks on [cm] |
Morphology |
| X2091 |
15045 |
Serum glucose level at 70 days in males on high fat diet (45% energy from fat) feeding from 4 weeks on [mmol/l] |
Morphology |
| X1850 |
15046 |
Serum glucose level at 140 days in males on high fat diet (45% energy from fat) feeding from 4 weeks on [mmol/l] |
Morphology |
| X1254 |
15047 |
Food Intake between 7 and 10 weeks in males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X2961 |
15049 |
Brain weight at 20 weeks in males fed a high fat diet (45% energy from fat) from weaning (4 weeks) [g] |
Morphology |
| X4311 |
15050 |
Liver weight at 20 weeks in males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X1590 |
15051 |
Kidney weight at 20 weeks in males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X568 |
15052 |
Spleen weight at 20 weeks in males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X3363 |
15053 |
Heart weight at 20 weeks in males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X1898 |
15054 |
Lung weight at 20 weeks in males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X1594 |
15055 |
Pancreas weight at 20 weeks in males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X1509 |
15056 |
Urogenital system, morphology, Testis weight at 20 weeks in males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X2997 |
15057 |
The quadriceps (musculus rectus femulus, musculus vastus intermedius, musculus vastus lateralis, musculus vastus medialis) weight at 20 weeks in males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X561 |
17579 |
Fat mass before activity wheel_CD, males [g] |
Morphology |
| X4072 |
15058 |
Muscle, Longissmus dorsi weight at 20 weeks in males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X2890 |
15059 |
Reproductive adipose tissue weight at 20 weeks (epididymal adipose tissue in males and the periuterine and the periovarian adipose tissues in females) in males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X2624 |
15060 |
Retroperitoneal adipose tissue weight at 20 weeks in males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X4528 |
15061 |
Peritoneal adipose tissue weight at 20 weeks in males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X3493 |
15062 |
Total retroperitoneal and peritneal adipose tissue weight at 20 weeks in males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X4476 |
15063 |
Adipose tissue hanging at the intestine in males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X2875 |
15064 |
Inguinal adipose tissue weight at 20 weeks in males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X3133 |
15065 |
Subcutaneous adipose tissue upon the gluteal Mucsculus maximus between the legs, left and right of the tail in males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X3166 |
15066 |
Total subcutaneous adipose tissue weight at 20 weeks in males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X4496 |
15067 |
White adipose weight, total of whole body, at 20 weeks in males on a high fat diet (45% energy from fat) initiated at 4 weeks [g] |
Morphology |
| X4599 |
15068 |
Brown adipose tissue located on the back, along the upper half of the spine and toward the shoulders in males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X2829 |
15069 |
Skeleton with muscle (excluding the Longissmus dorsi and femoral muscle) weight at 20 weeks in males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X2218 |
15070 |
Serum level of resistin at 20 weeks in males on high fat diet (45% energy from fat) feeding from 4 weeks on [pg/ml] |
Morphology |
| X2634 |
15071 |
Serum level of insulin at 20 weeks in males on high fat diet (45% energy from fat) feeding from 4 weeks on [pg/ml] |
Morphology |
| X1209 |
15072 |
Serum level of leptin at 20 weeks in males on high fat diet (45% energy from fat) feeding from 4 weeks on [pg/ml] |
Morphology |
| X4644 |
15073 |
Serum level of Interleukin 1 beta at 20 weeks in males on high fat diet (45% energy from fat) feeding from 4 weeks on [pg/ml] |
Morphology |
| X3134 |
15074 |
Serum level of Interleukin 6 at 20 weeks in males on high fat diet (45% energy from fat) feeding from 4 weeks on [pg/ml] |
Morphology |
| X2510 |
15075 |
Serum level of Interleukin 10 at 20 weeks in males on high fat diet (45% energy from fat) feeding from 4 weeks on [pg/ml] |
Morphology |
| X1549 |
15076 |
Serum level of Interleukin 17 at 20 weeks in males on high fat diet (45% energy from fat) feeding from 4 weeks on [pg/ml] |
Morphology |
| X2777 |
15077 |
Serum level of monocyte chemoattractant protein 1 at 20 weeks in males on high fat diet (45% energy from fat) feeding from 4 weeks on [pg/ml] |
Morphology |
| X479 |
15078 |
Serum level of tumor necrosis factor alpha at 20 weeks in males on high fat diet (45% energy from fat) feeding from 4 weeks on [pg/ml] |
Morphology |
| X2665 |
15079 |
Fat weight around the neck at 20 weeks in males on a high fat diet (45% energy from fat, Ssniff(R) diet S8074-E010, Germany) initiated at 4 weeks [g] |
Morphology |
| X1057 |
15080 |
Fat weight in the visceral organs (liver, lung) at 20 weeks in males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X2615 |
15081 |
Residual subcutaneous fat weight at 20 weeks in males on high fat diet (45% energy from fat) feeding from 4 weeks on [g] |
Morphology |
| X360 |
15082 |
Unsaturated fat content measured by Fourier Transform Infrared Spectroscopy (FTIR) in reproductive adipose tissue at 140 days in males on high fat diet (45% energy from fat) |
Morphology |
| X354 |
15083 |
Saturated fat content measured by Fourier Transform Infrared Spectroscopy (FTIR) in reproductive adipose tissue at 140 days in males on high fat diet (45% energy from fat) |
Morphology |
| X353 |
15084 |
Total fat content measured by Fourier Transform Infrared Spectroscopy (FTIR) in reproductive adipose tissue at 140 days in males on high fat diet (45% energy from fat) |
Morphology |
| X1111 |
15085 |
Acyl chain length measured by Fourier Transform Infrared Spectroscopy (FTIR) in reproductive adipose tissue at 140 days in males on high fat diet (45% energy from fat) |
Morphology |
| X3766 |
15086 |
Ratio of saturated to unsaturated fat content measured by Fourier Transform Infrared Spectroscopy (FTIR) in reproductive adipose tissue at 140 days in males on high fat diet (45% energy from fat) |
Morphology |
| X849 |
15087 |
Ratio of lipid to protein content measured by Fourier Transform Infrared Spectroscopy (FTIR) in reproductive adipose tissue at 140 days in males on high fat diet (45% energy from fat) |
Morphology |
| X389 |
15088 |
Ratio of total lipid to total protein content measured by Fourier Transform Infrared Spectroscopy (FTIR) spectroscopy in reproductive adipose tissue at 140 days in males on high fat diet (45% energy from fat) |
Morphology |
| X302 |
15089 |
Collagen content measured by Fourier Transform Infrared Spectroscopy (FTIR) in reproductive adipose tissue at 140 days in males on high fat diet (45% energy from fat) |
Morphology |
| X772 |
15090 |
Collagen integrity measured by Fourier Transform Infrared Spectroscopy (FTIR) in reproductive adipose tissue at 140 days in males on high fat diet (45% energy from fat) |
Morphology |
| X2607 |
15093 |
Acyl chain length measured by Fourier transform infrared spectroscopy (FTIR) in liver at 140 days in males on a high fat diet (45% energy from far) feeding from 4 weeks [arbitrary unit] |
Morphology |
| X2144 |
15096 |
Collagen content measured by Fourier Transform Infrared Spectroscopy (FTIR) in liver at 140 days in males on high fat diet (45% energy from fat) feeding from 4 weeks on [arbitrary unit] |
Morphology |
| X2210 |
15097 |
Collagen integrity measured by Fourier Transform Infrared Spectroscopy (FTIR) in liver at 140 days in males on high fat diet (45% energy from fat) feeding from 4 weeks on [arbitrary unit] |
Morphology |
| X3611 |
15098 |
Glycogen content measured by Fourier Transform Infrared Spectroscopy (FTIR) in liver at 140 days in males on high fat diet (45% energy from fat) feeding from 4 weeks on [arbitrary unit] |
Morphology |
| X4770 |
15099 |
Saturated fat content measured by Fourier Transform Infrared Spectroscopy (FTIR) in Muscle Femoralis at 140 days in males on high fat diet (45% energy from fat) feeding from 4 weeks on [arbitrary unit] |
Morphology |
| X3176 |
17580 |
Fat mass before activity wheel_HFD, males [g] |
Morphology |
| X4719 |
15100 |
Total fat content measured by Fourier Transform Infrared Spectroscopy (FTIR) in Muscle Femoralis at 140 days in males on high fat diet (45% energy from fat) feeding from 4 weeks on [arbitrary unit] |
Morphology |
| X4672 |
15101 |
Acyl chain length measured by Fourier Transform Infrared Spectroscopy (FTIR) in Muscle Femoralis at 140 days in males on high fat diet (45% energy from fat) feeding from 4 weeks on [arbitrary unit] |
Morphology |
| X4727 |
15102 |
Ratio of lipid to protein content measured by Fourier Transform Infrared Spectroscopy (FTIR) in Muscle Femoralis at 140 days in males on high fat diet (45% energy from fat) feeding from 4 weeks on [arbitrary unit] |
Morphology |
| X4778 |
15103 |
Ratio of total lipid to total protein content measured by Fourier Transform Infrared Spectroscopy (FTIR) in Muscle Femoralis at 140 days in males on high fat diet (45% energy from fat) feeding from 4 weeks on [arbitrary unit] |
Morphology |
| X843 |
15104 |
Collagen content measured by Fourier Transform Infrared Spectroscopy (FTIR) in Muscle Femoralis at 140 days in males on high fat diet (45% energy from fat) feeding from 4 weeks on [arbitrary unit] |
Morphology |
| X873 |
15105 |
Collagen integrity measured by Fourier Transform Infrared Spectroscopy (FTIR) in Muscle Femoralis at 140 days in males on high fat diet (45% energy from fat) feeding from 4 weeks on [arbitrary unit] |
Morphology |
| X3217 |
15106 |
Glycogen content measured by Fourier Transform Infrared Spectroscopy (FTIR) in Muscle Femoralis at 140 days in males on high fat diet (45% energy from fat) feeding from 4 weeks on [arbitrary unit] |
Morphology |
| X786 |
15131 |
Systolic blood pressure of adult males raised in Memphis measured using a tail cuff system (originally known as GN Trait 11017) [mm Hg] |
Morphology |
| X4339 |
15132 |
Systolic blood pressure of adult females raised in Memphis measured using a tail cuff system (originally known as GN Trait 12076) [mm Hg] |
Morphology |
| X4977 |
15175 |
Trait 1, SCNT 2 cell/constructs, percentage of somatic cell nuclear transfer (clone) embryos developing to the 2-cell stage (Table 1) [%] |
Morphology |
| X405 |
15176 |
Somatic cell nuclear transfer (SCNT) embryos (cloned) that successfully develop from the 2-cell to 4-cell stage (Table 1) [%] |
Morphology |
| X597 |
15177 |
Trait 3,; SCNT Blastocysts/2 cell;; lathamk1@msu.edu. Fraction (%) of somatic cell nuclear transfer (clone) embryos developing from the 2 cell to blastocyst stage (Table 1).; |
Morphology |
| X2131 |
15178 |
Trait 4,; SCNT Blastocysts/ 4 cell;; lathamk1@msu.edu. Fraction (%) of somatic cell nuclear transfer (clone) embryos developing from the 4 cell to blastocyst stage (Table 1).; |
Morphology |
| X63 |
15571 |
Hair coat color, ordinal scale version 3 where grey=1, black=2, brown=3, dba dilute=4 [color intensity] |
Morphology |
| X4852 |
15950 |
Trait 5,; Parthenote 2 cell/constructs;; lathamk1@msu.edu. Fraction (%) of parthenogenetic embryos developing to the 2 cell stage (Table 1).; |
Morphology |
| X4373 |
15951 |
Trait 6,; Parthenote 4cell/2cell;; lathamk1@msu.edu. Fraction (%) of parthenogenetic embryos developing from the 2 cell to 4 cell stage (Table 1).; |
Morphology |
| X4355 |
15952 |
Trait 7,; Parthenote Blastocyst/2cell;; lathamk1@msu.edu. Fraction (%) of parthenogenetic embryos developing from the 2 cell to blastocyst stage (Table 1).; |
Morphology |
| X3692 |
15953 |
Trait 8,; Parthenote Blastocyst/4cell;; lathamk1@msu.edu. Fraction (%) of parthenogenetic embryos developing from the 4 cell to blastocyst stage (Table 1).; |
Morphology |
| X4271 |
15954 |
Trait 9,; SCNT:Parthenote 2 cell/constructs;; lathamk1@msu.edu. Ratio of the fraction (%) of somatic cell nuclear transfer (clone) embryos : fraction (%) of parthenogenetic embryos for development to the 2 cell stage (Table 1).; |
Morphology |
| X5026 |
15955 |
Ratio of the fraction (%) of somatic cell nuclear transfer (clone) embryos to fraction (%) of parthenogenetic embryos for development from the 2-cell to 4-cell stage (Table 1) [%] |
Morphology |
| X4888 |
15956 |
Trait 11,; SCNT:Parthenote Blastocyst/2cell;; lathamk1@msu.edu. Ratio of the fraction (%) of somatic cell nuclear transfer (clone) embryos : fraction (%) of parthenogenetic embryos for development from the 2 cell to blastocyst sta; |
Morphology |
| X4653 |
15957 |
Somatic cell nuclear transfer (clone) embryo percentage divided by parthenogenetic embryo percentage for development from 4-cell stage to blastocyst stage (see Table 1) |
Morphology |
| X3005 |
15971 |
Intraocular pressure (IOP), 1 to 2 months old, both sexes, average of left and right eyes [mmHg] |
Morphology |
| X4411 |
15972 |
Intraocular pressure (IOP), 2.1 to 5 months old, both sexes, average of left and right eyes |
Morphology |
| X4556 |
15973 |
Intraocular pressure (IOP), 5.1 to 9 months old, both sexes, average of left and right eyes |
Morphology |
| X859 |
15974 |
Intraocular pressure (IOP), 9 to 13 months old, both sexes, average of left and right eyes (BXD44 winsorized from 21.8 to 19.4, BXD38 winsorized from 9.58 to 10.9, BXD48 outlier deleted (9.300 +/- 0.768 SE), BXD80/73a and B |
Morphology |
| X3771 |
15975 |
Intraocular pressure (IOP), more than 13 months old, both sexes, average of left and right eyes |
Morphology |
| X2041 |
15976 |
Intraocular pressure (IOP), all ages (1 to 30 months old), both sexes, average of left and right eyes |
Morphology |
| X617 |
16244 |
Heart weight, young adult males and females, unadjusted (BXD19 winsorized from 101.4 to 118) [mg] |
Morphology |
| X652 |
16245 |
Heart weight, young adult males and females, adjusted by age, sex, and body weight (BXD19 winsorized from 80.7 to 118) [mg] |
Morphology |
| X1296 |
16307 |
Intra- and infrapyramidal mossy fiber (IIPMF) volume as a percentage of total size of CA3 plus CA4 regions of hippocampus in males at 12 to 14 weeks of age [percent] |
Morphology |
| X2643 |
16313 |
Body weight of young adult females before immunization with TSHR A-subunit (human) adenovirus (see Traits 16314 by McLachlan and colleagues) [g] |
Morphology |
| X3481 |
16317 |
T4-0x, serum thyroxine (T4) before immunization with TSHR A-subunit adenovirus [micrograms/dL] |
Morphology |
| X2994 |
16318 |
T4-2x: serum thyroxine (T4) 1 week after 2 immunizations with TSHR A-subunit adenovirus [micrograms/dL] |
Morphology |
| X2910 |
16319 |
T4-3x, serum thyroxine (T4) 4 weeks after 3 immunizations of females with TSHR A-subunit adenovirus [micrograms/dL] |
Morphology |
| X4598 |
16322 |
Del T4-2x, serum thyroxine (T4) 1 week after 2 immunizations of female mice with TSHR A-subunit adenovirus minus baseline T4 [micrograms/dL] |
Morphology |
| X3205 |
16337 |
Intraocular pressure (IOP), 1 to 2 months old, both sexes,; average of left and right eyes. (BXD48 and BXD96 are merged;; BXD65 and BXD97 are merged;; BXD73;, BXD80 and BXD103 are merged). [mmHg] |
Morphology |
| X4897 |
16338 |
Intraocular pressure (IOP), 2.1 to 5 months old, both sexes,; average of left and right eyes. (BXD48 and BXD96 are merged;; BXD65 and BXD97 are merged;; BXD73;, BXD80 and BXD103 are merged). [mmHg] |
Morphology |
| X4523 |
16339 |
Intraocular pressure (IOP), 5.1 to 9 months old, both sexes,; average of left and right eyes. (BXD48 and BXD96 are merged;; BXD65 and BXD97 are merged;; BXD73;, BXD80 and BXD103 are merged). [mmHg] |
Morphology |
| X501 |
16340 |
Intraocular pressure (IOP), 9.1 to 13 months old, both sexes,; average of left and right eyes. (BXD48 and BXD96 are merged;; BXD65 and BXD97 are merged;; BXD73;, BXD80 and BXD103 are merged). [mmHg] |
Morphology |
| X2929 |
16341 |
Intraocular pressure (IOP), more than 13 months old, both sexes,; average of left and right eyes. (BXD48 and BXD96 are merged;; BXD65 and BXD97 are merged;; BXD73;, BXD80 and BXD103 are merged). [mmHg] |
Morphology |
| X1952 |
16342 |
Intraocular pressure (IOP), all ages (1 to 30 months old), both sexes,; average of left and right eyes. (BXD48 and BXD96 are merged;; BXD65 and BXD97 are merged;; BXD73;, BXD80 and BXD103 are merged). [mmHg] |
Morphology |
| X1193 |
16363 |
uterine weight at maturity, adjusted for age, body weight, dissector, source, and days in fixative [mg] |
Morphology |
| X2220 |
16364 |
ovarian weight at maturity, average of unilateral values, adjusted for age, birth weight, dissector, source, and days in fixative [mg] |
Morphology |
| X1336 |
16365 |
uterine body length at maturity, adjusted for age, body weight, dissector, source, and days in fixative [cm] |
Morphology |
| X3858 |
16366 |
uterine body width at maturity, adjusted for age, body weight, dissector, source, and days in fixative [cm] |
Morphology |
| X1287 |
16367 |
uterine horn length at maturity, average of unilateral values, adjusted for age, body weight, dissector, source, and days in fixative [cm] |
Morphology |
| X2453 |
17019 |
Kidney weight as a percentage of body weight in adult males and females without statistical adjustments [%] |
Morphology |
| X1434 |
17022 |
Eye weight as a percentage of body weight in adult males and females without statistical adjustments [%] |
Morphology |
| X3927 |
17024 |
Baculum shape factor 1 (principal component) [PC score] |
Morphology |
| X1222 |
17476 |
Intra- and infrapyramidal mossy fiber (IIPMF) volume as a percentage of total size of CA3 plus CA4 regions of hippocampus in females at 12 to 14 weeks of age [percent] |
Morphology |
| X2465 |
17477 |
Hilus volume as a percentage of total size of CA3 plus CA4 regions of hippocampus in females at 12 to 14 weeks of age [percent] |
Morphology |
| X3525 |
17478 |
Suprapyramidal mossy fibers volume as a percentage of total size of CA3 plus CA4 regions of hippocampus in females at 12 to 14 weeks of age [percent] |
Morphology |
| X338 |
17479 |
Stratum pyramidale volume as a percentage of total size of CA3 plus CA4 regions of hippocampus in females at 12 to 14 weeks of age [percent] |
Morphology |
| X3267 |
17480 |
Stratum oriens volume as a percentage of total size of CA3 plus CA4 regions of hippocampus in females at 12 to 14 weeks of age [percent] |
Morphology |
| X1874 |
17481 |
Stratum radiatum volume as a percentage of total size of CA3 plus CA4 regions of hippocampus in females at 12 to 14 weeks of age [percent] |
Morphology |
| X1369 |
17482 |
Stratum lacunosum volume as a percentage of total size of CA3 plus CA4 regions of hippocampus in females at 12 to 14 weeks of age [percent] |
Morphology |
| X2512 |
17484 |
Suprapyramidal mossy fibers volume as a percentage of total size of CA3 plus CA4 regions of hippocampus in males at 12 to 14 weeks of age [percent] |
Morphology |
| X3411 |
17485 |
Stratum pyramidale volume as a percentage of total size of CA3 plus CA4 regions of hippocampus in males at 12 to 14 weeks of age [percent] |
Morphology |
| X1515 |
17486 |
Stratum oriens volume as a percentage of total size of CA3 plus CA4 regions of hippocampus in males at 12 to 14 weeks of age [percent] |
Morphology |
| X4875 |
17488 |
Stratum lacunosum volume as a percentage of total size of CA3 plus CA4 regions of hippocampus in males at 12 to 14 weeks of age [percent] |
Morphology |
| X4337 |
17489 |
Body weight of males at 12 to 14 weeks of age [g] |
Morphology |
| X2471 |
17490 |
Brain weight of males at 12 to 14 weeks of age [g] |
Morphology |
| X3846 |
17491 |
Brain to body weight ratio in males at 12 to 14 weeks of age [percent] |
Morphology |
| X3708 |
17492 |
Body weight of females at 12 to 14 weeks of age [g] |
Morphology |
| X3816 |
17493 |
Brain weight of females at 12 to 14 weeks of age [g] |
Morphology |
| X1188 |
17494 |
Brain to body weight ratio in females at 12 to 14 weeks of age [percent] |
Morphology |
| X1942 |
17557 |
Body weight at 8 weeks_CD, males [g] |
Morphology |
| X4871 |
17558 |
Body weight at 8 weeks_HFD, males [g] |
Morphology |
| X1180 |
17559 |
Body weight at 16 weeks_CD, males [g] |
Morphology |
| X3019 |
17560 |
Body weight at 16 weeks_HFD, males [g] |
Morphology |
| X1429 |
17561 |
Body weight at 28 weeks_CD, males [g] |
Morphology |
| X747 |
17562 |
Body weight at 28 weeks_HFD, males [g] |
Morphology |
| X1967 |
17563 |
Body weight at sacrifice_CD, males [g] |
Morphology |
| X2694 |
17564 |
Body weight at sacrifice_HFD, males [g] |
Morphology |
| X417 |
17565 |
Body weight at blood pressure measurement_CD, males [g] |
Morphology |
| X2177 |
17566 |
Body weight at blood pressure measurement_HFD, males [g] |
Morphology |
| X806 |
17567 |
Body weight during metabolic cage experiment_CD, males [g] |
Morphology |
| X2825 |
17568 |
Body weight during metabolic cage experiment_HFD, males [g] |
Morphology |
| X1313 |
17569 |
Fat mass during metabolic cage experiment_CD, males [g] |
Morphology |
| X2682 |
17570 |
Fat mass during metabolic cage experiment_HFD, males [g] |
Morphology |
| X2270 |
17571 |
Fat mass as percentage of body weight during metabolic cage experiment_CD, males [%] |
Morphology |
| X5063 |
17572 |
Fat mass as percentage of body weight during metabolic cage experiment_HFD, males [%] |
Morphology |
| X690 |
17573 |
Lean mass during metabolic cage experiment_CD, males [g] |
Morphology |
| X3689 |
17574 |
Lean mass during metabolic cage experiment_HFD, males [g] |
Morphology |
| X2612 |
17575 |
Lean mass as percentage of body weight during metabolic cage experiment_CD, males [%] |
Morphology |
| X3956 |
17576 |
Lean mass as percentage of body weight during metabolic cage experiment_HFD, males [%] |
Morphology |
| X572 |
17577 |
Body weight before activity wheel_CD, males [g] |
Morphology |
| X1428 |
17581 |
Fat mass as percentage of body weight before activity wheel_CD, males [%] |
Morphology |
| X3978 |
17582 |
Fat mass as percentage of body weight before activity wheel_HFD, males [%] |
Morphology |
| X1866 |
17583 |
Lean mass before activity wheel_CD, males [g] |
Morphology |
| X3631 |
17584 |
Lean mass before activity wheel_HFD, males [g] |
Morphology |
| X1013 |
17585 |
Lean mass as percentage of body weight before activity wheel_CD, males [%] |
Morphology |
| X3801 |
17586 |
Lean mass as percentage of body weight before activity wheel_HFD, males [%] |
Morphology |
| X1168 |
17587 |
Body weight after activity wheel_CD, males [g] |
Morphology |
| X411 |
17588 |
Body weight after activity wheel_HFD, males [g] |
Morphology |
| X2660 |
17589 |
Fat mass after activity wheel_CD, males [g] |
Morphology |
| X330 |
17590 |
Fat mass after activity wheel_HFD, males [g] |
Morphology |
| X2652 |
17591 |
Fat mass as percentage of body weight after activity wheel_CD, males [%] |
Morphology |
| X390 |
17592 |
Fat mass as percentage of body weight after activity wheel_HFD, males [%] |
Morphology |
| X1857 |
17593 |
Lean mass after activity wheel_CD, males [g] |
Morphology |
| X3762 |
17594 |
Lean mass after activity wheel_HFD, males [g] |
Morphology |
| X1926 |
17595 |
Lean mass as percentage of body weight after activity wheel_CD, males [%] |
Morphology |
| X364 |
17596 |
Lean mass as percentage of body weight after activity wheel_HFD, males [%] |
Morphology |
| X647 |
17597 |
Body weight gain 8-16 weeks_CD, males [g] |
Morphology |
| X1962 |
17598 |
Body weight gain 8-16 weeks_HFD, males [g] |
Morphology |
| X4538 |
17599 |
Body weight percentage gain 8-16 weeks_CD, males [%] |
Morphology |
| X3977 |
17600 |
Body weight percentage gain 8-16 weeks_HFD, males [%] |
Morphology |
| X3182 |
17601 |
Body weight gain 8-28 weeks_CD, males [g] |
Morphology |
| X2671 |
17602 |
Body weight gain 8-28 weeks_HFD, males [g] |
Morphology |
| X2430 |
17603 |
Body weight percentage gain 8-28 weeks_CD, males [%] |
Morphology |
| X1021 |
17604 |
Body weight percentage gain 8-28 weeks_HFD, males [%] |
Morphology |
| X3915 |
17605 |
Body weight loss percentage after exercise_CD, males [%] |
Morphology |
| X899 |
17606 |
Body weight loss percentage after exercise_HFD, males [%] |
Morphology |
| X2670 |
17607 |
Body weight fat mass loss percentage after exercise_CD, males [%] |
Morphology |
| X1058 |
17608 |
Body weight fat mass loss percentage after exercise_HFD, males [%] |
Morphology |
| X3302 |
17609 |
Body weight loss pre-sacrifice_CD, males [g] |
Morphology |
| X4125 |
17610 |
Body weight loss pre-sacrifice_HFD, males [g] |
Morphology |
| X2461 |
17767 |
Liver mass at 29 weeks of age_CD, males [g] |
Morphology |
| X874 |
17768 |
Liver mass at 29 weeks of age_HFD, males [g] |
Morphology |
| X1267 |
17769 |
Heart mass at 29 weeks of age_CD, males [g] |
Morphology |
| X3412 |
17770 |
Heart mass at 29 weeks of age_HFD, males [g] |
Morphology |
| X4799 |
17771 |
Subcutaneous white adipose mass at 29 weeks of age_CD, males [g] |
Morphology |
| X2617 |
17772 |
Subcutaneous white adipose mass at 29 weeks of age_HFD, males [g] |
Morphology |
| X4790 |
17773 |
Perirenal white adipose mass at 29 weeks of age_CD, males [g] |
Morphology |
| X1341 |
17774 |
Perirenal white adipose mass at 29 weeks of age_HFD, males [g] |
Morphology |
| X698 |
17775 |
Kidney mass at 29 weeks of age_CD, males [g] |
Morphology |
| X3146 |
17776 |
Kidney mass at 29 weeks of age_HFD, males [g] |
Morphology |
| X3952 |
17777 |
Epididymal white adipose mass at 29 weeks of age_CD, males [g] |
Morphology |
| X488 |
17778 |
Epididymal white adipose mass at 29 weeks of age_HFD, males [g] |
Morphology |
| X1847 |
17783 |
Liver mass percentage _CD, males [%] |
Morphology |
| X1225 |
17784 |
Liver mass percentage _HFD, males [%] |
Morphology |
| X2260 |
17785 |
Heart mass percentage _CD, males [%] |
Morphology |
| X824 |
17786 |
Heart mass percentage _HFD, males [%] |
Morphology |
| X3742 |
17787 |
Subcutaneous white adipose mass percentage _CD, males [%] |
Morphology |
| X3103 |
17788 |
Subcutaneous white adipose mass percentage _HFD, males [%] |
Morphology |
| X4610 |
17789 |
Perirenal white adipose mass percentage _CD, males [%] |
Morphology |
| X1079 |
17790 |
Perirenal white adipose mass percentage _HFD, males [%] |
Morphology |
| X1610 |
17791 |
Kidney mass percentage _CD, males [%] |
Morphology |
| X193 |
17792 |
Kidney mass percentage _HFD, males [%] |
Morphology |
| X2298 |
17793 |
Epididymal white adipose mass percentage _CD, males [%] |
Morphology |
| X892 |
17794 |
Epididymal white adipose mass percentage _HFD, males [%] |
Morphology |
| X2766 |
18083 |
Weight of adrenal glands (left and right combined) of females after 7 weeks of chronic mild stress (CMS) [g] |
Morphology |
| X2775 |
18084 |
Body weight of females at end of study after 7 weeks of chronic mild stress (CMS) [g] |
Morphology |
| X4590 |
18085 |
Brain weight of females after 7 weeks of chronic mild stress (CMS) [g] |
Morphology |
| X854 |
18086 |
Heart weight of females after 7 weeks of chronic mild stress (CMS) [g] |
Morphology |
| X1521 |
18087 |
Thymus weight of females after 7 weeks of chronic mild stress (CMS) [g] |
Morphology |
| X2521 |
18098 |
Weight of adrenal glands (left and right combined) of females after 11 weeks of alcohol consumption (20% v/v), using the drinking in the dark (DID) method (4 hr access on day 4 of DID) [g] |
Morphology |
| X3778 |
18099 |
Body weight of females at end of study after 11 weeks of alcohol consumption (20% v/v), using the drinking in the dark (DID) method (4 hr access on day 4 of DID) [g] |
Morphology |
| X3136 |
18100 |
Brain weight of females after 11 weeks of alcohol consumption (20% v/v), using the drinking in the dark (DID) method (4 hr access on day 4 of DID) [g] |
Morphology |
| X4235 |
18101 |
Heart weight of females after after 11 weeks of alcohol consumption (20% v/v), using the drinking in the dark (DID) method (4 hr access on day 4 of DID) [g] |
Morphology |
| X4958 |
18102 |
Thymus weight of females after 11 weeks of alcohol consumption (20% v/v), using the drinking in the dark (DID) method (4 hr access on day 4 of DID) [g] |
Morphology |
| X2223 |
18109 |
Weight of adrenal glands (left and right combined) of females after 11 weeks of alcohol consumption (20% v/v), using the drinking in the dark (DID) method (4 hr access on day 4 of DID, second DID) and 7 we |
Morphology |
| X3057 |
18110 |
Body weight of females at end of study after 11 weeks of alcohol consumption (20% v/v), using the drinking in the dark (DID) method (4 hr access on day 4 of DID) and 7 weeks of chronic mild stress (CMS) [g] |
Morphology |
| X3413 |
18111 |
Brain weight of females after 11 weeks of alcohol consumption (20% v/v), using the drinking in the dark (DID) method (4 hr access on day 4 of DID) and 7 weeks of chronic mild stress (CMS) [g] |
Morphology |
| X1633 |
18112 |
Heart weight of females after after 11 weeks of alcohol consumption (20% v/v), using the drinking in the dark (DID) method (4 hr access on day 4 of DID) and 7 weeks of chronic mild stress (CMS) [g] |
Morphology |
| X4079 |
18113 |
Thymus weight of females after 11 weeks of alcohol consumption (20% v/v), using the drinking in the dark (DID) method (4 hr access on day 4 of DID) and 7 weeks of chronic mild stress (CMS) [g] |
Morphology |
| X3749 |
18405 |
Podocytes (WT1-positive cells) per glomerular section following longterm diabetes induced by streptozotocin (STZ) treatment [n cells /glomerulus section] |
Morphology |
| X716 |
18406 |
Wilms tumor 1 negative (WT1-neg) cells per glomerular cross section following longterm diabetes induced by streptozotocin (STZ) treatment [n cells/glomerulus section] |
Morphology |
| X2044 |
18407 |
Glomerular sectional area (GSA) in glomeruli following longterm diabetes induced by streptozotocin (STZ) treatment [um2] |
Morphology |
| X1548 |
18408 |
Cell density (total) in glomerular sections [um^2] following long term diabetes induced by streptozotocin (STZ) treatment [n/section] |
Morphology |
| X4098 |
18409 |
Podocyte cell density (WT1-positive cells per 1000 um2 glomerular area per glomerular section) following longterm diabetes induced by streptozotocin (STZ) treatment [n/1000 mn2] |
Morphology |
| X1885 |
18410 |
Wilms tumor 1 (WT1) negative cells per 1000 um2 glomerular area per glomerulus cross section following longterm diabetes induced by streptozotocin (STZ) treatment [n per 1000 um2] |
Morphology |
| X4413 |
18412 |
increment of systolic blood pressure (pressure at 4 wks minus pressure at baseline) in males after treatment with angiotensin II (1 mg/kg/day, minipump) for 4 weeks [mmhg] |
Morphology |
| X2517 |
10357 |
Bone mineral density (BMD) measured by DXA in 12-week-old females for whole body [mg/cm2] |
Musculoskeletal |
| X3140 |
10360 |
Femur bone cross-sectional area, weight corrected, in females [mm^2] |
Musculoskeletal |
| X1627 |
10443 |
Bone mineral density (WC-BMD) in males corrected for whole body weight [mg/cm2] |
Musculoskeletal |
| X3971 |
10444 |
Bone mineral density (WC-BMD) in females corrected for whole body weight [mg/cm2] |
Musculoskeletal |
| X3120 |
10739 |
Soleus muscle weight of 200-day-old males [mg] |
Musculoskeletal |
| X2393 |
10740 |
Soleus weight of 200-day-old females [mg] |
Musculoskeletal |
| X1455 |
10741 |
Extensor digitorum longus (EDL) muscle weight of 200-day-old males [mg] |
Musculoskeletal |
| X1176 |
10742 |
Extensor digitorum longus (EDL) weight of 200-day-old females [mg] |
Musculoskeletal |
| X1932 |
10743 |
Tibialis anterior (TA) muscle mass of 200-day-old males [mg] |
Musculoskeletal |
| X3109 |
10744 |
Tibialis anterior (TA) weight of 200-day-old females [mg] |
Musculoskeletal |
| X1688 |
10745 |
Gastrocnemius muscle mass of 200-day-old males [mg] |
Musculoskeletal |
| X549 |
10746 |
Gastrocnemius muscle weight of 200-day-old females [mg] |
Musculoskeletal |
| X2106 |
10758 |
Soleus muscle weight of males at 500 days [mg] |
Musculoskeletal |
| X1958 |
10759 |
Soleus muscle weight of females at 500-days-of-age [mg] |
Musculoskeletal |
| X3415 |
10760 |
Extensor digitorum longus (EDL) weight in 500-day-old males [mg] |
Musculoskeletal |
| X614 |
10761 |
Extensor digitorum longus (EDL) muscle weight of 500-day-old females [mg] |
Musculoskeletal |
| X3150 |
10762 |
Tibialis anterior muscle weight in 500-day-old males [mg] |
Musculoskeletal |
| X4014 |
10763 |
Tibialis anterior muscle weight in 500-day-old females [mg] |
Musculoskeletal |
| X1469 |
10764 |
Gastrocnemius muscle mass of 500-day-old males [mg] |
Musculoskeletal |
| X1440 |
10765 |
Gastrocnemius muscle mass in 500-day-old females [mg] |
Musculoskeletal |
| X711 |
11033 |
Soleus-femoral muscle attachment anomaly [frequency] |
Musculoskeletal |
| X559 |
12558 |
Diaphysis bone density of tibia of females at 4 months measured by micro computed tomography (microCT) (ImTek MicroCAT II, 2005) [mg/cc] |
Musculoskeletal |
| X902 |
12828 |
Bone mineral content for whole body by peripheral dual energy X-ray absorptiometer (PDEXA) of 19-week old females [g] |
Musculoskeletal |
| X2039 |
12829 |
Bone mineral density for whole body by peripheral dual energy X-ray absorptiometer (PDEXA) of 19-week old females [g/cm2] |
Musculoskeletal |
| X345 |
12830 |
Bone surface area for whole body by peripheral dual energy X-ray absorptiometer (PDEXA) of 19-week old females [cm2] |
Musculoskeletal |
| X3479 |
12854 |
Gastrocnemius muscle mass of 20-week old females [g] |
Musculoskeletal |
| X1906 |
12898 |
Bone mineral content for whole body by peripheral dual energy X-ray absorptiometer (PDEXA) of 19-week old males [g] |
Musculoskeletal |
| X1488 |
12899 |
Bone mineral density for whole body by peripheral dual energy X-ray absorptiometer (PDEXA) of 19-week old males [g/cm2] |
Musculoskeletal |
| X570 |
12900 |
Bone surface area for whole body by peripheral dual energy X-ray absorptiometer (PDEXA) of 19-week old males [cm2] |
Musculoskeletal |
| X2659 |
12905 |
Body weight of 16-week old males [g] |
Musculoskeletal |
| X1996 |
12924 |
Gastrocnemius muscle mass of 20-week old males [g] |
Musculoskeletal |
| X1090 |
13045 |
Bone mineral density (BMD) of the femur of males adjusted for age differences (dual energy X-ray absorptiometry PIXImus) [mg/cm2] |
Musculoskeletal |
| X672 |
13046 |
Bone mineral density (BMD) of the tibia of adult males adjusted for age differences (dual energy X-ray absorptiometry DEXA using PIXIimus) [mg/cm2] |
Musculoskeletal |
| X997 |
13047 |
Bone mineral density (BMD) of femurs of females adjusted for age differences (dual energy X-ray absorptiometry DEXA using PIXImus) [mg/cm2] |
Musculoskeletal |
| X4472 |
13048 |
Bone mineral density (BMD) of the tibia of females adjusted for age differences (dual energy X-ray absorptiometry DEXA using PIXImus) [mg/cm2] |
Musculoskeletal |
| X2516 |
13049 |
Bone mineral content (BMC) of femur of 10-week-old males (dual energy X-ray absorptiometry DEXA PIXImus) [g hydroxyapatite] |
Musculoskeletal |
| X1153 |
13050 |
Bone mineral content (BMC) of tibia of 10-week-old males (dual energy X-ray absorptiometry DEXA using PIXImus) [g hydroxyapatite] |
Musculoskeletal |
| X576 |
13051 |
Bone mineral content (BMC) of femur of 10-week-old females (dual energy X-ray absorptiometry PIXImus) [mg] |
Musculoskeletal |
| X2593 |
13052 |
Bone mineral content (BMC) of tibia of 10-week-old females (dual energy X-ray absorptiometry DEXA using PIXImus) [g hydroxyapatite] |
Musculoskeletal |
| X3869 |
13053 |
Surface area of femur of 10-week-old males (dual energy X-ray absorptiometry DEXA using PIXImus) [cm2] |
Musculoskeletal |
| X294 |
13054 |
Surface area of tibia of 10-week-old males (dual energy X-ray absorptiometry DEXA using PIXImus) [cm2] |
Musculoskeletal |
| X983 |
13055 |
Surface area of femur of 10-week-old females (dual energy X-ray absorptiometry DEXA using PIXImus) [cm2] |
Musculoskeletal |
| X1865 |
13056 |
Surface area of tibia of 10-week-old females (dual energy X-ray absorptiometry DEXA using PIXImus) [cm2] |
Musculoskeletal |
| X2687 |
14797 |
Hip cartilage aggrecan 1 (Acan, Agc1, Chr7 at 86.2 Mb) mRNA transcript abundance in adult males and females (100 - 300-days-old) corrected for age and sex and normalized to beta actin, measured initially as 2^(___delta delta) cycle |
Musculoskeletal |
| X3577 |
14798 |
Hip cartilage collagen, type II, alpha 1 (Col2a1) mRNA transcript abundance in adult males and females (100 - 300-days-old) corrected for age and sex and normalized to beta actin, measured initially as 2^(___delta delta) cycle tim |
Musculoskeletal |
| X915 |
14799 |
Hip cartilage cartilage oligomeric matrix protein (Comp) mRNA transcript abundance in adult males and females (100 - 300-days-old) corrected for age and sex and normalized to beta actin, measured initially as 2^(___delta delta) cyc |
Musculoskeletal |
| X4905 |
14800 |
Hip cartilage endothelial PAS domain protein 1 (Epas1) mRNA transcript abundance in adult males and females (100 - 300-days-old) corrected for age and sex and normalized to beta actin, measured initially as 2^(___delta delta) cycle |
Musculoskeletal |
| X1741 |
14801 |
Hip cartilage matrix metallopeptidase 13 (Mmp13) mRNA transcript abundance in adult males and females (100 - 300-days-old) corrected for age and sex and normalized to beta actin, measured initially as 2^(___delta delta) cycle time |
Musculoskeletal |
| X3924 |
14802 |
Malocclusion of incisors in females on 60% high fat diet [% cases] |
Musculoskeletal |
| X968 |
15967 |
Bone mineral density (BMD) of femur, adjusted for sex and age difference, measured by dual energy X-ray absorptiometry (DEXA) [mg/cm2] |
Musculoskeletal |
| X3462 |
15968 |
Bone mineral density (BMD) of the tibia in young adults corrected for sex and age [units] |
Musculoskeletal |
| X3356 |
17779 |
Gastrocnemius muscle mass at 29 weeks of age_CD, males [g] |
Musculoskeletal |
| X4277 |
17780 |
Gastrocnemius muscle mass at 29 weeks of age_HFD, males [g] |
Musculoskeletal |
| X1091 |
17781 |
Soleus muscle mass at 29 weeks of age_CD, males [g] |
Musculoskeletal |
| X1904 |
17782 |
Soleus muscle mass at 29 weeks of age_HFD, males [g] |
Musculoskeletal |
| X2209 |
17795 |
Gastrocnemius muscle mass percentage _CD, males [%] |
Musculoskeletal |
| X3257 |
17796 |
Gastrocnemius muscle mass percentage _HFD, males [%] |
Musculoskeletal |
| X1333 |
17797 |
Soleus muscle mass percentage _CD, males [%] |
Musculoskeletal |
| X1507 |
17798 |
Soleus muscle mass percentage _HFD, males [%] |
Musculoskeletal |
| X1570 |
18130 |
Femur length (age-adjusted, sex averaged) measured by microcomputed tomography (uCT) [mm] |
Musculoskeletal |
| X3213 |
18131 |
Femur mineralized volume (age-adjusted, sex averaged) measured by microcomputed tomography (uCT) (BXD13 winsorized from 10.375 to 11.5)[mm3] |
Musculoskeletal |
| X3147 |
18132 |
Femur material bone mineral density (age-adjusted, sex averaged) measured by microcomputed tomography (uCT) (BXD13 winsorized from 963 to 1016) [mgHA/cm3] |
Musculoskeletal |
| X1244 |
18133 |
Femur cortical envelop total volume (age-adjusted, sex averaged) measured at midshaft by microcomputed tomography (uCT) [mm3] |
Musculoskeletal |
| X1232 |
18134 |
Femur cortical envelop mineralized volume (age-adjusted, sex averaged) measured at midshaft by microcomputed tomography (uCT) [mm3] |
Musculoskeletal |
| X2455 |
18135 |
Femur cortical envelop porosity (age-adjusted, sex averaged) measured at midshaft by microcomputed tomography (uCT) [%] |
Musculoskeletal |
| X1723 |
18136 |
Femur cortical thickness (age-adjusted, sex averaged) measured at midshaft by microcomputed tomography (uCT) [mm] |
Musculoskeletal |
| X970 |
18137 |
Femur cortical material bone mineral density (age-adjusted, sex averaged) measured at midshaft by microcomputed tomography (uCT) [mgHA/cm3] |
Musculoskeletal |
| X3476 |
18138 |
Femur cross-sectional volume (age-adjusted, sex averaged) measured at midshaft by microcomputed tomography (uCT) [mm3] |
Musculoskeletal |
| X1217 |
18139 |
Femur cortical volume (age-adjusted, sex averaged) measured at midshaft by microcomputed tomography (uCT) [mm3] |
Musculoskeletal |
| X4389 |
18140 |
Femur cortical marrow volume (age-adjusted, sex averaged) measured at midshaft by microcomputed tomography (uCT) [mm3] |
Musculoskeletal |
| X3049 |
18141 |
Femur polar moment of inertia (age-adjusted, sex averaged) measured at midshaft by microcomputed tomography (uCT) [g*mm2] |
Musculoskeletal |
| X3104 |
18142 |
Femur moment of inertia around the shorter axis (age-adjusted, sex averaged) measured at midshaft by microcomputed tomography (uCT) [g*mm2] |
Musculoskeletal |
| X1726 |
18143 |
Femur moment of inertia around the longer axis (age-adjusted, sex averaged) measured at midshaft by microcomputed tomography (uCT) [g*mm2] |
Musculoskeletal |
| X4513 |
18144 |
Femur trabecular total volume (age-adjusted, sex averaged) measured by microcomputed tomography (uCT) [mm3] |
Musculoskeletal |
| X4478 |
18145 |
Femur trabecular mineralized bone volume (age-adjusted, sex averaged) measured by microcomputed tomography (uCT) [mm3] |
Musculoskeletal |
| X2852 |
10109 |
Striatum cholinergic neurons section 20 [n/section] |
Nervous system |
| X3288 |
18146 |
Femur trabecular bone volume fraction (age-adjusted, sex averaged) measured by microcomputed tomography (uCT) [ratio] |
Musculoskeletal |
| X3619 |
18147 |
Femur trabecular bone connectivity density (age-adjusted, sex averaged) measured by microcomputed tomography (uCT) [1/mm3] |
Musculoskeletal |
| X2195 |
18148 |
Femur trabecular bone structural model index (age-adjusted, sex averaged) measured by microcomputed tomography (uCT) [ratio] |
Musculoskeletal |
| X3152 |
18149 |
Femur trabecular number (age-adjusted, sex averaged) measured by microcomputed tomography (uCT) [1/mm] |
Musculoskeletal |
| X1559 |
18150 |
Femur trabecular thickness (age-adjusted, sex averaged) measured by microcomputed tomography (uCT) [mm] |
Musculoskeletal |
| X3503 |
18151 |
Femur trabecular seperation (age-adjusted, sex averaged) measured by microcomputed tomography (uCT) [mm] |
Musculoskeletal |
| X3900 |
18152 |
Femur trabecular apparent bone mineral density (age-adjusted, sex averaged) measured by microcomputed tomography (uCT) [mgHA/cm3] |
Musculoskeletal |
| X1337 |
18153 |
Femur trabecular material bone mineral density (age-adjusted, sex averaged) measured by microcomputed tomography (uCT) [mgHA/cm3] |
Musculoskeletal |
| X3003 |
18154 |
Femur trabecular bone degree of anisotropy (age-adjusted, sex averaged) measured by microcomputed tomography (uCT) [ratio] |
Musculoskeletal |
| X1265 |
18155 |
Tibia length (age-adjusted, sex averaged) measured by microcomputed tomography (uCT) [mm] |
Musculoskeletal |
| X1552 |
18156 |
Tibia mineralized volume (age-adjusted, sex averaged) measured by microcomputed tomography (uCT) [mm3] |
Musculoskeletal |
| X3966 |
18157 |
Tibia material bone mineral density (age-adjusted, sex averaged) measured by microcomputed tomography (uCT) [mgHA/cm3] |
Musculoskeletal |
| X875 |
18158 |
Tibia cortical envelop total volume (age-adjusted, sex averaged) measured at midshaft by microcomputed tomography (uCT) [mm3] |
Musculoskeletal |
| X829 |
18159 |
Tibia cortical envelop mineralized volume (age-adjusted, sex averaged) measured at midshaft by microcomputed tomography (uCT) [mm3] |
Musculoskeletal |
| X787 |
18160 |
Tibia cortical envelop porosity (age-adjusted, sex averaged) measured at midshaft by microcomputed tomography (uCT) [%] |
Musculoskeletal |
| X458 |
18161 |
Tibia cortical thickness (age-adjusted, sex averaged) measured at midshaft by microcomputed tomography (uCT) [mm] |
Musculoskeletal |
| X2437 |
18162 |
Tibia cortical material bone mineral density (age-adjusted, sex averaged) measured at midshaft by microcomputed tomography (uCT) [mgHA/cm3] |
Musculoskeletal |
| X1837 |
18163 |
Tibia cross-sectional volume (age-adjusted, sex averaged) measured at midshaft by microcomputed tomography (uCT) [mm3] |
Musculoskeletal |
| X817 |
18164 |
Tibia cortical volume (age-adjusted, sex averaged) measured at midshaft by microcomputed tomography (uCT) [mm3] |
Musculoskeletal |
| X1664 |
18165 |
Tibia cortical marrow volume (age-adjusted, sex averaged) measured at midshaft by microcomputed tomography (uCT) [mm3] |
Musculoskeletal |
| X1368 |
18166 |
Tibia polar moment of inertia (age-adjusted, sex averaged) measured at midshaft by microcomputed tomography (uCT) [g*mm2] |
Musculoskeletal |
| X1896 |
18167 |
Tibia moment of inertia around the shorter axis (age-adjusted, sex averaged) measured at midshaft by microcomputed tomography (uCT) [g*mm2] |
Musculoskeletal |
| X282 |
18191 |
Femur polar moment of inertia (age-adjusted, females only) measured at midshaft by microcomputed tomography (uCT) [g*mm2] |
Musculoskeletal |
| X1425 |
18168 |
Tibia moment of inertia around the longer axis (age-adjusted, sex averaged) measured at midshaft by microcomputed tomography (uCT) [g*mm2] |
Musculoskeletal |
| X3849 |
18169 |
Tibia trabecular total volume (age-adjusted, sex averaged) measured by microcomputed tomography (uCT) [mm3] |
Musculoskeletal |
| X4580 |
18170 |
Tibia trabecular mineralized bone volume (age-adjusted, sex averaged) measured by microcomputed tomography (uCT) [mm3] |
Musculoskeletal |
| X4065 |
18171 |
Tibia trabecular bone volume fraction (age-adjusted, sex averaged) measured by microcomputed tomography (uCT) [ratio] |
Musculoskeletal |
| X2103 |
18172 |
Tibia trabecular bone connectivity density (age-adjusted, sex averaged) measured by microcomputed tomography (uCT) [1/mm3] |
Musculoskeletal |
| X1994 |
18173 |
Tibia trabecular bone structural model index (age-adjusted, sex averaged) measured by microcomputed tomography (uCT) [ratio] |
Musculoskeletal |
| X2970 |
18174 |
Tibia trabecular number (age-adjusted, sex averaged) measured by microcomputed tomography (uCT) [1/mm] |
Musculoskeletal |
| X4847 |
18175 |
Tibia trabecular thickness (age-adjusted, sex averaged) measured by microcomputed tomography (uCT) [mm] |
Musculoskeletal |
| X2909 |
18176 |
Tibia trabecular seperation (age-adjusted, sex averaged) measured by microcomputed tomography (uCT) [mm] |
Musculoskeletal |
| X3798 |
18177 |
Tibia trabecular apparent bone mineral density (age-adjusted, sex averaged) measured by microcomputed tomography (uCT) [mgHA/cm3] |
Musculoskeletal |
| X2433 |
18178 |
Tibia trabecular material bone mineral density (age-adjusted, sex averaged) measured by microcomputed tomography (uCT) [mgHA/cm3] |
Musculoskeletal |
| X769 |
18179 |
Tibia trabecular bone degree of anisotropy (age-adjusted, sex averaged) measured by microcomputed tomography (uCT) [ratio] |
Musculoskeletal |
| X2515 |
18180 |
Femur length (age-adjusted, females only) measured by microcomputed tomography (uCT) [mm] |
Musculoskeletal |
| X935 |
18181 |
Femur mineralized volume (age-adjusted, females only) measured by microcomputed tomography (uCT) [mm3] |
Musculoskeletal |
| X1636 |
18182 |
Femur material bone mineral density (age-adjusted, females only) measured by microcomputed tomography (uCT) [mgHA/cm3] |
Musculoskeletal |
| X526 |
18183 |
Femur cortical envelop total volume (age-adjusted, females only) measured at midshaft by microcomputed tomography (uCT) [mm3] |
Musculoskeletal |
| X513 |
18184 |
Femur cortical envelop mineralized volume (age-adjusted, females only) measured at midshaft by microcomputed tomography (uCT) [mm3] |
Musculoskeletal |
| X2632 |
18185 |
Femur cortical envelop porosity (age-adjusted, females only) measured at midshaft by microcomputed tomography (uCT) [%] |
Musculoskeletal |
| X1679 |
18186 |
Femur cortical thickness (age-adjusted, females only) measured at midshaft by microcomputed tomography (uCT) [mm] |
Musculoskeletal |
| X1226 |
18187 |
Femur cortical material bone mineral density (age-adjusted, females only) measured at midshaft by microcomputed tomography (uCT) [mgHA/cm3] |
Musculoskeletal |
| X1858 |
18188 |
Femur cross-sectional volume (age-adjusted, females only) measured at midshaft by microcomputed tomography (uCT) [mm3] |
Musculoskeletal |
| X520 |
18189 |
Femur cortical volume (age-adjusted, females only) measured at midshaft by microcomputed tomography (uCT) [mm3] |
Musculoskeletal |
| X3187 |
18190 |
Femur cortical marrow volume (age-adjusted, females only) measured at midshaft by microcomputed tomography (uCT) [mm3] |
Musculoskeletal |
| X269 |
18192 |
Femur moment of inertia around the shorter axis (age-adjusted, females only) measured at midshaft by microcomputed tomography (uCT) [g*mm2] |
Musculoskeletal |
| X295 |
18193 |
Femur moment of inertia around the longer axis (age-adjusted, females only) measured at midshaft by microcomputed tomography (uCT) [g*mm2] |
Musculoskeletal |
| X3326 |
18194 |
Femur trabecular total volume (age-adjusted, females only) measured by microcomputed tomography (uCT) [mm3] |
Musculoskeletal |
| X1059 |
18195 |
Femur trabecular mineralized bone volume (age-adjusted,; females only) measured by microcomputed tomography (BXD12 winsorized from 0.035 to 0.08;; BXD39 winsorized from 0.334 to 0.26;; BXD64 winsorized from 0.386 to 0.26; |
Musculoskeletal |
| X1560 |
18196 |
Femur trabecular bone volume fraction (age-adjusted,; females only) measured by microcomputed tomography (BXD12 winsorized from 0.035 to 0.08;; BXD39 winsorized from 0.219 to 0.174;; BXD64 winsorized from 0.260 to 0.175) (; |
Musculoskeletal |
| X3068 |
18197 |
Femur trabecular bone connectivity density (age-adjusted, females only) measured by microcomputed tomography (uCT) [1/mm3] |
Musculoskeletal |
| X1136 |
18198 |
Femur trabecular bone structural model index (age-adjusted, females only) measured by microcomputed tomography (uCT) [ratio] |
Musculoskeletal |
| X3305 |
18199 |
Femur trabecular number (age-adjusted, females only) measured by microcomputed tomography (uCT) [1/mm] |
Musculoskeletal |
| X415 |
18200 |
Femur trabecular thickness (age-adjusted, females only) measured by microcomputed tomography (uCT) [mm] |
Musculoskeletal |
| X2842 |
18201 |
Femur trabecular seperation (age-adjusted, females only) measured by microcomputed tomography (BXD74 winsorized from 0.081 to 0.181) (uCT) [mm] |
Musculoskeletal |
| X1252 |
18202 |
Femur trabecular apparent bone mineral density (age-adjusted,; females only) measured by microcomputed tomography (BXD12 winsorized from 33.601 to 46;; BXD39 winsorized from 210.695 to 182;; BXD64 winsorized from 251.126 t; |
Musculoskeletal |
| X2186 |
18203 |
Femur trabecular material bone mineral density (age-adjusted, females only) measured by microcomputed tomography (BXD78 winsorized from 787 to 806) (uCT) [mgHA/cm3] |
Musculoskeletal |
| X3758 |
18204 |
Femur trabecular bone degree of anisotropy (age-adjusted,; females only) measured by microcomputed tomography (BXD66 winsorized from 1.319 to 1.345;; BXD64 winsorized from 1.895 to 1.79) to (uCT) [ratio]; |
Musculoskeletal |
| X3402 |
18205 |
Tibia length (age-adjusted, females only) measured by microcomputed tomography (uCT) [mm] |
Musculoskeletal |
| X2772 |
18206 |
Tibia mineralized volume (age-adjusted, females only) measured by microcomputed tomography (uCT) [mm3] |
Musculoskeletal |
| X2581 |
18207 |
Tibia material bone mineral density (age-adjusted, females only) measured by microcomputed tomography (uCT) [mgHA/cm3] |
Musculoskeletal |
| X1103 |
18208 |
Tibia cortical envelop total volume (age-adjusted, females only) measured at midshaft by microcomputed tomography (uCT) [mm3] |
Musculoskeletal |
| X1087 |
18209 |
Tibia cortical envelop mineralized volume (age-adjusted, females only) measured at midshaft by microcomputed tomography (uCT) [mm3] |
Musculoskeletal |
| X1732 |
18210 |
Tibia cortical envelop porosity (age-adjusted, females only) measured at midshaft by microcomputed tomography (uCT) [%] |
Musculoskeletal |
| X752 |
18211 |
Tibia cortical thickness (age-adjusted, females only) measured at midshaft by microcomputed tomography (BXD39 winsorized from 0.161 to 0.17) (uCT) [mm] |
Musculoskeletal |
| X4747 |
18212 |
Tibia cortical material bone mineral density (age-adjusted, females only) measured at midshaft by microcomputed tomography (uCT) [mgHA/cm3] |
Musculoskeletal |
| X2251 |
18213 |
Tibia cross-sectional volume (age-adjusted,; females only) measured at midshaft by microcomputed tomography (BXD63 winsorized from 0.734 to 0.86;; BXD39 winsorized from 0.767 to 0.87;; BXD48a winsorized from 1.54 to 1.40;;; |
Musculoskeletal |
| X1067 |
18214 |
Tibia cortical volume (age-adjusted, females only) measured at midshaft by microcomputed tomography (uCT) [mm3] |
Musculoskeletal |
| X3322 |
18215 |
Tibia cortical marrow volume (age-adjusted,; females only) measured at midshaft by microcomputed tomography (BXD63 winsorized from 0.406 to 0.52;; BXD 39 winsorized from 0.465 to 0.53;; BXD1 winsorized from 1.157 to 1.04;;B; |
Musculoskeletal |
| X901 |
18216 |
Tibia polar moment of inertia (age-adjusted, females only) measured at midshaft by microcomputed tomography (uCT) [g*mm2] |
Musculoskeletal |
| X1354 |
18217 |
Tibia moment of inertia around the shorter axis (age-adjusted, females only) measured at midshaft by microcomputed tomography (uCT) [g*mm2] |
Musculoskeletal |
| X679 |
18218 |
Tibia moment of inertia around the longer axis (age-adjusted, females only) measured at midshaft by microcomputed tomography (uCT) [g*mm2] |
Musculoskeletal |
| X767 |
18219 |
Tibia trabecular total volume (age-adjusted, females only) measured by microcomputed tomography (BXD24 winsorized from 0.555 to 0.74) (uCT) [mm3] |
Musculoskeletal |
| X1060 |
18220 |
Tibia trabecular mineralized bone volume (age-adjusted, females only) measured by microcomputed tomography (BXD64 winsorized from 0.303 to 0.24) (uCT) [mm3] |
Musculoskeletal |
| X2927 |
18221 |
Tibia trabecular bone volume fraction (age-adjusted, females only) measured by microcomputed tomography (uCT) [ratio] |
Musculoskeletal |
| X1207 |
18222 |
Tibia trabecular bone connectivity density (age-adjusted,; females only) measured by microcomputed tomography (BXD12 winsorized from 22.65 to 43;; BXD64 winsorized from 289.367 to 255) (uCT) [1/mm3]; |
Musculoskeletal |
| X2742 |
18223 |
Tibia trabecular bone structural model index (age-adjusted, females only) measured by microcomputed tomography (uCT) [ratio] |
Musculoskeletal |
| X459 |
18224 |
Tibia trabecular number (age-adjusted, females only) measured by microcomputed tomography (uCT) [1/mm] |
Musculoskeletal |
| X2313 |
18225 |
Tibia trabecular thickness (age-adjusted, females only) measured by microcomputed tomography (uCT) [mm] |
Musculoskeletal |
| X558 |
18226 |
Tibia trabecular seperation (age-adjusted, females only) measured by microcomputed tomography (uCT) [mm] |
Musculoskeletal |
| X2649 |
18227 |
Tibia trabecular apparent bone mineral density (age-adjusted, females only) measured by microcomputed tomography (uCT) [mgHA/cm3] |
Musculoskeletal |
| X4388 |
18228 |
Tibia trabecular material bone mineral density (age-adjusted, females only) measured by microcomputed tomography (uCT) [mgHA/cm3] |
Musculoskeletal |
| X582 |
18229 |
Tibia trabecular bone degree of anisotropy (age-adjusted, females only) measured by microcomputed tomography (uCT) [ratio] |
Musculoskeletal |
| X2404 |
18230 |
Femur length (age-adjusted, males only) measured by microcomputed tomography (uCT) [mm] |
Musculoskeletal |
| X2938 |
18231 |
Femur mineralized volume (age-adjusted, males only) measured by microcomputed tomography (uCT) [mm3] |
Musculoskeletal |
| X1450 |
18254 |
Femur trabecular bone degree of anisotropy (age-adjusted, males only) measured by microcomputed tomography (uCT) [ratio] |
Musculoskeletal |
| X3458 |
18232 |
Femur material bone mineral density (age-adjusted, males only) measured by microcomputed tomography (BXD78 winsorised from 1158 to 1105) (uCT) [mgHA/cm3] |
Musculoskeletal |
| X4636 |
18233 |
Femur cortical envelop total volume (age-adjusted, males only) measured at midshaft by microcomputed tomography (uCT) [mm3] |
Musculoskeletal |
| X4426 |
18234 |
Femur cortical envelop mineralized volume (age-adjusted, males only) measured at midshaft by microcomputed tomography (uCT) [mm3] |
Musculoskeletal |
| X3573 |
18235 |
Femur cortical envelop porosity (age-adjusted, males only) measured at midshaft by microcomputed tomography (uCT) [%] |
Musculoskeletal |
| X3353 |
18236 |
Femur cortical thickness (age-adjusted, males only) measured at midshaft by microcomputed tomography (uCT) [mm] |
Musculoskeletal |
| X1505 |
18237 |
Femur cortical material bone mineral density (age-adjusted, males only) measured at midshaft by microcomputed tomography (uCT) [mgHA/cm3] |
Musculoskeletal |
| X3843 |
18238 |
Femur cross-sectional volume (age-adjusted, males only) measured at midshaft by microcomputed tomography (uCT) [mm3] |
Musculoskeletal |
| X4417 |
18239 |
Femur cortical volume (age-adjusted, males only) measured at midshaft by microcomputed tomography (uCT) [mm3] |
Musculoskeletal |
| X4134 |
18240 |
Femur cortical marrow volume (age-adjusted, males only) measured at midshaft by microcomputed tomography (uCT) [mm3] |
Musculoskeletal |
| X3937 |
18241 |
Femur polar moment of inertia (age-adjusted, males only) measured at midshaft by microcomputed tomography (uCT) [g*mm2] |
Musculoskeletal |
| X4586 |
18242 |
Femur moment of inertia around the shorter axis (age-adjusted, males only) measured at midshaft by microcomputed tomography (uCT) [g*mm2] |
Musculoskeletal |
| X3077 |
18243 |
Femur moment of inertia around the longer axis (age-adjusted, males only) measured at midshaft by microcomputed tomography (uCT) [g*mm2] |
Musculoskeletal |
| X1929 |
18244 |
Femur trabecular total volume (age-adjusted, males only) measured by microcomputed tomography (uCT) [mm3] |
Musculoskeletal |
| X3315 |
18245 |
Femur trabecular mineralized bone volume (age-adjusted, males only) measured by microcomputed tomography (uCT) [mm3] |
Musculoskeletal |
| X1055 |
18246 |
Femur trabecular bone volume fraction (age-adjusted, males only) measured by microcomputed tomography (uCT) [ratio] |
Musculoskeletal |
| X4877 |
18247 |
Femur trabecular bone connectivity density (age-adjusted, males only) measured by microcomputed tomography (uCT) [1/mm3] |
Musculoskeletal |
| X497 |
18248 |
Femur trabecular bone structural model index (age-adjusted, males only) measured by microcomputed tomography (uCT) [ratio] |
Musculoskeletal |
| X2502 |
18249 |
Femur trabecular number (age-adjusted, males only) measured by microcomputed tomography (uCT) [1/mm] |
Musculoskeletal |
| X4304 |
18250 |
Femur trabecular thickness (age-adjusted, males only) measured by microcomputed tomography (uCT) [mm] |
Musculoskeletal |
| X1433 |
18251 |
Femur trabecular seperation (age-adjusted, males only) measured by microcomputed tomography (uCT) [mm] |
Musculoskeletal |
| X1993 |
18252 |
Femur trabecular apparent bone mineral density (age-adjusted, males only) measured by microcomputed tomography (uCT) [mgHA/cm3] |
Musculoskeletal |
| X3447 |
18253 |
Femur trabecular material bone mineral density (age-adjusted, males only) measured by microcomputed tomography (uCT) [mgHA/cm3] |
Musculoskeletal |
| X3119 |
18255 |
Tibia length (age-adjusted, males only) measured by microcomputed tomography (uCT) [mm] |
Musculoskeletal |
| X2137 |
18256 |
Tibia mineralized volume (age-adjusted, males only) measured by microcomputed tomography (uCT) [mm3] |
Musculoskeletal |
| X3343 |
18257 |
Tibia material bone mineral density (age-adjusted, males only) measured by microcomputed tomography (uCT) [mgHA/cm3] |
Musculoskeletal |
| X3295 |
18258 |
Tibia cortical envelop total volume (age-adjusted, males only) measured at midshaft by microcomputed tomography (uCT) [mm3] |
Musculoskeletal |
| X3282 |
18259 |
Tibia cortical envelop mineralized volume (age-adjusted, males only) measured at midshaft by microcomputed tomography (uCT) [mm3] |
Musculoskeletal |
| X2576 |
18260 |
Tibia cortical envelop porosity (age-adjusted, males only) measured at midshaft by microcomputed tomography (uCT) [%] |
Musculoskeletal |
| X2303 |
18261 |
Tibia cortical thickness (age-adjusted, males only) measured at midshaft by microcomputed tomography (uCT) [mm] |
Musculoskeletal |
| X2861 |
18262 |
Tibia cortical material bone mineral density (age-adjusted, males only) measured at midshaft by microcomputed tomography (uCT) [mgHA/cm3] |
Musculoskeletal |
| X2882 |
18263 |
Tibia cross-sectional volume (age-adjusted, males only) measured at midshaft by microcomputed tomography (uCT) [mm3] |
Musculoskeletal |
| X3268 |
18264 |
Tibia cortical volume (age-adjusted, males only) measured at midshaft by microcomputed tomography (uCT) [mm3] |
Musculoskeletal |
| X2714 |
18265 |
Tibia cortical marrow volume (age-adjusted, males only) measured at midshaft by microcomputed tomography (uCT) [mm3] |
Musculoskeletal |
| X1338 |
18266 |
Tibia polar moment of inertia (age-adjusted, males only) measured at midshaft by microcomputed tomography (uCT) [g*mm2] |
Musculoskeletal |
| X1742 |
18267 |
Tibia moment of inertia around the shorter axis (age-adjusted, males only) measured at midshaft by microcomputed tomography (uCT) [g*mm2] |
Musculoskeletal |
| X1702 |
18268 |
Tibia moment of inertia around the longer axis (age-adjusted, males only) measured at midshaft by microcomputed tomography (uCT) [g*mm2] |
Musculoskeletal |
| X3832 |
18269 |
Tibia trabecular total volume (age-adjusted, males only) measured by microcomputed tomography (uCT) [mm3] |
Musculoskeletal |
| X4126 |
18270 |
Tibia trabecular mineralized bone volume (age-adjusted, males only) measured by microcomputed tomography (uCT) [mm3] |
Musculoskeletal |
| X4630 |
18271 |
Tibia trabecular bone volume fraction (age-adjusted, males only) measured by microcomputed tomography (uCT) [ratio] |
Musculoskeletal |
| X2524 |
18272 |
Tibia trabecular bone connectivity density (age-adjusted, males only) measured by microcomputed tomography (uCT) [1/mm3] |
Musculoskeletal |
| X4348 |
18273 |
Tibia trabecular bone structural model index (age-adjusted, males only) measured by microcomputed tomography (uCT) [ratio] |
Musculoskeletal |
| X4254 |
18274 |
Tibia trabecular number (age-adjusted, males only) measured by microcomputed tomography (uCT) [1/mm] |
Musculoskeletal |
| X4347 |
18275 |
Tibia trabecular thickness (age-adjusted, males only) measured by microcomputed tomography (uCT) [mm] |
Musculoskeletal |
| X2002 |
18276 |
Tibia trabecular seperation (age-adjusted, males only) measured by microcomputed tomography (uCT) [mm] |
Musculoskeletal |
| X3519 |
18277 |
Tibia trabecular apparent bone mineral density (age-adjusted, males only) measured by microcomputed tomography (uCT) [mgHA/cm3] |
Musculoskeletal |
| X3427 |
18278 |
Tibia trabecular material bone mineral density (age-adjusted, males only) measured by microcomputed tomography (uCT) [mgHA/cm3] |
Musculoskeletal |
| X1157 |
18279 |
Tibia trabecular bone degree of anisotropy (age-adjusted, males only) measured by microcomputed tomography (uCT) [ratio] |
Musculoskeletal |
| X1069 |
18416 |
Femur gracility index (length /volume, age-adjusted, females only) measured by microcomputed tomography (uCT) [1/mm2] |
Musculoskeletal |
| X626 |
18417 |
Tibia gracility index (length /volume, age-adjusted, females only) measured by microcomputed tomography (uCT) [1/mm2] |
Musculoskeletal |
| X3836 |
18418 |
Femur gracility index 2 (total femur volume/body weight, age-adjusted, females only) measured by microcomputed tomography (uCT) [mm3/mg] |
Musculoskeletal |
| X2988 |
18419 |
Tibia gracility index 2 (total tibia volume/body weight, age-adjusted, females only) measured by microcomputed tomography (uCT) [mm3/mg] |
Musculoskeletal |
| X1856 |
18420 |
Femur gracility index (length /volume, age-adjusted, males only) measured by microcomputed tomography (uCT) [1/mm2] |
Musculoskeletal |
| X1846 |
18421 |
Tibia gracility index (length /volume, age-adjusted, males only) measured by microcomputed tomography (uCT) [1/mm2] |
Musculoskeletal |
| X4405 |
18422 |
Femur gracility index 2 (total femur volume/body weight, age-adjusted, males only) measured by microcomputed tomography (uCT) [mm3/mg] |
Musculoskeletal |
| X3923 |
18423 |
Tibia gracility index 2 (total tibia volume/body weight, age-adjusted, males only) measured by microcomputed tomography (uCT) [mm3/mg] |
Musculoskeletal |
| X1169 |
18424 |
Principal Component 1, accounting for 23% of variance and representing bone volume of both males and females (PC score) |
Musculoskeletal |
| X1122 |
18425 |
Principal Component 2, accounting for 15% of variance (PC score) |
Musculoskeletal |
| X976 |
18426 |
Principal Component 3, accounting for 12% of variance (PC score) |
Musculoskeletal |
| X2356 |
18427 |
Principal Component 4, accounting for 8% of variance (PC score) |
Musculoskeletal |
| X3260 |
18428 |
Principal Component 5, accounting for 7% of variance (PC score) |
Musculoskeletal |
| X2725 |
18429 |
Principal Component 6, accounting for 5% of variance and representing general material bone mineral density (PC score) |
Musculoskeletal |
| X4518 |
18467 |
Principal component 1 for bone development (GO:0060348) accounting for 26% of variance using the UCLA GSE27483 BXD Bone Femur ILM Mouse WG-6 v1, v1.1 (Jan13) RSN database (gene list:Amer1, Ankrd11, Asxl |
Musculoskeletal |
| X2107 |
18468 |
Principal component 2 for bone development (GO:0060348) accounting for 12% of variance using the UCLA GSE27483 BXD Bone Femur ILM Mouse WG-6 v1, v1.1 (Jan13) RSN database (gene list:Amer1, Ankrd11, Asxl |
Musculoskeletal |
| X3616 |
18469 |
Principal component 3 for bone development (GO:0060348) accounting for 8% of variance using the UCLA GSE27483 BXD Bone Femur ILM Mouse WG-6 v1, v1.1 (Jan13) RSN database (gene list:Amer1, Ankrd11, Asxl1 |
Musculoskeletal |
| X1473 |
18470 |
Principal component 1 for osteoblast differentiation(GO:0001649) accounting for 26% of variance using the UCLA GSE27483 BXD Bone Femur ILM Mouse WG-6 v1, v1.1 (Jan13) RSN database (gene list:Akt1, Asf1a |
Musculoskeletal |
| X2885 |
18471 |
Principal component 2 for osteoblast differentiation(GO:0001649) accounting for 12% of variance using the UCLA GSE27483 BXD Bone Femur ILM Mouse WG-6 v1, v1.1 (Jan13) RSN database (gene list:Akt1, Asf1a |
Musculoskeletal |
| X1579 |
10106 |
Striatum cholinergic neurons, section 11 [n/section] |
Nervous system |
| X1503 |
10107 |
Striatum cholinergic neurons section 14 [n/section] |
Nervous system |
| X2083 |
18472 |
Principal component 3 for osteoblast differentiation(GO:0001649) accounting for 7.5% of variance using the UCLA GSE27483 BXD Bone Femur ILM Mouse WG-6 v1, v1.1 (Jan13) RSN database (gene list:Akt1, Asf1 |
Musculoskeletal |
| X876 |
18473 |
Principal component 1 for bone mineralization (GO:0030282) accounting for 17% of variance using the UCLA GSE27483 BXD Bone Femur ILM Mouse WG-6 v1, v1.1 (Jan13) RSN database (gene list:Ali18, Alox15, As |
Musculoskeletal |
| X4345 |
18474 |
Principal component 2 for bone mineralization (GO:0030282) accounting for 12% of variance using the UCLA GSE27483 BXD Bone Femur ILM Mouse WG-6 v1, v1.1 (Jan13) RSN database (gene list:Ali18, Alox15, As |
Musculoskeletal |
| X3253 |
18475 |
Principal component 3 for bone mineralization (GO:0030282) accounting for 9.5% of variance using the UCLA GSE27483 BXD Bone Femur ILM Mouse WG-6 v1, v1.1 (Jan13) RSN database (gene list:Ali18, Alox15, A |
Musculoskeletal |
| X1667 |
18476 |
Principal component 1 for ossification (GO:0001503) accounting for 18.5% of variance using the UCLA GSE27483 BXD Bone Femur ILM Mouse WG-6 v1, v1.1 (Jan13) RSN database (gene list:Ahsg, Alox15, Atp6v0a4 |
Musculoskeletal |
| X3534 |
18477 |
Principal component 2 for ossification (GO:0001503) accounting for 10.5% of variance using the UCLA GSE27483 BXD Bone Femur ILM Mouse WG-6 v1, v1.1 (Jan13) RSN database (gene list:Ahsg, Alox15, Atp6v0a4 |
Musculoskeletal |
| X4240 |
18478 |
Principal component 3 for ossification (GO:0001503) accounting for 7.5% of variance using the UCLA GSE27483 BXD Bone Femur ILM Mouse WG-6 v1, v1.1 (Jan13) RSN database (gene list:Ahsg, Alox15, Atp6v0a4, |
Musculoskeletal |
| X1331 |
18479 |
Principal component 1 for bone trabecula formation (GO:0060346) accounting for 29.5% of variance using the UCLA GSE27483 BXD Bone Femur ILM Mouse WG-6 v1, v1.1 (Jan13) RSN database (gene list:Col1a1, Fb |
Musculoskeletal |
| X1674 |
18480 |
Principal component 2 for bone trabecula formation (GO:0060346) accounting for 12% of variance using the UCLA GSE27483 BXD Bone Femur ILM Mouse WG-6 v1, v1.1 (Jan13) RSN database (gene list:Col1a1, Fbn2 |
Musculoskeletal |
| X4180 |
18481 |
Principal component 3 for bone trabecula formation (GO:0060346) accounting for 11% of variance using the UCLA GSE27483 BXD Bone Femur ILM Mouse WG-6 v1, v1.1 (Jan13) RSN database (gene list:Col1a1, Fbn2 |
Musculoskeletal |
| X2677 |
18482 |
Principal component 1 for regulation of bone remodeling (GO:0046850) accounting for 24% of variance using the UCLA GSE27483 BXD Bone Femur ILM Mouse WG-6 v1, v1.1 (Jan13) RSN database (gene list: Cartpt |
Musculoskeletal |
| X4230 |
18483 |
Principal component 2 for regulation of bone remodeling (GO:0046850) accounting for 10% of variance using the UCLA GSE27483 BXD Bone Femur ILM Mouse WG-6 v1, v1.1 (Jan13) RSN database (gene list: Cartpt |
Musculoskeletal |
| X3735 |
18484 |
Principal component 3 for regulation of bone remodeling (GO:0046850) accounting for 9% of variance using the UCLA GSE27483 BXD Bone Femur ILM Mouse WG-6 v1, v1.1 (Jan13) RSN database (gene list: Cartpt, |
Musculoskeletal |
| X1772 |
18485 |
Principal component 1 for response to vitamin D (GO:0033280) accounting for 34% of variance using the UCLA GSE27483 BXD Bone Femur ILM Mouse WG-6 v1, v1.1 (Jan13) RSN database (gene list:Cdkn2d, Cyp24a1 |
Musculoskeletal |
| X4964 |
18486 |
Principal component 2 for response to vitamin D (GO:0033280) accounting for 20% of variance using the UCLA GSE27483 BXD Bone Femur ILM Mouse WG-6 v1, v1.1 (Jan13) RSN database (gene list:Cdkn2d, Cyp24a1 |
Musculoskeletal |
| X5019 |
18487 |
Principal component 3 for response to vitamin D (GO:0033280) accounting for 14.5% of variance using the UCLA GSE27483 BXD Bone Femur ILM Mouse WG-6 v1, v1.1 (Jan13) RSN database (gene list: Cdkn2d, Cyp2 |
Musculoskeletal |
| X2726 |
18488 |
Principal component 1 for endochondral ossification (GO:0001958) accounting for 22% of variance using the UCLA GSE27483 BXD Bone Femur ILM Mouse WG-6 v1, v1.1 (Jan13) RSN database (gene list:Alpl, Bmp4, |
Musculoskeletal |
| X3113 |
18489 |
Principal component 2 for endochondral ossification (GO:0001958) accounting for 17% of variance using the UCLA GSE27483 BXD Bone Femur ILM Mouse WG-6 v1, v1.1 (Jan13) RSN database (gene list:Alpl, Bmp4, |
Musculoskeletal |
| X4039 |
18490 |
Principal component 3 for endochondral ossification (GO:0001958) accounting for 12% of variance using the UCLA GSE27483 BXD Bone Femur ILM Mouse WG-6 v1, v1.1 (Jan13) RSN database (gene list:Alpl, Bmp4, |
Musculoskeletal |
| X2261 |
10010 |
Saline control response (0.9%, ip), locomotor activity from 0-60 min after injection (just prior to injection of phencyclidine) [cm] |
Nervous system |
| X1140 |
10013 |
Saline control response (0.9% ip), locomotor activity from 0-60 min after injection (just prior to injection of 5 mg/kg amphetamine) [cm] |
Nervous system |
| X71 |
10014 |
Calcium (Ca2+) stimulated ecto-ATPase (NTPase) activity in brain microsomes (monogenic trait mapping to Entpd8) [umolPi /mg protein/hr] |
Nervous system |
| X68 |
10015 |
Magnesium (Mg2+) stimulated ecto-ATPase (NTPase) activity in brain microsomes (monogenic trait mapping to Entpd8) [umolPi /mg protein/hr] |
Nervous system |
| X2905 |
10020 |
Pain response, hot plate latency after saline control injection [seconds] |
Nervous system |
| X4076 |
10022 |
Saccharin sweet taste response, saccharin preference versus water ratio [%] |
Nervous system |
| X4815 |
10023 |
Saccharin sweet taste water consumption (BXD5 value of 1228 units winsorized to 700 units) [mg/kg/day] |
Nervous system |
| X1156 |
10024 |
Handling-induced convulsions (HIC) baseline scores [units] |
Nervous system |
| X2222 |
10030 |
Naloxone ([3H]-naloxone) Bmax concentration (binding maximum) [pM/mg] |
Nervous system |
| X2473 |
10037 |
Locomotor activity in a novel environment (Day 1) in young adult males over a 5 min trial (Digiscan 16-beam automated activity monitor) [cm] |
Nervous system |
| X89 |
10038 |
Habituation measured as difference in locomotor activity between day 1 and day 3 in young adult males over a 5 min test trial (Digiscan 16-beam automated activity monitor) [cm] |
Nervous system |
| X1852 |
10049 |
Saline response (ip injection), locomotor activation (control for quinpirole study) [cm] |
Nervous system |
| X2548 |
10054 |
Saline baseline response (ip, control for quinpirole study), vertical activity (rears, beam breaks) after injection [n] |
Nervous system |
| X5025 |
10093 |
Floor preference baseline, time on grid textured floor for experimental group of males [sec/min] |
Nervous system |
| X3013 |
10099 |
Saline control response (vehicle ip), habituation, locomotion from 1-5 min after a single saline injection for the experimental group of males [activity/min] |
Nervous system |
| X3190 |
10101 |
Floor preference baseline, intrinsic preference for the grid-textured floor for the control group of males [s/min] |
Nervous system |
| X4279 |
10103 |
Floor preference baseline, intrinsic preference for the grid-textured floor for the control group of males [s/min] |
Nervous system |
| X3739 |
10110 |
Striatum cholinergic neurons section 22 [n/section] |
Nervous system |
| X1911 |
10111 |
Striatum cholinergic neurons section 24 [n/section] |
Nervous system |
| X3437 |
10130 |
Saline control response (ip injection), locomotor activity, distance traveled 0 to 5 min after injection [cm] |
Nervous system |
| X3852 |
10131 |
Saline control response (ip injection), locomotor activity, distance traveled 5 to 10 min after injection [cm] |
Nervous system |
| X3366 |
10132 |
Saline control response (ip injection), locomotor activity, distance traveled 10 to 15 min after injection [cm] |
Nervous system |
| X3617 |
10133 |
Saline control response (ip injection), locomotor activity, distance traveled 15 to 20 min after injection [cm] |
Nervous system |
| X4094 |
10134 |
Saline control response (ip injection), locomotor activity, distance traveled 5 to 20 min after injection [cm] |
Nervous system |
| X1189 |
10143 |
Sleep need, slow wave sleep delta EEG power after 6 hrs sleep deprivation, 4-6 males per strain at 92 days of age [%] |
Nervous system |
| X3252 |
10164 |
Home cage activity level 10-14 week old males after saline injection [quadrant crossings/min] |
Nervous system |
| X838 |
10165 |
Methamphetamine response (4 mg/kg ip), locomotor activity difference from saline in 10-14 week males [quadrant crossings/min] |
Nervous system |
| X819 |
10166 |
Methamphetamine response (8 mg/kg ip), locomotor activity difference from saline in 10-14 week males [quadrant crossings/min] |
Nervous system |
| X1783 |
10167 |
Methamphetamine response (16 mg/kg ip), locomotor activity difference from saline control in 10-14 week males [quadrant crossings/min] |
Nervous system |
| X3510 |
10168 |
Methamphetamine response (16 mg/kg ip), frequency of sterotyped chewing events 33 min after injection in 10-14 week males [quadrant crossings/min] |
Nervous system |
| X665 |
10170 |
Methamphetamine response (8 mg/kg ip), body temperature change 48 min after injection in 10-14 week males [degree C] |
Nervous system |
| X1454 |
10173 |
Methamphetamine response (16 mg/kg ip), climbing scores of 10-14 week females 1 hr period after injection, 0=on floor,; 1=two paws up;; 3=climbing [index]; |
Nervous system |
| X3279 |
10220 |
Striatum (caudate putamen) DRD2/DRD3 receptor density binding of (125I) epidepride [fmol/mg] |
Nervous system |
| X3469 |
10221 |
Nucleus accumbens core DRD2/DRD3 receptor density binding of (125I) epidepride [fmol/mg] |
Nervous system |
| X3769 |
10222 |
Nucleus accumbens shell DRD2/DRD3 receptor density binding of (125I) epidepride [fmol/mg] |
Nervous system |
| X4489 |
10223 |
Tyrosine hydroxylase dopaminergic neurons in ventral tegmental area [n/section] |
Nervous system |
| X4365 |
10224 |
Tyrosine hydroxylase dopaminergic neurons in substantia nigra compacta [n/section] |
Nervous system |
| X242 |
10234 |
Dopamine transporter (DAT, SLC6A3) protein density in the dorsal striatum (caudate putamen) [Bmax, pmol/mg] |
Nervous system |
| X4571 |
10239 |
Iron level in medial prefrontal cortex of males [ug/g] |
Nervous system |
| X2367 |
10240 |
Iron level in medial prefrontal cortex of females [ug/g] |
Nervous system |
| X2899 |
10241 |
Iron level in dorsal striatum (caudate putamen) of males [ug/g] |
Nervous system |
| X2400 |
10242 |
Iron level in dorsal striatum (caudate putamen) of females [ug/g] |
Nervous system |
| X3703 |
10243 |
Iron level in nucleus accumbens of males [ug/g] |
Nervous system |
| X4779 |
10244 |
Iron level in nucleus accumbens of females [ug/g] |
Nervous system |
| X2240 |
10245 |
Iron level in ventral midbrain of males [ug/g] |
Nervous system |
| X3393 |
10246 |
Iron level in ventral midbrain of females [ug/g] |
Nervous system |
| X4138 |
10249 |
Dopamine receptor 1 (DRD1) binding maximum (Bmax) in membrane fragments in nucleus accumbens of males and females (Schering compound 3H-23390 ligand) [fmol/mg wet weight] |
Nervous system |
| X4246 |
10250 |
Dopamine receptor 1 (DRD1) binding maximum (Bmax) in membrane fragments in nucleus accumbens of males (Schering compound 3H-23390 ligand) [fmol/mg wet weight] |
Nervous system |
| X1889 |
10251 |
Dopamine receptor 1 (DRD1) binding maximum (Bmax) in membrane fragments in the nucleus accumbens of females (Schering compound 3H-23390 ligand) [fmol/mg wet weight] |
Nervous system |
| X3036 |
10252 |
Dopamine receptor 1 (DRD1) binding maximum (Bmax) in membrane fragments in the dorsal striatum (caudate putamen) of males (Schering compound 3H-23390 ligand) [fmol/mg wet weight] |
Nervous system |
| X317 |
10253 |
Dopamine receptor 1 (DRD1) binding maximum (Bmax) in membrane fragments in the dorsal striatum (caudate putamen) of females (Schering compound 3H-23390 ligand) [fmol/mg wet weight] |
Nervous system |
| X1005 |
10254 |
Dopamine receptor 1 (DRD1) binding maximum (Bmax) in membrane fragments in the dorsal striatum (caudate putamen) of males and females (Schering compound 3H-23390 ligand) [fmol/mg wet weight] |
Nervous system |
| X4717 |
10255 |
Dopamine receptor 1 (DRD1) binding maximum (Bmax) in membrane fragments in the prefrontal cortex of males (Schering compound 3H-23390 ligand) [fmol/mg wet weight] |
Nervous system |
| X4731 |
10256 |
Dopamine receptor 1 (DRD1) binding maximum (Bmax) in membrane fragments in the prefrontal cortex of females (Schering compound 3H-23390 ligand) [fmol/mg wet weight] |
Nervous system |
| X3877 |
10257 |
Dopamine receptor 1 (DRD1) binding maximum (Bmax) in membrane fragments in the prefrontal cortex of males and females (Schering compound 3H-23390 ligand) [fmol/mg wet weight] |
Nervous system |
| X3790 |
10258 |
Dopamine receptor 1 (DRD1) binding maximum (Bmax) in membrane fragments in the ventral midbrain (including the ventral tegmental area and substantia nigra) of males (Schering compound 3H-23390 liga |
Nervous system |
| X2613 |
10259 |
Dopamine receptor 1 (DRD1) binding maximum (Bmax) in membrane fragments in the ventral midbrain of females (Schering compound 3H-23390 ligand) [fmol/mg wet weight] |
Nervous system |
| X2879 |
10260 |
Dopamine receptor 1 (DRD1) binding maximum (Bmax) in membrane fragments in the ventral midbrain (including the ventral tegmental area and substantia nigra) of males and females (Schering compound 3 |
Nervous system |
| X357 |
10261 |
Dopamine receptor 2 (DRD2) binding maximum (Bmax) in membrane fragments in the nucleus accumbens of males (125I-epidepride ligand) [fmol/mg wet weight] |
Nervous system |
| X4866 |
10262 |
Dopamine receptor 2 (DRD2) binding maximum (Bmax) in membrane fragments in the nucleus accumbens of females (125I-epidepride ligand) [fmol/mg wet weight] |
Nervous system |
| X1086 |
10263 |
Dopamine receptor 2 (DRD2) binding maximum (Bmax) in membrane fragments in the nucleus accumbens of males and females (125I-epidepride ligand) [fmol/mg wet weight] |
Nervous system |
| X4627 |
10797 |
;New neurons in the adult dentate gyrus [BrdU/NeuN;; residuals]; |
Nervous system |
| X1812 |
10264 |
Dopamine receptor 2 (DRD2) binding maximum (Bmax) in membrane fragments in the dorsal striatum (caudate putamen) of males (125I-epidepride ligand) [fmol/mg wet weight] |
Nervous system |
| X200 |
10265 |
Dopamine receptor 2 (DRD2) binding maximum (Bmax) in membrane fragments in the dorsal striatum (caudate putamen) of females (125I-epidepride ligand) [fmol/mg wet weight] |
Nervous system |
| X1681 |
10266 |
Dopamine receptor 2 (DRD2) binding maximum (Bmax) in membrane fragments in the dorsal striatum (caudate putamen) of males and females (125I-epidepride ligand) [fmol/mg wet weight] |
Nervous system |
| X1992 |
10267 |
Dopamine receptor 2 (DRD2) binding maximum (Bmax) in membrane fragments in the prefrontal cortex of males (125I-epidepride ligand) [fmol/mg wet weight] |
Nervous system |
| X5007 |
10268 |
Dopamine receptor 2 (DRD2) binding maximum (Bmax) in membrane fragments in prefrontal cortex of females (125I-epidepride ligand) [fmol/mg wet weight] |
Nervous system |
| X4748 |
10269 |
Dopamine receptor 2 (DRD2) binding maximum (Bmax) in membrane fragments in the prefrontal cortex of males and females (125I-epidepride ligand) [fmol/mg wet weight] |
Nervous system |
| X3976 |
10270 |
Dopamine receptor 2 (DRD2) binding maximum (Bmax) in membrane fragments in the ventral midbrain (including the ventral tegmental area and substantia nigra) of males (125I-epidepride ligand) [fmol/m |
Nervous system |
| X2244 |
10271 |
Dopamine receptor 2 (DRD2) binding maximum (Bmax) in membrane fragments in the ventral midbrain (including the ventral tegmental area and substantia nigra) of females (125I-epidepride ligand) [fmol |
Nervous system |
| X1815 |
10272 |
Dopamine receptor 2 (DRD2) binding maximum (Bmax) in membrane fragments in the ventral midbrain (including the ventral tegmental area and substantia nigra) of males and females (125I-epidepride lig |
Nervous system |
| X2798 |
10273 |
Dopamine transporter (SLC6A3) binding maximum (Bmax) in membrane fragments in nucleus accumbens of males (3H GBR-12935 ligand) [fmol/mg wet weight] |
Nervous system |
| X2546 |
10274 |
Dopamine transporter (SLC6A3) binding maximum (Bmax) in membrane fragments in nucleus accumbens of females (3H GBR-12935 ligand) [fmol/mg wet weight] |
Nervous system |
| X3886 |
10275 |
Dopamine transporter (SLC6A3) binding maximum (Bmax) in membrane fragments in nucleus accumbens of males and females (3H GBR-12935 ligand) [fmol/mg wet weight] |
Nervous system |
| X1486 |
10276 |
Dopamine transporter (SLC6A3) binding maximum (Bmax) in membrane fragments in dorsal striatum (caudate putamen) of males (3H GBR-12935 ligand) [fmol/mg wet weight] |
Nervous system |
| X2180 |
10277 |
Dopamine transporter (SLC6A3) binding maximum (Bmax) in membrane fragments in dorsal striatum (caudate putamen) of females (3H GBR-12935 ligand) [fmol/mg wet weight] |
Nervous system |
| X1027 |
10278 |
Dopamine transporter (SLC6A3) binding maximum (Bmax) in membrane fragments in dorsal striatum (caudate putamen) of males and females (3H GBR-12935 ligand) [fmol/mg wet weight] |
Nervous system |
| X4293 |
10279 |
Dopamine transporter (SLC6A3) binding maximum (Bmax) in membrane fragments in prefrontal cortex of males (3H GBR-12935 ligand) [fmol/mg wet weight] |
Nervous system |
| X4285 |
10280 |
Dopamine transporter (SLC6A3) binding maximum (Bmax) in membrane fragments in prefrontal cortex of females (3H GBR-12935 ligand) [fmol/mg wet weight] |
Nervous system |
| X2858 |
10281 |
Dopamine transporter (SLC6A3) binding maximum (Bmax) in membrane fragments in prefrontal cortex of males and females (3H GBR-12935 ligand) [fmol/mg wet weight] |
Nervous system |
| X4681 |
10282 |
Dopamine transporter (SLC6A3) binding maximum (Bmax) in membrane fragments in the ventral midbrain (including the ventral tegmental area and substantia nigra) of males (3H GBR-12935 ligand) [fmol/m |
Nervous system |
| X3029 |
10283 |
Dopamine transporter (SLC6A3) binding maximum (Bmax) in membrane fragments in the ventral midbrain (including the ventral tegmental area and substantia nigra) of females (3H GBR-12935 ligand) [fmol |
Nervous system |
| X5033 |
10284 |
Dopamine transporter (SLC6A3) binding maximum (Bmax) in membrane fragments in the ventral midbrain (including the ventral tegmental area and substantia nigra) of males and females (3H GBR-12935 lig |
Nervous system |
| X2392 |
10336 |
Haloperidol response, induced catalepsy at ED50 [mg/kg] |
Nervous system |
| X80 |
10384 |
Saccharin sweet taste response (3.2 mM in water), consumption [%] |
Nervous system |
| X73 |
10385 |
Acesulfame sweet taste response (3.2 mM in water), consumption [%] |
Nervous system |
| X92 |
10386 |
Glycine (sweet) taste response (10 mM in water), consumption [%] |
Nervous system |
| X3876 |
10387 |
Seizure threshold pressure at compression rate of 100 atm hr-1 (100iPc) (also see McCall,2011, 21384758) [atm] |
Nervous system |
| X272 |
10388 |
Seizure threshold pressure at compression rate of 1000 atm hr-1 (1000iPc) (also see McCall,2011, 21384758) [atm] |
Nervous system |
| X3614 |
10389 |
High frequency hearing loss, acoustic startle response to 5 kHz white-noise bursts at 100 dB SPL [force] |
Nervous system |
| X4981 |
10390 |
High frequency hearing loss, acoustic startle response to 10 kHz white noise bursts at 100 dB [force] |
Nervous system |
| X4932 |
10391 |
High frequency hearing loss, acoustic startle response to 15 kHz white-noise bursts at 100 dB SPL [force] |
Nervous system |
| X4938 |
10392 |
High frequency hearing loss, acoustic startle response to 20 kHz white-noise bursts at 100 dB [g] |
Nervous system |
| X4949 |
10393 |
High frequency hearing loss, acoustic startle response to 25 kHz white noise bursts at 100 dB SPL [force] |
Nervous system |
| X4904 |
10394 |
Acoustic startle response to a 110 dB SPL, 10 kHz tone without prepulse stimulus [force] |
Nervous system |
| X4471 |
10395 |
High frequency hearing loss, acoustic startle response to white-noise bursts at 110 dB SPL [force] |
Nervous system |
| X1126 |
10396 |
Prepulse inhibition of the acoustic startle response to 110 dB SPL white-noise bursts, 5 kHz, 80 dB prepulse stimulus [%] |
Nervous system |
| X1191 |
10397 |
Prepulse inhibition of the acoustic startle response to 110 dB SPL white-noise bursts, 10 kHz, 80 dB prepulse stimulus [%] |
Nervous system |
| X3723 |
10398 |
Prepulse inhibiition of the acoustic startle response to 110 dB SPL white-noise bursts, 15 kHz, 80 dB prepulse stimulus [%] |
Nervous system |
| X3812 |
10399 |
Prepulse inhibition of the acoustic startle response to 110 dB SPL white-noise bursts, 20 kHz, 80 dB prepulse stimulus [%] |
Nervous system |
| X1068 |
10400 |
Prepulse inhibition of the acoustic startle response to a 110 db SPL, 10 kHz tone, 56 db SPL white-noise prepulse stimulus [%] |
Nervous system |
| X2886 |
11028 |
Iron level in hippocampus of females [ug/g] |
Nervous system |
| X1923 |
10401 |
Prepulse inhibition of the acoustic startle response to a 110 db SPL 10 kHz tone, following a 68 db SPL white noise prepulse stimulus [%] |
Nervous system |
| X3555 |
10402 |
Prepulse inhibition of the acoustic startle response to a 110 db SPL, 10 kHz tone, 80 db SPL white-noise prepulse stimulus [%] |
Nervous system |
| X2185 |
10413 |
Spatial navigation, latency to reach hidden platform using Morris water maze (test 1, Trait Llat1 Table 1), males and females combined [log sec] |
Nervous system |
| X105 |
10414 |
Spatial navigation, latency to reach hidden platform using Morris water maze (test 2, Trait Llat2 Table 1), males and females combined [log sec] |
Nervous system |
| X1241 |
10415 |
Spatial navigation, latency to reach hidden platform using Morris water maze (test 3, Trait Llat3 Table 1), males and females combined [log sec] |
Nervous system |
| X2830 |
10418 |
Pain response, thermal nociception, 54 degree C hot plate latency baseline test (before 3 min forced swim in 15 degree C water) for males and females [sec] |
Nervous system |
| X2953 |
10419 |
Pain response, thermal nociception, 54 degree C hot plate latency baseline test (before 3 min forced swim in 15 degree C water) for females [sec] |
Nervous system |
| X3165 |
10420 |
Pain response, 54 degree C hot plate latencies baseline (before 3 min forced swim in 15 degree C water), male [sec] |
Nervous system |
| X3131 |
10421 |
Pain response, thermal nociception, 54 degree C hot plate latencies post-swim, male and female average [sec] |
Nervous system |
| X753 |
10422 |
Pain response, 54 degree C hot plate latencies post-swim in female [seconds] |
Nervous system |
| X1662 |
10423 |
Pain response, 54 degree C hot plate latencies post-swim in male [sec] |
Nervous system |
| X2396 |
10424 |
Pain response, thermal nociception, 54 degree C hot plate latency baseline and post swim in maximum possible effect for males and females [%MPE=(postswim-baseline)/(cut-off-baselin |
Nervous system |
| X974 |
10425 |
Pain response, thermal nociception, 54 degree C hot plate latency baseline and post swim in maximum possible effect for females [%MPE=(postswim-baseline)/(cut-off-baseline)*100)] |
Nervous system |
| X2865 |
10426 |
Pain response, thermal nociception, 54 degree C hot plate latency baseline and post swim in maximum possible effect for males [%MPE=(postswim-baseline)/(cut-off-baseline)*100)] |
Nervous system |
| X2235 |
10434 |
Audiogenic seizure incidence [% cases] |
Nervous system |
| X1123 |
10435 |
Audiogenic seizure severity [score] |
Nervous system |
| X1127 |
10437 |
Audiogenic seizure, severity score in response to pure tone [score] |
Nervous system |
| X2217 |
10438 |
Audiogeneic seizure, relative frequency [%] |
Nervous system |
| X4517 |
10445 |
Fear response control (unconditioned auditory stimulus stimulus, US) in a contextualized fear conditioning paradigm [% freezing] |
Nervous system |
| X1009 |
10446 |
Fear response to context [% freezing] |
Nervous system |
| X4775 |
10447 |
Fear response to preconditioned (altered) context stimulus [% freezing] |
Nervous system |
| X4562 |
10448 |
ATPase activity (total activity) for whole brain homogenate [umol Pi/h/mg protein] |
Nervous system |
| X3500 |
10449 |
ATPase activity (Mg2+ ATPase, magnesium ATPase, Mg-ATPase) for whole brain homogenate [umol Pi/h/mg protein] |
Nervous system |
| X4406 |
10450 |
ATPase activity (Na+/K+-ATPase, sodium-potassium ATPase, sodium-potassium pump) for whole brain homogenate [umol Pi/h/mg protein] |
Nervous system |
| X3199 |
10451 |
Seizure susceptibility, audiogenic seizure severity [scale] |
Nervous system |
| X3682 |
10452 |
Seizure susceptibility, clonic-tonic audiogenic seizure incidence [%] |
Nervous system |
| X1697 |
10453 |
Control response (20% 2-hydroxypropyl-beta-cyclodextrin ip), difference in locomotion between day 3 (third vehicle injection) and day 2 (vehicle baseline) using Accuscan activity monitors [cm/30 min] |
Nervous system |
| X2042 |
10470 |
Quinine response, consumption using two-bottle choice test (quinine at 0.1 to 0.4 mg/ml) [ml/test period] |
Nervous system |
| X5040 |
10471 |
Saccharin response, consumption using two-bottle choice test (concentration) [ml/test period] |
Nervous system |
| X4198 |
10472 |
Saccharin response, preference using two-bottle choice test [ratio] |
Nervous system |
| X2059 |
10473 |
Saccharin response, consumption using a two-bottle choice test (0.2%, mg/kg) vs. tap water, mean of day 2 and day 4 over a 4-day 24-hr access period [g/kg/day] |
Nervous system |
| X3129 |
10486 |
Acute locomotor baseline activity response (horizontal distance), 1-5 min after saline injection on day 2 in young adult females (BASACT in the CD group) [cm] |
Nervous system |
| X3000 |
10487 |
Saline control response (vehicle ip), locomotion (baseline) on day 2 using Accuscan activity monitors, mean all cases [cm/15 min test] |
Nervous system |
| X3785 |
10503 |
Saline response (vehicle ip control), baseline locomotor activity using grid test on day 2 after injection [n beam breaks/10 min test] |
Nervous system |
| X2372 |
10504 |
Audiogenic seizure susceptibility and severity at 21 days [score] |
Nervous system |
| X3650 |
10506 |
Seizure susceptibility, seizure initiation atmospheric pressure at 100 atmospheres (14.7 PSI per atm) [atm] |
Nervous system |
| X384 |
10507 |
Seizure susceptibility atmospheric pressure to high atmospheric pressure at 1000 atmospheres (14.7 PSI per atm) [atm] |
Nervous system |
| X1135 |
10509 |
Antinociceptive responsive (pain analgesia), nitrous oxide antinociception in the acetic acid writhing (abdominal constriction) test [%] |
Nervous system |
| X1118 |
10595 |
Dorsal lateral geniculate nucleus (dLGN) volume, unilateral, corrected for shrinkage [mm^3] |
Nervous system |
| X3463 |
10596 |
Dorsal lateral geniculate nucleus (dLGN) total cell number, unilateral [n x10^3] |
Nervous system |
| X4707 |
10597 |
Dorsal lateral geniculate nucleus (dLGN) neuron number, unilateral [n x10^3] |
Nervous system |
| X3951 |
10598 |
Dorsal lateral geniculate nucleus (dLGN) glial cell number, unilateral [n x10^3] |
Nervous system |
| X2058 |
10599 |
Dorsal lateral geniculate nucleus (dLGN) endothelial cell number, unilateral [n x10^3] |
Nervous system |
| X2834 |
10600 |
Retinal ganglion cell number, unilateral [x 1000] |
Nervous system |
| X4591 |
10601 |
Retinal ganglion cells (RGC) to lateral geniculate nucleus (LGN) principal neuron number ratio [ratio] |
Nervous system |
| X2263 |
10606 |
High affinity choline uptake (concentration of 0.5 10xE-6 M) in frontal cortex [pmole/4min/mg protein] |
Nervous system |
| X4624 |
10607 |
High affinity choline uptake (concentration of 0.5*10^-6M) in hippocampus [pmole/4min/mg protein] |
Nervous system |
| X603 |
10608 |
High affinity choline uptake (concentration of 0.5*10^-6M) in striatum [pmole/4min/mg protein] |
Nervous system |
| X4396 |
10642 |
Olfactory bulb weight, bilateral, without any statistical corrections (raw) [mg] |
Nervous system |
| X2098 |
10643 |
Olfactory bulb weight, adjusted by age, sex, body weight, and brain minus olfactory bulb weight (Hager et al. 2012) [mg] |
Nervous system |
| X813 |
10645 |
Olfactory bulb weight, bilateral, fixed tissue, hand-dissected, unadjusted [mg] |
Nervous system |
| X946 |
10649 |
Retinal ganglion cell number, unilateral [n x10^3] |
Nervous system |
| X445 |
10650 |
Retinal ganglion cell number residuals, unilateral, corrected for variation in brain and body size, sex, and age [residual n x10^3] |
Nervous system |
| X3418 |
10651 |
Spiral ganglion cell density hook [cells per 10000 um2] |
Nervous system |
| X4216 |
10652 |
Spiral ganglion cell density mid base [cells per 10000 um2] |
Nervous system |
| X4419 |
10653 |
Spiral ganglion cell density mid-apical [cells per 10000 um2] |
Nervous system |
| X4533 |
10654 |
Spiral ganglion cell density apical [cells per 10000 um2] |
Nervous system |
| X4379 |
10655 |
Spiral ganglion cell density total [cells per 10000 um2] |
Nervous system |
| X969 |
10669 |
Retinal area, adults of both sexes [mm2] |
Nervous system |
| X945 |
10670 |
Retinal ganglion cell number, unilateral [x1000] |
Nervous system |
| X1884 |
10674 |
Amygdala, basolateral complex volume (LaDL, LaVL, LaVM, BLP, and BLA), unilateral, shrinkage corrected from serial histological sections [mm^3] |
Nervous system |
| X1047 |
10675 |
Amygdala, basolateral complex volume (LaDL, LaVL, LaVM, BLP, and BLA), unilateral shrinkage corrected and adjusted for variation in body weight and plane of section from serial histological sections [mm^3] |
Nervous system |
| X3557 |
10676 |
Amygdala, basolateral complex (LaDL, LaVL, LaVM, BLP, and BLA), neuron number, unilateral [n/mm^3] |
Nervous system |
| X4130 |
10677 |
Amygdala, basolateral complex (LaDL, LaVL, LaVM, BLP, and BLA), glial cell number, unilateral without adjustment [n] |
Nervous system |
| X4780 |
10679 |
New neurons in dentate gyrus [density index] |
Nervous system |
| X2200 |
10680 |
Amygdala, basolateral complex (LaDL, LaVL, LaVM, BLP, and BLA), glial cell number, unilateral, adjusted for data-collector as a predictor [n] |
Nervous system |
| X3770 |
10681 |
Amygdala, basolateral complex (LaDL, LaVL, LaVM, BLP, and BLA), total cell number (neurons, glia, and endothelial cells), unilateral without adjustment [n] |
Nervous system |
| X3554 |
10682 |
Amygdala, basolateral complex (LaDL, LaVL, LaVM, BLP, and BLA), total cell number (neurons, glia, and endothelial cells), unilateral and adjusted for data-collector as a predictor [n] |
Nervous system |
| X3799 |
10683 |
Amygdala, basolateral complex (LaDL, LaVL, LaVM, BLP, and BLA), non-neuronal cell number (glial and endothelial cells), unilateral [n] |
Nervous system |
| X3885 |
10684 |
Amygdala, basolateral complex (LaDL, LaVL, LaVM, BLP, and BLA), non-neuronal cell number (glial and endothelial cells), unilateral and adjusted for data-collector as a predictor [n] |
Nervous system |
| X5049 |
10685 |
Polyglucosan bodies in the hippocampus of 18-month-old females [density] |
Nervous system |
| X3391 |
10686 |
Polyglucosan bodies in 18-month-old females (also see AXB/BXA data) [log density] |
Nervous system |
| X4581 |
10702 |
Cocaine and amphetamine-regulated transcript (CART) expression in hypothalamus [rtPCR cycles] |
Nervous system |
| X4374 |
10709 |
New astrocytes in the dentate gyrus [n per gyrus] |
Nervous system |
| X2196 |
10720 |
Zinc level in ventral midbrain of males [ug/g] |
Nervous system |
| X2648 |
10721 |
Zinc level in ventral midbrain of females [ug/g] |
Nervous system |
| X3574 |
10722 |
Zinc levels in nucleus accumbens of males [ug/g] |
Nervous system |
| X1035 |
10723 |
Zinc level in nucleus accumbens of females [ug/g] |
Nervous system |
| X709 |
10724 |
Zinc level in medial prefrontal cortex of males [ug/g] |
Nervous system |
| X211 |
10725 |
Zinc level in medial prefrontal cortex of females [ug/g] |
Nervous system |
| X5008 |
10726 |
Zinc level in dorsal striatum (caudate putamen) of males [ug/g] |
Nervous system |
| X4525 |
10727 |
Zinc level in dorsal striatum (caudate putamen) of females [ug/g] |
Nervous system |
| X1619 |
10728 |
Copper level in ventral midbrain of males [ug/g] |
Nervous system |
| X2685 |
10729 |
Copper level in ventral midbrain of females [ug/g] |
Nervous system |
| X1171 |
10730 |
Copper level in nucleus accumbens of males [ug/g] |
Nervous system |
| X3516 |
10731 |
Copper level in nucleus accumbens of females [ug/g] |
Nervous system |
| X618 |
10732 |
Copper level in medial prefrontal cortex of males [ug/g] |
Nervous system |
| X3325 |
10733 |
Copper level in medial prefrontal cortex of females [ug/g] |
Nervous system |
| X920 |
10734 |
Copper level in dorsal striatum (caudate putamen) of males [ug/g] |
Nervous system |
| X1066 |
10735 |
Copper level in dorsal striatum (caudate putamen) of females [ug/mg] |
Nervous system |
| X1197 |
10747 |
Polydipsia, drinking slope (contact G Mittleman, g.mittleman@mail.psyc.memphis.edu) |
Nervous system |
| X1744 |
10781 |
Preference for cinnamon-flavored food with pre-exposure to only plain-flavored food [percentage of total diet] |
Nervous system |
| X1061 |
10782 |
Preference for cinnamon-flavored food with pre-exposure to cinnamon-flavored food [percentage of total diet] |
Nervous system |
| X777 |
10783 |
Novel food preference for cinnamon-flavored food [difference score, percentage total diet without pre-exposure minus percentage total diet with pre-exposure to cinnamon] |
Nervous system |
| X4425 |
10786 |
Corticotropin-releasing factor (CRF) transcript abundance in total hypothalamic RNA [detection threshold cycle (higher values correspond to lower abundance)] |
Nervous system |
| X5009 |
10787 |
Corticotropin releasing factor receptor 1 (Crf-R1, CRF1, CRHR1) mRNA transcript abundance in total hypothalamic RNA [detection threshold cycle (higher values correspond to lower abundance)] |
Nervous system |
| X3513 |
10788 |
Corticotropin-releasing factor binding protein (CRFBP, CRHBP) mRNA expression level in total hypothalamic RNA [detection threshold cycle (higher values correspond to lower abundance)] |
Nervous system |
| X3342 |
10789 |
Arginine vasopressin (AVP) transcript abundance in total hypothalamic RNA [detection threshold cycle (higher values correspond to lower abundance)] |
Nervous system |
| X2227 |
10795 |
Cell proliferation in the adult dentate gyrus, Ki67-positive cells [residuals] |
Nervous system |
| X3032 |
10796 |
Survival of new cells in the adult dentate gyrus, BrdU-positive cells [residual n] |
Nervous system |
| X4831 |
10798 |
New astrocyte production level based on ratio of total BrdU cells to S100b+BrdU labeled cells [residuals of the ratio] |
Nervous system |
| X1408 |
10805 |
Rostral migratory stream (RMS) BrdU-labeled cells in adults [number per mm] |
Nervous system |
| X4470 |
10877 |
Amygdala, basolateral complex (LaDL, LaVL, LaVM, BLP, and BLA), neuron number, unilateral without adjustment (revised) [n] |
Nervous system |
| X3280 |
10878 |
Amygdala, basolateral complex (LaDL, LaVL, LaVM, BLP, and BLA), neuron cell density [n/mm^3] |
Nervous system |
| X3277 |
10879 |
Amygdala, basolateral complex (LaDL, LaVL, LaVM, BLP, and BLA), glial cell density [n/mm^3] |
Nervous system |
| X1181 |
10887 |
Primary somatosensory cortex, posterior medial barrel subfield area without statistical adjustments [mm2] |
Nervous system |
| X1545 |
10891 |
Photoreceptor density (rods and cones) in young adults of both sexes (BXD32 excluded due to retinal degeneration, 201980+/-30851) [cells/mm^3] |
Nervous system |
| X4369 |
10897 |
Pain response, thermal nociception, latency to paw withdrawal and licking response using a hot plate test [sec] |
Nervous system |
| X3870 |
10899 |
Fear conditioning, baseline preconditioning freezing during a 2 min acclimation period prior to first pairing of conditioned stimulus (CS) and unconditioned stimulus (US) [%] |
Nervous system |
| X4501 |
10900 |
Fear conditioning, freezing during consolidation period after final pairing of conditioned stimulus (CS) and unconditioned stimulus (US) [%] |
Nervous system |
| X3972 |
10901 |
Fear conditioning, freezing in response to context exposure 48 hr after conditioning [%] |
Nervous system |
| X1172 |
10902 |
Fear conditioning, freezing during conditioned stimulus exposure, 24 hr after conditioning [%] |
Nervous system |
| X2302 |
10903 |
Depression assay, immobility from 2-10 min in a 10 min Porsolt forced swim test [%] |
Nervous system |
| X3350 |
10918 |
Pain response, chemical nociception, acetic acid writhing test [writhes] |
Nervous system |
| X1811 |
10919 |
Primary somatosensory cortex, posterior medial barrel subfield, statistically adjusted for variation in brain weight [mm2] |
Nervous system |
| X4214 |
11004 |
Rotarod performance, baseline control (supplementary data to Brigman et al.) [sec] |
Nervous system |
| X3024 |
11005 |
Motor performance, improvement in rotarod training measured as change in time on rod [sec] |
Nervous system |
| X2657 |
11007 |
Startle response to loud acoustic stimulus [force] |
Nervous system |
| X615 |
11008 |
Prepulse inhibition of the acoustic startle response [%] |
Nervous system |
| X3549 |
11009 |
Fear conditioning, freezing response time to conditioned cue after 48 hours [%] |
Nervous system |
| X3787 |
11010 |
Fear conditioning, freezing response time to conditioned cue after 24 hours [%] |
Nervous system |
| X1876 |
11011 |
Fear conditioning, freezing response to context after 48 hours [%] |
Nervous system |
| X1646 |
11023 |
Ectopia incidence in the neocortex (cerebral cortex) of adults, affected cases detected in the Mouse Brain Library [2x arcsine of % cases] |
Nervous system |
| X2281 |
11024 |
Photoreceptor number (rods and cones), unilateral per retina in young adults of both sexes (BXD32 excluded due to retinal degeneration (3.46+/-0.096 million) [n x10^6] |
Nervous system |
| X3107 |
11027 |
Iron level in hippocampus of males [ug/g] |
Nervous system |
| X1311 |
11029 |
Copper level in hippocampus of males [ug/g wet tissue] |
Nervous system |
| X340 |
11030 |
Copper level in hippocampus of females [ug/g wet weight] |
Nervous system |
| X2568 |
11031 |
Zinc level in hippocampus of males [ug/g] |
Nervous system |
| X4439 |
11032 |
Zinc level in hippocampus of females [ug/g] |
Nervous system |
| X4973 |
11281 |
Ocular dominance index (imaged ocular dominance index of undeprived mice at P35 given by (control_OD_contra - control_OD_ipsi) / (control_OD_contra+control_OD_ipsi) [ratio] |
Nervous system |
| X3890 |
11282 |
Visual cortex (V1) optical signal strength to stimulation of contralateral eye [intensity] |
Nervous system |
| X4867 |
11283 |
Visual cortex (V1) optical signal strength to stimulation of ipsilateral eye [intensity] |
Nervous system |
| X4794 |
11284 |
Ocular dominance index shift after monocular deprivation of the contralateral eye from P28 to P35 |
Nervous system |
| X557 |
11296 |
mechanical sensitivity, Von Frey hair test threshold [units] |
Nervous system |
| X4220 |
11302 |
Pain sensitivity, vocalization threshold to mild foot shock for males [mA] |
Nervous system |
| X4884 |
11305 |
Motor coordination, time on dowel over a 2 min baseline test period for males [sec] |
Nervous system |
| X1215 |
11306 |
Depression assay, Porsolt behavioral despair test, time immobile for males [sec] |
Nervous system |
| X579 |
11307 |
Pain response, thermal nociception using Hargreaves' test for males [units] |
Nervous system |
| X3405 |
11308 |
Pain response, thermal nociception, hot plate test, average of two trials for males [sec] |
Nervous system |
| X1461 |
11309 |
Pain response, mechanical nociception, tail clip latency for males [sec] |
Nervous system |
| X1014 |
11310 |
Pain response, thermal nociception, tail withdrawal latency for males [sec] |
Nervous system |
| X2385 |
11311 |
Somatosensory response, mechanical sensitivity using Von Frey test, threshold for males [Force in mg] |
Nervous system |
| X2122 |
11376 |
Locomotor activity after first saline injection (day 1) for males (MDMA control) [cm/ test period] |
Nervous system |
| X2376 |
11377 |
Saline control response, locomotor activity after second injection for males (control for MDMA response experiment) [cm/test period] |
Nervous system |
| X4575 |
11381 |
Seizure susceptibility, handling-induced convulsion (HIC) baseline for males (0=no effect, 1=facial grimace during tail spin, 2=tonic convulsion during spin, 3=tonic-clonic convulsion during spin, 4= tonic convulsion on l |
Nervous system |
| X4127 |
11383 |
Pain response, thermal nociception, hot plate latency for males [sec] |
Nervous system |
| X4401 |
11384 |
Locomotion in dark compartment of a light-dark box for males [cm] |
Nervous system |
| X4298 |
11386 |
Locomotion in both compartments of a light-dark box for males [cm] |
Nervous system |
| X1349 |
11392 |
Fear conditioning response, activity in altered context for males [units] |
Nervous system |
| X624 |
11393 |
Fear conditioning behavior, baseline activity in apparatus for males [units] |
Nervous system |
| X2525 |
11394 |
Fear conditioning response, contextual activity for males [units] |
Nervous system |
| X1880 |
11395 |
Fear conditioning response, activity in altered context during presentation of cue for males [n beam breaks] |
Nervous system |
| X2250 |
11396 |
Fear conditioning response, suppression of activity in altered context for males [units] |
Nervous system |
| X4887 |
11397 |
Fear conditioning response, activity during first tone-shock pairing for males [units] |
Nervous system |
| X4148 |
11398 |
Fear conditioning response, activity during second tone-shock pairing for males [units] |
Nervous system |
| X2279 |
11399 |
Fear conditioning response, activity during third tone-shock pairing for males [units] |
Nervous system |
| X1006 |
11400 |
Fear conditioning response, activity after first tone shock pairing for males [n beam breaks/30 sec test] |
Nervous system |
| X977 |
11401 |
Fear conditioning response, activity after second tone-shock pairing for males [n beam breaks/30 sec test] |
Nervous system |
| X4133 |
11402 |
Fear conditioning response, activity after third tone-shock pairing for males [n beam breaks/30 sec test] |
Nervous system |
| X2600 |
11403 |
Fear conditioning response, cue conditioning, activity suppression after third tone-shock pairing for males [units] |
Nervous system |
| X5060 |
11421 |
Startle response, baseline level for males [units] |
Nervous system |
| X1677 |
11422 |
Acoustic startle response, maximum response at 120 db for males (65 dB background noise, Hamilton-Kinder SM100 startle chamber, 10 msec interval, 120 dB startle stimulus, prepulse PPI control data by M Cook, UMemphis) [fo |
Nervous system |
| X3141 |
11423 |
Acoustic startle response, maximum response at 70 db for males (65 dB background noise, Hamilton-Kinder SM100 startle chamber, 10 msec interval, 120 dB startle stimulus, prepulse PPI control data by M Cook, UMemphis) [for |
Nervous system |
| X2815 |
11424 |
Acoustic startle response, maximum response at 80 db for males (65 dB background noise, Hamilton-Kinder SM100 startle chamber, 10 msec interval, 120 dB startle stimulus, prepulse PPI control data by M Cook, UMemphis) [for |
Nervous system |
| X2695 |
11425 |
Acoustic startle response, maximum response at 85 db for males (65 dB background noise, Hamilton-Kinder SM100 startle chamber, 10 msec interval, 120 dB startle stimulus, prepulse PPI control data by M Cook, UMemphis) [for |
Nervous system |
| X1671 |
11426 |
Acoustic startle response, prepulse inhibition (PPI) at 70 dB for males (65 dB background noise, Hamilton-Kinder SM100 startle chamber, 10 msec interval, 120 dB startle stimulus, data by M Cook, UMemphis) [% inhibition] |
Nervous system |
| X2236 |
11427 |
Acoustic startle response, prepulse inhibition (PPI) at 80 dB for males (65 dB background noise, Hamilton-Kinder SM100 startle chamber, 10 msec interval, 120 dB startle stimulus, data by M Cook, UMemphis) [% inhibition] |
Nervous system |
| X270 |
11428 |
Acoustic startle response, prepulse inhibition (PPI) at 85 dB for males (65 dB background noise, Hamilton-Kinder SM100 startle chamber, 10 msec interval, 120 dB startle stimulus, data by M Cook, UMemphis) [% inhibition] |
Nervous system |
| X671 |
11432 |
Depression assay, immobility using a tail suspension test (TST) for males [sec below threshold movement level] |
Nervous system |
| X666 |
11433 |
Locomotion in zero maze for males [n beam breaks] |
Nervous system |
| X3499 |
11436 |
Zero maze, latency to enter an open quadrant for males [sec] |
Nervous system |
| X3504 |
11443 |
Saline control response (10 ml/kg ip), locomotor activity after injection from 5-10 min after injection for males [cm] |
Nervous system |
| X3745 |
11445 |
Saline control response (10 ml/kg ip), locomotor activity after injection from 10-15 min for males [cm] |
Nervous system |
| X3805 |
11464 |
Motor coordination effect of saline control injection (ip), difference in time on rotarod between training session and saline for males [sec] |
Nervous system |
| X1405 |
11465 |
Motor coordination, rotarod performance, untreated training trial for males [sec] |
Nervous system |
| X4714 |
11483 |
Cocaine response (2 x 10 mg/kg ip), locomotion from 30-45 min after second injection in an activity chamber for males [n beam breaks] |
Nervous system |
| X1883 |
11493 |
Conditioned place preference (CPP) baseline control for cocaine CPP test, time in drug-paired compartment for males [sec] |
Nervous system |
| X4596 |
11494 |
Conditioned place preference (CPP) baseline control for cocaine CPP test, time spent in saline-paired unconditioned side before conditioning for males [sec] |
Nervous system |
| X3909 |
11497 |
Conditioned place preference (CPP) baseline control for cocaine CPP test, percentage of time spent in conditioned side before conditioning for males [%] |
Nervous system |
| X1600 |
11556 |
BrdU-labeled cells in the rostral migratory stream 1 hr after BrdU injection for adult males [density] |
Nervous system |
| X4947 |
11559 |
Pain sensitivity, vocalization threshold to mild foot shock for females [mA] |
Nervous system |
| X4946 |
11562 |
Motor coordination, time on dowel over a 2 min baseline test period for females [sec] |
Nervous system |
| X3776 |
11563 |
Depression assay, Porsolt behavioral despair test, time immobile for females [sec] |
Nervous system |
| X4102 |
11564 |
Pain response, thermal nociception, Hargreaves' test for females [units] |
Nervous system |
| X431 |
11565 |
Pain response, thermal nociception, hot plate test, average of two trials for females [sec] |
Nervous system |
| X1097 |
11566 |
Pain response, mechanical nociception, tail clip latency for females [sec] |
Nervous system |
| X2341 |
11567 |
Pain response, thermal nociception, tail withdrawal latency for females [sec] |
Nervous system |
| X4209 |
11568 |
Mechanical sensitivity using Von Frey test, threshold for females [force in mg] |
Nervous system |
| X3344 |
11638 |
Seizure susceptibility, handling-induced convulsion (HIC) baseline for females (0=no effect, 1=facial grimace during tail spin, 2=tonic convulsion during spin, 3=tonic-clonic convulsion during spin, 4= tonic convulsion on |
Nervous system |
| X4870 |
11640 |
Pain response, thermal nociception, hot plate latency for females [sec] |
Nervous system |
| X770 |
11641 |
Locomotion in dark compartment of a light-dark box for females [cm] |
Nervous system |
| X1727 |
11643 |
Locomotion in both compartments of a light-dark box for females [cm] |
Nervous system |
| X336 |
11649 |
Fear conditioning response, activity in altered context for females [units] |
Nervous system |
| X779 |
11650 |
Fear conditioning response, baseline activity in apparatus for females [units] |
Nervous system |
| X936 |
11651 |
Fear conditioning response, contextual activity for females [units] |
Nervous system |
| X733 |
11652 |
Fear conditioning response, activity in altered context during presentation of cue for females [units] |
Nervous system |
| X4219 |
11653 |
Fear conditioning response, suppression of activity in altered context for females [units] |
Nervous system |
| X1414 |
11654 |
Fear conditioning response, activity during first tone-shock pairing for females [units] |
Nervous system |
| X4255 |
11655 |
Fear conditioning response, activity during second tone-shock pairing for females [units] |
Nervous system |
| X621 |
11656 |
Fear conditioning response, activity during third tone-shock pairing for females [units] |
Nervous system |
| X1535 |
11657 |
Fear conditioning response, activity after first tone-shock pairing for females [n beam breaks/30 sec test] |
Nervous system |
| X514 |
11658 |
Fear conditioning response, activity after second tone-shock pairing for females [n beam breaks/30 sec test] |
Nervous system |
| X3022 |
11659 |
Fear conditioning response, activity after third tone-shock pairing for females [n beam breaks/30 sec test] |
Nervous system |
| X1379 |
11660 |
Fear conditioning response, cue conditioning, activity suppression after third tone-shock pairing for females [units] |
Nervous system |
| X4665 |
11678 |
Startle response, baseline level for females [amplitude] |
Nervous system |
| X4555 |
11679 |
Acoustic startle response, maximum response at 120 db for females (65 dB background noise, Hamilton-Kinder SM100 startle chamber, 10 msec interval, 120 dB startle stimulus, prepulse PPI control data by M Cook, UMemphis) [ |
Nervous system |
| X4557 |
11680 |
Acoustic startle response, maximum response at 70 db for females (65 dB background noise, Hamilton-Kinder SM100 startle chamber, 10 msec interval, 120 dB startle stimulus, prepulse PPI control data by M Cook, UMemphis) [f |
Nervous system |
| X4702 |
11681 |
Acoustic startle response, maximum response at 80 db for females (65 dB background noise, Hamilton-Kinder SM100 startle chamber, 10 msec interval, 120 dB startle stimulus, prepulse PPI control data by M Cook, UMemphis) [f |
Nervous system |
| X4805 |
11682 |
Acoustic startle response, maximum response at 85 db for females (65 dB background noise, Hamilton-Kinder SM100 startle chamber, 10 msec interval, 120 dB startle stimulus, prepulse PPI control data by M Cook, UMemphis) [f |
Nervous system |
| X3082 |
11683 |
Acoustic startle response, prepulse inhibition (PPI) at 70 dB for females (65 dB background noise, Hamilton-Kinder SM100 startle chamber, 10 msec interval, 120 dB startle stimulus, data by M Cook, UMemphis) [% inhibition] |
Nervous system |
| X4716 |
11684 |
Acoustic startle response, prepulse inhibition (PPI) at 80 dB for females (65 dB background noise, Hamilton-Kinder SM100 startle chamber, 10 msec interval, 120 dB startle stimulus, data by M Cook, UMemphis) [% inhibition] |
Nervous system |
| X4054 |
11685 |
Acoustic startle response, prepulse inhibition (PPI) at 85 dB for females (65 dB background noise, Hamilton-Kinder SM100 startle chamber, 10 msec interval, 120 dB startle stimulus, data by M Cook, UMemphis) [% inhibition] |
Nervous system |
| X2720 |
11689 |
Depression assay, immobility using a tail suspension test (TST) for females [sec below threshold movement level] |
Nervous system |
| X407 |
11690 |
Activity level, locomotion in zero maze for females [n beam breaks] |
Nervous system |
| X3054 |
11693 |
Zero maze, latency to enter an open quadrant for females [sec] |
Nervous system |
| X1640 |
11698 |
Saline control response (10 ml/kg ip), locomotor activity after injection from 0-5 min for females [cm] |
Nervous system |
| X1228 |
11700 |
Saline control response (10 ml/kg ip), locomotor activity after injection from 5-10 min after injection for females [cm] |
Nervous system |
| X1072 |
11702 |
Saline control response (10 ml/kg ip), locomotor activity after injection from 10-15 min for females [cm] |
Nervous system |
| X3370 |
18003 |
Midbrain serine level in adult females [ug/mg protein] |
Nervous system |
| X2111 |
11704 |
Saline control response (10 ml/kg ip), locomotion from 15-20 min after injection for females [cm] |
Nervous system |
| X1116 |
11707 |
Saline control response (10 ml/kg ip), locomotion 0-20 min after injection for females [cm] |
Nervous system |
| X1656 |
11721 |
Saline control response (dose ip), motor coordination effects, difference in time on rotarod between training session and saline for females [sec] |
Nervous system |
| X1042 |
11722 |
Motor coordination, rotarod performance, untreated training trial for females [sec] |
Nervous system |
| X4827 |
11754 |
Conditioned place preference (CPP) baseline control for cocaine CPP test, percentage of time spent in conditioned side before conditioning for females [%] |
Nervous system |
| X1902 |
11779 |
Novel open field behavior, locomotion from 0-15 min in the periphery for females in the cocaine test battery [cm] |
Nervous system |
| X4160 |
11813 |
BrdU-labeled cells in the rostral migratory stream 1 hr after BrdU injection for adult females [density] |
Nervous system |
| X4841 |
11816 |
Pain sensitivity, vocalization threshold to mild foot shock for males and females [mA] |
Nervous system |
| X4746 |
11819 |
Motor coordination, time on dowel over a 2 min baseline test period for males and females [sec] |
Nervous system |
| X2545 |
11820 |
Depression assay, Porsolt behavioral despair test, time immobile for males and females [sec] |
Nervous system |
| X3492 |
11825 |
Somatosensory response, mechanical sensitivity using Von Frey test, threshold for males and females [force in mg] |
Nervous system |
| X4856 |
11890 |
Locomotor activity after first saline injection (day 1) for males and females (MDMA control) [cm/ test period] |
Nervous system |
| X5042 |
11891 |
Saline control response, locomotor activity after second injection for males and females (control for MDMA response experiment) [cm/test period] |
Nervous system |
| X3376 |
11893 |
Ethanol response (4.0 g/kg i.p.), handling-induced convulsions (HIC) 6 hrs after injections for males and females [units] |
Nervous system |
| X1760 |
11895 |
Seizure susceptibility, handling-induced convulsion (HIC) baseline for males and females (0=no effect, 1=facial grimace during tail spin, 2=tonic convulsion during spin, 3=tonic-clonic convulsion during spin, 4= tonic con |
Nervous system |
| X4334 |
11897 |
Pain response, thermal nociception, hot plate latency for males and females [sec] |
Nervous system |
| X4092 |
11898 |
Locomotion in dark compartment of a light-dark box for males and females [cm] |
Nervous system |
| X4037 |
11900 |
Locomotion in both compartments of a light-dark box for males and females [cm] |
Nervous system |
| X731 |
11906 |
Fear conditioning response, activity in altered context for males and females [units] |
Nervous system |
| X1575 |
11907 |
Fear conditioning response, baseline activity in apparatus for males and females [units] |
Nervous system |
| X2080 |
11908 |
Fear conditioning response, contextual activity for males and females [units] |
Nervous system |
| X1295 |
11909 |
Fear conditioning response, activity in altered context during presentation of cue for males and females [units] |
Nervous system |
| X2285 |
11910 |
Fear conditioning response, suppression of activity in altered context for males and females [units] |
Nervous system |
| X4798 |
11911 |
Fear conditioning response, activity during first tone-shock pairing for males and females [units] |
Nervous system |
| X4652 |
11912 |
Fear conditioning response, activity during second tone-shock pairing for males and females [units] |
Nervous system |
| X1205 |
11913 |
Fear conditioning response, activity during third tone-shock pairing for males and females [units] |
Nervous system |
| X612 |
11914 |
Fear conditioning response, activity after first tone-shock pairing for males and females [n beam breaks/30 sec test] |
Nervous system |
| X868 |
11915 |
Fear conditioning response, activity after second tone-shock pairing for males and females [n beam breaks/30 sec test] |
Nervous system |
| X3751 |
11916 |
Fear conditioning response, activity after third tone-shock pairing for males and females [n beam breaks/30 sec test] |
Nervous system |
| X2060 |
11917 |
Fear conditioning response, cue conditioning, activity suppression after third tone-shock pairing for males and females [units] |
Nervous system |
| X4543 |
11935 |
Startle response, baseline level for males and females [amplitude] |
Nervous system |
| X2419 |
11936 |
Acoustic startle response, maximum response at 120 db for males and females (65 dB background noise, Hamilton-Kinder SM100 startle chamber, 10 msec interval, 120 dB startle stimulus, prepulse PPI control data by M Cook, U |
Nervous system |
| X3595 |
11937 |
Acoustic startle response, maximum response at 70 db for males and females (65 dB background noise, Hamilton-Kinder SM100 startle chamber, 10 msec interval, 120 dB startle stimulus, prepulse PPI control data by M Cook, UM |
Nervous system |
| X3754 |
11938 |
Acoustic startle response, maximum response at 80 db for males and females (65 dB background noise, Hamilton-Kinder SM100 startle chamber, 10 msec interval, 120 dB startle stimulus, prepulse PPI control data by M Cook, UM |
Nervous system |
| X3731 |
11939 |
Acoustic startle response, maximum response at 85 db for males and females (65 dB background noise, Hamilton-Kinder SM100 startle chamber, 10 msec interval, 120 dB startle stimulus, prepulse PPI control data by M Cook, UM |
Nervous system |
| X3522 |
11940 |
Acoustic startle response, prepulse inhibition (PPI) at 70 dB for males and females (65 dB background noise, Hamilton-Kinder SM100 startle chamber, 10 msec interval, 120 dB startle stimulus, data by M Cook, UMemphis) [% i |
Nervous system |
| X4123 |
11941 |
Acoustic startle response, prepulse inhibition (PPI) at 80 dB for males and females (65 dB background noise, Hamilton-Kinder SM100 startle chamber, 10 msec interval, 120 dB startle stimulus, data by M Cook, UMemphis) [% i |
Nervous system |
| X1446 |
11942 |
Acoustic startle response, prepulse inhibition (PPI) at 85 dB for males and females (65 dB background noise, Hamilton-Kinder SM100 startle chamber, 10 msec interval, 120 dB startle stimulus, data by M Cook, UMemphis) [% i |
Nervous system |
| X1155 |
11946 |
Depression assay, immobility using a tail suspension test (TST) for males and females [sec below threshold movement level] |
Nervous system |
| X466 |
11947 |
Locomotion in zero maze for males and females [n beam breaks] |
Nervous system |
| X1242 |
11979 |
Motor coordination, rotarod performance, untreated training trial for males and females [sec] |
Nervous system |
| X2686 |
12070 |
BrdU-labeled cells in the rostral migratory stream 1 hr after BrdU injection for adult males and females [density] |
Nervous system |
| X205 |
12296 |
Central motor pattern generation (CPG), mean primary interlick interval (MPI, time between licks) for 0.1 M sucrose over 20 min (Davis MS160 lickometer), male and female adults [mSec] |
Nervous system |
| X220 |
12297 |
Central motor pattern generation (CPG), mean primary interlick interval (MPI, time between licks) for water over 20 min (Davis MS160 lickometer), male and female adults [mSec] |
Nervous system |
| X1651 |
12486 |
Iron level in dorsal striatum (caudate-putamen) of 120-day-old females fed 3 ppm Fe diet [ug/g] |
Nervous system |
| X2753 |
12487 |
Iron level in ventral midbrain of 120-day-old in females fed 3 ppm Fe diet [ug/g] |
Nervous system |
| X882 |
12494 |
Iron level in dorsal striatum (caudate-putamen) of 120-day-old males fed 3 ppm Fe diet [ug/g] |
Nervous system |
| X4025 |
12495 |
Iron level in ventral midbrain of 120-day-old in males fed 3 ppm Fe diet [ug/g] |
Nervous system |
| X2911 |
12502 |
Iron level in dorsal striatum (caudate-putamen) of 120-day-old females fed 270 ppm Fe diet [ug/g] |
Nervous system |
| X1285 |
12503 |
Iron level in ventral midbrain of 120-day-old in females fed 270 ppm Fe diet [ug/g] |
Nervous system |
| X1750 |
12510 |
Iron level in dorsal striatum (caudate-putamen) of 120-day-old males fed 270 ppm Fe diet [ug/g] |
Nervous system |
| X929 |
12511 |
Iron level in ventral midbrain of 120-day-old in males fed 270 ppm Fe diet [ug/g] |
Nervous system |
| X994 |
12518 |
Iron level in caudate-putamen of 120-day-old males and females fed 3 ppm Fe diet [ug/g] |
Nervous system |
| X3473 |
12519 |
Iron level in ventral midbrain of 120-day-old males and females fed 3 ppm Fe diet [ug/g] |
Nervous system |
| X2870 |
12529 |
Iron level in caudate-putamen of 120-day-old males and females fed 270 ppm Fe diet [ug/g] |
Nervous system |
| X644 |
12530 |
Iron level in ventral midbrain of 120-day-old in males and females fed 270 ppm Fe diet [ug/g] |
Nervous system |
| X2005 |
12553 |
Cart gene mRNA expression level in hypothalamus [relative concentration by qt RT-PCR cycle count] |
Nervous system |
| X1449 |
12554 |
Depression assay, duration of immobility during trial 1 of a tail suspension test (TST) using a 20% mobility threshold over a 5 min test for males [sec] |
Nervous system |
| X192 |
12557 |
Neurexin 1 (Nrxn1) expression in hippocampus, first principal component generated using all coding exon probe sets and UMUTAffyExon_0209_RMA data [relative residual concentration] |
Nervous system |
| X4031 |
12566 |
Deoxycorticosterone (DOC) in blood plasma 6 hours after dexamethasone (0.075 mg/kg ip) in adult males [ng/g] |
Nervous system |
| X578 |
12567 |
Deoxycorticosterone (DOC) in blood plasma 6 hours after saline control injection (ip) in adult males [ng/g] |
Nervous system |
| X141 |
12568 |
Deoxycorticosterone (DOC) in cerebral cortex 6 hours after saline control injection (ip) in adult males [ng/g] |
Nervous system |
| X1523 |
12569 |
Deoxycorticosterone (DOC) in cerebral cortex 6 hours after dexamethasone (0.075 mg/kg ip) in adult males [ng/g] |
Nervous system |
| X1016 |
12601 |
Central motor pattern generator, lick count for water over 20 minutes (MS160 lickometer), male and female adults [n/20 min] |
Nervous system |
| X3407 |
12602 |
Central motor pattern generation, lick count for 0.1 M sucrose over 20 minutes (MS160 lickometer), male and female adults [n/20 min] |
Nervous system |
| X2573 |
12604 |
Central motor pattern generation (CPG), volume per lick, water over 20 min (MS160 lickometer), male and female adults [ul] |
Nervous system |
| X3553 |
16618 |
Infant vocalization, body weight on day 7, mixed sexes from 2 to 5 litters [gm] |
Nervous system |
| X2764 |
12605 |
Central motor pattern generation, volume per lick, 0.1 M sucrose over 20 minutes (MS160 lickometer), male and female adults [ul] |
Nervous system |
| X1622 |
12621 |
Catechol-o-methyl transferase expression level by RNA-seq, last two coding exons and entire 3' UTR, whole brain [normalized RNA-seq counts] |
Nervous system |
| X2323 |
12622 |
Catechol-o-methyl transferase expression level by RNA-seq, distal 3' UTR, whole brain [normalized RNA-seq counts] |
Nervous system |
| X4116 |
12730 |
Learning speed, initial acquisition of task, trials to criterion in naive 4-month adult males (Med Associates nose poke chamber, low values = faster learning) [n] |
Nervous system |
| X541 |
12731 |
Reversal learning, impulsivity, trials to criterion after acquisition in 4-month adult males (Med Associates nose poke chamber, low values = faster learning) [n] |
Nervous system |
| X811 |
12732 |
Reversal learning, impulsivity, residual trials to criterion after acquisition in 4-month adult males corrected for variation in acquisition learning (Med Associates nose poke chamber) [residual n] |
Nervous system |
| X4797 |
12735 |
3alpha,5alpha-tetrahydroprogesterone (THP, allopregnanolone) level in the olfactory bulb and tubercle 6 hrs after saline injection, afternoon sample collection (control for dexamethasone injection) [pg/ |
Nervous system |
| X2743 |
12737 |
3a,5a-pregnane-3a,21-diol-20-one (THDOC) level in the olfactory bulb and tubercle 1 hour after saline injection, morning sample collection (control for dexamethasone injection) in young adult males [pg/ |
Nervous system |
| X4916 |
12753 |
Total distance in open-field (OFA) in 8-week-old F1 hybrids between male BXD strains and female C57BL/6J-R6/2 Huntington model, wildtype cases only [cm] |
Nervous system |
| X2173 |
12754 |
Total distance in open-field (OFA) in 8-week-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, R6/2 cases only [cm] |
Nervous system |
| X4106 |
12755 |
Total distance in open-field (OFA) in 8-week-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model [% WT] |
Nervous system |
| X3487 |
12756 |
Rearing behavior in open-field (OFA) in 8-week-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, wildtype cases only [n vertical beam breaks] |
Nervous system |
| X973 |
12757 |
Rearing behavior in open-field (OFA) in 8-week-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, R6/2 cases only [n vertical beam breaks] |
Nervous system |
| X4202 |
12758 |
Rearing behavior in open-field (OFA) in 8-week-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model [% WT] |
Nervous system |
| X4124 |
12759 |
Rotarod, average time walking for day 2 in 8-week-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, wildtype cases only [sec] |
Nervous system |
| X4455 |
12763 |
Rotarod, average time walking for day 2 in 8-week-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, R6/2 cases only [sec] |
Nervous system |
| X1620 |
12764 |
Rotarod, average time walking for day 2 in 8-week-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model [% WT] |
Nervous system |
| X4213 |
12768 |
Acoustic startle response (ASR) in 8 week old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, wildtype cases only [arbitrary units] |
Nervous system |
| X3706 |
13061 |
Non-neuronal cell number in cerebral neocortex of adults, bilateral (direct 3D counting method) [millions] |
Nervous system |
| X3704 |
12769 |
Acoustic startle response (ASR) in 8 week old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, R6/2 cases only [arbitrary units] |
Nervous system |
| X3783 |
12770 |
Acoustic startle response (ASR) in 8 week old F1 hybrids between male BXD strains and female C57BL/6J-R6/2 Huntington model mouse [% of WT] |
Nervous system |
| X1786 |
12771 |
Prepulse inhibition (PPI), average inhibition for 4,8, and 12 dB above background in 8 week old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, wildtype cases only [%] |
Nervous system |
| X247 |
12772 |
Prepulse inhibition, average inhibition for 4,8, and 12 dB above background in 8-week-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, R6/2 cases only [%] |
Nervous system |
| X1084 |
12773 |
Prepulse inhibition, average difference in inhibition for 4,8, and 12 dB above background in 8-week-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington mode (all R6/2 hybrids, including the B6-R6/2 and F |
Nervous system |
| X4723 |
12774 |
Passive avoidance, latency to enter dark on day 1 in 8-week F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, wildtype cases only [sec] |
Nervous system |
| X5002 |
12775 |
Passive avoidance, latency to enter dark on day 1 in 8-week F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, R6/2 cases only [sec] |
Nervous system |
| X4435 |
12776 |
Passive avoidance, latency to enter dark on day 2 in 8-week F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, wildtype cases only [sec] |
Nervous system |
| X4064 |
12777 |
Passive avoidance, latency to enter dark on day 2 in 8-week F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, R6/2 cases only [sec] |
Nervous system |
| X4988 |
12778 |
Passive avoidance, latency to enter dark on day 3 in 8-week-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, wildtype cases only [sec] |
Nervous system |
| X4183 |
12779 |
Passive avoidance, latency to enter dark on day 3 in 8-week-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, R6/2 cases only [sec] |
Nervous system |
| X2354 |
12819 |
Passive avoidance, latency to enter dark on day 2 in 8-weeK-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model [% WT] |
Nervous system |
| X4008 |
12820 |
Passive avoidance, latency to enter dark on day 3 in 8-week-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model [% WT] |
Nervous system |
| X4693 |
12962 |
Ethanol response, consumption of 15% ethanol (v/v) using two-bottle choice system (ethanol vs water), 2-hour access after cycle 3 of air exposure (control group) in vapor chambers, average of 5 days ethanol |
Nervous system |
| X4539 |
12966 |
Ethanol response, consumption of 15% ethanol (v/v) using two-bottle choice system (ethanol vs water), 2-hour access after cycle 2 of ethanol exposure in vapor chamber, average of 5 days ethanol intake [g/kg/ |
Nervous system |
| X2118 |
12974 |
Hippocampus dentate gyrus cells positive for calretinin protein (CALB2) by immunohistochemistry [n total, unilateral] |
Nervous system |
| X4675 |
12975 |
Hippocampus dentate gyrus cells positive for doublecortin protein (DCX) by immunohistochemistry [n total, unilateral] |
Nervous system |
| X4236 |
13044 |
Body weight in 3-4 month old test naive females [g]. |
Nervous system |
| X4201 |
13060 |
Neuron number in cerebral neocortex of adults, bilateral (direct 3D counting method) [millions] |
Nervous system |
| X1767 |
13346 |
Acoustic startle response for males, 100 db white noise pulse, average of 10 trials, 40 ms pulse duration, 75 dB background noise, Med Associates startle chamber [force] |
Nervous system |
| X1953 |
13347 |
Acoustic startle response for males, 105 db white noise pulse, average of 10 trials, 40 ms pulse duration, 75 dB background noise, Med Associates startle chamber [force] |
Nervous system |
| X1448 |
13348 |
Acoustic startle response for males, 110 db white noise pulse, average of 10 trials, 40 ms pulse duration, 75 dB background noise, Med Associates startle chamber [force] |
Nervous system |
| X2762 |
13349 |
Acoustic startle response for males, 115 db white noise pulse, average of 10 trials, 40 ms pulse duration, 75 dB background noise, Med Associates startle chamber [force] |
Nervous system |
| X2199 |
13350 |
Acoustic startle response for males, 120 db white noise pulse, average of 10 trials, 40 ms pulse duration, 75 dB background noise, Med Associates startle chamber [force] |
Nervous system |
| X2757 |
13351 |
Acoustic startle response for males, 65 db white noise pulse, average of 10 trials, 40 ms pulse duration, 75 dB background noise, Med Associates startle chamber [force] |
Nervous system |
| X736 |
13352 |
Acoustic startle response for males, 70 db white noise pulse, average of 10 trials, 40 ms pulse duration, 75 dB background noise, Med Associates startle chamber [force] |
Nervous system |
| X4972 |
13353 |
Acoustic startle response for males, 75 db white noise pulse, average of 10 trials, 40 ms pulse duration, 75 dB background noise, Med Associates startle chamber [force] |
Nervous system |
| X2625 |
13354 |
Acoustic startle response for males, 80 db white noise pulse, average of 10 trials, 40 ms pulse duration, 75 dB background noise, Med Associates startle chamber [force] |
Nervous system |
| X4323 |
13355 |
Acoustic startle response for males, 85 db white noise pulse, average of 10 trials, 40 ms pulse duration, 75 dB background noise, Med Associates startle chamber [force] |
Nervous system |
| X3359 |
13356 |
Acoustic startle response for males, 90 db white noise pulse, average of 10 trials, 40 ms pulse duration, 75 dB background noise, Med Associates startle chamber [force] |
Nervous system |
| X2560 |
13357 |
Acoustic startle response for males, 95 db white noise pulse, average of 10 trials, 40 ms pulse duration, 75 dB background noise, Med Associates startle chamber [force] |
Nervous system |
| X565 |
13358 |
Prepulse inhibition of acoustic starte response for males, prepulse intensity 10 dB below startle threshold, 20 ms white noise prepulse, 40 ms 120 dB white noise pulse, 60 ms prepulse-pulse onset interval, 75 dB backgroun |
Nervous system |
| X1756 |
13359 |
Prepulse inhibition of acoustic starte response for males, prepulse intensity 65 dB, 20 ms white noise prepulse, 40 ms 120 dB white noise pulse, 60 ms prepulse-pulse onset interval, 75 dB background noise, Med Associates |
Nervous system |
| X1387 |
13360 |
Prepulse inhibition of acoustic starte response for males, prepulse intensity 70 dB, 20 ms white noise prepulse, 40 ms 120 dB white noise pulse, 60 ms prepulse-pulse onset interval, 75 dB background noise, Med Associates |
Nervous system |
| X1322 |
13361 |
Prepulse inhibition of acoustic starte response for males, prepulse intensity 75 dB, 20 ms white noise prepulse, 40 ms 120 dB white noise pulse, 60 ms prepulse-pulse onset interval, 75 dB background noise, Med Associates |
Nervous system |
| X4568 |
13476 |
Rotarod, average time walking for day 1 in 8-week-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model female only [% WT], |
Nervous system |
| X3293 |
13362 |
Prepulse inhibition of acoustic starte response for males, prepulse intensity 80 dB, 20 ms white noise prepulse, 40 ms 120 dB white noise pulse, 60 ms prepulse-pulse onset interval, 75 dB background noise, Med Associates |
Nervous system |
| X3856 |
13363 |
Response accuracy, measure of attention in the 5-choice serial reaction time task (5CSRT), Med Associates 5-hole operant chambers, high value = good performance [%] |
Nervous system |
| X2073 |
13364 |
Errors of omission, measure of attention/motivation in the 5-choice serial reaction time task (5CSRT), Med Associates 5-hole operant chambers, low value = good performance [%] |
Nervous system |
| X1818 |
13365 |
Mean correct response latency, measure of attention/motivation/motor function in the 5-choice serial reaction time task (5CSRT), Med Associates 5-hole operant chambers, low value = faster [s] |
Nervous system |
| X463 |
13366 |
Mode of correct response latencies, measure of processing speed/motor function in the 5-choice serial reaction time task (5CSRT), Med Associates 5-hole operant chambers, low value = faster [s] |
Nervous system |
| X778 |
13367 |
Standard deviation of correct response latencies, measure of lapses in attention/motivation in the 5-choice serial reaction time task (5CSRT), Med Associates 5-hole operant chambers, low value = better performa |
Nervous system |
| X1669 |
13368 |
Mean latency to retrieve food pellet, measure of motivation in the 5-choice serial reaction time task (5CSRT), Med Associates 5-hole operant chambers, high value = low motivation [s] |
Nervous system |
| X2583 |
13369 |
Number of completed trials in a 25 min session, measure of motivation in the 5-choice serial reaction time task (5CSRT), Med Associates 5-hole operant chambers, low value = low motivation [n] |
Nervous system |
| X4073 |
13370 |
Response accuracy during a session with variable stimulus duration (1,0.5, 0.25 s), measure of attention in the 5-choice serial reaction time task (5CSRT), Med Associates 5-hole operant chambers, high value = |
Nervous system |
| X816 |
13371 |
Errors of omission during a session with variable stimulus duration (1,0.5, 0.25 s), measure of attention in the 5-choice serial reaction time task (5CSRT), Med Associates 5-hole operant chambers, low value = |
Nervous system |
| X1442 |
13372 |
Acoustic startle threshold for males, lowest sound pressure level at which startle response can be detected [dB] |
Nervous system |
| X225 |
13399 |
Septum volume corrected for shrinkage, age, sex, plane of section, brain weight, and epoch [mm3] |
Nervous system |
| X3337 |
13441 |
Rotarod, average time walking for day 1 in 8-week-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model , R6/2 cases only [sec] |
Nervous system |
| X2574 |
13446 |
Rotarod, average time walking for day 1 in 8-week-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model , wildtype cases only |
Nervous system |
| X3235 |
13447 |
Rotarod, average time walking for day 1 in 8-week-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model [% WT] |
Nervous system |
| X4931 |
13448 |
Rotarod, improvement from day 1 to day 2 in 8-week-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model , R6/2 cases only [percentage improvement] |
Nervous system |
| X3498 |
13449 |
Rotarod, improvement from day 1 to day 2 in 8-week-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model , R6/2 cases only [day 2 - day 1, sec] |
Nervous system |
| X1083 |
18005 |
Midbrain glycine level in adult females [ug/mg protein] |
Nervous system |
| X2566 |
13450 |
Rotarod, improvement from day 1 to day 2 in 8-week-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model , wildtype cases only [day 2 - day 1, sec] |
Nervous system |
| X1426 |
13451 |
Rotarod, improvement from day 1 to day 2 in 8-week-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model , wildtype cases only [percentage improvement] |
Nervous system |
| X4819 |
13452 |
Rotarod, improvement from day 1 to day 2 in 8-week-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model [% WT] [percentage improvement] |
Nervous system |
| X3533 |
13453 |
Rotarod, improvement from day 1 to day 2 in 8-week-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model [% WT] [day 2 - day 1] |
Nervous system |
| X3122 |
13454 |
Total distance in open-field (OFA) in 8-week-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, Female R6/2 cases only [cm |
Nervous system |
| X3488 |
13455 |
Total distance in open-field (OFA) in 8-week-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, Male R6/2 cases only [cm] |
Nervous system |
| X4589 |
13456 |
Total distance in open-field (OFA) in 8-week-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, Female wildtype cases only [cm] |
Nervous system |
| X4772 |
13457 |
Total distance in open-field (OFA) in 8-week-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, male wildtype cases only [cm] |
Nervous system |
| X4436 |
13459 |
Total distance in open-field (OFA) in 8-week-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model males only [% WT] |
Nervous system |
| X867 |
13461 |
Rearing behavior in open-field (OFA) in 8-week-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, male R6/2 cases only [n vertical beam breaks], |
Nervous system |
| X2878 |
13462 |
Rearing behavior in open-field (OFA) in 8-week-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, female wildtype cases only [n vertical beam breaks], |
Nervous system |
| X3550 |
13463 |
Rearing behavior in open-field (OFA) in 8-week-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, male wildtype cases only [n vertical beam breaks], |
Nervous system |
| X2915 |
13464 |
Rearing behavior in open-field (OFA) in 8-week-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model female only [% WT], |
Nervous system |
| X4978 |
13465 |
Rearing behavior in open-field (OFA) in 8-week-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model male only [% WT], |
Nervous system |
| X3540 |
13472 |
Rotarod, average time walking for day 1 in 8-week-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model , female R6/2 cases only [sec] |
Nervous system |
| X450 |
13473 |
Rotarod, average time walking for day 1 in 8-week-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, male R6/2 cases only [sec], |
Nervous system |
| X2484 |
13474 |
Rotarod, average time walking for day 1 in 8-week-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model , female wildtype cases only [sec], |
Nervous system |
| X3995 |
13475 |
Motor performance, accelerating rotarod test, average time walking for day 1 in 8-week-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, male wildtype cases only [sec], |
Nervous system |
| X4881 |
16619 |
Infant vocalization, body weight on day 8, mixed sexes from 2 to 5 litters [gm] |
Nervous system |
| X4002 |
13477 |
Rotarod, average time walking for day 1 in 8-week-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model male only [% WT], |
Nervous system |
| X1724 |
13478 |
Rotarod, average time walking for day 2 in 8-week-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model male only [% WT], |
Nervous system |
| X4251 |
13479 |
Rotarod, average time walking for day 2 in 8-week-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model female only [% WT], |
Nervous system |
| X4241 |
13480 |
Rotarod, average time walking for day 2 in 8-week-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, female R6/2 cases only [sec] |
Nervous system |
| X1615 |
13481 |
Rotarod, average time walking for day 2 in 8-week-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, male R6/2 cases only [sec] |
Nervous system |
| X630 |
13482 |
Rotarod, average time walking for day 2 in 8-week-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, female wildtype cases only [sec] |
Nervous system |
| X4592 |
13483 |
Rotarod, average time walking for day 2 in 8-week-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, male wildtype cases only [sec] |
Nervous system |
| X1680 |
13484 |
Hippocampus network activity in vitro, spontaneous activity, integrated (1-45 Hz) local field potential amplitude, both sexes at 2 weeks-of-age [ln(uV)] |
Nervous system |
| X1051 |
13485 |
Prepulse inhibition, average inhibition for 4,8, and 12 dB above background in 8-week-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, female R6/2 cases only [%] |
Nervous system |
| X1695 |
13486 |
Hippocampus network activity in vitro, spontaneous activity, mean correlation of local field potentials, both sexes at 2 weeks-of-age [ln(r)] |
Nervous system |
| X681 |
13487 |
Hippocampus network activity in vitro, carbachol (25 uM) induced oscillations, normalized local field potential peak amplitude, both sexes at 2 weeks-of-age [ln(uV)] |
Nervous system |
| X2556 |
13488 |
Hippocampus network activity in vitro, carbachol (25 uM) induced oscillations, normalized local field potential peak frequency, both sexes at 2 weeks-of-age [Hz] |
Nervous system |
| X1246 |
13489 |
Prepulse inhibition, average inhibition for 4,8, and 12 dB above background in 8-week-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, male R6/2 cases only [%] |
Nervous system |
| X1703 |
13490 |
Hippocampus network activity in vitro, carbachol (25 uM) induced oscillations, normalized integrated (1-45 Hz) local field potential amplitude, both sexes at 2 weeks-of-age [ln(uV)] |
Nervous system |
| X395 |
13491 |
Hippocampus network activity in vitro, carbachol (25 uM) induced oscillations, normalized mean correlation of local field potentials, both sexes at 2 weeks-of-age [ln(r)] |
Nervous system |
| X3434 |
13492 |
Prepulse inhibition, average inhibition for 4,8, and 12 dB above background in 8-week-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, female wildtype cases only [%] |
Nervous system |
| X2969 |
13493 |
Prepulse inhibition, average inhibition for 4,8, and 12 dB above background in 8-week-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, male wildtype cases only [%] |
Nervous system |
| X4012 |
13494 |
Prepulse inhibition, average difference in inhibition compared to wildtype for 4,8, and 12 dB above background in 8-week-old F1 hybrids between male BXDs and C57BL/6J-R6/2 Huntington model females only [% of WT] |
Nervous system |
| X3414 |
13495 |
Prepulse inhibition, average difference in inhibition for 4,8, and 12 dB above background in 8-week-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model male only [% of WT PPI%] |
Nervous system |
| X2691 |
13511 |
Left hemisphere brain weight in 8-week-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, wildtype cases only [mg] |
Nervous system |
| X4294 |
13512 |
Left hemisphere brain weight in 8-week-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, R6/2 cases only [mg] |
Nervous system |
| X4444 |
13513 |
Left hemisphere brain weight in 8-week-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model [% WT] |
Nervous system |
| X2621 |
13520 |
RROD day 1 in 8-week F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington mode, CORRECTED R6/2 cases only [sec] |
Nervous system |
| X5032 |
13522 |
RROD day 2 in 8-week F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington mode, CORRECTED R6/2 cases only [sec] |
Nervous system |
| X802 |
13523 |
Motor performance measured by the rotarod test on day 1 (first test) in 8-week F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model (corrected female R6/2 cases only) [sec] |
Nervous system |
| X4837 |
13524 |
RROD day 1 in 8-week F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington mode, CORRECTED male R6/2 cases only [sec] |
Nervous system |
| X5048 |
13525 |
RROD day 2 in 8-week F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington mode, CORRECTED female R6/2 cases only [sec] |
Nervous system |
| X85 |
13526 |
motor performance, accelerating rotarod test, day 2 in 8-week F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington mode, CORRECTED male R6/2 cases only [sec] |
Nervous system |
| X2358 |
13527 |
Total distance in open-field (OFA) in 8-week-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, CORRECTED Female R6/2 cases only [cm] |
Nervous system |
| X3641 |
13528 |
Total distance in open-field (OFA) in 8-week-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, CORRECTED male R6/2 cases only [cm] |
Nervous system |
| X4900 |
13529 |
Rearing behavior in open-field (OFA) in 8-week-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, CORRECTED female R6/2 cases only [n vertical beam breaks] |
Nervous system |
| X5036 |
13530 |
Rearing behavior in open-field (OFA) in 8-week-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, CORRECTED male R6/2 cases only [n vertical beam breaks] |
Nervous system |
| X3837 |
13531 |
Prepulse inhibition, average inhibition for 4,8, and 12 dB above background in 8-week-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, CORRECTED Female R6/2 cases only [%] |
Nervous system |
| X4604 |
13532 |
Prepulse inhibition, average inhibition for 4,8, and 12 dB above background in 8-week-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, CORRECTED male R6/2 cases only [%] |
Nervous system |
| X4390 |
13534 |
Total distance in open-field (OFA) in 8-week-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, CORRECTED R6/2 cases only [cm] |
Nervous system |
| X4698 |
13535 |
Rearing behavior in open-field (OFA) in 8-week-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, CORRECTED R6/2 cases only [n vertical beam breaks] |
Nervous system |
| X4327 |
16620 |
Infant vocalization, body weight on day 9, mixed sexes from 2 to 5 litters [gm] |
Nervous system |
| X4319 |
13537 |
Passive avoidance, latency to enter dark on day 1 in 8-week F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, R6/2 cases only [sec] |
Nervous system |
| X606 |
13538 |
Passive avoidance, latency to enter dark on day 2 in 8-week F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, CORRECTED R6/2 cases only [sec] |
Nervous system |
| X4335 |
13539 |
Passive avoidance, latency to enter dark on day 3 in 8-week-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, CORRECTED R6/2 cases only [sec] |
Nervous system |
| X4944 |
13540 |
Acoustic startle response (ASR) in 8 week old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, CORRECTED R6/2 cases only [arbitrary units] |
Nervous system |
| X4507 |
13541 |
Prepulse inhibition, average inhibition for 4,8, and 12 dB above background in 8-week-old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, CORRECTED R6/2 cases only [%] |
Nervous system |
| X129 |
13545 |
Newly generated BrdU-labeled cells in young adult rostral migratory stream (RMS), unadjusted data [N per mm of RMS length] |
Nervous system |
| X1602 |
13549 |
Basolateral amygdala residual volume, statistically adjusted for variation in sex, age, body weight (Hager et al.,2012, data from Mozhui et al. 2007) [residual mm^3] |
Nervous system |
| X131 |
13586 |
Newly generated BrdU-labeled cells in the rostral migratory stream of adult mouse brain, data corrected for age effects [N cells per mm of RMS length] |
Nervous system |
| X4893 |
13965 |
Soluble (2B7/2B7) FRET in 8 week old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, R62 only [ratio] |
Nervous system |
| X3502 |
13966 |
Aggregate (4C9/4C9) FRET in 8 week old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, R62 only [ratio] |
Nervous system |
| X3016 |
14786 |
Proliferation of BrdU-labeled cells in subgranular zone, 1h BrdU injection, unadjusted data [n cells] |
Nervous system |
| X524 |
14787 |
soluble/aggregate protein by FRET ratio in 8 week old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, 2B7/4C9 R6/2 cases only [FRETT florescence ratio] |
Nervous system |
| X1977 |
14788 |
Midsagittal area of the corpus callosum corrected for shrinkage [mm2] |
Nervous system |
| X4032 |
14791 |
R62 soluble/WT soluble protein by FRET ratio in 8 week old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, [FRETT florescence ratio] |
Nervous system |
| X2022 |
14792 |
R62 aggregate/WT aggregate protein by FRET ratio in 8 week old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, [FRETT florescence ratio] |
Nervous system |
| X4832 |
14793 |
R6 soluble minus WT soluble protein by FRET ratio in 8 week old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, [FRETT florescence ratio] |
Nervous system |
| X1396 |
15169 |
Spatial navigation, crossing events over location of trained platform in Morris water maze, final probe trial, males and females combined [n annulus crossings] |
Nervous system |
| X814 |
15170 |
Spatial navigation, latency to reach hidden platform using Morris water maze (test 4, Trait Llat4 Table 1), males and females combined [log sec] |
Nervous system |
| X1748 |
15171 |
Spatial navigation, latency to reach hidden platform using Morris water maze (test 1, Trait Lat1 Table 1), males and females combined [sec] |
Nervous system |
| X3089 |
18006 |
Midbrain histidine level in adult females [ug/mg protein] |
Nervous system |
| X266 |
15172 |
Spatial navigation, latency to reach hidden platform using Morris water maze (test 2, Trait Lat2 Table 1), males and females combined [sec] |
Nervous system |
| X1325 |
15173 |
Spatial navigation, latency to reach hidden platform using Morris water maze (test 3, Trait Lat3 Table 1), males and females combined [sec] |
Nervous system |
| X1404 |
15174 |
Spatial navigation, latency to reach hidden platform using Morris water maze (test 4, Trait Lat4 Table 1), males and females combined [sec] |
Nervous system |
| X486 |
15181 |
Kcnq5 mRNA expression in hippocampus (Kv7.5, potassium voltage-gated channel, subfamily Q, member 5, M-current, slowly activating muscarinic acetylcholine receptor sensitive), first principal component generated us |
Nervous system |
| X2170 |
15183 |
Prodynorphin (Pdyn, dynorphin, D1 medium spiny neuron expression signature) mRNA expression in striatum (caudate-putamen), first principal component generated using five Affymetrix exon-level Pdyn probe sets and St |
Nervous system |
| X1689 |
15184 |
Substance P (tachykinin 1, Tac1, substance P, D1 medium spiny neuron expression signature) mRNA expression in striatum (caudate-putamen), first principal component generated using ten Affymetrix exon-level Tac1 pro |
Nervous system |
| X4440 |
15185 |
Dopamine D1 receptor (Drd1a, D1 medium spiny neuron expression signature) mRNA expression in striatum (caudate-putamen), first principal component generated using three Affymetrix exon-level Drd1a probe sets and St |
Nervous system |
| X1817 |
15186 |
Dopamine D2 receptor (Drd2, D2 medium spiny neuron expression signature) mRNA expression in striatum (caudate-putamen), first principal component generated using eight Affymetrix exon-level Drd2 probe sets and Stri |
Nervous system |
| X2286 |
15552 |
Early B-cell factor 1 (Ebf1, D1 medium spiny neuron expression signature) mRNA expression in striatum (caudate-putamen), first principal component generated using 8 Affymetrix exon-level probe sets (exons 4 to 11) |
Nervous system |
| X3467 |
15553 |
Dock1 (D2 medium spiny neuron expression signature) mRNA expression in striatum (caudate-putamen), first principal component generated using six Affymetrix exon-level Dock1 probe sets (exon 45 to 50) and Striatum_E |
Nervous system |
| X4206 |
15554 |
Dopamine receptor ratio in striatum based on relative expression using Affymetrix Exon array probe sets for Drd1 and Drd2 [ratio] |
Nervous system |
| X1278 |
15948 |
;Central nervous system;; embryonic neurogenesis;; Cell death in brainstem following exposure to ethanol at E9 (TUNEL+ cells/mm2); |
Nervous system |
| X1999 |
15949 |
;Central nervous system;; embryonic neurogenesis;; Cell death in the forebrain following ethanol exposure at E9 (TUNEL+ cells/mm2); |
Nervous system |
| X705 |
15959 |
3-nitropropionic acid neurodegeneration in striatum (caudate putamen) (50 mg/kg ip) in young adults, presence or absence of lesions [-1 = lesions, +1 = no lesions] |
Nervous system |
| X441 |
15960 |
;Central nervous system;; embryonic neurogenesis;; Cell death in brainstem following exposure to ethanol at E9 (TUNEL+ cells/mm2); |
Nervous system |
| X4989 |
15961 |
;Central nervous system;; embryonic neurogenesis;; Cell death in forebrain following exposure to ethanol at E9 (TUNEL+ cells/mm2); |
Nervous system |
| X196 |
15965 |
Vasopressin receptor expression gene family mapping to Avpr1a using Hypothalamus data set (BXD84 winsorized from 6.26 to 3.7) |
Nervous system |
| X3396 |
16362 |
Infant vocalization, peak amplitude of call on day 9 (Avisoft analysis software), mixed sexes from 2 to 5 litters [dB] |
Nervous system |
| X128 |
15969 |
Newly generated BrdU-labeled cells in the rostral migratory stream of adult mouse brain, data corrected for age, sex, body weight, and strain epoch effects [N cells per mm of RMS length] |
Nervous system |
| X185 |
16177 |
Apoptosis on postnatal day 7 in CA1 region of the hippocampus of both sexes (TUNEL assay) [cells/section or whatever it really is] |
Nervous system |
| X2458 |
16178 |
;Central nervous system;; embryonic neurogenesis;; Cell death in brainstem following exposure to maltose dextrin at E9 (TUNEL+ cells/mm2); |
Nervous system |
| X2438 |
16179 |
;Central nervous system;; embryonic neurogenesis;; Cell death in forebrain following exposure to maltose dextrin at E9 (TUNEL+ cells/mm2); |
Nervous system |
| X2914 |
16187 |
Proliferation of BrdU-labeled cells in subgranular zone, 1h BrdU injection, data corrected for age effects [n cells] |
Nervous system |
| X3360 |
16188 |
soluble/brain weight by FRET ratio in 8 week old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, 2B7/left hemishere wt R6/2 cases only [FRETT florescence ratio] |
Nervous system |
| X4303 |
16189 |
aggregate/brain weight by FRET ratio in 8 week old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, 4C9/left hemishere wt R6/2 cases only [FRETT florescence ratio] |
Nervous system |
| X4524 |
16190 |
soluble:aggregate ratio/brain weight by FRET ratio in 8 week old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, 2B7:4C9/left hemishere wt R6/2 cases only [FRETT florescence ratio] |
Nervous system |
| X4635 |
16202 |
Visual discrimination using a touchscreen assay, sessions required to reach the learning criterion during pre-training phase 2 (touch phase, animals must learn to nose-poke the screen) where low value |
Nervous system |
| X4029 |
16203 |
Visual discrimination using a touchscreen assay, sessions required to reach the learning criterion during pre-training phase 3 (punish phase, animals must learn to nose-poke only random shaped visual |
Nervous system |
| X4902 |
16204 |
Visual discrimination learning using a touchscreen assay, sessions to discriminate between rewarded and unrewarded stimuli (low value = fast to learn, see Figure 4B blue bars) in 3-month-old males [n] |
Nervous system |
| X4913 |
16205 |
Reversal learning using a touchscreen assay, number of sessions to reverse previously learned stimulus-reward pairings (low value = fast to reverse responding, see Figure 4B red bars of Graybeal et al |
Nervous system |
| X4587 |
16206 |
Extinction learning, sessions to extinguish a well learned instrumental response using a touchscreen assay (low value = fast to extinguish unrewarded response, see Figure 4B yellow bars) in 3-month-ol |
Nervous system |
| X4907 |
16207 |
Discrimination test correct responses using a touchscreen assay in 3-month-old males (supplementary trait data not in paper) [n] |
Nervous system |
| X5005 |
16208 |
Visual discrimination learning using a touchscreen assay, total mean number of errors during discrimination learning (see Figure 4C) in 3-month-old males [n] |
Nervous system |
| X4996 |
16209 |
Visual discrimination learning using a touchscreen assay, total mean number of corrections errors (incorrect responses following an initial error) during discrimination learning (see Figure 4D) in 3-m |
Nervous system |
| X760 |
16210 |
Visual discrimination learning using a touchscreen assay, mean reaction time to nose-poke the stimulus across all discrimination learning sessions (see Figure S4A) in 3-month-old males [sec] |
Nervous system |
| X4168 |
16211 |
Visual discrimination learning using a touchscreen assay, mean magazine latency (time to retrieve reward) across all discrimination learning sessions (see Figure S4B) in 3-month-old males [sec] |
Nervous system |
| X4952 |
16212 |
Reversal learning correct responses using a touchscreen assay in 3-month-old males (supplementary trait data not in paper) [n] |
Nervous system |
| X5012 |
16213 |
Reversal learning correct responses <50% using a touchscreen assay in 3-month-old males (supplementary trait data not in paper) [n] |
Nervous system |
| X5052 |
16214 |
Reversal learning correct responses >50% using a touchscreen assay in 3-month-old males (supplementary trait data not in paper) [n] |
Nervous system |
| X5051 |
16215 |
Reversal learning errors using a touchscreen assay across all reversal learning sessions (see Figure 5A) in 3-month-old males [n] |
Nervous system |
| X5056 |
16216 |
Reversal learning using a touchscreen assay, number of errors during early reversal learning when performance was at or below 50% accuracy (see Figure 5C) in 3-month-old males [n] |
Nervous system |
| X4968 |
16217 |
Reversal learning errors using a touchscreen assay during the late reversal learning phase when performance was above 50% accuracy (Figure 5E) in 3-month-old males [n] |
Nervous system |
| X4970 |
16218 |
Reversal learning correction errors using a touchscreen assay, means across all reversal learning trials (Figure 5B ) in 3-month-old males [n] |
Nervous system |
| X5030 |
16219 |
Reversal learning correction errors using a touchscreen assay during the early phase trials when performance was at or below 50% accuracy (Figure 5D) in 3-month-old males [n] |
Nervous system |
| X5013 |
16220 |
Reversal learning correction errors using a touchscreen assay during the late phase trials when performance was above 50% accuracy (Figure 5F) in 3-month-old males [n] |
Nervous system |
| X4974 |
16221 |
Reversal learning reaction time to nose-poke stimuli using a touchscreen assay averaged across all reversal learning trials (Figure S4C) in 3-month-old males [sec] |
Nervous system |
| X2401 |
16222 |
Reversal learning magazine latency using a touchscreen assay (time to retrieve food reward) averaged across all reversal learning trials (Figure S4D) in 3-month-old males [sec] |
Nervous system |
| X492 |
16223 |
Extinction learning, correct responses during extinction of a well learned instrumental response using a touchscreen assay (low value = fast to extinguish unrewarded response, supplementary trait data |
Nervous system |
| X2681 |
16224 |
Extinction learning using a touchscreen assay, error responses during extinction training of a well learned instrumental response (low value = fast to extinguish unrewarded response, Figure S5A of Gra |
Nervous system |
| X2336 |
16225 |
Extinction learning correction errors using a touchscreen assay (low value = fast to extinguish unrewarded response, Figure S5B) in 3-month-old males [n] |
Nervous system |
| X4895 |
16226 |
Extinction learning reaction time using a touchscreen assay during extinction of a well learned instrumental response (Figure S5C) in 3-month-old males [sec] |
Nervous system |
| X2183 |
16227 |
Extinction of a learned stimulus using a touchscreen assay, food pellet magazine latency for a non-rewarded but well learned instrumental response in 3-month-old males (supplementary trait data not in |
Nervous system |
| X2735 |
17967 |
Blood 5-hydroxytryptamine (5-HT, serotonin) level in adult males [pg/ul] |
Nervous system |
| X3965 |
16241 |
Tnik mRNA expression in hippocampus (TRAF2 and NCK interacting kinase), first principal component generated using exon probe sets and UMUTAffyExon_0209_RMA data [relative residual concentration] |
Nervous system |
| X365 |
16246 |
;Central nervous system;; post-natal neurogenesis;; Apoptosis in cortex L2/3 (% caspase 3+ cells); |
Nervous system |
| X4239 |
16297 |
Photoreceptor density (rods and cones) in young adults of both sexes (BXD97, BXD92, and BXD65 merged, BXD96 and BXD48 merged, BXD80 and BXD73 merged) [cells/mm^3] |
Nervous system |
| X3838 |
16298 |
Photoreceptor number (rods and cones), unilateral per retina in young adults of both sexes (BXD97, BXD92, and BXD65 merged, BXD96 and BXD48 merged, BXD80 and BXD73 merged ) [n x10^6] |
Nervous system |
| X3200 |
16300 |
Photoreceptor density (rods and cones), unilateral per retina in young adults of both sexes [cells/mm^3] |
Nervous system |
| X3455 |
16301 |
Photoreceptor number (rods and cones), unilateral per retina in young adults of both sexes [n x10^6] |
Nervous system |
| X2432 |
16302 |
Depression assay, tail suspension test (TST) control levels of immobility before drug treatment (data of Dr. Gang Chen) [sec] |
Nervous system |
| X911 |
16303 |
;Central nervous system;; post-natal neurogenesis;; Apoptosis in cortex L5 (% caspase 3+ cells); |
Nervous system |
| X810 |
16308 |
Please enter full trait information even before publication |
Nervous system |
| X4917 |
16309 |
New neurons in the dentate gyrus of the young adult hippocampus corrected for number of proliferating precursors (data derived from Record IDs 10797 and 10795) [z score] |
Nervous system |
| X1710 |
16310 |
Erbb4 mRNA expression in hippocampus (receptor tyrosine-protein kinase erbB-4), first principal component generated using exon probe sets and UMUTAffyExon_0209_RMA data [relative residual concentration] |
Nervous system |
| X1025 |
16311 |
Impulsivity measured as motor impulsivity in the 5-choice serial reaction time task (5CSRT), premature responses before stimulus presentation (Med Associates 5-hole operant chambers) in males (high value = high |
Nervous system |
| X1381 |
16312 |
Fear conditioning, freezing time on first context trial 24 hours after shock training, both sexes at 3-4 months of age [percent time] |
Nervous system |
| X1130 |
16355 |
Infant ultrasonic vocalization (USV), duration of call on day 7 (AviSoft analysis software), mixed sexes from 2 to 5 litters [msec] |
Nervous system |
| X3234 |
16356 |
Infant ultrasonic vocalization (USV), duration of call on day 8 (AviSoft analysis software), mixed sexes from 2 to 5 litters [msec] |
Nervous system |
| X1120 |
16357 |
Infant vocalization, peak amplitude of call on day 7 (Avisoft analysis software), mixed sexes from 2 to 5 litters [dB] |
Nervous system |
| X1335 |
16358 |
Infant vocalization, peak amplitude of call on day 8 (Avisoft analysis software), mixed sexes from 2 to 5 litters [dB] |
Nervous system |
| X766 |
16359 |
Infant vocalization, mean peak frequency of call on day 7, mixed sexes from 2 to 5 litters [kHz] |
Nervous system |
| X2485 |
16360 |
Infant vocalization, mean peak frequency of call on day 8 (Avisoft analysis software), mixed sexes from 2 to 5 litters [kHz] |
Nervous system |
| X3041 |
16361 |
Infant ultrasonic vocalization (USV), duration of call on day 9 (AviSoft analysis software), mixed sexes from 2 to 5 litters [msec] |
Nervous system |
| X2334 |
16385 |
Infarct volume in neocortex following experimental stroke (permanent middle cerebral artery and ipsilateral common carotid artery occlusion) in adult males and females (2- to 4-months old), 24 hr survival (al |
Nervous system |
| X1206 |
16386 |
Infarct volume in neocortex (log transformed) following experimental stroke (permanent middle cerebral artery and ipsilateral common carotid artery occlusion) in adult males and females (2- to 4-months old), |
Nervous system |
| X1776 |
16387 |
Infarct volume in neocortex following experimental stroke (permanent middle cerebral artery and ipsilateral common carotid artery occlusion) in adult males and females (2- to 4-months old), 24 hr survival (pa |
Nervous system |
| X1802 |
16388 |
Infarct volume in neocortex (log transformed) following experimental stroke (permanent middle cerebral artery and ipsilateral common carotid artery occlusion) in adult males and females (2- to 4-months old), |
Nervous system |
| X885 |
16389 |
Infarct volume in neocortex, binary score, following experimental stroke (permanent middle cerebral artery and ipsilateral common carotid artery occlusion) in adult males and females (2- to 4-months old), 24 |
Nervous system |
| X2908 |
16600 |
Infant vocalization, mean peak frequency of call on day 9 (Avisoft analysis software), mixed sexes from 2 to 5 litters [kHz] |
Nervous system |
| X2486 |
16601 |
Infant vocalization, duration of call, days P7-9 combined (AviSoft analysis software), mixed sexes from 2 to 5 litters [msec] |
Nervous system |
| X1275 |
16602 |
Infant vocalization, mean peak frequency, P7 to 9 combined (Avisoft analysis software), mixed sexes from 2 to 5 litters [kHz] |
Nervous system |
| X2351 |
16603 |
Infant vocalization, peak amplitude, days P7-9 combined (Avisoft analysis software), mixed sexes from 2 to 5 litters [dB] |
Nervous system |
| X960 |
16609 |
Trpc3 mRNA expression in hippocampus (transient receptor potential cation channel, subfamily C, member 3), first principal component generated using exon probe sets and with high expression (<8.5, covaries well wit |
Nervous system |
| X4498 |
16610 |
Infant vocalization, energy of calls (peak amplitude x duration) on day 7 (AviSoft analysis software), mixed sexes from 2 to 5 litters (BXD89 winsorised from -2.223 to -1.55 [dBsec] |
Nervous system |
| X3346 |
16611 |
Infant vocalization, energy of calls (peak amplitude x duration) on day 8 (AviSoft analysis software), mixed sexes from 2 to 5 litters [dBsec] |
Nervous system |
| X2715 |
16612 |
Infant vocalization, energy of calls (peak amplitude x duration) on day 9 (AviSoft analysis software), mixed sexes from 2 to 5 litters [dBsec] |
Nervous system |
| X2791 |
16613 |
Social approach preference assayed using 3-chamber paradigm, time spent with social partner minus time spent in chamber with an empty wire cup [sec] |
Nervous system |
| X3957 |
16614 |
Whole body sniffing, time subject male sniffed unfamiliar juvenile male during direct social interaction trial [sec] |
Nervous system |
| X2699 |
16616 |
Ultrasonic vocalizations (USV) emitted by subject adult male (10 to 16 weeks) during direct social interaction with an unfamiliar juvenile male (3 to 4 weeks) over a 6 min interval [n] |
Nervous system |
| X4448 |
16617 |
Infant vocalization, energy of calls (peak amplitude x duration), combined (P7 to P9) (AviSoft analysis software), [dBsec] |
Nervous system |
| X4375 |
18007 |
Midbrain taurine level in adult females [ug/mg protein] |
Nervous system |
| X4131 |
16621 |
Infant vocalization, body weight on day 7 to 9 combined, mixed sexes from 2 to 5 litters [gm] |
Nervous system |
| X4782 |
16965 |
Eigentrait for TRPC3 expression generated using exon 1, exon 1 or 5' UTR, 3' UTR, exon 6, and exon 8 [PC score] |
Nervous system |
| X3864 |
16966 |
Trpc3 mRNA expression in hippocampus (transient receptor potential cation channel, subfamily C, member 3), first principal component generated using exon probe sets 5115892 (exon 6), 4650080 (exon 5), 4674708 (exon |
Nervous system |
| X1930 |
16967 |
Mep1b eigentrait generated using probe sets 4972258 (exon 7), 4627542 (exon 9), 4977437 (5' UTR), 5091054 (exon 10), 4557674 (exon 11), all verified to be SNP-free and with expression greater than 7 unit using UMUT |
Nervous system |
| X866 |
16968 |
Cell death in otic vesicles following exposure to ethanol at E9 [TUNEL+ cells/mm2] |
Nervous system |
| X1314 |
16969 |
Cell death in otic vesicles following exposure to maltose dextrin at E9 [TUNEL+ cells/mm2] |
Nervous system |
| X1761 |
16970 |
;Central nervous system;; embryonic neurogenesis;; Cell death in otic vesicles following exposure to ethanol at E9 (TUNEL+ cells/mm2); |
Nervous system |
| X947 |
17082 |
Brain activity and coherences of electrical field oscillations with respiratory rhythm, coherence at 1 Hz between local field potential in L2/3 of the primary whisker motor cortex an |
Nervous system |
| X1312 |
17083 |
Brain activity and coherences of electrical field oscillations with respiratory rhythm, coherence at 2 Hz between local field potential in L2/3 of the primary whisker motor cortex an |
Nervous system |
| X2610 |
17084 |
Brain activity and coherences of electrical field oscillations with respiratory rhythm, coherence at 3 Hz between local field potential in L2/3 of the primary whisker motor cortex an |
Nervous system |
| X2268 |
17085 |
Brain activity and coherences of electrical field oscillations with respiratory rhythm, coherence at 4 Hz between local field potential in L2/3 of the primary whisker motor cortex an |
Nervous system |
| X895 |
17086 |
Brain activity and coherences of electrical field oscillations with respiratory rhythm, coherence at 5 Hz between local field potential in L2/3 of the primary whisker motor cortex an |
Nervous system |
| X839 |
17087 |
Brain activity and coherences of electrical field oscillations with respiratory rhythm, coherence at 6 Hz between local field potential in L2/3 of the primary whisker motor cortex an |
Nervous system |
| X2021 |
17088 |
Brain activity and coherences of electrical field oscillations with respiratory rhythm, coherence at 7 Hz between local field potential in L2/3 of the primary whisker motor cortex an |
Nervous system |
| X2288 |
17089 |
Brain activity and coherences of electrical field oscillations with respiratory rhythm, coherence at 8 Hz between local field potential in L2/3 of the primary whisker motor cortex an |
Nervous system |
| X2429 |
17090 |
Brain activity and coherences of electrical field oscillations with respiratory rhythm, coherence at 9 Hz between local field potential in L2/3 of the primary whisker motor cortex an |
Nervous system |
| X359 |
17091 |
Brain activity and coherences of electrical field oscillations with respiratory rhythm, coherence at 10 Hz between local field potential in L2/3 of the primary whisker motor cortex a |
Nervous system |
| X3390 |
17092 |
Brain activity and coherences of electrical field oscillations with respiratory rhythm, coherence at 11 Hz between local field potential in L2/3 of the primary whisker motor cortex a |
Nervous system |
| X684 |
17093 |
Brain activity and coherences of electrical field oscillations with respiratory rhythm, coherence at 12 Hz between local field potential in L2/3 of the primary whisker motor cortex a |
Nervous system |
| X812 |
17094 |
Brain activity and coherences of electrical field oscillations with respiratory rhythm, coherence at 13 Hz between local field potential in L2/3 of the primary whisker motor cortex a |
Nervous system |
| X150 |
17095 |
Brain activity and coherences of electrical field oscillations with respiratory rhythm, coherence at 14 Hz between local field potential in L2/3 of the primary whisker motor cortex a |
Nervous system |
| X1159 |
17096 |
Brain activity and coherences of electrical field oscillations with respiratory rhythm, coherence at 15 Hz between local field potential in L2/3 of the primary whisker motor cortex a |
Nervous system |
| X581 |
17097 |
Brain activity and coherences of electrical field oscillations with respiratory rhythm, coherence at 16 Hz between local field potential in L2/3 of the primary whisker motor cortex a |
Nervous system |
| X547 |
17098 |
Brain activity and coherences of electrical field oscillations with respiratory rhythm, coherence at 17 Hz between local field potential in L2/3 of the primary whisker motor cortex a |
Nervous system |
| X862 |
17099 |
Brain activity and coherences of electrical field oscillations with respiratory rhythm, coherence at 18 Hz between local field potential in L2/3 of the primary whisker motor cortex a |
Nervous system |
| X1316 |
17100 |
Brain activity and coherences of electrical field oscillations with respiratory rhythm, coherence at 19 Hz between local field potential in L2/3 of the primary whisker motor cortex a |
Nervous system |
| X197 |
17101 |
Brain activity and coherences of electrical field oscillations with respiratory rhythm, coherence at 20 Hz between local field potential in L2/3 of the primary whisker motor cortex a |
Nervous system |
| X159 |
17102 |
Brain activity and coherences of electrical field oscillations with respiratory rhythm, coherence at 21 Hz between local field potential in L2/3 of the primary whisker motor cortex a |
Nervous system |
| X2331 |
17103 |
Brain activity and coherences of electrical field oscillations with respiratory rhythm, coherence at 22 Hz between local field potential in L2/3 of the primary whisker motor cortex a |
Nervous system |
| X3536 |
17104 |
Brain activity and coherences of electrical field oscillations with respiratory rhythm, coherence at 23 Hz between local field potential in L2/3 of the primary whisker motor cortex a |
Nervous system |
| X1121 |
17105 |
Brain activity and coherences of electrical field oscillations with respiratory rhythm, coherence at 24 Hz between local field potential in L2/3 of the primary whisker motor cortex a |
Nervous system |
| X1257 |
17106 |
Brain activity and coherences of electrical field oscillations with respiratory rhythm, coherence at 25 Hz between local field potential in L2/3 of the primary whisker motor cortex a |
Nervous system |
| X2241 |
17969 |
Blood 5-hydroxytryptamine turnover rates (5-HIAA/5-HT) in adult males [units] |
Nervous system |
| X3529 |
17107 |
Brain activity and coherence of electrical field oscillations, coherence at 1 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 t |
Nervous system |
| X2758 |
17108 |
Brain activity and coherence of electrical field oscillations, coherence at 2 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 t |
Nervous system |
| X2926 |
17109 |
Brain activity and coherence of electrical field oscillations, coherence at 3 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 t |
Nervous system |
| X905 |
17110 |
Brain activity and coherence of electrical field oscillations, coherence at 4 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 t |
Nervous system |
| X1799 |
17111 |
Brain activity and coherence of electrical field oscillations, coherence at 5 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 t |
Nervous system |
| X1346 |
17112 |
Brain activity and coherence of electrical field oscillations, coherence at 6 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 t |
Nervous system |
| X1564 |
17113 |
Brain activity and coherence of electrical field oscillations, coherence at 7 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 t |
Nervous system |
| X718 |
17114 |
Brain activity and coherence of electrical field oscillations, coherence at 8 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 t |
Nervous system |
| X283 |
17115 |
Brain activity and coherence of electrical field oscillations, coherence at 9 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 t |
Nervous system |
| X147 |
17116 |
Brain activity and coherence of electrical field oscillations, coherence at 10 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X95 |
17117 |
Brain activity and coherence of electrical field oscillations, coherence at 11 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X280 |
17118 |
Brain activity and coherence of electrical field oscillations, coherence at 12 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X1789 |
17119 |
Brain activity and coherence of electrical field oscillations, coherence at 13 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X337 |
17120 |
Brain activity and coherence of electrical field oscillations, coherence at 14 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X204 |
17121 |
Brain activity and coherence of electrical field oscillations, coherence at 15 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X230 |
17122 |
Brain activity and coherence of electrical field oscillations, coherence at 16 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X208 |
17123 |
Brain activity and coherence of electrical field oscillations, coherence at 17 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X160 |
17124 |
Brain activity and coherence of electrical field oscillations, coherence at 18 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X174 |
17125 |
Brain activity and coherence of electrical field oscillations, coherence at 19 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X184 |
17126 |
Brain activity and coherence of electrical field oscillations, coherence at 20 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X344 |
17127 |
Brain activity and coherence of electrical field oscillations, coherence at 21 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X503 |
17128 |
Brain activity and coherence of electrical field oscillations, coherence at 22 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X498 |
17129 |
Brain activity and coherence of electrical field oscillations, coherence at 23 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X952 |
17130 |
Brain activity and coherence of electrical field oscillations, coherence at 24 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X754 |
17131 |
Brain activity and coherence of electrical field oscillations, coherence at 25 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X279 |
17132 |
Brain activity and coherence of electrical field oscillations, coherence at 26 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X287 |
17133 |
Brain activity and coherence of electrical field oscillations, coherence at 27 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X393 |
17134 |
Brain activity and coherence of electrical field oscillations, coherence at 28 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X1466 |
17135 |
Brain activity and coherence of electrical field oscillations, coherence at 29 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X1780 |
17136 |
Brain activity and coherence of electrical field oscillations, coherence at 30 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X350 |
17137 |
Brain activity and coherence of electrical field oscillations, coherence at 31 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X1238 |
17138 |
Brain activity and coherence of electrical field oscillations, coherence at 32 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X2096 |
17139 |
Brain activity and coherence of electrical field oscillations, coherence at 33 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X1370 |
17140 |
Brain activity and coherence of electrical field oscillations, coherence at 34 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X430 |
17141 |
Brain activity and coherence of electrical field oscillations, coherence at 35 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X473 |
17142 |
Brain activity and coherence of electrical field oscillations, coherence at 36 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X717 |
17143 |
Brain activity and coherence of electrical field oscillations, coherence at 37 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X588 |
17144 |
Brain activity and coherence of electrical field oscillations, coherence at 38 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X886 |
17145 |
Brain activity and coherence of electrical field oscillations, coherence at 39 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X2800 |
17146 |
Brain activity and coherence of electrical field oscillations, coherence at 40 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X2189 |
17147 |
Brain activity and coherence of electrical field oscillations, coherence at 41 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X1277 |
17148 |
Brain activity and coherence of electrical field oscillations, coherence at 42 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X1828 |
17149 |
Brain activity and coherence of electrical field oscillations, coherence at 43 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X938 |
17150 |
Brain activity and coherence of electrical field oscillations, coherence at 44 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X1305 |
17151 |
Brain activity and coherence of electrical field oscillations, coherence at 45 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X3517 |
17152 |
Brain activity and coherence of electrical field oscillations, coherence at 46 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X2647 |
17153 |
Brain activity and coherence of electrical field oscillations, coherence at 47 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X3067 |
17154 |
Brain activity and coherence of electrical field oscillations, coherence at 48 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X3031 |
17155 |
Brain activity and coherence of electrical field oscillations, coherence at 49 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X3335 |
17156 |
Brain activity and coherence of electrical field oscillations, coherence at 50 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X2531 |
17157 |
Brain activity and coherence of electrical field oscillations, coherence at 51 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X1771 |
17158 |
Brain activity and coherence of electrical field oscillations, coherence at 52 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X3794 |
17159 |
Brain activity and coherence of electrical field oscillations, coherence at 53 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X3563 |
17160 |
Brain activity and coherence of electrical field oscillations, coherence at 54 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X2898 |
17161 |
Brain activity and coherence of electrical field oscillations, coherence at 55 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X1519 |
17162 |
Brain activity and coherence of electrical field oscillations, coherence at 56 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X653 |
17163 |
Brain activity and coherence of electrical field oscillations, coherence at 57 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X2078 |
17164 |
Brain activity and coherence of electrical field oscillations, coherence at 58 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X1088 |
17165 |
Brain activity and coherence of electrical field oscillations, coherence at 59 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X881 |
17166 |
Brain activity and coherence of electrical field oscillations, coherence at 60 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X1935 |
17167 |
Brain activity and coherence of electrical field oscillations, coherence at 61 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X1424 |
17168 |
Brain activity and coherence of electrical field oscillations, coherence at 62 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X1187 |
17169 |
Brain activity and coherence of electrical field oscillations, coherence at 63 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X1409 |
17170 |
Brain activity and coherence of electrical field oscillations, coherence at 64 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X755 |
17171 |
Brain activity and coherence of electrical field oscillations, coherence at 65 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X689 |
17172 |
Brain activity and coherence of electrical field oscillations, coherence at 66 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X598 |
17173 |
Brain activity and coherence of electrical field oscillations, coherence at 67 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X616 |
17174 |
Brain activity and coherence of electrical field oscillations, coherence at 68 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X788 |
17175 |
Brain activity and coherence of electrical field oscillations, coherence at 69 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X757 |
17176 |
Brain activity and coherence of electrical field oscillations, coherence at 70 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X850 |
17177 |
Brain activity and coherence of electrical field oscillations, coherence at 71 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X1810 |
17178 |
Brain activity and coherence of electrical field oscillations, coherence at 72 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X4679 |
17179 |
Brain activity and coherence of electrical field oscillations, coherence at 73 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X4433 |
17180 |
Brain activity and coherence of electrical field oscillations, coherence at 74 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X3910 |
17181 |
Brain activity and coherence of electrical field oscillations, coherence at 75 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X3254 |
17182 |
Brain activity and coherence of electrical field oscillations, coherence at 76 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X2265 |
17183 |
Brain activity and coherence of electrical field oscillations, coherence at 77 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X3224 |
17184 |
Brain activity and coherence of electrical field oscillations, coherence at 78 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X4611 |
17185 |
Brain activity and coherence of electrical field oscillations, coherence at 79 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X4979 |
17186 |
Brain activity and coherence of electrical field oscillations, coherence at 80 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X4855 |
17187 |
Brain activity and coherence of electrical field oscillations, coherence at 81 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X4822 |
17188 |
Brain activity and coherence of electrical field oscillations, coherence at 82 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X4767 |
17189 |
Brain activity and coherence of electrical field oscillations, coherence at 83 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X4828 |
17190 |
Brain activity and coherence of electrical field oscillations, coherence at 84 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X3345 |
17191 |
Brain activity and coherence of electrical field oscillations, coherence at 85 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X3880 |
17192 |
Brain activity and coherence of electrical field oscillations, coherence at 86 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X1024 |
17193 |
Brain activity and coherence of electrical field oscillations, coherence at 87 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X434 |
17194 |
Brain activity and coherence of electrical field oscillations, coherence at 88 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X2255 |
17195 |
Brain activity and coherence of electrical field oscillations, coherence at 89 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X4067 |
17196 |
Brain activity and coherence of electrical field oscillations, coherence at 90 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X2747 |
17197 |
Brain activity and coherence of electrical field oscillations, coherence at 91 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X469 |
17198 |
Brain activity and coherence of electrical field oscillations, coherence at 92 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X402 |
17199 |
Brain activity and coherence of electrical field oscillations, coherence at 93 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X2192 |
17200 |
Brain activity and coherence of electrical field oscillations, coherence at 94 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X2124 |
17201 |
Brain activity and coherence of electrical field oscillations, coherence at 95 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X4600 |
17202 |
Brain activity and coherence of electrical field oscillations, coherence at 96 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X1713 |
17203 |
Brain activity and coherence of electrical field oscillations, coherence at 97 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X4804 |
17204 |
Brain activity and coherence of electrical field oscillations, coherence at 98 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X4582 |
17205 |
Brain activity and coherence of electrical field oscillations, coherence at 99 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X1746 |
17206 |
Brain activity and coherence of electrical field oscillations, coherence at 100 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X3530 |
17207 |
Brain activity and coherence of electrical field oscillations, coherence at 101 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X1052 |
17208 |
Brain activity and coherence of electrical field oscillations, coherence at 102 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X3174 |
17209 |
Brain activity and coherence of electrical field oscillations, coherence at 103 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X4806 |
17210 |
Brain activity and coherence of electrical field oscillations, coherence at 104 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X4400 |
17211 |
Brain activity and coherence of electrical field oscillations, coherence at 105 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X3907 |
17212 |
Brain activity and coherence of electrical field oscillations, coherence at 106 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X1356 |
17213 |
Brain activity and coherence of electrical field oscillations, coherence at 107 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X3243 |
17214 |
Brain activity and coherence of electrical field oscillations, coherence at 108 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X3505 |
17215 |
Brain activity and coherence of electrical field oscillations, coherence at 109 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X1467 |
17216 |
Brain activity and coherence of electrical field oscillations, coherence at 110 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X485 |
17217 |
Brain activity and coherence of electrical field oscillations, coherence at 111 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X864 |
17218 |
Brain activity and coherence of electrical field oscillations, coherence at 112 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X750 |
17219 |
Brain activity and coherence of electrical field oscillations, coherence at 113 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X2320 |
17220 |
Brain activity and coherence of electrical field oscillations, coherence at 114 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X3127 |
17221 |
Brain activity and coherence of electrical field oscillations, coherence at 115 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X3060 |
17222 |
Brain activity and coherence of electrical field oscillations, coherence at 116 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X3222 |
17223 |
Brain activity and coherence of electrical field oscillations, coherence at 117 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X4519 |
17224 |
Brain activity and coherence of electrical field oscillations, coherence at 118 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X2996 |
17225 |
Brain activity and coherence of electrical field oscillations, coherence at 119 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X3438 |
17226 |
Brain activity and coherence of electrical field oscillations, coherence at 120 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X120 |
17227 |
Brain activity and coherence of electrical field oscillations, coherence at 121 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X2445 |
17228 |
Brain activity and coherence of electrical field oscillations, coherence at 122 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X1380 |
17229 |
Brain activity and coherence of electrical field oscillations, coherence at 123 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X465 |
17230 |
Brain activity and coherence of electrical field oscillations, coherence at 124 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X1167 |
17231 |
Brain activity and coherence of electrical field oscillations, coherence at 125 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X744 |
17232 |
Brain activity and coherence of electrical field oscillations, coherence at 126 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X550 |
17233 |
Brain activity and coherence of electrical field oscillations, coherence at 127 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X510 |
17234 |
Brain activity and coherence of electrical field oscillations, coherence at 128 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X879 |
17235 |
Brain activity and coherence of electrical field oscillations, coherence at 129 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X1046 |
17236 |
Brain activity and coherence of electrical field oscillations, coherence at 130 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X538 |
17237 |
Brain activity and coherence of electrical field oscillations, coherence at 131 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X534 |
17238 |
Brain activity and coherence of electrical field oscillations, coherence at 132 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X1459 |
17239 |
Brain activity and coherence of electrical field oscillations, coherence at 133 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X4143 |
17240 |
Brain activity and coherence of electrical field oscillations, coherence at 134 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X4620 |
17241 |
Brain activity and coherence of electrical field oscillations, coherence at 135 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X1415 |
17242 |
Brain activity and coherence of electrical field oscillations, coherence at 136 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X963 |
17243 |
Brain activity and coherence of electrical field oscillations, coherence at 137 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X898 |
17244 |
Brain activity and coherence of electrical field oscillations, coherence at 138 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X1483 |
17245 |
Brain activity and coherence of electrical field oscillations, coherence at 139 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X3949 |
17246 |
Brain activity and coherence of electrical field oscillations, coherence at 140 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X4301 |
17247 |
Brain activity and coherence of electrical field oscillations, coherence at 141 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X3034 |
17248 |
Brain activity and coherence of electrical field oscillations, coherence at 142 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X2012 |
17249 |
Brain activity and coherence of electrical field oscillations, coherence at 143 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X1104 |
17250 |
Brain activity and coherence of electrical field oscillations, coherence at 144 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X1531 |
17251 |
Brain activity and coherence of electrical field oscillations, coherence at 145 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X1162 |
17252 |
Brain activity and coherence of electrical field oscillations, coherence at 146 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X3269 |
17253 |
Brain activity and coherence of electrical field oscillations, coherence at 147 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X1798 |
17254 |
Brain activity and coherence of electrical field oscillations, coherence at 148 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X1533 |
17255 |
Brain activity and coherence of electrical field oscillations, coherence at 149 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X305 |
17256 |
Brain activity and coherence of electrical field oscillations, coherence at 150 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X356 |
17257 |
Brain activity and coherence of electrical field oscillations, coherence at 151 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X791 |
17258 |
Brain activity and coherence of electrical field oscillations, coherence at 152 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X301 |
17259 |
Brain activity and coherence of electrical field oscillations, coherence at 153 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X427 |
17260 |
Brain activity and coherence of electrical field oscillations, coherence at 154 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X409 |
17261 |
Brain activity and coherence of electrical field oscillations, coherence at 155 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X1634 |
17262 |
Brain activity and coherence of electrical field oscillations, coherence at 156 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X206 |
17263 |
Brain activity and coherence of electrical field oscillations, coherence at 157 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X422 |
17264 |
Brain activity and coherence of electrical field oscillations, coherence at 158 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X2474 |
17265 |
Brain activity and coherence of electrical field oscillations, coherence at 159 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X1985 |
17266 |
Brain activity and coherence of electrical field oscillations, coherence at 160 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X1216 |
17267 |
Brain activity and coherence of electrical field oscillations, coherence at 161 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X1028 |
17268 |
Brain activity and coherence of electrical field oscillations, coherence at 162 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X688 |
17269 |
Brain activity and coherence of electrical field oscillations, coherence at 163 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X1182 |
17270 |
Brain activity and coherence of electrical field oscillations, coherence at 164 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X906 |
17271 |
Brain activity and coherence of electrical field oscillations, coherence at 165 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X334 |
17272 |
Brain activity and coherence of electrical field oscillations, coherence at 166 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X678 |
17273 |
Brain activity and coherence of electrical field oscillations, coherence at 167 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X1377 |
17274 |
Brain activity and coherence of electrical field oscillations, coherence at 168 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X759 |
17275 |
Brain activity and coherence of electrical field oscillations, coherence at 169 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X1840 |
17276 |
Brain activity and coherence of electrical field oscillations, coherence at 170 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X2018 |
17277 |
Brain activity and coherence of electrical field oscillations, coherence at 171 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X210 |
17278 |
Brain activity and coherence of electrical field oscillations, coherence at 172 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X834 |
17279 |
Brain activity and coherence of electrical field oscillations, coherence at 173 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X1738 |
17280 |
Brain activity and coherence of electrical field oscillations, coherence at 174 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X1403 |
17281 |
Brain activity and coherence of electrical field oscillations, coherence at 175 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X878 |
17282 |
Brain activity and coherence of electrical field oscillations, coherence at 176 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X2374 |
17283 |
Brain activity and coherence of electrical field oscillations, coherence at 177 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X2344 |
17284 |
Brain activity and coherence of electrical field oscillations, coherence at 178 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X1554 |
17285 |
Brain activity and coherence of electrical field oscillations, coherence at 179 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X478 |
17286 |
Brain activity and coherence of electrical field oscillations, coherence at 180 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X1784 |
17287 |
Brain activity and coherence of electrical field oscillations, coherence at 181 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X721 |
17288 |
Brain activity and coherence of electrical field oscillations, coherence at 182 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X258 |
17289 |
Brain activity and coherence of electrical field oscillations, coherence at 183 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X392 |
17290 |
Brain activity and coherence of electrical field oscillations, coherence at 184 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X367 |
17291 |
Brain activity and coherence of electrical field oscillations, coherence at 185 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X110 |
17292 |
Brain activity and coherence of electrical field oscillations, coherence at 186 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X135 |
17293 |
Brain activity and coherence of electrical field oscillations, coherence at 187 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X564 |
17294 |
Brain activity and coherence of electrical field oscillations, coherence at 188 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X1240 |
17295 |
Brain activity and coherence of electrical field oscillations, coherence at 189 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X668 |
17296 |
Brain activity and coherence of electrical field oscillations, coherence at 190 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X3835 |
17297 |
Brain activity and coherence of electrical field oscillations, coherence at 191 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X965 |
17298 |
Brain activity and coherence of electrical field oscillations, coherence at 192 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X490 |
17299 |
Brain activity and coherence of electrical field oscillations, coherence at 193 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X452 |
17300 |
Brain activity and coherence of electrical field oscillations, coherence at 194 Hz between local field potentials (LFP) at two sites (0.3 mm apart) in L2/3 of the primary whisker motor cortex in awake 6 |
Nervous system |
| X1712 |
17301 |
PCA trait 1 that maps to Chr 1 in the Qrr1 interval (used for statistical control) [PC value] |
Nervous system |
| X664 |
17971 |
Blood 5-hydroxyindoleacetic acid (5-HIAA) level in adult females [pg/ul] |
Nervous system |
| X4088 |
17302 |
Cell proliferation in culture, percentage of cells incorporating BrdU (BXD2 winsorized from 52.77% to 44.0%) [%] |
Nervous system |
| X1696 |
17303 |
Neuron differentiation in culture, percentage of cells staining for Map2 (BXD86 winsorized from 36.43% to 21.0%, BXD33 from 23.66% to 20%) [%] |
Nervous system |
| X4196 |
17304 |
Astrocyte differentiation in culture, percentage of cells staining for GFAP (BXD48a winsorised from 42.59% to 59.0% and BXD51 from 85.67% to 78.0%) [%] |
Nervous system |
| X4572 |
17305 |
Central nervous system, endocrinology, Air control response, 3a,5a-tetrahydroprogesterone (3a,5a-THP or allopregnanolone) in plasma 72 h after the 5th cycle of chronic intermittent air control in 16 to 18 week-old males and/or females (20 |
Nervous system |
| X3030 |
17306 |
Central nervous system, endocrinology, chronic intermittent ethanol response, 3a,5a-tetrahydroprogesterone (3a,5a-THP or allopregnanolone) in plasma 72 h after the 5th cycle of chronic intermittent ethanol in 16 to 18 week-old males and/o |
Nervous system |
| X2212 |
17339 |
Withdrawal nociception assay after 7 days of nicotine treatment (24 mg/kg/day, s.c. minipump) and day 8 saline injection or mecamylamine (2.0 mg/kg, s.c.), difference in hot plate latency (saline - mecamylam |
Nervous system |
| X4629 |
17340 |
Central nervous system, pharmacology,; behavior;; Withdrawal nociception assay;, 7-day nicotine treatment (24 mg/kg/day, s.c. minipump) + day 8 saline (0.01mL/g, s.c.) or mecamylamine (2.0 mg/kg, s.c.), difference in activity (saline - mecamylamine) (sec) |
Nervous system |
| X3922 |
17341 |
Nicotine response (0.5 mg/kg, s.c., b.i.d., on days 1), locomotor difference in CPP box (saline - nicotine) in 7-8-week old males |
Nervous system |
| X5010 |
17342 |
Nicotine response (0.5 mg/kg, s.c., b.i.d., on days 5), locomotor difference in CPP box (saline - nicotine) on day 5 in 7-8-week old males |
Nervous system |
| X2653 |
17344 |
Eigentrait for Cadm1 expression generated from probes that are SNP-free across BXDs using BXD Aged Hippocampus rev3 Affy Mouse Gene 1.0 ST (Sep12) RMA [PC Score] |
Nervous system |
| X4259 |
17347 |
Cell proliferation in culture, percentage of cells incorporating BrdU [%] |
Nervous system |
| X4929 |
17348 |
Neuron differentiation in culture, percentage of cells staining for Map2 [%] |
Nervous system |
| X5022 |
17349 |
Astrocyte differentiation in culture, percentage of cells staining for GFAP [%] |
Nervous system |
| X1597 |
17352 |
Spontaneous activity, infrared beam breaks in a touchscreen chamber in 30 minutes in 2.5 to 3.5-month-old females [n breaks] |
Nervous system |
| X846 |
17353 |
Spontaneous activity, traversals (e.g., front to back to front) of a touchscreen chamber in 30 minutes in 2.5 to 3.5-month-old females [n traversals] |
Nervous system |
| X1114 |
17354 |
Spontaneous activity, touchscreen touches in 30 minutes in 2.5 to 3.5-month-old females [n touches] |
Nervous system |
| X1841 |
17355 |
Spontaneous activity, magazine entries in a touchscreen chamber in 30 minutes in 2.5 to 3.5-month-old females [n entries] |
Nervous system |
| X408 |
17357 |
Gabra1 mRNA expression (Chr 11 at 42 Mb), first principal component from whole brain RNA-seq of 28 strains [PC1 value] |
Nervous system |
| X4713 |
17387 |
Object-location paired-associates learning in 2.5 to 4-month-old females using a touchscreen assay, sessions required to reach the learning criterion during pre-training phase 2 (touch phase, animals |
Nervous system |
| X5067 |
17388 |
Object-location paired-associates learning in 2.5 to 4-month-old females using a touchscreen assay, sessions required to reach the learning criterion during pre-training phase 3a (initiation phase, an |
Nervous system |
| X2309 |
17389 |
Object-location paired-associates learning in 2.5 to 4-month-old females using a touchscreen assay, sessions required to reach the learning criterion during pre-training phase 3b (punish phase, animal |
Nervous system |
| X4708 |
17390 |
Ethanol-induced conditioned taste aversion, saccharin intake during trial 1 before first saline control injection (Group 0 g/kg) in 60 to 130-day-old males (from Table 1, upper left panel, left column) [ml] |
Nervous system |
| X3782 |
17391 |
Ethanol-induced conditioned taste aversion, saccharin intake during trials 2-4 after saline control injections (Group 0 g/kg) in 60 to 130-day-old males (from Table 1, upper left panel, middle column) [ml] |
Nervous system |
| X2594 |
17393 |
Ethanol-induced conditioned taste aversion, saccharin intake during trials 2-4 after saline control injections expressed as a residual (regression of mean intake score on trail 1 intakes) (Group 0 g/kg) in 60 to 130-day-o |
Nervous system |
| X4063 |
17395 |
Ethanol-induced conditioned taste aversion, saccharin intake during trial 1 before first 2 g/kg ethanol injection (Group 2 g/kg) in 60 to 130-day-old males (from Table 1, lower left panel, left column) [ml] |
Nervous system |
| X2843 |
17396 |
Ethanol-induced conditioned taste aversion, saccharin intake during trials 2-4 after 2 g/kg ethanol injections (Group 2 g/kg) in 60 to 130-day-old males (from Table 1, lower left panel, middle column)[ml] |
Nervous system |
| X3660 |
17397 |
Ethanol-induced conditioned taste aversion, saccharin intake during trials 2-4 after 2 g/kg ethanol injections expressed as a residual (regression of mean intake scores on trial 1 intakes) (Group 2 g/kg) in 60 to 130-day- |
Nervous system |
| X4265 |
17398 |
Ethanol-induced conditioned taste aversion, saccharin intake during trial 1 before first 4 g/kg ethanol injection (Group 4 g/kg) in 60 to 130-day-old males (from Table 1, upper right panel, left column) [ml] |
Nervous system |
| X2729 |
17399 |
Ethanol-induced conditioned taste aversion, saccharin intake during trials 2-4 after 4 g/kg ethanol injections (Group 4 g/kg) in 60 to 130-day-old males (from Table 1, upper right pa |
Nervous system |
| X3023 |
17402 |
Ethanol-induced conditioned taste aversion, saccharin intake during trials 2-4 after 4 g/kg ethanol injections expressed as a residual (regression of mean intake scores on trial 1 intakes)(Group 4 g/kg) in 60 to 130-day-o |
Nervous system |
| X2193 |
17403 |
Ethanol-induced conditioned taste aversion, saccharin intake during trial 1 before first unpaired 4 g/kg ethanol injections (Group UP) in 60 to 130-day-old males (from Table 1, lower right panel, left column) [ml] |
Nervous system |
| X2165 |
17405 |
Ethanol-induced conditioned taste aversion, saccharin intake during trials 2-4 after unpaired 4 g/kg ethanol injections (Group UP) in 60 to 130-day-old males (from Table 1, lower right panel, middle column) [ml] |
Nervous system |
| X4418 |
17407 |
Ethanol-induced conditioned taste aversion, saccharin intake during trials 2-4 after unpaired 4 g/kg ethanol injections expressed as a residual (regression of mean intake scores on trial 2 intakes) (Group UP) in 60 to 130 |
Nervous system |
| X3410 |
17409 |
Striatum (caudate putamen) neuron number, bilateral, both sexes between 50 and 300 days, using the optical disector [n x 10^6] |
Nervous system |
| X4244 |
17410 |
Striatum (caudate putamen) non-neuronal number, bilateral, both sexes between 50 and 300 days, using the optical disector [n x 10^6] |
Nervous system |
| X3875 |
17411 |
Striatum (caudate putamen) total cell number, bilateral, both sexes between 50 and 300 days, using the optical disector [n x 10^6] |
Nervous system |
| X1853 |
17412 |
Striatum (caudate putamen) volume, shrinkage corrected, bilateral, both sexes between 50 and 300 days, using the Cavalieri probe [mm3] |
Nervous system |
| X2249 |
17413 |
Striatum (caudate putamen) neuron cell packing density, bilateral, both sexes between 50 and 300 days, using the optical disector [cells/mm3 x 10^3] |
Nervous system |
| X3618 |
17414 |
Striatum (caudate putamen) non-neuronal cell packing density, bilateral, both sexes between 50 and 300 days, using the optical disector [cells/mm3 x 10^3] |
Nervous system |
| X2606 |
17415 |
Striatum (caudate putamen) total cell packing density, bilateral, both sexes between 50 and 300 days, using the optical disector [cells/mm3 x 10^3] |
Nervous system |
| X3425 |
17416 |
Striatum (caudate putamen) neuron number corrected for age, sex, plane of section, and brain weight, bilateral, both sexes between 50 and 300 days, using the optical disector [n x 10^6] |
Nervous system |
| X3333 |
17417 |
Striatum (caudate putamen) non-neuronal number corrected for age, sex, plane of section, and brain weight, bilateral, both sexes between 50 and 300 days, using the optical disector [n x 10^6] |
Nervous system |
| X3088 |
17418 |
Striatum (caudate putamen) total cell number corrected for age, sex, plane of section, and brain weight, bilateral, both sexes between 50 and 300 days, using the optical disector [n x 10^6] |
Nervous system |
| X190 |
17419 |
Striatum (caudate putamen) volume, shrinkage corrected and corrected for age, sex, plane of section, and brain weight, bilateral, both sexes between 50 and 300 days, using Cavalieri probes [mm3] |
Nervous system |
| X3633 |
17420 |
Striatum (caudate putamen) neuron cell packing density corrected for age, sex, plane of section, and brain weight, bilateral, both sexes between 50 and 300 days, using the optical disector [cells/mm3 x 10^3] |
Nervous system |
| X3474 |
17421 |
Striatum (caudate putamen) non-neuronal cell packing density corrected for age, sex, plane of section, and brain weight, bilateral, both sexes between 50 and 300 days, using the optical disector [cells/mm3 x 10^3] |
Nervous system |
| X2959 |
17422 |
Striatum (caudate putamen) total cell packing density corrected for age, sex, plane of section, and brain weight, bilateral, both sexes between 50 and 300 days, using the optical disector [cells/mm3 x 10^3] |
Nervous system |
| X3004 |
17423 |
Neocortex neuron number, bilateral, both sexes between 50 and 300 days, using the optical disector [n x 10^6] |
Nervous system |
| X3792 |
17424 |
Neocortex non-neuron number, bilateral, both sexes between 50 and 300 days, using the optical disector [n x 10^6] |
Nervous system |
| X2966 |
17425 |
Neocortex total cell number, bilateral, both sexes between 50 and 300 days, using the optical disector [n x 10^6] |
Nervous system |
| X2172 |
17426 |
Neocortex volume, shrinkage corrected, bilateral, both sexes between 50 and 300 days, using the Cavalieri probe [mm3] |
Nervous system |
| X1303 |
17427 |
Neocortex neuron cell packing density, bilateral, both sexes between 50 and 300 days, using the optical disector [cells/mm3 x 10^3] |
Nervous system |
| X1460 |
17428 |
Neocortex non-neuronal cell packing density, bilateral, both sexes between 50 and 300 days, using the optical disector [cells/mm3 x 10^3] |
Nervous system |
| X4282 |
17429 |
Neocortex total cell packing density, bilateral, both sexes between 50 and 300 days, using the optical disector [cells/mm3 x 10^3] |
Nervous system |
| X3773 |
17430 |
Neocortex neuron number corrected for age, sex, plane of section, and brain weight, bilateral, both sexes between 50 and 300 days, using the optical disector [n x 10^6] |
Nervous system |
| X2095 |
17431 |
Neocortex non-neuronal number corrected for age, sex, plane of section, and brain weight, bilateral, both sexes between 50 and 300 days, using the optical disector [n x 10^6] |
Nervous system |
| X4566 |
17432 |
Neocortex total cell number corrected for age, sex, plane of section, and brain weight, bilateral, both sexes between 50 and 300 days, using the optical disector [n x 10^6] |
Nervous system |
| X3162 |
17434 |
Neocortex neuron cell packing density corrected for age, sex, plane of section, and brain weight, bilateral, both sexes between 50 and 300 days, using the optical disector [cells/mm3 x 10^3] |
Nervous system |
| X1593 |
17435 |
Neocortex non-neuronal cell packing density corrected for age, sex, plane of section, and brain weight, bilateral, both sexes between 50 and 300 days, using the optical disector [cells/mm3 x 10^3] |
Nervous system |
| X4626 |
17436 |
Neocortex total cell packing density corrected for age, sex, plane of section, and brain weight, bilateral, both sexes between 50 and 300 days, using the optical disector [cells/mm3 x 10^3] |
Nervous system |
| X3284 |
17448 |
Central nervous system, endocrinology, Air control response, 3a,5a-tetrahydroprogesterone (3a,5a-THP or allopregnanolone) in plasma 72 h after the 5th cycle of chronic intermittent ethanol in 16 to 18 week-old males (2010-2014-2015 data c |
Nervous system |
| X4752 |
17449 |
Central nervous system, endocrinology, Air control response, 3a,5a-tetrahydroprogesterone (3a,5a-THP or allopregnanolone) in plasma 72 h after the 5th cycle of chronic intermittent air control in 16 to 18 week-old females (2010-2014-2015 |
Nervous system |
| X3398 |
17450 |
Central nervous system, endocrinology, chronic intermittent ethanol response, 3a,5a-tetrahydroprogesterone (3a,5a-THP or allopregnanolone) in plasma 72 h after the 5th cycle of chronic intermittent ethanol in 16 to 18 week-old males (2010 |
Nervous system |
| X4341 |
17451 |
Central nervous system, endocrinology, chronic intermittent ethanol response, 3a,5a-tetrahydroprogesterone (3a,5a-THP or allopregnanolone) in plasma 72 h after the 5th cycle of chronic intermittent ethanol in 16 to 18 week-old females (20 |
Nervous system |
| X4712 |
17452 |
Central nervous system, endocrinology, Air control response, 3a,5a-tetrahydrodeoxycorticosterone (3a,5a-THDOC) in plasma 72 h after the 5th cycle of chronic intermittent air control in 16 to 18 week-old males and/or females (2010-2014-201 |
Nervous system |
| X4660 |
17453 |
Central nervous system, endocrinology, Air control response, 3a,5a-tetrahydrodeoxycorticosterone (3a,5a-THDOC) in plasma 72 h after the 5th cycle of chronic intermittent air control in 16 to 18 week-old males (2010-2014-2015 data combined |
Nervous system |
| X4674 |
17455 |
Central nervous system, endocrinology, chronic intermittent ethanol response, 3a,5a-tetrahydrodeoxycorticosterone (3a,5a-THDOC) in plasma 72 h after the 5th cycle of chronic intermittent ethanol in 16 to 18 week-old males and/or females ( |
Nervous system |
| X2707 |
17456 |
Central nervous system, endocrinology, chronic intermittent ethanol response, 3a,5a-tetrahydrodeoxycorticosterone (3a,5a-THDOC) in plasma 72 h after the 5th cycle of chronic intermittent ethanol in 16 to 18 week-old males (2010-2014-2015 |
Nervous system |
| X4120 |
18004 |
Midbrain glutamic acid level in adult females [ug/mg protein] |
Nervous system |
| X4010 |
17457 |
Central nervous system, endocrinology, chronic intermittent ethanol response, 3a,5a-tetrahydrodeoxycorticosterone (3a,5a-THDOC) in plasma 72 h after the 5th cycle of chronic intermittent ethanol in 16 to 18 week-old females (2010-2014-201 |
Nervous system |
| X2205 |
17458 |
Central nervous system, endocrinology, Air control response, Pregnenolone in plasma 72 h after the 5th cycle of chronic intermittent air control in 16 to 18 week-old males and/or females (2010-2014-2015 data combined) [pg/ml] |
Nervous system |
| X2913 |
17459 |
Central nervous system, endocrinology, Air control response, Pregnenolone in plasma 72 h after the 5th cycle of chronic intermittent air control in 16 to 18 week-old males (2010-2014-2015 data combined) [pg/ml] |
Nervous system |
| X3748 |
17460 |
Central nervous system, endocrinology, Air control response, Pregnenolone in plasma 72 h after the 5th cycle of chronic intermittent air control in 16 to 18 week-old females (2010-2014-2015 data combined) [pg/ml] |
Nervous system |
| X636 |
17461 |
Central nervous system, endocrinology, chronic intermittent ethanol response, Pregnenolone in plasma 72 h after the 5th cycle of chronic intermittent ethanol in 16 to 18 week-old males and/or females (2010-2014-2015 data combined) [pg/ml] |
Nervous system |
| X202 |
17462 |
Central nervous system, endocrinology, chronic intermittent ethanol response, Pregnenolone in plasma 72 h after the 5th cycle of chronic intermittent ethanol in 16 to 18 week-old males (2010-2014-2015 data combined) [pg/ml] |
Nervous system |
| X1844 |
17463 |
Central nervous system, endocrinology, chronic intermittent ethanol response, Pregnenolone in plasma 72 h after the 5th cycle of chronic intermittent ethanol in 16 to 18 week-old females (2010-2014-2015 data combined) [pg/ml] |
Nervous system |
| X4069 |
17470 |
Object-location paired-associates learning using a touchscreen assay in 3 to 9-month-old females, overall percentage of trials correct in approximately 1800 training trials, where higher values means |
Nervous system |
| X2716 |
17471 |
Object-location paired-associates learning using a touchscreen assay in 3 to 9-month-old females, percentage of trials correct in the first approximately 900 training trials, where higher values means |
Nervous system |
| X4006 |
17472 |
Object-location paired-associates learning using a touchscreen assay in 3 to 9-month-old females, percentage of trials correct in the final 180 trials at the end of training, where higher values means |
Nervous system |
| X2027 |
17473 |
Object-location paired-associates learning using a touchscreen assay in 3 to 9-month-old females, change in performance when switched to same-objects probe stimuli at end of training (change in percen |
Nervous system |
| X809 |
17483 |
Hilus volume as a percentage of total size of CA3 plus CA4 regions of hippocampus in males at 12 to 14 weeks of age [percent] |
Nervous system |
| X880 |
17487 |
Stratum radiatum volume as a percentage of total size of CA3 plus CA4 regions of hippocampus in males at 12 to 14 weeks of age [percent] |
Nervous system |
| X3906 |
17495 |
Number of errors during an 8-arm radial maze test on day 3 in males at 11 to 13 weeks of age [sec] |
Nervous system |
| X3264 |
17496 |
Number of errors during an 8-arm radial maze test on day 4 in males at 11 to 13 weeks of age [sec] |
Nervous system |
| X3855 |
17497 |
Number of errors during an 8-arm radial maze test on day 5 in males at 11 to 13 weeks of age [sec] |
Nervous system |
| X3680 |
17498 |
Number of errors during an 8-arm radial maze test on days 3 to 5 in males at 11 to 13 weeks of age [sec] |
Nervous system |
| X3477 |
17499 |
Number of new entries-5.3 during an 8-arm radial maze test on day 3 in males at 11 to 13 weeks of age [sec] |
Nervous system |
| X2589 |
17500 |
Number of new entries-5.3 during an 8-arm radial maze test on day 4 in males at 11 to 13 weeks of age [sec] |
Nervous system |
| X2968 |
17501 |
Number of new entries-5.3 during an 8-arm radial maze test on day 5 in males at 11 to 13 weeks of age [sec] |
Nervous system |
| X3495 |
17502 |
Number of new entries-5.3 during an 8-arm radial maze test on days 3 to 5 in males at 11 to 13 weeks of age [sec] |
Nervous system |
| X3486 |
17503 |
Time per arm visit during an 8-arm radial maze test on day 3 in males at 11 to 13 weeks of age [sec] |
Nervous system |
| X1201 |
17504 |
Time per arm visit during an 8-arm radial maze test on day 4 in males at 11 to 13 weeks of age [sec] |
Nervous system |
| X4431 |
17505 |
Time per arm visit during an 8-arm radial maze test on day 5 in males at 11 to 13 weeks of age [sec] |
Nervous system |
| X1860 |
17506 |
Time per arm visit during an 8-arm radial maze test on days 3 to 5 in males at 11 to 13 weeks of age [sec] |
Nervous system |
| X4709 |
17507 |
Error number during an 8-arm radial maze test on day 3 in females at 11 to 13 weeks of age [n] |
Nervous system |
| X3367 |
17508 |
Number of errors during an 8-arm radial maze test on day 4 in females at 11 to 13 weeks of age [sec] |
Nervous system |
| X3117 |
17509 |
Number of errors during an 8-arm radial maze test on day 5 in females at 11 to 13 weeks of age [sec] |
Nervous system |
| X1647 |
17510 |
Number of errors during an 8-arm radial maze test on days 3 to 5 in females at 11 to 13 weeks of age [sec] |
Nervous system |
| X2623 |
17511 |
Number of new entries-5.3 during an 8-arm radial maze test on day 3 in females at 11 to 13 weeks of age [sec] |
Nervous system |
| X3901 |
17512 |
Number of new entries-5.3 during an 8-arm radial maze test on day 4 in females at 11 to 13 weeks of age [sec] |
Nervous system |
| X4724 |
17513 |
Number of new entries-5.3 during an 8-arm radial maze test on day 5 in females at 11 to 13 weeks of age [sec] |
Nervous system |
| X3862 |
17514 |
Number of new entries-5.3 during an 8-arm radial maze test on days 3 to 5 in females at 11 to 13 weeks of age [sec] |
Nervous system |
| X3216 |
17515 |
Time per arm visit during an 8-arm radial maze test on day 3 in females at 11 to 13 weeks of age [sec] |
Nervous system |
| X2608 |
17516 |
Time per arm visit during an 8-arm radial maze test on day 4 in females at 11 to 13 weeks of age [sec] |
Nervous system |
| X4976 |
17517 |
Time per arm visit during an 8-arm radial maze test on day 5 in females at 11 to 13 weeks of age [sec] |
Nervous system |
| X3572 |
17518 |
Time per arm visit during an 8-arm radial maze test on days 3 to 5 in females at 11 to 13 weeks of age [sec] |
Nervous system |
| X1003 |
17935 |
Spontaneous activity, infrared beam breaks in a touchscreen chamber in 30 minutes in 2.5 to 3.5-month-old females (winsorized BXD39 from 206.667 +/- 12.556 to 249, BXD40 from 424.333 +/- 28.345 to 386 |
Nervous system |
| X739 |
17936 |
Spontaneous activity, traversals (e.g., front to back to front) of a touchscreen chamber in 30 minutes in 2.5 to 3.5-month-old females [n traversals] |
Nervous system |
| X3115 |
17976 |
Diencephalon 5-hydroxytryptamine (5-HT, serotonin) level in adult males [ng/mg protein] |
Nervous system |
| X440 |
17937 |
Spontaneous activity, touchscreen touches in 30 minutes in 2.5 to 3.5-month-old females (winsorized BXD55 from 419.667 +/- 40.916 to 340) [n touches] |
Nervous system |
| X2672 |
17938 |
Spontaneous activity, magazine entries in a touchscreen chamber in 30 minutes in 2.5 to 3.5-month-old females (winsorized BXD6 from 114.667 +/- 14.845 to 95, BXD61 from 121.600 +/- 23.687 to 99) [n en |
Nervous system |
| X1606 |
17939 |
Object-location paired-associates learning in 2.5 to 4-month-old females using a touchscreen assay, total sessions required to complete all pre-training phases (including learning to touch stimuli on |
Nervous system |
| X237 |
17940 |
Object-location paired-associates learning in 2.5 to 4-month-old females using a touchscreen assay, average blank touch latency (time between visual stimulus being displayed on screen in one location |
Nervous system |
| X1011 |
17941 |
Object-location paired-associates learning in 2.5 to 4-month-old females using a touchscreen assay, average reward collection latency (time between reward delivery and mouse entering reward magazine) |
Nervous system |
| X1008 |
17942 |
Object-location paired-associates learning in 2.5 to 4-month-old females using a touchscreen assay, average correct touch latency (time between visual stimulus being displayed on screen and mouse touc |
Nervous system |
| X4493 |
17943 |
Object-location paired-associates learning using a touchscreen assay in 3 to 9-month-old females, total sessions required to complete approximately 1800 training trials, where higher values means infe |
Nervous system |
| X1632 |
17944 |
Object-location paired-associates learning using a touchscreen assay in 3 to 9-month-old females, overall percentage of trials correct in first approximately 360 training trials, where higher values m |
Nervous system |
| X3821 |
17945 |
Object-location paired-associates learning using a touchscreen assay in 3 to 9-month-old females, average number of correction trials per trial in first approximately 360 training trials, where lower |
Nervous system |
| X4262 |
17946 |
Object-location paired-associates learning using a touchscreen assay in 3 to 9-month-old females, average number of screen touches per trial during inter-trial interval in first approximately 360 trai |
Nervous system |
| X2522 |
17947 |
Object-location paired-associates learning using a touchscreen assay in 3 to 9-month-old females, average number of touches to blank locations per trial (when there is a visual stimulus present on the |
Nervous system |
| X1941 |
17948 |
Object-location paired-associates learning using a touchscreen assay in 3 to 9-month-old females, overall percentage of trials correct in first approximately 900 training trials, where higher values m |
Nervous system |
| X2820 |
17949 |
Object-location paired-associates learning using a touchscreen assay in 3 to 9-month-old females, average number of correction trials per trial in first approximately 900 training trials, where lower |
Nervous system |
| X4227 |
17950 |
Object-location paired-associates learning using a touchscreen assay in 3 to 9-month-old females, average number of screen touches per trial during inter-trial interval in first approximately 900 trai |
Nervous system |
| X2816 |
17951 |
Object-location paired-associates learning using a touchscreen assay in 3 to 9-month-old females, average number of touches to blank locations per trial (when there is a visual stimulus present on the |
Nervous system |
| X3993 |
17952 |
Object-location paired-associates learning using a touchscreen assay in 3 to 9-month-old females, overall percentage of trials correct in first approximately 1800 training trials, where higher values |
Nervous system |
| X3552 |
17953 |
Object-location paired-associates learning using a touchscreen assay in 3 to 9-month-old females, average number of correction trials per trial in first approximately 1800 training trials, where lower |
Nervous system |
| X3889 |
17954 |
Object-location paired-associates learning using a touchscreen assay in 3 to 9-month-old females, average number of screen touches per trial during inter-trial interval in first approximately 1800 tra |
Nervous system |
| X1525 |
17955 |
Object-location paired-associates learning using a touchscreen assay in 3 to 9-month-old females, average number of touches per trial to blank locations (when there is a visual stimulus present on the |
Nervous system |
| X3726 |
17956 |
Object-location paired-associates learning using a touchscreen assay in 3 to 9-month-old females, overall percentage of trials correct in last approximately 180 training trials, where higher values me |
Nervous system |
| X2498 |
17957 |
Object-location paired-associates learning using a touchscreen assay in 3 to 9-month-old females, average number of correction trials per trial in last approximately 180 training trials, where lower v |
Nervous system |
| X4288 |
17958 |
Object-location paired-associates learning using a touchscreen assay in 3 to 9-month-old females, average number of screen touches per trial during inter-trial interval in last approximately 180 train |
Nervous system |
| X2280 |
17959 |
Object-location paired-associates learning using a touchscreen assay in 3 to 9-month-old females, average number of touches to blank locations per trial (when there is a visual stimulus present on the |
Nervous system |
| X1979 |
17960 |
Object-location paired-associates learning using a touchscreen assay in 3 to 9-month-old females, average percentage performance change when mice are tested on \same stimulus\ probe after training (% |
Nervous system |
| X3419 |
17961 |
Object-location paired-associates learning using a touchscreen assay in 3 to 9-month-old females, average number of correction trials per trial in approximately 72 same-stimulus probe trials, where lo |
Nervous system |
| X3811 |
17962 |
Object-location paired-associates learning using a touchscreen assay in 3 to 9-month-old females, average number of screen touches per trial during inter-trial interval in approximately 72 same-stimul |
Nervous system |
| X1077 |
17963 |
Object-location paired-associates learning using a touchscreen assay in 3 to 9-month-old females, average number of touches to blank locations per trial (when there is a visual stimulus present on the |
Nervous system |
| X1890 |
17964 |
Object-location paired-associates learning using a touchscreen assay in 3 to 9-month old females, average correct touch latency (time between visual stimuli being displayed on screen and mouse touchin |
Nervous system |
| X3440 |
17965 |
Object-location paired-associates learning using a touchscreen assay in 3 to 9-month old females, average incorrect touch latency (time between visual stimuli being displayed on screen and mouse touch |
Nervous system |
| X4267 |
17966 |
Object-location paired-associates learning using a touchscreen assay in 3 to 9-month old females, average reward collection latency (time between reward delivery and mouse entering reward magazine) in |
Nervous system |
| X3245 |
17977 |
Diencephalon 5-hydroxyindoleacetic acid (5-HIAA) level in adult males [ng/mg protein] |
Nervous system |
| X4560 |
17978 |
Diencephalon 5-hydroxytryptamine turnover rates (5-HIAA/5-HT) in adult males [units] |
Nervous system |
| X2767 |
17979 |
Diencephalon 5-hydroxytryptamine (5-HT, serotonin) level in adult females [ng/mg protein] |
Nervous system |
| X1562 |
17980 |
Diencephalon 5-hydroxyindoleacetic acid (5-HIAA) level in adult females [ng/mg protein] |
Nervous system |
| X3184 |
17981 |
Diencephalon 5-hydroxytryptamine turnover rates (5-HIAA/5-HT) in adult females [units] |
Nervous system |
| X2955 |
17982 |
Diencephalon 5-hydroxytryptamine (5-HT, serotonin) level in adult males and females [ng/mg protein] |
Nervous system |
| X3760 |
17983 |
Diencephalon 5-hydroxyindoleacetic acid (5-HIAA) level in adult males and females [ng/mg protein] |
Nervous system |
| X4447 |
17984 |
Diencephalon 5-hydroxytryptamine turnover rates (5-HIAA/5-HT) in adult males and females [units] |
Nervous system |
| X4024 |
17985 |
Midbrain 5-hydroxytryptamine (5-HT, serotonin) level in adult males [ng/mg protein] |
Nervous system |
| X4879 |
17986 |
Midbrain 5-hydroxyindoleacetic acid (5-HIAA) level in adult males [ng/mg protein] |
Nervous system |
| X2518 |
17987 |
Midbrain 5-hydroxytryptamine turnover rates (5-HIAA/5-HT) in adult males [units] |
Nervous system |
| X2982 |
17988 |
Midbrain 5-hydroxytryptamine (5-HT, serotonin) level in adult females [ng/mg protein] |
Nervous system |
| X3231 |
17989 |
Midbrain 5-hydroxyindoleacetic acid (5-HIAA) level in adult females [ng/mg protein] |
Nervous system |
| X807 |
17990 |
Midbrain 5-hydroxytryptamine turnover rates (5-HIAA/5-HT) in adult females [units] |
Nervous system |
| X2543 |
17991 |
Midbrain 5-hydroxytryptamine (5-HT, serotonin) level in adult males and females [ng/mg protein] |
Nervous system |
| X3819 |
17992 |
Midbrain 5-hydroxyindoleacetic acid (5-HIAA) level in adult males and females [ng/mg protein] |
Nervous system |
| X1263 |
17993 |
Midbrain 5-hydroxytryptamine turnover rate (5-HIAA/5-HT) in adult males and females [units] |
Nervous system |
| X1371 |
17994 |
Midbrain serotonin transporter (SERT) expression level quantified by Western blotting in adult males [intensity score] |
Nervous system |
| X3203 |
17995 |
Midbrain serotonin transporter (SERT) expression level quantified by Western blotting in adult females [intensity score] |
Nervous system |
| X2038 |
17996 |
Midbrain serotonin transporter (SERT) expression level quantified by Western blotting in adult males and females [intensity score] |
Nervous system |
| X3524 |
17997 |
Diencephalon serotonin transporter (SERT) expression level quantified by Western blotting in adult males [intensity score] |
Nervous system |
| X1822 |
17998 |
Diencephalon serotonin transporter (SERT) expression level quantified by Western blotting in adult females [intensity score] |
Nervous system |
| X4650 |
17999 |
Diencephalon serotonin transporter (SERT) expression level quantified by Western blotting in adult males and females [intensity score] |
Nervous system |
| X221 |
18000 |
Midbrain cysteic acid level in adult females [ug/mg protein] |
Nervous system |
| X4859 |
18001 |
Midbrain homocysteic acid level in adult females [ug/mg protein] |
Nervous system |
| X2580 |
18002 |
Midbrain aspartic acid level in adult females [ug/mg protein] |
Nervous system |
| X2161 |
18008 |
Midbrain arginine level in adult females [ug/mg protein] |
Nervous system |
| X4594 |
18009 |
Midbrain threonine level in adult females [ug/mg protein] |
Nervous system |
| X4649 |
18010 |
Midbrain alanine level in adult females [ug/mg protein] |
Nervous system |
| X3775 |
18011 |
Midbrain proline level in adult females [ug/mg protein] |
Nervous system |
| X4735 |
18012 |
Midbrain GABA level in adult females [ug/mg protein] |
Nervous system |
| X5057 |
18013 |
Midbrain cystine level in adult females [ug/mg protein] |
Nervous system |
| X3401 |
18014 |
Midbrain tyrosine level in adult females [ug/mg protein] |
Nervous system |
| X4082 |
18015 |
Midbrain valine level in adult females [ug/mg protein] |
Nervous system |
| X950 |
18016 |
Midbrain methionine level in adult females [ug/mg protein] |
Nervous system |
| X4943 |
18017 |
Midbrain lysine level in adult females [ug/mg protein] |
Nervous system |
| X4812 |
18018 |
Midbrain isoleucine level in adult females [ug/mg protein] |
Nervous system |
| X2115 |
18019 |
Midbrain leucine level in adult females [ug/mg protein] |
Nervous system |
| X3845 |
18020 |
Midbrain phenylalanine level in adult females [ug/mg protein] |
Nervous system |
| X734 |
18021 |
Midbrain Glu/GABA ratios in adult females [ratio] |
Nervous system |
| X2065 |
18022 |
Midbrain cysteic acid level in adult males [pmol/ug protein] |
Nervous system |
| X4848 |
18023 |
Midbrain homocysteic acid level in adult males [pmol/ug protein] |
Nervous system |
| X3055 |
18024 |
Midbrain aspartic acid level in adult males [pmol/ug protein] |
Nervous system |
| X3011 |
18025 |
Midbrain serine level in adult males [pmol/ug protein] |
Nervous system |
| X2335 |
18026 |
Midbrain glutamic acid level in adult males [pmol/ug protein] |
Nervous system |
| X1764 |
18027 |
Midbrain glycine level in adult males [pmol/ug protein] |
Nervous system |
| X2003 |
18028 |
Midbrain histidine level in adult males [pmol/ug protein] |
Nervous system |
| X3960 |
18029 |
Midbrain taurine level in adult males [pmol/ug protein] |
Nervous system |
| X3142 |
18030 |
Midbrain arginine level in adult males [pmol/ug protein] |
Nervous system |
| X4270 |
18031 |
Midbrain threonine level in adult males [pmol/ug protein] |
Nervous system |
| X1591 |
18032 |
Midbrain alanine level in adult males [pmol/ug protein] |
Nervous system |
| X4272 |
18033 |
Midbrain proline level in adult males [ug/mg protein] |
Nervous system |
| X4677 |
18034 |
Midbrain GABA level in adult males [ug/mg protein] |
Nervous system |
| X519 |
18035 |
Midbrain cystine level in adult males [ug/mg protein] |
Nervous system |
| X2293 |
18036 |
Midbrain tyrosine level in adult males [ug/mg protein] |
Nervous system |
| X1803 |
18037 |
Midbrain valine level in adult males [ug/mg protein] |
Nervous system |
| X3100 |
18038 |
Midbrain methionine level in adult males [ug/mg protein] |
Nervous system |
| X3108 |
18039 |
Midbrain lysine level in adult males [ug/mg protein] |
Nervous system |
| X5068 |
18040 |
Midbrain isoleucine level in adult males [ug/mg protein] |
Nervous system |
| X4177 |
18041 |
Midbrain leucine level in adult males [ug/mg protein] |
Nervous system |
| X3714 |
18042 |
Midbrain phenylalanine level in adult males [ug/mg protein] |
Nervous system |
| X4446 |
18043 |
Midbrain Glu/GABA ratios in adult males [ratio] |
Nervous system |
| X4537 |
18044 |
Midbrain 4,5-trihydroxyphenethylamine (Norepinephrine, noradrenaline) level in adult males [ng/mg protein] |
Nervous system |
| X4109 |
18045 |
Midbrain 3,4-dihydroxyphenylacetic acid (DOPAC) level in adult males [ng/mg protein] |
Nervous system |
| X4015 |
18046 |
Midbrain 3,4-dihydroxyphenethylamine (dopamine) level in adult males [ng/mg protein] |
Nervous system |
| X1329 |
18047 |
Midbrain 3-methoxy-4-hydroxyphenyl acetic acid (Homovanillic acid, HVA) level in adult males [ng/mg protein] |
Nervous system |
| X2171 |
18048 |
Midbrain 3-methoxy-4-hydroxyphenethylamine (3-MT) level in adult males [ng/mg protein] |
Nervous system |
| X3892 |
18049 |
Midbrain dopamine transporter (DAT) expression level quantified by Western blotting in adult males [intensity score] |
Nervous system |
| X1684 |
18050 |
Midbrain choline transporter (CHT) expression level quantified by Western blotting in adult males [intensity score] |
Nervous system |
| X956 |
18051 |
Effects of chronic variable stress (unstressed control) freezing during training (Med Associates chamber, 2 sec 0.75 mA shock, 85 dB 3KHz tone, 4 tone-shock pairings) in singly-housed 3-4 month-old males (Figure 2A left |
Nervous system |
| X922 |
18052 |
Effects of chronic variable stress (CVS for four weeks) freezing during training (Med Associates chamber, 2 sec 0.75 mA shock, 85 dB 3KHz tone, 4 tone-shock pairings) in singly-housed 3-4 month-old males (Figure 2A midd |
Nervous system |
| X2007 |
18053 |
Effects of chronic variable stress, difference between stress and control groups freezing during training (Med Associates chamber, 2 sec 0.75 mA shock, 85 dB 3KHz tone, 4 tone-shock pairings) in singly-housed 3-4 month- |
Nervous system |
| X1457 |
18054 |
Effects of chronic variable stress (unstressed control) locomoter distance in an elevated plus maze (measured for 5 minutes) in singly-housed 3-4 month-old males (Figure 3A left)[m] |
Nervous system |
| X1039 |
18055 |
Effects of chronic variable stress (CVS for four weeks) locomoter distance in an elevated plus maze (measured for 5 minutes) in singly-housed 3-4 month-old males (Figure 3A middle)[m] |
Nervous system |
| X923 |
18056 |
Effects of chronic variable stress, difference between stress and control groups locomoter distance in an elevated plus maze (measured for 5 minutes) in singly-housed 3-4 month-old males (Figure 3A right)[m] |
Nervous system |
| X861 |
18057 |
Effects of chronic variable stress (unstressed control) freezing to tone after fear conditioning, nine exposures to a 85 dB 3KHz tones in singly-housed 3-4 month-old males (Figure 2C left)[sec] |
Nervous system |
| X298 |
18058 |
Effects of chronic variable stress (CVS for four weeks) freezing to tone after fear conditioning, nine exposures to a 85 dB 3KHz tones in singly-housed 3-4 month-old males (Figure 2C middle)[sec] |
Nervous system |
| X2972 |
18059 |
Effects of chronic variable stress, difference between stress and control groups freezing to tone after fear conditioning, nine exposures to a 85 dB 3KHz tones in singly-housed 3-4 month-old males (Figure 2C right)[sec] |
Nervous system |
| X2443 |
18060 |
Effects of chronic variable stress (unstressed control) time in open arm of an elevated plus maze (measured for 5 minutes) in singly-housed 3-4 month-old males (Figure 3C left)[sec] |
Nervous system |
| X2813 |
18061 |
Effects of chronic variable stress (CVS for four weeks) time in open arm of an elevated plus maze (measured for 5 minutes) in singly-housed 3-4 month-old males (Figure 3C middle)[sec] |
Nervous system |
| X2709 |
18062 |
Effects of chronic variable stress, difference between stress and control groups time in open arm of an elevated plus maze (measured for 5 minutes) in singly-housed 3-4 month-old males (Figure 3C right)[sec] |
Nervous system |
| X2980 |
18063 |
Effects of chronic variable stress (unstressed control) time in closed arm of an elevated plus maze (measured for 5 minutes) in singly-housed 3-4 month-old males (Figure 3B left)[sec] |
Nervous system |
| X2746 |
18064 |
Effects of chronic variable stress (CVS for four weeks) time in closed arm of an elevated plus (measured for 5 minutes) in singly-housed 3-4 month-old males (Figure 3B middle)[sec] |
Nervous system |
| X2156 |
18065 |
Effects of chronic variable stress, difference between stress and control groups time in closed arm of an elevated plus maze (measured for 5 minutes) in singly-housed 3-4 month-old males (Figure 3B right)[sec] |
Nervous system |
| X3025 |
18066 |
Effects of chronic variable stress (unstressed control) freezing to context after fear conditioning (measured for 10 minutes) in singly-housed 3-4 month-old males (Figure 2B left)[sec] |
Nervous system |
| X1451 |
18067 |
Effects of chronic variable stress (CVS for four weeks) freezing to context after fear conditioning (measured for 10 minutes) in singly-housed 3-4 month-old males (Figure 2B middle)[sec] |
Nervous system |
| X3829 |
18068 |
Effects of chronic variable stress, difference between stress and control groups freezing to context after fear conditioning (measured for 10 minutes) in singly-housed 3-4 month-old males (Figure 2B right)[sec] |
Nervous system |
| X3092 |
18125 |
;Central nervous system;; embryonic neurogenesis;; Cell death in brainstem following exposure to ethanol at E9 (TUNEL+ cells/mm2) (Total); |
Nervous system |
| X3866 |
18126 |
;Central nervous system;; embryonic neurogenesis;; Cell death in brainstem following exposure to ethanol at E9 (TUNEL+ cells/mm2) (MD subtracted from total); |
Nervous system |
| X3895 |
18127 |
;Central nervous system;; embryonic neurogenesis;; Cell death in forebrain following exposure to ethanol at E9 (TUNEL+ cells/mm2) (Total); |
Nervous system |
| X537 |
18128 |
;Central nervous system;; embryonic neurogenesis;; Cell death in forebrain following exposure to ethanol at E9 (TUNEL+ cells/mm2) (MD subtracted from total); |
Nervous system |
| X148 |
18280 |
Cut-off value to separate short and long movements determined by Gaussian mixture model fitting to the histogram of movement distances of each mouse (long movement threshold) measured over 3 days using Noldus home cage vi |
Nervous system |
| X3566 |
18281 |
Average velocity of the 95th percentile fastest long movement segments (long movement max. velocity) measured over 3 days using Noldus home cage video tracking [cm/s] |
Nervous system |
| X3409 |
18282 |
Fraction of movement segments with distance longer than long movement threshold (long movement fraction of total movement) measured over 3 days using Noldus home cage video tracking [fraction] |
Nervous system |
| X1330 |
18283 |
Cumulative long movement distance during the dark phase (long movement distance dark) measured over 3 days using Noldus home cage video tracking [cm] |
Nervous system |
| X4685 |
18284 |
Cumulative long movement distance during the light phase (long movement distance light) measured over 3 days using Noldus home cage video tracking [cm] |
Nervous system |
| X1652 |
18285 |
Cumulative long movement number during the dark phase (long movement number dark) measured over 3 days using Noldus home cage video tracking [n] |
Nervous system |
| X2889 |
10407 |
Antigenic activity of irradiated BXD spleen cells for Thy-1+CD3+CD4+CD8- T-cell clone E4.3 [thymidine uptake cpm] |
Immune |
| X4564 |
18286 |
Cumulative long movement number during the light phase (long movement number light) measured over 3 days using Noldus home cage video tracking [n] |
Nervous system |
| X2050 |
18287 |
Mean distance per long movement during the dark phase (mean long movement distance dark) measured over 3 days using Noldus home cage video tracking [cm] |
Nervous system |
| X619 |
18288 |
Mean distance per long movement during the light phase (mean long movement distance light) measured over 3 days using Noldus home cage video tracking [cm] |
Nervous system |
| X124 |
18289 |
Mean distance per short movement during the dark phase (mean short movement distance dark) measured over 3 days using Noldus home cage video tracking [cm] |
Nervous system |
| X127 |
18290 |
Mean distance per short movement during the light phase (mean short movement distance light) measured over 3 days using Noldus home cage video tracking [cm] |
Nervous system |
| X2783 |
18291 |
Cumulative short movement distance during the dark phase (short movement distance dark) measured over 3 days using Noldus home cage video tracking [cm] |
Nervous system |
| X3106 |
18292 |
Cumulative short movement distance during the light phase (short movement distance light) measured over 3 days using Noldus home cage video tracking [cm] |
Nervous system |
| X2289 |
18293 |
Cumulative short movement number during the dark phase (short movement number dark) measured over 3 days using Noldus home cage video tracking [n] |
Nervous system |
| X4107 |
18294 |
Cumulative short movement number during the light phase (short movement number light) measured over 3 days using Noldus home cage video tracking [n] |
Nervous system |
| X3784 |
18295 |
Cut-off value to separate short and long arrests, determined by Gaussian mixture model fitting to the histogram of arrest durations of each individual mouse (long arrest threshold) measured over 3 days using Noldus home c |
Nervous system |
| X2138 |
18296 |
Cumulative duration of long arrests during the dark phase (long arrest duration dark) measured over 3 days using Noldus home cage video tracking [s] |
Nervous system |
| X2224 |
18297 |
Cumulative duration of long arrests during the light phase (long arrest duration light) measured over 3 days using Noldus home cage video tracking [s] |
Nervous system |
| X1960 |
18298 |
Cumulative number of long arrests during the dark phase (long arrest number dark) measured over 3 days using Noldus home cage video tracking [n] |
Nervous system |
| X4394 |
18299 |
Cumulative number of long arrests during the light phase (long arrest number light) measured over 3 days using Noldus home cage video tracking [n] |
Nervous system |
| X4505 |
18300 |
Mean duration per long arrest during the dark phase (mean long arrest duration dark) measured over 3 days using Noldus home cage video tracking [s] |
Nervous system |
| X1342 |
18301 |
Mean duration per long arrest during the light phase (mean long arrest duration light) measured over 3 days using Noldus home cage video tracking [s] |
Nervous system |
| X4597 |
18302 |
Mean duration per short arrest during the dark phase (mean short arrest duration dark) measured over 3 days using Noldus home cage video tracking [s] |
Nervous system |
| X3988 |
18303 |
Mean duration per short arrest during the light phase (mean short arrest duration light) measured over 3 days using Noldus home cage video tracking [s] |
Nervous system |
| X2273 |
18304 |
Cumulative duration of short arrests during the dark phase (short arrest duration dark) measured over 3 days using Noldus home cage video tracking [s] |
Nervous system |
| X2120 |
18305 |
Cumulative duration of short arrests during the light phase (short arrest duration light) measured over 3 days using Noldus home cage video tracking [s] |
Nervous system |
| X2475 |
18306 |
Cumulative number of short arrests during the dark phase (short arrest number dark) measured over 3 days using Noldus home cage video tracking [n] |
Nervous system |
| X4178 |
18307 |
Cumulative number of short arrests during the light phase (short arrest number light) measured over 3 days using Noldus home cage video tracking [n] |
Nervous system |
| X4159 |
18308 |
Cut-off value to separate intermediate and long shelter visits, determined by Gaussian mixture model fitting to the histogram of shelter visit durations of each individual mouse (long shelter visit threshold) measured ove |
Nervous system |
| X2176 |
18309 |
Cut-off value to separate short and intermediate shelter visits, determined by Gaussian mixture model fitting to the histogram of shelter visit durations of each individual mouse (short shelter visit threshold) measured o |
Nervous system |
| X1851 |
18310 |
Cumulative duration of long shelter visits during the dark phase (long shelter visit duration dark) measured over 3 days using Noldus home cage video tracking [s] |
Nervous system |
| X2520 |
18311 |
Cumulative duration of long shelter visits during the light phase (long shelter visit duration light) measured over 3 days using Noldus home cage video tracking [s] |
Nervous system |
| X2537 |
18312 |
Fraction of shelter visits with duration longer than long shelter visit threshold (long shelter visit fraction of total visits) measured over 3 days using Noldus home cage video tracking [fraction] |
Nervous system |
| X4715 |
18313 |
Cumulative number of long shelter visits during the dark phase (long shelter visit number dark) measured over 3 days using Noldus home cage video tracking [n] |
Nervous system |
| X695 |
18314 |
Cumulative number of long shelter visits during the light phase (long shelter visit number light) measured over 3 days using Noldus home cage video tracking [n] |
Nervous system |
| X4351 |
18315 |
Mean duration per long shelter visit during the first 3 days (mean long shelter visit duration) measured over 3 days using Noldus home cage video tracking [s] |
Nervous system |
| X4307 |
18316 |
Mean duration per short shelter visit during the dark phase (mean short shelter visit duration dark) measured over 3 days using Noldus home cage video tracking [s] |
Nervous system |
| X1638 |
18317 |
Mean duration per short shelter visit during the light phase (mean short shelter visit duration light) measured over 3 days using Noldus home cage video tracking [s] |
Nervous system |
| X1709 |
18318 |
Cumulative duration of short shelter visits during the dark phase (short shelter visit duration dark) measured over 3 days using Noldus home cage video tracking [s] |
Nervous system |
| X3157 |
18319 |
Cumulative duration of short shelter visits during the light phase (short shelter visit duration light) measured over 3 days using Noldus home cage video tracking [s] |
Nervous system |
| X3589 |
18320 |
Cumulative number of short shelter visits during the dark phase (short shelter visit number dark) measured over 3 days using Noldus home cage video tracking [n] |
Nervous system |
| X3883 |
18321 |
Cumulative number of short shelter visits during the light phase (short shelter visit number light) measured over 3 days using Noldus home cage video tracking [n] |
Nervous system |
| X14 |
10151 |
Ethanol response (10% in water po), total fluid intake during 4-day forced 10% ethanol exposure period [ml/day] |
Drug response |
| X4061 |
18322 |
Habituation ratio describing the change in cumulative activity duration during the dark phase of day 3 compared to the dark phase of day 1 (ratio > 1 indicates that third > first day) (activity duration habituation ratio |
Nervous system |
| X3671 |
18323 |
Habituation ratio describing the change in cumulative Feeding zone duration during the dark phase of day 3 compared to the dark phase of day 1 (ratio > 1 indicates that third > first day) (feeding zone duration habituatio |
Nervous system |
| X4826 |
18324 |
Habituation ratio describing the change in cumulative long shelter visit duration during the dark phase of day 3 compared to the dark phase of day 1 (ratio > 1 indicates that third > first day) (long shelter visit duratio |
Nervous system |
| X3711 |
18325 |
Habituation ratio describing the change in cumulative OnShelter zone duration during the dark phase of day 3 compared to the dark phase of day 1 (ratio > 1 indicates that third > first day) (OnShelter zone duration habitu |
Nervous system |
| X4688 |
18326 |
Habituation ratio describing the change in mean short movement distance during the dark phase of day 3 compared to the dark phase of day 1 (ratio > 1 indicates that third > first day) (mean short movement distance habitua |
Nervous system |
| X4749 |
18327 |
Habituation ratio describing the change in mean activity duration during the dark phase of day 3 compared to the dark phase of day 1 (ratio > 1 indicates that third > first day) (mean activity duration habituation ratio d |
Nervous system |
| X3114 |
18328 |
Habituation ratio describing the change in cumulative activity number during the dark phase of day 3 compared to the dark phase of day 1 (ratio > 1 indicates that third > first day) (activity number habituation ratio dark |
Nervous system |
| X4218 |
18329 |
Habituation ratio describing the change in mean short arrest duration during the dark phase of day 3 compared to the dark phase of day 1 (ratio > 1 indicates that third > first day) (mean short arrest duration habituation |
Nervous system |
| X4937 |
18330 |
Habituation ratio describing the change in cumulative long arrest long arrest duration during the dark phase of day 3 compared to the dark phase of day 1 (ratio > 1 indicates that third > first day) (long arrest duration |
Nervous system |
| X2663 |
18331 |
Habituation ratio describing the change in mean long arrest duration during the dark phase of day 3 compared to the dark phase of day 1 (ratio > 1 indicates that third > first day) (mean long arrest duration habituation r |
Nervous system |
| X3654 |
18332 |
Habituation ratio describing the change in cumulative long arrest long arrest number during the dark phase of day 3 compared to the dark phase of day 1 (ratio > 1 indicates that third > first day) (long arrest number habi |
Nervous system |
| X2425 |
18333 |
Habituation ratio describing the change in mean short shelter visit duration during the dark phase of day 3 compared to the dark phase of day 1 (ratio > 1 indicates that third > first day) (mean short shelter visit durati |
Nervous system |
| X3743 |
18334 |
Habituation ratio describing the change in mean long movement distance during the dark phase of day 3 compared to the dark phase of day 1 (ratio > 1 indicates that third > first day) (mean long movement distance habituati |
Nervous system |
| X4105 |
18335 |
Habituation ratio describing the change in cumulative spout zone duration during the dark phase of day 3 compared to the dark phase of day 1 (ratio > 1 indicates that third > first day) (spout zone duration habituation ra |
Nervous system |
| X18 |
10152 |
Fluid intake (total) during free choice ethanol period [ml/day] |
Drug response |
| X5087 |
18336 |
Habituation ratio describing the change in cumulative activity duration during the light phase of day 3 compared to the light phase of day 1 (ratio > 1 indicates that third > first day) (activity duration habituation rati |
Nervous system |
| X3896 |
18337 |
Habituation ratio describing the change in cumulative Feeding zone duration during the light phase of day 3 compared to the light phase of day 1 (ratio > 1 indicates that third > first day) (feeding zone duration habituat |
Nervous system |
| X4619 |
18338 |
Habituation ratio describing the change in cumulative long shelter visit duration during the light phase of day 3 compared to the light phase of day 1 (ratio > 1 indicates that third > first day) (long shelter visit durat |
Nervous system |
| X4223 |
18339 |
Habituation ratio describing the change in cumulative OnShelter zone duration during the light phase of day 3 compared to the light phase of day 1 (ratio > 1 indicates that third > first day) (OnShelter zone duration habi |
Nervous system |
| X4416 |
18340 |
Habituation ratio describing the change in mean short movement distance during the light phase of day 3 compared to the light phase of day 1 (ratio > 1 indicates that third > first day) (mean short movement distance habit |
Nervous system |
| X5090 |
18341 |
Habituation ratio describing the change in mean activity duration during the light phase of day 3 compared to the light phase of day 1 (ratio > 1 indicates that third > first day) (mean activity duration habituation ratio |
Nervous system |
| X358 |
18342 |
Habituation ratio describing the change in cumulative activity number during the light phase of day 3 compared to the light phase of day 1 (ratio > 1 indicates that third > first day) (activity number habituation ratio li |
Nervous system |
| X2328 |
18343 |
Habituation ratio describing the change in mean short arrest duration during the light phase of day 3 compared to the light phase of day 1 (ratio > 1 indicates that third > first day) (mean short arrest duration habituati |
Nervous system |
| X4603 |
18344 |
Habituation ratio describing the change in cumulative long arrest long arrest duration during the light phase of day 3 compared to the light phase of day 1 (ratio > 1 indicates that third > first day) (long arrest duratio |
Nervous system |
| X5069 |
18345 |
Habituation ratio describing the change in mean long arrest duration during the light phase of day 3 compared to the light phase of day 1 (ratio > 1 indicates that third > first day) (mean long arrest duration habituation |
Nervous system |
| X4268 |
18346 |
Habituation ratio describing the change in cumulative long arrest long arrest number during the light phase of day 3 compared to the light phase of day 1 (ratio > 1 indicates that third > first day) (long arrest number ha |
Nervous system |
| X4412 |
18347 |
Habituation ratio describing the change in mean short shelter visit duration during the light phase of day 3 compared to the light phase of day 1 (ratio > 1 indicates that third > first day) (mean short shelter visit dura |
Nervous system |
| X1080 |
18348 |
Habituation ratio describing the change in mean long movement distance during the light phase of day 3 compared to the light phase of day 1 (ratio > 1 indicates that third > first day) (mean long movement distance habitua |
Nervous system |
| X2047 |
18349 |
Habituation ratio describing the change in cumulative spout zone duration during the light phase of day 3 compared to the light phase of day 1 (ratio > 1 indicates that third > first day) (spout zone duration habituation |
Nervous system |
| X4284 |
10626 |
Protein kinase C (PKC) activity in cortex cytosol [pmol/min/mg protein] |
Nervous system |
| X3803 |
18350 |
DarkLight index describing the difference in cumulative activity duration between light and dark phase (index between 0.5 and 1 indicates that dark > light phase) (activity duration darklight index) measured over 3 days u |
Nervous system |
| X3444 |
18351 |
DarkLight index describing the difference in cumulative long shelter visit duration between light and dark phase (index between 0.5 and 1 indicates that dark > light phase) (long shelter visit duration darklight index) me |
Nervous system |
| X3808 |
18352 |
DarkLight index describing the difference in mean short movement distance between light and dark phase (index between 0.5 and 1 indicates that dark > light phase) (mean short movement distance darklight index) measured ov |
Nervous system |
| X2347 |
18353 |
DarkLight index describing the difference in cumulative Feeding zone duration between light and dark phase (index between 0.5 and 1 indicates that dark > light phase) (feeding zone duration darklight index) measured over |
Nervous system |
| X939 |
18354 |
DarkLight index describing the difference in mean activity duration between light and dark phase (index between 0.5 and 1 indicates that dark > light phase) (mean activity duration darklight index) measured over 3 days us |
Nervous system |
| X3697 |
18355 |
DarkLight index describing the difference in cumulative activity number between light and dark phase (index between 0.5 and 1 indicates that dark > light phase) (activity number darklight index) measured over 3 days using |
Nervous system |
| X4678 |
18356 |
DarkLight index describing the difference in mean short arrest duration between light and dark phase (index between 0.5 and 1 indicates that dark > light phase) (mean short arrest duration darklight index) measured over 3 |
Nervous system |
| X2439 |
18357 |
DarkLight index describing the difference in cumulative long arrest long arrest duration between light and dark phase (index between 0.5 and 1 indicates that dark > light phase) (long arrest duration darklight index) meas |
Nervous system |
| X4689 |
18358 |
DarkLight index describing the difference in mean long arrest duration between light and dark phase (index between 0.5 and 1 indicates that dark > light phase) (mean long arrest duration darklight index) measured over 3 d |
Nervous system |
| X2639 |
18359 |
DarkLight index describing the difference in cumulative long arrest long arrest number between light and dark phase (index between 0.5 and 1 indicates that dark > light phase) (long arrest number darklight index) measured |
Nervous system |
| X4502 |
18360 |
DarkLight index describing the difference in mean short shelter visit duration between light and dark phase (index between 0.5 and 1 indicates that dark > light phase) (mean short shelter visit duration darklight index) m |
Nervous system |
| X4541 |
18361 |
DarkLight index describing the difference in cumulative long shelter visit number between light and dark phase (index between 0.5 and 1 indicates that dark > light phase) (long shelter visit number darklight index) measur |
Nervous system |
| X1757 |
18362 |
DarkLight index describing the difference in mean long movement distance between light and dark phase (index between 0.5 and 1 indicates that dark > light phase) (mean long movement distance darklight index) measured over |
Nervous system |
| X3934 |
18363 |
DarkLight index describing the difference in cumulative OnShelter zone duration between light and dark phase (index between 0.5 and 1 indicates that dark > light phase) (OnShelter zone duration darklight index) measured o |
Nervous system |
| X3585 |
18364 |
DarkLight index describing the difference in cumulative Spout zone duration between light and dark phase (index between 0.5 and 1 indicates that dark > light phase) (spout zone duration darklight index) measured over 3 da |
Nervous system |
| X1944 |
18365 |
Change in activity during the last 2 hours of the dark phase in comparison to the preceeding 3 hours of the dark phase, describing the anticipation of the upcoming light phase (activity change in anticipation of light) me |
Nervous system |
| X1351 |
18366 |
Change in activity during the first 2 hours of the light phase in comparison to the last hours of the preceeding dark phase, describing the response to the onset of the light phase (activity change in response to light) m |
Nervous system |
| X5004 |
18367 |
Change in activity during the last 5 hours of the light phase in comparison to the preceeding 3 hours of the light phase, describing the anticipation of the upcoming dark phase (activity change in anticipation of dark) me |
Nervous system |
| X4101 |
18368 |
Change in activity during the first 2 hours of the dark phase in comparison to the last hours of the preceeding light phase, describing the response to the onset of the dark phase (activity change in response to dark) mea |
Nervous system |
| X2866 |
18369 |
Change in Feeding zone duration during the first 2 hours of the dark phase in comparison to the last hours of the preceeding light phase, describing the response to the onset of the dark phase (feeding zone change in anti |
Nervous system |
| X4771 |
18370 |
Change in Feeding zone duration during the first 2 hours of the light phase in comparison to the last hours of the preceeding dark phase, describing the response to the onset of the light phase (feeding zone change in res |
Nervous system |
| X4754 |
18371 |
Change in Feeding zone duration during the last 5 hours of the light phase in comparison to the preceeding 3 hours of the light phase, describing the anticipation of the upcoming dark phase (feeding zone change in anticip |
Nervous system |
| X3542 |
18372 |
Change in Feeding zone duration during the last 2 hours of the dark phase in comparison to the preceeding 3 hours of the dark phase, describing the anticipation of the upcoming light phase (feeding zone change in response |
Nervous system |
| X842 |
18373 |
Change in OnShelter zone during the first 2 hours of the dark phase in comparison to the last hours of the preceeding light phase, describing the response to the onset of the dark phase (OnShelter zone change in anticipat |
Nervous system |
| X4892 |
18374 |
Change in OnShelter zone during the first 2 hours of the light phase in comparison to the last hours of the preceeding dark phase, describing the response to the onset of the light phase (OnShelter zone change in response |
Nervous system |
| X1567 |
18375 |
Change in OnShelter zone during the last 5 hours of the light phase in comparison to the preceeding 3 hours of the light phase, describing the anticipation of the upcoming dark phase (OnShelter zone change in anticipation |
Nervous system |
| X3756 |
18376 |
Change in OnShelter zone during the last 2 hours of the dark phase in comparison to the preceeding 3 hours of the dark phase, describing the anticipation of the upcoming light phase (OnShelter zone change in response to d |
Nervous system |
| X4546 |
18377 |
Change in OnShelter zone duration duration during the first 2 hours of the dark phase in comparison to the last hours of the preceeding light phase, describing the response to the onset of the dark phase (spout zone chang |
Nervous system |
| X2651 |
18378 |
Change in OnShelter zone duration duration during the first 2 hours of the light phase in comparison to the last hours of the preceeding dark phase, describing the response to the onset of the light phase (spout zone chan |
Nervous system |
| X4329 |
18379 |
Change in OnShelter zone duration duration during the last 5 hours of the light phase in comparison to the preceeding 3 hours of the light phase, describing the anticipation of the upcoming dark phase (spout zone change i |
Nervous system |
| X1527 |
18380 |
Change in OnShelter zone duration duration during the last 2 hours of the dark phase in comparison to the preceeding 3 hours of the dark phase, describing the anticipation of the upcoming light phase (spout zone change in |
Nervous system |
| X3626 |
18381 |
Mean duration per activity bout during the dark phase (mean activity duration dark) measured over 3 days using Noldus home cage video tracking [s] |
Nervous system |
| X1626 |
18382 |
Cumulative number of activity bouts during the dark phase (activity number dark) measured over 3 days using Noldus home cage video tracking [n] |
Nervous system |
| X1520 |
18383 |
Cumulative number of visits to OnShelter zone during the dark phase (OnShelter zone number dark) measured over 3 days using Noldus home cage video tracking [n] |
Nervous system |
| X2848 |
18384 |
Cumulative duration of activity during the dark phase (activity duration dark) measured over 3 days using Noldus home cage video tracking [s] |
Nervous system |
| X2034 |
18385 |
Cumulative duration in Feeding zone during the dark phase (feeding zone duration dark) measured over 3 days using Noldus home cage video tracking [s] |
Nervous system |
| X2278 |
18386 |
Cumulative duration in OnShelter zone during the dark phase (OnShelter zone duration dark) measured over 3 days using Noldus home cage video tracking [s] |
Nervous system |
| X3189 |
18387 |
Cumulative duration in Spout zone during the dark phase (spout zone duration dark) measured over 3 days using Noldus home cage video tracking [s] |
Nervous system |
| X5059 |
18388 |
Mean duration per activity bout during the light phase (mean activity duration light) measured over 3 days using Noldus home cage video tracking [s] |
Nervous system |
| X3823 |
18389 |
Cumulative number of activity bouts during the light phase (activity number light) measured over 3 days using Noldus home cage video tracking [n] |
Nervous system |
| X4576 |
18390 |
Cumulative number of visits to OnShelter zone during the light phase (OnShelter zone number light) measured over 3 days using Noldus home cage video tracking [n] |
Nervous system |
| X4142 |
18391 |
Cumulative duration of activity during the light phase (activity duration light) measured over 3 days using Noldus home cage video tracking [s] |
Nervous system |
| X2467 |
18392 |
Cumulative duration in Feeding zone during the light phase (feeding zone duration light) measured over 3 days using Noldus home cage video tracking [s] |
Nervous system |
| X4777 |
18393 |
Cumulative duration in OnShelter zone during the light phase (OnShelter zone duration light) measured over 3 days using Noldus home cage video tracking [cm] |
Nervous system |
| X4141 |
18394 |
Cumulative duration in Spout zone during the light phase (spout zone duration light) measured over 3 days using Noldus home cage video tracking [s] |
Nervous system |
| X227 |
18395 |
Fear conditioning, freezing in response to context 24 hours after training, percent freezing |
Nervous system |
| X1062 |
10406 |
Antigenic activity of irradiated spleen cells for Thy-1+CD3+CD4+CD8- T-cell clone D9 [thymidine uptake cpm] |
Immune |
| X72 |
18411 |
Average Hp1bp3 exon expression, average of SNP-free probes 10338180 (exon 2), 10344447 (exon 5), 10342675 (exon 9), and 10340971 (exon 12) from BXD Aged Hippocampus Affy MoGene1.0 ST (May 15) RMA Gene Level |
Nervous system |
| X207 |
18436 |
Retinal ganglion cell expression PCA eigengene generated using the DoD CDMRP Retina Affy MoGene 2.0 ST (May15) RMA Gene Level database (PC03, 8% of variance) and a set of 73 known and putative RG |
Nervous system |
| X897 |
18437 |
Retinal ganglion cell expression PCA eigengene generated using the DoD CDMRP Retina Affy MoGene 2.0 ST (May15) RMA Gene Level database (PC01, 50% of variance) and a set of 9 genes that covary we |
Nervous system |
| X424 |
18438 |
Retinal ganglion cell expression PCA eigengene generated using the Full HEI Retina Illumina RankInv database (PC01, 37% of variance) and a set of 7 genes that covary well with RGC Trait 10600 (Ab |
Nervous system |
| X971 |
18439 |
Retinal ganglion cell expression metatrait generated as the PC01 of 18438, 18437 and 18436 [PC score] |
Nervous system |
| X4521 |
18442 |
Iron (Fe) level in ventral midbrain (VMB) of mice age less than 120 days [ug/g wet weight] |
Nervous system |
| X4066 |
18443 |
Copper (Cu) level in ventral midbrain (VMB) of mice age less than 120 days [ug/g wet weight] |
Nervous system |
| X2721 |
18444 |
Zinc (Zn) level in ventral midbrain (VMB) of mice age less than 120 days [ug/g wet weight] |
Nervous system |
| X3973 |
18445 |
Iron (Fe) level in hippocampus (HIP) of mice age less than 120 days [ug/g wet weight] |
Nervous system |
| X2769 |
18446 |
Copper (Cu) level in hippocampus (HIP) of mice age less than 120 days [ug/g wet weight] |
Nervous system |
| X1685 |
18447 |
Zinc (Zn) level in hippocampus (HIP) of mice age less than 120 days [ug/g wet weight] |
Nervous system |
| X3904 |
18448 |
Iron (Fe) level in cortex (CTX) of mice age less than 120 days [ug/g wet weight] |
Nervous system |
| X4469 |
18449 |
Copper (Cu) level in cortex (CTX) of mice age less than 120 days [ug/g wet weight] |
Nervous system |
| X4808 |
18450 |
Zinc (Zn) level in cortex (CTX) of mice age less than 120 days [ug/g wet weight] |
Nervous system |
| X909 |
18459 |
Infant ultrasonic vocalization (USV), number of calls on day 7 (AviSoft analysis software), mixed sexes from 2 to 5 litters [n] |
Nervous system |
| X3722 |
18460 |
Infant ultrasonic vocalization (USV), number of calls on day 8 (AviSoft analysis software), mixed sexes from 2 to 5 litters [n] |
Nervous system |
| X1931 |
18461 |
Infant ultrasonic vocalization (USV), number of calls on day 9 (AviSoft analysis software), mixed sexes from 2 to 5 litters [n] |
Nervous system |
| X4686 |
18462 |
trait_1 |
Nervous system |
| X3582 |
18463 |
trait_2 |
Nervous system |
| X2881 |
18464 |
trait_3 |
Nervous system |
| X3594 |
18465 |
trait_4 |
Nervous system |
| X3797 |
18466 |
trait_5 |
Nervous system |
| X3570 |
18491 |
Heart weight without statistical adjustment of older females at UTHSC (longevity cohort: 300 to 900 days of age using combined data for standard chow and high fat diets, CD: n=293, HFD: n=276) [mg] |
Nervous system |
| X2950 |
18492 |
Sessions to acquire intravenous cocaine self-administration (0.56 mg/kg/infusion) |
Nervous system |
| X1699 |
18493 |
Cocaine self-administration - Infusions - Principal Component 1 |
Nervous system |
| X297 |
18494 |
Cocaine intravenous self-administration (IVSA), principal component 2 that corresponds well to infusion rate during the ascending limb of the dose-response curve (IAL trait, see Fig 4) (this trait maps to Cy |
Nervous system |
| X180 |
18495 |
Cocaine self-administration - CAL trait |
Nervous system |
| X1903 |
18496 |
Cocaine self-administration - Infusions (0.032 mg/kg/infusion) |
Nervous system |
| X1480 |
18497 |
Cocaine self-administration - Infusions (0.056 mg/kg/infusion) |
Nervous system |
| X2788 |
18498 |
Cocaine self-administration - Infusions (0.1 mg/kg/infusion) |
Nervous system |
| X4846 |
18499 |
Cocaine self-administration - Infusions (0.18 mg/kg/infusion) |
Nervous system |
| X2738 |
18500 |
Cocaine self-administration - Infusions (0.32 mg/kg/infusion) |
Nervous system |
| X3404 |
18501 |
Cocaine self-administration - Infusions (0.56 mg/kg/infusion) |
Nervous system |
| X3546 |
18502 |
Cocaine self-administration - Infusions (1.0 mg/kg/infusion) |
Nervous system |
| X1630 |
18503 |
Cocaine self-administration - Infusions (1.8 mg/kg/infusion) |
Nervous system |
| X2435 |
18504 |
Cocaine self-administration - Active lever presses (0.032 mg/kg/infusion) |
Nervous system |
| X765 |
18505 |
Cocaine self-administration - Active lever presses (0.056 mg/kg/infusion) |
Nervous system |
| X4969 |
18506 |
Cocaine self-administration - Active lever presses (0.1 mg/kg/infusion) |
Nervous system |
| X3514 |
18507 |
Cocaine self-administration - Active lever presses (0.18 mg/kg/infusion) |
Nervous system |
| X4330 |
18508 |
Cocaine self-administration - Active lever presses (0.32 mg/kg/infusion) |
Nervous system |
| X4781 |
18509 |
Cocaine self-administration - Active lever presses (0.56 mg/kg/infusion) |
Nervous system |
| X3863 |
18510 |
Cocaine self-administration - Active lever presses (1.0 mg/kg/infusion) |
Nervous system |
| X2234 |
18511 |
Cocaine self-administration - Active lever presses (1.8 mg/kg/infusion) |
Nervous system |
| X4549 |
18512 |
Cocaine self-administration - Inactive lever presses (0.032 mg/kg/infusion) |
Nervous system |
| X3921 |
18513 |
Cocaine self-administration - Inactive lever presses (0.056 mg/kg/infusion) |
Nervous system |
| X4625 |
18514 |
Cocaine self-administration - Inactive lever presses (0.1 mg/kg/infusion) |
Nervous system |
| X1861 |
18515 |
Cocaine self-administration - Inactive lever presses (0.18 mg/kg/infusion) |
Nervous system |
| X2712 |
18516 |
Cocaine self-administration - Inactive lever presses (0.32 mg/kg/infusion) |
Nervous system |
| X3139 |
18517 |
Cocaine self-administration - Inactive lever presses (0.56 mg/kg/infusion) |
Nervous system |
| X3958 |
18518 |
Cocaine self-administration - Inactive lever presses (1.0 mg/kg/infusion) |
Nervous system |
| X2340 |
18519 |
Cocaine self-administration - Inactive lever presses (1.8 mg/kg/infusion) |
Nervous system |
| X4473 |
11300 |
Mitochondrial strain origin (-1 = C57BL/6J and 1 = DBA/2J) [genotype] |
Other |
| X152 |
12688 |
BXD epoch or phase of production trait 1 [-1 = Taylor BXD series BXD1 to 32, 0 = Taylor series BXD33 to 42, 1 = UTHSC BXD series BXD43 and higher] |
Other |
| X111 |
12689 |
BXD epoch or phase of production trait 2 [-1 = Taylor BXD series BXD1 to 42, 1 = UTHSC BXD series BXD43 and higher] |
Other |
| X546 |
12690 |
BXD epoch or phase of production trait 3 [-1 = Taylor BXD series BXD1 to 32, 1 = Taylor series BXD33 to 42 and all UTHSC BXD series BXD43 and higher] |
Other |
| X1012 |
13033 |
BXD epoch or phase of production trait 4 [-1 = Taylor BXD series BXD1 to 30, 0 = BXD31 and higher] |
Other |
| X1063 |
15966 |
Somite counts at E9.5, measure of developmental stage [n] |
Other |
| X1612 |
15970 |
Filiform papillae number [adjusted n] |
Other |
| X4482 |
16243 |
Age at death (average) of hippocampal samples (use only with UTHSC BXD Aged Hippocampus Affy expression data sets) [days] |
Other |
| X3285 |
16323 |
Del T4-3x, serum thyroxine (T4) 4 weeks after 3 immunizations of female mice with TSHR A-subunit adenovirus minus baseline T4 [micrograms/dL] |
Other |
| X2533 |
16368 |
CPV map 2 |
Other |
| X4378 |
16369 |
CPV map 4 (please enter full detail here on trait BEFORE publication) |
Other |
| X822 |
16370 |
CPV mapping 4 |
Other |
| X2369 |
16371 |
CPV map 10 |
Other |
| X4110 |
16372 |
CPV map 9 (Amanda Rice, Dick Moyer and colleagues 2013) |
Other |
| X2233 |
16373 |
CPV map 8 (please enter full detail here on trait BEFORE publication and add Abbreviations) |
Other |
| X2678 |
16374 |
CPV map 7 |
Other |
| X2835 |
16381 |
CPV map 6 |
Other |
| X3908 |
16382 |
CPV map 5 (please enter full detail here on trait BEFORE publication) |
Other |
| X4377 |
16383 |
CPV map 3 (please enter full detail here on trait BEFORE publication) |
Other |
| X4157 |
16384 |
CPV mapping Amanda Data map 1 |
Other |
| X2832 |
17309 |
Batch processing lot number for BXD Lung expression, where batch 1 processed by Jesse Ziebarth, batch 2 and 3 processed by Ashutosh Pandey (HZI PR8M-Infected Lungs Females RNAseq (Oct14) RPKM Log2) [lot n] |
Other |
| X914 |
17328 |
1416531_at (Gsto1) Residual [partial correlation with markers rs13483647 and rs13483649 using Hippocampus Consortium M430v2 (Jun06) RMA Database] |
Other |
| X748 |
17343 |
Glaucoma, morphological optic nerve severity score to be used only with BXD Eye expression data (Howell et al. 2011, DBA/2J Glaucoma M430 2.0 (Sep11) RMA database). Not BXD data but DBA/2J data at different stages of dis |
Other |
| X3820 |
17350 |
Breeding performance at the Jackson Laboratory between 2008 and 2014 scored as a qualitative trait, where a score of 1 indicates that a strain may require special maintenance, exhibit reduced productivity, and/or experience some incidence of |
Other |
| X2837 |
17351 |
Breeding performance at UTHSC between 2008 and 2014 scored as a qualitative trait, where a score of 1 indicates that a strain may require special maintenance, exhibit reduced productivity, and/or experience some incidence of non-productive m |
Other |
| X3185 |
17437 |
Glaucoma, optic nerve molecular PCA severity score used only with BXD Eye expression data (Howell et al. 2011, DBA/2J Glaucoma M430 2.0 (Sep11) RMA database). Not BXD data but DBA/2J at different stages of disease from |
Other |
| X1032 |
17438 |
Glaucoma, retina molecular severity score to be used only with BXD Eye expression data (Howell et al. 2011, DBA/2J Glaucoma M430 2.0 (Sep11) RMA databases). Not BXD data but DBA/2J data at different stages of disease whe |
Other |
| X2979 |
17440 |
Breeding performance, litters per year per breeding trio (two females, one male) at the EPFL in Lausanne Switzerland between 2012 and 2015 [n litters/yr] |
Other |
| X3547 |
17441 |
Breeding performance, pups per year per breeding trio (two females, one male) at the EPFL in Lausanne Switzerland between 2012 and 2015(excluding trios that never produced offspring) [n pups/yr] |
Other |
| X3732 |
17442 |
Breeding performance, productive trio matings (ratio of productive to non-productive trio cages) at the EPFL in Lausanne Switzerland between 2012 and 2015 (excludes trios with less than 6 weeks of cohabitation) [ratio] |
Other |
| X1820 |
17443 |
Breeding performance, litter size at birth (within 24 hrs) at the Jackson Laboratory (BXD29-Tlr4 not entered but value is 4.25+/-0.639 n=8), Mouse Phenome Database traits MDP:42302,423033, and 44403 (TyJ in standard barrier room, RwwJ set i |
Other |
| X3050 |
17444 |
Breeding performance, litter size at weaning (circa 20 days) at the Jackson Laboratory (BXD29-Tlr4 not entered but value is 3.11+/-0.1.16 with n=8), Mouse Phenome Database traits MDP:42303,42304, and 44404 (minimum SE for n<4 set to 1.0) [n |
Other |
| X2446 |
17445 |
Breeding performance, interval between litters at the Jackson Laboratory (BXD29-Tlr4 not entered but value is 4.96 +/- 0.58 n=7), Mouse Phenome Database traits MDP:44301 and 42302 (TyJ in standard barrier room, RwwJ set in SPF maximum barrie |
Other |
| X2397 |
17446 |
Breeding performance, litter size within 24 hrs of birth at UTHSC (2000 to 2010) |
Other |
| X3736 |
17447 |
Breeding performance, litter size at birth for breeding trio at the EPFL in Lausanne Switzerland between 2012 and 2015 [n] |
Other |
| X76 |
17464 |
GABRA2 receptor expression status where 1 = normal high expression and 0 = low expression as seen in C57BL/6J after 1990 [level] |
Other |
| X553 |
17553 |
Cohort study order_CD, males [rank] |
Other |
| X646 |
17554 |
Cohort study order_HFD, males [rank] |
Other |
| X461 |
17555 |
Cohort study order_CD, males [weeks] |
Other |
| X343 |
17556 |
Cohort study order_HFD, males [weeks] |
Other |
| X311 |
18069 |
Trait 1a |
Other |
| X517 |
18070 |
Trait 1b |
Other |
| X5089 |
18071 |
Polynomial_Slopes_of Medians |
Other |
| X2655 |
18072 |
Linear_Slopes_of Medians |
Other |
| X2292 |
10416 |
Locomotion, distance traveled in 30 min in open field, baseline [cm] |
Anxiety |
| X5031 |
10819 |
Open field behavior, locomotion from 0-45 min [n beam breaks] |
Anxiety |
| X2135 |
13458 |
Open field activity (OFA), total distance by 8-week-old F1 hybrids generated by crossing male BXDs with female C57BL/6J-R6/2 Huntington carriers [% of wildtype control] |
Anxiety |
| X1355 |
10078 |
Ethanol response (2.5 g/kg ip), ataxia on grid test, 10 to 12 min after injection in 24-28 week-old males, foot fall errors/distance run in the apparatus [n/distance] |
Drug response |
| X4807 |
10079 |
Ethanol response (3 day exposure to 8-11 g/kg ethanol in vapor chamber with pyrazole 1 mM/kg/day), handling-induced convulsion (HIC) withdrawal severity score (15x 1 hour measurements) in 24-28 week-old male |
Drug response |
| X2765 |
10080 |
Ethanol response (3 day exposure to 8-11 g/kg ethanol in vapor chamber with pyrazole 1 mM/kg/day), handling-induced convulsion (HIC) withdrawal severity score (15x 1 hour measurements) in 24-28 week-old male |
Drug response |
| X1472 |
10081 |
Ethanol response (3 day exposure to 8-11 g/kg ethanol in vapor chamber with pyrazole 1 mM/kg/day), handling-induced convulsion (HIC) withdrawal severity score (15x 1 hour measurements) in 24-28 week-old male |
Drug response |
| X17 |
10153 |
Ethanol response (10% in water, po), preference during 3-week free choice period using two-bottle choice test for males [fraction] |
Drug response |
| X13 |
10154 |
Ethanol response (10% in water po), preference during free choice period for females using two-bottle choice test [ratio] |
Drug response |
| X15 |
10155 |
Ethanol response (10% in water, po), consumption during 3-week free choice period using two-bottle choice test for males [gm/kg/day] |
Drug response |
| X16 |
10156 |
Ethanol response (10% in water, po), consumption during free choice period for females using two-bottle choice test [gm/kg/day] |
Drug response |
| X12 |
10158 |
Ethanol response (10% in water po), ethanol preference ratio using a two-bottle choice test [ratio] |
Drug response |
| X11 |
10159 |
Ethanol response (10% in tap water), voluntary consumption ratio using a two-bottle choice test [gm/kg] |
Drug response |
| X924 |
10417 |
Cocaine response (dose), locomotor activation after injection, distance in 30 min test [cm] |
Drug response |
| X3527 |
10593 |
Amphetamine response (20 mg/kg ip d amphetamine), core body temperature change after injection [degree C] |
Drug response |
| X315 |
11297 |
Ethanol response (10% w/v in water), consumption using a two-bottle choice for males and females, average between days 5-11, new BXD strains only [g/kg/24h] |
Drug response |
| X125 |
11632 |
3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) response (10 mg/kg subcutaneous), locomotion on day 2 for females [cm/90 min test] |
Drug response |
| X121 |
11634 |
Saline control response, locomotor activity after second injection for females (control for MDMA response experiment) [cm/test period] |
Drug response |
| X44 |
13021 |
Ethanol response (CIE), 3a,5b-tetrahydrodeoxycorticosterone (THDOC) neurosteroid in blood plasma 3 days after cycle 5 of chronic intermittent ethanol (CIE) vapor treatment [pg/g] |
Drug response |
| X43 |
13028 |
Control for ethanol response, 3a,5b-tetrahydrodeoxycorticosterone (THDOC) neurosteroid in blood plasma 3 days after cycle 5 of chronic intermittent air vapor [pg/g] |
Drug response |
| X1584 |
15134 |
Saline response, control for MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), dihydroxyphenylacetic acid (DOPAC, a dopamine metabolite) in caudate-putamen (striatum) in 2-4 month-old males 48 h after s |
Drug response |
| X1556 |
15135 |
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) response (12.5 mg/kg ip), dihydroxyphenylacetic acid (DOPAC, a dopamine metabolite) level in caudate-putamen (striatum) in males 48 h after injection (MPT |
Drug response |
| X2883 |
15136 |
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) response (12.5 mg/kg ip), dihydroxyphenylacetic acid (DOPAC, a dopamine metabolite) in caudate-putamen (striatum) concentration in males 48 h after inject |
Drug response |
| X4096 |
15137 |
Saline response, control for MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), dopamine (DA) in caudate-putamen (striatum) in 2-4 month-old males 48 h after saline injection (sc) [ug/mg wet weight] |
Drug response |
| X2901 |
15138 |
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) response (12.5 mg/kg sc), dopamine (DA) concentration in caudate-putamen (striatum) in males 48 h after injection (MPTP group) [ug/mg wet weight] |
Drug response |
| X3511 |
15140 |
Saline response, control for MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), homovanillic acid (HVA, a dopamine metabolite) in caudate-putamen (striatum) in 2-4 month-old males 48 h after saline injec |
Drug response |
| X1637 |
15141 |
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) response (12.5 mg/kg sc), homovanillic acid (HVA) concentration in caudate-putamen (striatum) in males 48 h after injection (MPTP group) [ug/mg wet weigh |
Drug response |
| X1418 |
15143 |
Saline response, control for MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), 3-methoxytyramine (3-MT, a dopamine metabolite) in caudate-putamen (striatum) in 2-4 month-old males 48 h after saline inje |
Drug response |
| X4358 |
15144 |
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) response (12.5 mg/kg sc), 3-methoxytyramine (3-MT, a dopamine metabolite) concentration in caudate-putamen (striatum) in males 48 h after injection (MPTP |
Drug response |
| X2989 |
15145 |
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) response (12.5 mg/kg sc) on 3-methoxytyramine (3-MT, a dopamine metabolite) concentration in caudate-putamen (striatum) in 2-4 month-old males 48 h after |
Drug response |
| X4554 |
15146 |
Saline response, control for MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), DOPAC/DA ratio (index of presynaptic dopamine utilization) in caudate-putamen (striatum) in 2-4 month-old males 48 h after |
Drug response |
| X1608 |
15147 |
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) response (12.5 mg/kg ip), DOPAC/DA ratio (index of presynaptic dopamine utilization) in caudate-putamen (striatum) in males 48 h after injection (MPTP gr |
Drug response |
| X1131 |
15148 |
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) response (12.5 mg/kg ip), DOPAC/DA ratio (index of presynaptic dopamine utilization) in caudate-putamen (striatum) in males 48 h after injection (saline-M |
Drug response |
| X2421 |
15149 |
Saline response, control for MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), HVA/DA concentration ratio (index of postsynaptic dopamine utilization) in caudate-putamen (striatum) in 2-4 month-old male |
Drug response |
| X1901 |
15150 |
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) response (12.5 mg/kg sc), HVA/DA (index of postsynaptic dopamine utilization) in caudate-putamen (striatum) in males 48 h after injection (MPTP group) (B |
Drug response |
| X183 |
15151 |
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) response (12.5 mg/kg, sc), HVA/DA (index of postsynaptic dopamine utilization) in caudate-putamen (striatum) in males 48 h after injection (saline minus |
Drug response |
| X1943 |
15152 |
Saline response, control for MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), serotonin (5-HT) concentration in caudate-putamen (striatum) in 2-4 month-old males 48 h after saline injection (sc) [ug/mg |
Drug response |
| X3373 |
15153 |
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) response (12.5 mg/kg s.c.), 5-HT concentration in caudate-putamen (striatum) in males 48 h after injection (MPTP group) [ug/g wet weight] |
Drug response |
| X1115 |
15154 |
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) response (12.5 mg/kg ip), serotonin (5-HT) concentration in caudate-putamen (striatum) in males 48 h after injection (saline-MPTP group) [ug/mg total prot |
Drug response |
| X2823 |
15155 |
Saline response, control for MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), 5-HIAA (serotonin metabolite) concentration in caudate-putamen (striatum) in 2-4 month-old males 48 h after saline injectio |
Drug response |
| X1478 |
15157 |
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) response (12.5 mg/kg sc), 5-HIAA (5-HT metabolite) level in caudate-putamen (striatum) in males 48 h after injection (saline-MPTP group) [ug/mg total pro |
Drug response |
| X1125 |
15158 |
Saline response, control for MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), glial acidic fibrillary protein (GFAP, a marker of neurotoxicity) in caudate-putamen (striatum) in 2-4 month-old males 48 h |
Drug response |
| X2434 |
15159 |
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) response (12.5 mg/kg s.c.), glial fibrillary acidic protein (GFAP, a marker of neurotoxicity) in caudate-putamen (striatum) in males 48 h after injectio |
Drug response |
| X2061 |
15160 |
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) response (12.5 mg/kg s.c.), glial fibrillary acidic protein (GFAP, a marker of neurotoxicity) in caudate-putamen (striatum) in males 48 h after injectio |
Drug response |
| X2063 |
15161 |
Saline response, control for MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), tyrosine hydroxylase (TH, rate limiting enzyme for catecholamine synthesis) in caudate-putamen (striatum) in 2-4 month-old |
Drug response |
| X3255 |
15162 |
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) response (12.5 mg/kg s.c.), tyrosine hydroxylase (TH, rate limiting enzyme for catecholamine synthesis) in caudate-putamen (striatum) in males 48 h after |
Drug response |
| X949 |
15163 |
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) response (12.5 mg/kg s.c.), tyrosine hydroxylase (TH, rate limiting enzyme for catecholamine synthesis) in caudate-putamen (striatum) in males 48 h afte |
Drug response |
| X3970 |
15164 |
Saline response, control for MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), iron concentration in ventral midbrain (SN and VTA) in 2-4 month-old males 48 h after saline injection (sc) [ug/mg wet weig |
Drug response |
| X2214 |
15165 |
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) response (12.5 mg/kg sc), iron concentration in ventral midbrain (SN and VTA) in 2-4 month-old males 48 h after injection (MPTP group) [ug/mg wet weight] |
Drug response |
| X2867 |
15166 |
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) response difference (12.5 mg/kg sc vs saline), iron concentration in ventral midbrain (SN and VTA) in 2-4 month-old males 48 h after injection [differenc |
Drug response |
| X961 |
17025 |
Saline response, control for MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), dihydroxyphenylacetic acid (DOPAC, a dopamine metabolite) in caudate-putamen (striatum) in 2-4 month-old females 48 h after |
Drug response |
| X456 |
17026 |
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) response (12.5 mg/kg sc), dihydroxyphenylacetic acid (DOPAC, a dopamine metabolite) level in caudate-putamen (striatum) in females 48 h after injection ( |
Drug response |
| X2536 |
17027 |
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) response (12.5 mg/kg sc) on dihydroxyphenylacetic acid (DOPAC, a dopamine metabolite) concentration in caudate-putamen (striatum) in females 48h after in |
Drug response |
| X3218 |
17028 |
Saline response, control for MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), dopamine (DA) in caudate-putamen (striatum) in 2-4 month-old females 48 h after saline injection (sc) [ug/mg wet weight] |
Drug response |
| X1643 |
17029 |
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) response (12.5 mg/kg sc), dopamine (DA) concentration in caudate-putamen (striatum) in females 48 h after injection (MPTP group) [ug/mg wet weight] |
Drug response |
| X3383 |
17031 |
Saline response, control for MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), homovanillic acid (HVA, a dopamine metabolite) in caudate-putamen (striatum) in 2-4 month-old females 48 h after saline inj |
Drug response |
| X1465 |
17032 |
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) response (12.5 mg/kg sc), homovanillic acid (HVA) concentration in caudate-putamen (striatum) in females 48 h after injection (MPTP group) [ug/mg wet wei |
Drug response |
| X1231 |
17034 |
Saline response, control for MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), serotonin (5-HT) concentration in caudate-putamen (striatum) in 2-4 month-old females 48 h after saline injection (sc) [ug/ |
Drug response |
| X1893 |
17035 |
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) response (12.5 mg/kg sc), serotonin (5-HT) concentration in caudate-putamen (striatum) in females 48 h after injection (MPTP group) [ug/mg wet weight] |
Drug response |
| X1751 |
17036 |
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) response (12.5 mg/kg sc) on serotonin (5-HT) concentration in caudate-putamen (striatum) in 2-4 month-old females 48 h after injection (saline-MPTP group |
Drug response |
| X4705 |
17037 |
Saline response, control for MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), DOPAC/DA ratio (index of presynaptic dopamine utilization) in caudate-putamen (striatum) in 2-4 month-old females 48 h afte |
Drug response |
| X3351 |
17039 |
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) response (12.5 mg/kg sc), 5-HIAA (5-HT metabolite) level in caudate-putamen (striatum) in females 48 h after injection (saline-MPTP group) [ug/mg total p |
Drug response |
| X421 |
17040 |
Saline response, control for MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), glial fibrillary acidic protein (GFAP, a marker of neurotoxicity) in caudate-putamen (striatum) in 2-4 month-old females 48 |
Drug response |
| X827 |
17041 |
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) response (12.5 mg/kg s.c.), glial fibrillary acidic protein (GFAP, a marker of neurotoxicity) in caudate-putamen (striatum) in females 48 h after inject |
Drug response |
| X1477 |
17042 |
MPTP-Saline group (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) response (12.5 mg/kg s.c.), glial fibrillary acidic protein (GFAP, a marker of neurotoxicity) in caudate-putamen (striatum) in females 48 h |
Drug response |
| X3768 |
17043 |
Saline response, control for MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), tyrosine hydroxylase (TH, rate limiting enzyme for catecholamine synthesis) in caudate-putamen (striatum) in 2-4 month-old |
Drug response |
| X3262 |
17044 |
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) response (12.5 mg/kg s.c.), tyrosine hydroxylase (TH, rate limiting enzyme for catecholamine synthesis) in caudate-putamen (striatum) in females 48 h aft |
Drug response |
| X3673 |
17045 |
Saline-MPTP group (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) response (12.5 mg/kg s.c.), tyrosine hydroxylase (TH, rate limiting enzyme for catecholamine synthesis) in caudate-putamen (striatum) in fe |
Drug response |
| X2974 |
17046 |
Saline response, control for MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), DOPAC/DA ratio (index of presynaptic dopamine utilization) in caudate-putamen (striatum) in 2-4 month-old females, 48 h aft |
Drug response |
| X1555 |
17049 |
Saline response, control for MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), HVA/DA concentration ratio (index of postsynaptic dopamine utilization) in caudate-putamen (striatum) in 2-4 month-old fema |
Drug response |
| X3831 |
17050 |
MPTP group (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) response (12.5 mg/kg sc), HVA/DA (index of postsynaptic dopamine utilization) in caudate-putamen (striatum) in 2-4 month old females, 48 h after MP |
Drug response |
| X4795 |
17051 |
Saline-MPTP group (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) response (12.5 mg/kg, sc), HVA/DA (index of postsynaptic dopamine utilization) in caudate-putamen (striatum) in 2-4 month old females (Salin |
Drug response |
| X1367 |
17052 |
Saline response, control for MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), dihydroxyphenylacetic acid (DOPAC, a dopamine metabolite) in caudate-putamen (striatum) in 2-4 month-old mice, sexes combin |
Drug response |
| X1587 |
17053 |
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) response (12.5 mg/kg sc), dihydroxyphenylacetic acid (DOPAC, a dopamine metabolite) level in caudate-putamen (striatum) in mice, sexes combined, 48 h aft |
Drug response |
| X3193 |
17054 |
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) response (12.5 mg/kg sc) on dihydroxyphenylacetic acid (DOPAC, a dopamine metabolite) concentration in caudate-putamen (striatum) in mice, sexes combined |
Drug response |
| X2971 |
17055 |
Saline response, control for MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), dopamine (DA) in caudate-putamen (striatum) in 2-4 month-old mice, sexes combined, 48 h after saline injection (sc) [ug/mg |
Drug response |
| X4745 |
17056 |
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) response (12.5 mg/kg sc), dopamine (DA) concentration in caudate-putamen (striatum) in mice, sexes combined, 48 h after injection (MPTP group) [ug/mg wet |
Drug response |
| X3240 |
17058 |
Saline response, control for MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), homovanillic acid (HVA, a dopamine metabolite) in caudate-putamen (striatum) in 2-4 month-old mice, sexes combined, 48 h af |
Drug response |
| X1229 |
17059 |
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) response (12.5 mg/kg sc), homovanillic acid (HVA) concentration in caudate-putamen (striatum) in mice, sexes combined, 48 h after injection (MPTP group) |
Drug response |
| X1065 |
17061 |
Saline response, control for MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), serotonin (5-HT) concentration in caudate-putamen (striatum) in 2-4 month-old mice, sexes combined, 48 h after saline injec |
Drug response |
| X4733 |
17064 |
Saline response, control for MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), 5-HIAA (serotonin metabolite) concentration in caudate-putamen (striatum) in 2-4 month-old mice, sexed combined, 48 h after |
Drug response |
| X3656 |
17066 |
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) response (12.5 mg/kg sc), 5-HIAA (5-HT metabolite) level in caudate-putamen (striatum) in 2-4 month old mice, sexes combined. 48 h after injection (salin |
Drug response |
| X800 |
17067 |
Saline response, control for MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), glial acidic fibrillary protein (GFAP, a marker of neurotoxicity) in caudate-putamen (striatum) in 2-4 month-old mice, sexe |
Drug response |
| X3323 |
17070 |
Saline response, control for MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), tyrosine hydroxylase (TH, rate limiting enzyme for catecholamine synthesis) in caudate-putamen (striatum) in 2-4 month-old |
Drug response |
| X1494 |
17073 |
Saline response, control for MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), DOPAC/DA ratio (index of presynaptic dopamine utilization) in caudate-putamen (striatum) in 2-4 month-old mice, sexes combi |
Drug response |
| X4410 |
17076 |
Saline response, control for MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), HVA/DA concentration ratio (index of postsynaptic dopamine utilization) in caudate-putamen (striatum) in 2-4 month-old mice |
Drug response |
| X2381 |
17077 |
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) response (12.5 mg/kg sc), HVA/DA (index of postsynaptic dopamine utilization) in caudate-putamen (striatum) in 2-4 month old mice, sexes combined, 48 h |
Drug response |
| X2125 |
17078 |
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) response (12.5 mg/kg, sc), HVA/DA (index of postsynaptic dopamine utilization) in caudate-putamen (striatum) in 2-4 month old mice, sexes combined, 48 h |
Drug response |
| X42 |
17465 |
Ethanol response (2 g/kg ip), acute locomotor activity response (horizontal distance), 1-5 min after injection, difference between day 2 saline injection response and day 3 ethanol injection in young adult f |
Drug response |
| X113 |
15792 |
Bile acids, fasted state, chow diet, males [umol/L] |
Hematology |
| X5054 |
15810 |
Bile acids, fasted state, high fat diet, males [umol/L] |
Hematology |
| X33 |
18520 |
Gelsolin protein level in plasma from young adults, 1 sample with triplicate technical replicates [mg/l) |
Hematology |
| X349 |
10057 |
T-cell anergy induced by Bacillus Calmette___Guê©rin tuberculosis vaccine (BCG), delayed type hypersensitivity in footpad increments [mm] |
Immune |
| X3081 |
10188 |
Syngeneic breast cancer tumor growth at day 30 [mm3] |
Immune |
| X3930 |
10189 |
Syngeneic breast cancer tumor growth, day 35 [mm3] |
Immune |
| X6 |
10190 |
Growth of syngeneic breast cancer tumors day 40 [mm3] |
Immune |
| X7 |
10191 |
Growth of syngeneic breast cancer tumors day 45 [mm3] |
Immune |
| X8 |
10192 |
Growth of syngeneic breast cancer tumors day 50 [mm3] |
Immune |
| X9 |
10193 |
Leukocyte infiltration in metastatic breast tumor on day 5 (0 means no leukocyte infiltration and no destruction of implanted tumor cells and 4 means most severe destruction) [index] |
Immune |
| X776 |
10194 |
Leukocyte infiltration in metastatic breast tumor on day 12 (0 means no leukocyte infiltration and no destruction of implanted tumor cells and 4 means most severe destruction) [index] |
Immune |
| X10 |
10195 |
Leukocyte infiltration in metastatic breast tumor on day 30 (0 means no leukocyte infiltration and no destruction of implanted tumor cells and 4 means most severe destruction) [index] |
Immune |
| X5 |
10196 |
T cell infiltration at tumor site in breast cancer cells on day 5 (0 means no leukocyte infiltration and no destruction of implanted tumor cells and 4 means most severe destruction) [index] |
Immune |
| X420 |
10197 |
T cell infiltration at tumor site in breast cancer cells on day 1 (0 means no leukocyte infiltration and no destruction of implanted tumor cells and 4 means most severe destruction) [index] |
Immune |
| X432 |
10198 |
T cell infiltration at tumor site in breast cancer cells on day 30 (0 means no leukocyte infiltration and no destruction of implanted tumor cells and 4 means most severe destruction) [index] |
Immune |
| X140 |
10199 |
Apoptosis of breast tumor cells on day 12 (0 means no apoptosis infiltration and no destruction of implanted tumor cell and 4 means most severe) [index] |
Immune |
| X1301 |
10200 |
Apoptosis of breast tumor cells on day 30 (0 means no apoptosis infiltration and no destruction of implanted tumor cell and 4 means most severe) [index] |
Immune |
| X93 |
10201 |
Mixed lymphocyte reaction (MLR) with BALB/c spleen cells [cpm stimulated/cpm unstimulated] |
Immune |
| X2945 |
10405 |
Antigenic activity of irradiated spleen cells for Thy-1+CD3+CD4+CD8- T-cell clone (11.1B/c) [thymidine uptake cpm] |
Immune |
| X3827 |
10408 |
Graft-vs-host reaction, antigenic activity of irradiated spleen cells for Thy-1+CD3+CD4+CD8- T-cell clone 11.4 B/c [thymidine uptake, cpm] |
Immune |
| X998 |
10409 |
Antigenic activity of irradiated BXD spleen cells for Thy-1+CD3+CD4+CD8- T-cell clone TGVH 9 [thymidine uptake cpm] |
Immune |
| X123 |
10410 |
Antigenic activity of irradiated BXD spleen cells for Thy1+CD3+CD4+CD8- T-cell clone TGVH32 [thymidine uptake, cpm] |
Immune |
| X2269 |
10411 |
Antigenic activity of irradiated spleen cells for Thy-1+CD3+CD4-CD8+ H-2(d) specific T-cell clone F10 ECK [thymidine uptake cpm] |
Immune |
| X1512 |
10412 |
Antigenic activity of irradiated spleen cells for Thy-1+CD3+CD4+CD8- Mls(a) specific T-cell clone F5J10 [thymidine uptake cpm] |
Immune |
| X710 |
10430 |
Tumor growth and size, 2 weeks post-implantation [mm3] |
Immune |
| X3850 |
10431 |
Tumor growth 3 weeks post-implantation [mm3] |
Immune |
| X5017 |
10432 |
Tumor growth 7 weeks post-implantation [mm3] |
Immune |
| X562 |
10441 |
Anti-F antigen (liver protein) titer, experiment 1, log10 of the reciprocal of the dilution of serum required to bind 50% of the labeled antigen [log binding] |
Immune |
| X1108 |
10442 |
Anti-F antigen (liver protein) titer, experiment 2, log10 of the reciprocal of the dilution of serum required to bind 50% of the labeled antigen [log binding] |
Immune |
| X27 |
10602 |
Serum thyroxine (T4), total serum T4 content [ug/100ml] |
Immune |
| X26 |
10603 |
Serum thyroxine (T4) content (free) [ug/100ml] |
Immune |
| X30 |
10615 |
Proliferation of T cell clone (A9.4 subclone) without 50 ug/ml KLH experiment 1 [cpm] |
Immune |
| X28 |
10616 |
Proliferation of T cell clone (A9.4 subclone) with 50 ug/ml KLH experiment 1, 5X10E5 stimulator cells [cpm] |
Immune |
| X31 |
10617 |
Proliferation of T cell clone (A9.4 subclone) without 50 ug/ml KLH experiment 2 [cpm] |
Immune |
| X29 |
10618 |
Proliferation of T cell clone (A9.4 subclone) with 50 ug/ml KLH experiment 2, 1X10E6 stimulator cells [cpm] |
Immune |
| X4363 |
10627 |
T-cell response, cytotoxic T lymphocytes, 51Cr release at 20:1 E:T after spleen cells primed and boosted in MLC in pool of 5 responders [units] |
Immune |
| X2704 |
10628 |
T-cell response, cytotoxic T lymphocytes, Mean 51Cr release at 10:1 E:T after spleen cells primed and boosted in MLC in pool of 5 responders [units] |
Immune |
| X4814 |
10629 |
T-cell response, antibody-dependent cell-mediated cytotoxicity, 51Cr release at 5:1 E:T after spleen cells primed and boosted in mixed lymphocyte culture (MLC) in pool of five responders [units] |
Immune |
| X4074 |
10630 |
T-cell response, cytotoxic T lymphocytes, 51Cr release at 20:1 E:T after spleen cells primed and boosted in MLC in responder 1 [units] |
Immune |
| X4577 |
10631 |
T-cell response, cytotoxic T lymphocytes, 51Cr release at 10:1 E:T after spleen cells primed and boosted in MLC in responder 1 [units] |
Immune |
| X1410 |
10632 |
T-cell response, cytotoxic T lymphocytes, 51Cr release at 5:1 E:T after spleen cells primed and boosted in MLC in responder 1 [units] |
Immune |
| X1546 |
10633 |
T-cell response, cytotoxic T lymphocytes, 51Cr release at 20:1 E:T after spleen cells primed and boosted in MLC in responder 2 [units] |
Immune |
| X4458 |
10634 |
T-cell response, cytotoxic T lymphocytes, 51Cr release at 10:1 E:T after spleen cells primed and boosted with mixed lymphocyte culture in responder 2 [units] |
Immune |
| X4710 |
10635 |
T-cell response, cytotoxic T lymphocytes, 51Cr release at 5:1 E:T after spleen cells primed and boosted in MLC in responder 2 [units] |
Immune |
| X2013 |
10636 |
T-cell response, cytotoxic T lymphocytes, 51Cr release at 20:1 E:T after spleen cells primed and boosted in MLC in responder 3 [units] |
Immune |
| X2247 |
10637 |
T-cell response, cytotoxic T lymphocytes, 51Cr release at 10:1 E:T after spleen cells primed and boosted in MLC in responder 3 [units] |
Immune |
| X1957 |
10638 |
T-cell response, cytotoxic T lymphocytes, 51Cr release at 5:1 E:T after spleen cells primed and boosted in MLC in responder 3 [units] |
Immune |
| X32 |
10718 |
Leishmania L. mexicana lesion diameter after subcutaneous injection in males (this entry is missing data) [mm] |
Immune |
| X3251 |
10719 |
Leishmania L. mexicana skin lesion diameter in females [mm] |
Immune |
| X3382 |
10867 |
Infection disease, Cox-Hasty trait 1 |
Immune |
| X233 |
12560 |
Weight loss after Francisella tularensis live vaccine strain (FTLVS) intratracheal [percent] |
Immune |
| X563 |
12561 |
Weight loss after Francisella tularensis live vaccine strain (FTLVS) intratracheal [slope] |
Immune |
| X4967 |
12562 |
Survival after Francisella tularensis live vaccine strain (FTLVS) intratracheal [coefficient] |
Immune |
| X52 |
12687 |
Bovine spongioform encephalopathy (prion disease, mouse-adapted scrapie strain ME7), primary transmission incubation period in females [days] |
Immune |
| X5023 |
14311 |
Candida albicans titer, renal, at 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus performed immediately after light onset [CFU x 10^4 per gram tissue we |
Immune |
| X1 |
14313 |
Blood chemistry, infectious disease, White blood cell (WBC) count 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [number per ul of whole blood] |
Immune |
| X3 |
14314 |
Ratio of number of neutrophil to lymphocyte ratio at 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [neutrophil to lymphocyte ratio, whole b |
Immune |
| X2 |
14315 |
Hematocrit 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [proportional packed cell volume of RBCs in whole blood] |
Immune |
| X2821 |
14325 |
Temperature during h 12-24 after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset (difference from baseline, C) |
Immune |
| X3387 |
14327 |
Temperature during h 36-48 after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [difference from baseline, C] |
Immune |
| X1038 |
14329 |
;\Temperature during h 60-72 after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus ;; immediately after light onset [difference from baseline; C] |
Immune |
| X4899 |
14336 |
Candida albicans titer in brain (log) at 72 h after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus immediately after light onset [CFU x 10^4 per gram tissue |
Immune |
| X4226 |
14348 |
locomotor activity (log) during h 0-12 after inoculation with 1 x 10^6 cfu Candida albicans (ATCC 10231) IV via retroorbital sinus performed immediately after light onset [ratio to baseline, log] |
Immune |
| X53 |
15180 |
Burkholderia pseudomallei (strain 1026b, 100 CFU intranasal under isoflurane) survival to 11-days in 12___13 week-old males and females [%] |
Immune |
| X51 |
17080 |
Immunology, infectious disease: Staphloccocus pyogenes (sq injection of 1.0x10x8 CFU) survival index in males and females injected at 10___16 week of age (death before day 3 = 1, death from 3 to 7 = 2, death after day 7 =3) [index] |
Immune |
| X2633 |
18092 |
Thymus weight of females after 7 weeks of chronic mild stress (CMS) followed by an acute stressor (30 min restraint) [g] |
Immune |
| X4985 |
18396 |
S. rectivirgula response (100 ug, three times/week for 2 weeks, one time in third week, (farmer's lung disease), Mice were analyzed 20hrs after the last exposure. Alveolitis was measured by cell counting using trypan blu |
Immune |
| X1393 |
18397 |
S. rectivirgula response (100 ug, three times/week for 2 weeks, one time in third week, (farmer's lung disease) and analyzed 20hrs after the last exposure. Neutrophils were identified by flow cytometry and analysis of F |
Immune |
| X49 |
18398 |
S. rectivirgula response (100 ug, three times/week for 2 weeks, one time in third week, (farmer's lung disease), Mice were analyzed 20hrs after the last exposure. Flow cytometry was performed on the BAL cells and B cells |
Immune |
| X694 |
18399 |
S. rectivirgula response (100 ug, three times/week for 2 weeks, one time in third week, (farmer's lung disease), T cells in bronchioalveolar lavage (BAL) samples 20 hours after last exposure exposure in males (BXD32 wins |
Immune |
| X3613 |
18400 |
S. rectivirgula response (100 ug, three times/week for 2 weeks, one time in third week, (farmer's lung disease), Mice were analyzed 20hrs after the last exposure. Flow cytometry was performed on the BAL cells and gated o |
Immune |
| X1137 |
18401 |
S. rectivirgula response (100 ug, three times/week for 2 weeks, one time in third week, (farmer's lung disease), Mice were analyzed 20hrs after the last exposure. Flow cytometry was performed on the BAL cells in males |
Immune |
| X1095 |
18402 |
S. rectivirgula response (100 ug, three times/week for 2 weeks, one time in third week, (farmer's lung disease), CD8+ T cell in bronchioalveolar lavage (BAL) samples 20 hours after last exposure exposure [%] |
Immune |
| X1984 |
18403 |
S. rectivirgula response (100 ug, three times/week for 2 weeks, one time in third week, (farmer's lung disease), Flow cytometry was performed on the BAL cells from male mice and gated on CD8+/bTcR+/CD69+ expressed as %. |
Immune |
| X818 |
18434 |
Respiratory syncytial virus (RSV) response, viral load in whole lung (NS1 gene) 4 days after infection of 5 day old neonates [mean ratio of NS1 to reference NS1] |
Immune |
| X1347 |
18451 |
S. rectivirgula response (100 ug, three times/week for 2 weeks, one time in third week, (farmer's lung disease), Mice were analyzed 20hrs after the last exposure. Flow cytometry was performed on the BAL cells and PMNs we |
Immune |
| X156 |
18452 |
S. rectivirgula response (100 ug, three times/week for 2 weeks, one time in third week, (farmer's lung disease), Mice were analyzed 20hrs after the last exposure. Flow cytometry was performed and the % of BtcR+ cells in |
Immune |
| X3389 |
18453 |
S. rectivirgula response (100 ug, three times/week for 2 weeks, one time in third week, (farmer's lung disease), Mice were analyzed 20hrs after the last exposure. Flow cytometry was performed and the % of CD4+/BTcR+ cell |
Immune |
| X2877 |
18454 |
S. rectivirgula response (100 ug, three times/week for 2 weeks, one time in third week, (farmer's lung disease), Mice were analyzed 20hrs after the last exposure. Flow cytometry was performed on the BAL cells and gated o |
Immune |
| X2011 |
18455 |
S. rectivirgula response (100 ug, three times/week for 2 weeks, one time in third week, (farmer's lung disease), Mice were analyzed 20hrs after the last exposure. Flow cytometry was performed on the BAL cells and gated o |
Immune |
| X601 |
18456 |
S. rectivirgula response (100 ug, three times/week for 2 weeks, one time in third week, (farmer's lung disease), Mice were analyzed 20hrs after the last exposure. Flow cytometry was performed on the BAL cells and gated o |
Immune |
| X22 |
10160 |
Catalase activity in liver [uMol] |
Metabolism |
| X21 |
10162 |
Aldehyde dehydrogenase (ALDH) activity in liver [nMol NADH/min/mg] |
Metabolism |
| X4 |
10873 |
Corticosterone in plasma, baseline control level [ng/ml] |
Metabolism |
| X1001 |
15773 |
OGTT_ increase rate, chow diet, males [mg/mL/min] |
Metabolism |
| X130 |
15774 |
OGTT_ decrease rate, chow diet, males [mg/mL/min] |
Metabolism |
| X399 |
15776 |
OGTT_ increase rate, high fat diet, males [mg/mL/min] |
Metabolism |
| X4011 |
15777 |
OGTT_ decrease rate, high fat diet, males [mg/mL/min] |
Metabolism |
| X303 |
15958 |
Diabetes model, alloxan response (80 mg/kg iv to induce diabetes by killing pancretic beta cells), retinopathy severity score, males and females from 7 to 17 weeks of age [ordinal scale, 1=normal, 2=slight retinopathy, |
Metabolism |
| X55 |
16336 |
Demo data, Blood glucose level (intraperitoneal glucose tolerance test) at time = 30 min of XX-week old males after inject of XX mg 2DG (2-deoxyglucose) [mg/dl] |
Metabolism |
| X1968 |
17021 |
Diabetes model, response to alloxan (80 mg/kg iv to induce diabetes by killing pancretic beta cells), kidney weight 21 days after treatment as a percentage of body weight in adult males and females without statistical adjus |
Metabolism |
| X23 |
10157 |
Body weight [g] |
Morphology |
| X1920 |
10337 |
Hippocampus granule cell number [n total per side] |
Morphology |
| X1037 |
10639 |
Hindbrain medulla weight (unadjusted) [mg] |
Morphology |
| X1743 |
10717 |
Epidermal ornithine decarboxylase (ODC) activity induced by topical administration of 12-O-tetradecanoylphorbol-13-acetate (TPA) [units] |
Morphology |
| X2074 |
10870 |
Corticosterone in plasma, level after a 10 min forced Porsolt swim test (blood taken 30 min after stressor) [ng/ml] |
Morphology |
| X1912 |
10895 |
Hippocampus volume, bilateral, in situ postmortem from high field MRI [mm^3] |
Morphology |
| X2998 |
10921 |
Cerebellum volume, in situ postmortem from high field MRI [bilateral mm^3] |
Morphology |
| X362 |
10922 |
Cerebral cortex volume, bilateral, in situ postmortem from high field MRI [mm^3] |
Morphology |
| X2305 |
10925 |
Hypothalamus volume, bliateral, in situ postmortem from high field MRI [mm^3] |
Morphology |
| X3942 |
10926 |
Superior colliculus volume, bilateral, from in situ postmortem high field MRI) [mm^3] |
Morphology |
| X2362 |
10927 |
Inferior colliculus volume, bilateral, in situ postmortem from high field MRI [mm^3] |
Morphology |
| X474 |
10928 |
Brain volume, in situ postmortem from high field MRI [mm^3] |
Morphology |
| X4018 |
10929 |
Brain ventricle volume (bilateral, all ventricles, in situ postmortem from high field MRI [mm^3] |
Morphology |
| X3316 |
10930 |
Corpus callosum volume, bilateral, in situ postmortem from high field MRI [mm^3] |
Morphology |
| X3073 |
10931 |
Trigeminal tract volume, bilateral, in situ postmortem from high field MRI [mm^3] |
Morphology |
| X2157 |
10935 |
Laterodorsal nucleus of thalamus volume, bilateral, in situ postmortem from high field MRI [mm^3] |
Morphology |
| X4755 |
10936 |
Deep mesencephalic nuclei (MRN, RN, right and left combined) volume in situ from high field MRI [mm3] |
Morphology |
| X1938 |
10937 |
Globus pallidus volume, in situ postmortem from high field MRI [bilateral mm^3] |
Morphology |
| X4090 |
10939 |
Interpeduncular nucleus volume, bilateral, in situ postmortem from high field MRI [mm^3] |
Morphology |
| X4199 |
10940 |
Cerebral peduncle volume, bilateral, from in situ postmortem high field MRI [mm^3] |
Morphology |
| X2776 |
10941 |
Substantia nigra, bilateral, in situ postmortem from high field MRI [mm^3] |
Morphology |
| X2985 |
10945 |
Ventral thalamic nuclei volume, bilateral from in situ postmortem from high field MRI (includes the VPL, VPM, VP, and VA) [mm^3] |
Morphology |
| X3643 |
10946 |
Fimbria volume, bilateral, in situ postmortem from high field MRI [mm^3] |
Morphology |
| X3464 |
10949 |
Lateral lemniscus (right and left combined), in situ postmortem from high field MRI [mm3] |
Morphology |
| X1611 |
10950 |
Thalamus volume, bilateral, in situ postmortem from high field MRI [mm^3] |
Morphology |
| X2519 |
10951 |
Midbrain partial volume, bilateral (excludes individually segmented nuclei) in situ postmortem from high field MRI [mm^3] |
Morphology |
| X2326 |
10952 |
Brainstem partial volume, bilateral including DpMe, APT, pons, but excluding other individually segmented nuclei, in situ postmortem from high field MRI [mm^3] |
Morphology |
| X641 |
10953 |
Brain volume minus cerebellum volume, in situ postmortem value from high field MRI [mm^3] |
Morphology |
| X2540 |
12334 |
Adrenal X-zone width in males [um] |
Morphology |
| X5086 |
13521 |
Body weight in 8-week F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington mode, CORRECTED R6/2 cases [gm] |
Morphology |
| X40 |
17433 |
Neocortex volume (shrinkage corrected) corrected for age, sex, plane of section, and brain weight, bilateral, both sexes between 50 and 300 days, using the Cavalieri probe [mm3] |
Morphology |
| X45 |
18078 |
Weight of adrenal glands (left and right combined) of females under baseline conditions [g] |
Morphology |
| X54 |
18079 |
Body weight of females at end of study under baseline conditions [g] |
Morphology |
| X39 |
18080 |
Brain weight of females under baseline conditions [g] |
Morphology |
| X34 |
18081 |
Heart weight of females under baseline conditions [g] |
Morphology |
| X50 |
18082 |
Thymus weight of females under baseline conditions [g] |
Morphology |
| X426 |
18088 |
Weight of adrenal glands (left and right combined) of females after 7 weeks of chronic mild stress (CMS) followed by an acute stressor (30 min restraint) [g] |
Morphology |
| X4683 |
18089 |
Body weight of females at end of study after 7 weeks of chronic mild stress (CMS) followed by an acute stressor (30 min restraint) [g] |
Morphology |
| X2311 |
18090 |
Brain weight of females after 7 weeks of chronic mild stress (CMS) followed by an acute stressor (30 min restraint) [g] |
Morphology |
| X3587 |
18091 |
Heart weight of females after 7 weeks of chronic mild stress (CMS) followed by an acute stressor (30 min restraint) [g] |
Morphology |
| X3248 |
18093 |
Weight (baseline) of adrenal glands (left and right combined) of females 30 min after exposue to acute stressor (30 min restraint) [g] |
Morphology |
| X460 |
18094 |
Body weight (baseline) of females at end of study 30 min after exposue to acute stressor (30 min restraint) [g] |
Morphology |
| X3485 |
18095 |
Brain weight (baseline) of females 30 min after exposue to acute stressor (30 min restraint)) [g] |
Morphology |
| X3158 |
18096 |
Heart weight (baseline) of females 30 min after exposue to acute stressor (30 min restraint) [g] |
Morphology |
| X1838 |
18097 |
Thymus weight (baseline) of females 30 min after exposue to acute stressor (30 min restraint) [g] |
Morphology |
| X56 |
15179 |
Malocclusion of incisors in adults of both sexes [frequency scale: 3 = common, 2 = occasional, 1 = rare, 0 =none] |
Musculoskeletal |
| X20 |
10161 |
Catalase activity in brain [nMol] |
Nervous system |
| X19 |
10163 |
Aldehyde dehydrogenase (ALDH) activity in brain [nMol NADH/min/mg protein] |
Nervous system |
| X1706 |
10338 |
Proliferation of BrdU-labeled cells in subgranular zone, day 1 after last BrdU injection [n cells] |
Nervous system |
| X263 |
10339 |
Survival of BrdU-labeled cells in the hippocampal dentate gyrus subgranular zone 4 weeks after last injection [n cells] |
Nervous system |
| X3080 |
10340 |
New neuron percentage in hippocampal dentate gyrus 4 weeks after last BrdU injection [%] |
Nervous system |
| X2862 |
10341 |
Astrocyte cell number percentage 4 weeks after last cell labeling (BrdU) injection [%] |
Nervous system |
| X667 |
10342 |
Newly generated neurons in the dentate gyrus 4 weeks after last BrdU injection [n BrdU cells X ratio of NeuN / BrdU labeled cells] |
Nervous system |
| X2956 |
10343 |
New astrocytes, 4 weeks after last BrdU injection [n BrdU cells X ratio of S100 beta/BrdU labeled cells] |
Nervous system |
| X4423 |
10344 |
Learning measured by the time spent in target quadrant on day 5 (probe trial) using the Morris water maze [%] |
Nervous system |
| X3678 |
10345 |
Learning and memory function, Morris water maze, swim time for the probe trial on day 5 [%] |
Nervous system |
| X82 |
10382 |
Raffinose bitter taste response (raffinose undecaacetate 0.4 mM in water), consumption [%] |
Nervous system |
| X273 |
10383 |
Lactose sweet taste response (0.3 mM beta-lactose acetate in water), consumption [%] |
Nervous system |
| X25 |
10604 |
Seizure susceptibility (audiogenic), severity [score] |
Nervous system |
| X24 |
10605 |
Seizure susceptibility (audiogenic), clonic tonic percentage [%] |
Nervous system |
| X3009 |
10619 |
Learning and memory performance measured using Morris water maze, site preference computed as crosses over trained site minus crosses over alternative sites [n] |
Nervous system |
| X4383 |
10620 |
Morris water maze search-time preference, amount of time spent in the trained quadrant of the pool minus mean time in the alternative quadrants [seconds] |
Nervous system |
| X2190 |
10621 |
Protein kinase C (PKC) activity in hippocampus [pmol/min/mg protein total hippocampus] |
Nervous system |
| X522 |
10622 |
Protein kinase C (PKC) activity for hippocampus particulate fraction [pmol/min/mg protein] |
Nervous system |
| X3259 |
10623 |
Protein kinase C (PKC) activity in hippocampus cytosol [pmol/min/mg protein] |
Nervous system |
| X5066 |
10624 |
Protein kinase C (PKC) activity for neocortex (total sample) [pmol/min/mg protein] |
Nervous system |
| X5046 |
10625 |
Protein kinase C (PKC) activity for cortex particulate fraction [pmol/min/mg protein] |
Nervous system |
| X4060 |
10693 |
Morphine metabolism, morphine UDP-glucuronyltransferase activity [units] |
Nervous system |
| X4153 |
10694 |
Morphine UDP-glucouronytransferease activity (B3GAT genes) [units] |
Nervous system |
| X1376 |
10807 |
Memory performance measured as fraction of swim distance spent in the learned target quadrant [%] |
Nervous system |
| X4156 |
10808 |
Learning performance measured as the latency to reach the platform during acquisition of Morris water maze task [s] |
Nervous system |
| X3397 |
10810 |
Average path length to reach the platform during acquisition of task using Morris water maze [cm] |
Nervous system |
| X948 |
10814 |
Swimming speed during acquisition of task using Morris water maze [cm/s] |
Nervous system |
| X640 |
10815 |
Learning performance measured as the difference in swim path to reach the platform between days 1 and 4 of training using Morris water maze [cm] |
Nervous system |
| X2357 |
10816 |
Learning measured by the difference in time (latency) to reach the platform between day 1 and day 4 of training using Morris water maze [s] |
Nervous system |
| X3428 |
10824 |
Locomotor performance, duration on an accelerating rotarod, mean of three trials [s] |
Nervous system |
| X4811 |
10893 |
Septal nuclei volume, bilateral, in situ postmortem from high field MRI [mm^3] |
Nervous system |
| X4004 |
10894 |
Striatum (caudate-putamen), bilateral, in situ postmortem from high field MRI [mm^3] |
Nervous system |
| X1152 |
10923 |
Olfactory bulb volume, bilateral, in situ postmortem from high field MRI [mm^3] |
Nervous system |
| X4434 |
10924 |
Amygdala volume, bilateral, in situ postmortem from high field MRI [mm^3] |
Nervous system |
| X2070 |
10932 |
Optic tract volume, bilateral, in situ postmortem from high field MRI [mm^3] |
Nervous system |
| X4634 |
10933 |
Anterior pretectal nucleus volume, bilateral, from in situ postmortem high field MRI [mm^3] |
Nervous system |
| X2277 |
10934 |
Geniculate nuclei volume of thalamus (MGN and LGN combined, bilateral, in situ postmortem from high field MRI) [mm^3] |
Nervous system |
| X2507 |
10938 |
Cochlear nuclei volume (right and left combined), in situ postmortem from high field MRI [mm3] |
Nervous system |
| X3047 |
10942 |
Pontine nuclei volume, bilateral, in situ postmortem from high field MRI [mm^3] |
Nervous system |
| X1400 |
10943 |
Nucleus accumbens volume, bilateral, in situ postmortem from high field MRI [mm^3] |
Nervous system |
| X1499 |
10944 |
Anterior commissure volume, bilateral, from in situ postmortem high field MRI [mm^3] |
Nervous system |
| X3559 |
10948 |
Periaqueductal gray volume, bilateral, in situ postmortem from high field MRI [mm^3] |
Nervous system |
| X604 |
11285 |
Contralateral visual cortex (V1) shift in intrinsic response to contralateral eye stimulation after monocular deprivation of the contralateral eye from P28 to P35 |
Nervous system |
| X4740 |
11286 |
Visual cortex (V1) activity, ipsilateral shift in intrinsic response to ipsilateral eye stimulation after monocular deprivation of the contralateral eye from P28 to P35 |
Nervous system |
| X274 |
11633 |
Locomotor activity after first saline injection (day 1) for females (MDMA control) [cm/ test period] |
Nervous system |
| X3261 |
12736 |
3alpha,5alpha-tetrahydroprogesterone (THP) level in the olfactory bulb and tubercle 1 hrs after saline injection, morning sample collection (control for ethanol experiments) [pg/g] |
Nervous system |
| X38 |
12746 |
Infarct volume in neocortex following experimental stroke (permanent middle cerebral artery and ipsilateral common carotid artery occlusion) in adult males and females (2- to 4-months old), 24 hr survival [mm |
Nervous system |
| X37 |
14789 |
R6/2 soluble/WT soluble protein by FRET ratio in 8 week old F1 hybrids between male BXD strains and C57BL/6J-R6/2 Huntington model, [FRETT florescence ratio] |
Nervous system |
| X36 |
14794 |
Sleep percent in 10-14 week-old males [% day] |
Nervous system |
| X268 |
15139 |
Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on dopamine concentration in caudate-putamen (striatum) in males 48 h after injection (saline-MPTP group) [ug/mg wet weight] |
Nervous system |
| X3984 |
15142 |
Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on homovanilic acid (HVA) concentration in caudate-putamen in males 48h after injection (saline-MPTP group) [ug/mg wet weight] |
Nervous system |
| X1839 |
15156 |
Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on 5-HIAA (5-HT metabolite) concentration in caudate-putamen (striatum) in males 48 h after injection (MPTP group) [ug/mg total protein] |
Nervous system |
| X3086 |
16198 |
;Central nervous system;; embryonic neurogenesis;; Cell death in untreated brainstem at E9 (TUNEL+ cells/mm2); |
Nervous system |
| X4515 |
16199 |
;Central nervous system;; embryonic neurogenesis;; Cell death in untreated forebrain at E9 (TUNEL+ cells/mm2); |
Nervous system |
| X41 |
16352 |
3-nitropropionic acid neurodegeneration in striatum (caudate putamen) (50 mg/kg ip) in young adults (mostly females) |
Nervous system |
| X3842 |
16606 |
Impulsivity in a 5-choice serial reaction time task in males (arsin transformed percentage of premature responses in a long ITI challenge) [% time] |
Nervous system |
| X2271 |
16615 |
Conditioned fear expression using tone-shock pairing in adult males (12 to 18 weeks) [%] |
Nervous system |
| X2973 |
17030 |
Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on dopamine concentration in caudate-putamen (striatum) in females 48 h after injection (saline-MPTP group) [ug/mg wet weight] |
Nervous system |
| X232 |
17033 |
Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on homovanilic acid (HVA) concentration in caudate-putamen in females 48h after injection (saline-MPTP group) [ug/mg wet weight] |
Nervous system |
| X3048 |
17038 |
Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on DOPAC/DA (index of presynaptic dopamine utilization) in caudate-putamen in females 48h after injection (MPTP group) [ug/mg wet weight] |
Nervous system |
| X4016 |
17047 |
Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP group) on DOPAC/DA (index of presynaptic dopamine utilization) in caudate-putamen in 2-4 month old females, 48 h after saline injection (sc) [ra |
Nervous system |
| X3071 |
17048 |
Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on DOPAC/DA (index of presynaptic dopamine utilization) in caudate-putamen in 2-4 month old females, 48 h after saline injection (sc) [ratio of |
Nervous system |
| X596 |
17057 |
Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on dopamine concentration in caudate-putamen (striatum) in mice, sexes combined, 48 h after injection (saline-MPTP group) [ug/mg wet weight] |
Nervous system |
| X3443 |
17060 |
Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on homovanilic acid (HVA) concentration in caudate-putamen in mice, sexes combined, 48h after injection (saline-MPTP group) [ug/mg wet weight] |
Nervous system |
| X3538 |
17062 |
Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) 5-HT Concentration in Caudate-putamen (ug/mg wet weight) in 2-4 month old mice, sexes combined, 48h after injection (MPTP group) [ug/mg wet wei |
Nervous system |
| X3991 |
17063 |
Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) 5-HT Concentration in Caudate-putamen in2-4 month old mice, sexes combined, 48h after injection (Saline-MPTP group) [ug/mg wet weight] |
Nervous system |
| X3902 |
17065 |
Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) 5-HIAA (5-HT metabolite) concentration in caudate-putamen in 2-4 month old mice, sexes combined, 48h after injection (MPTP group) [ug/mg wet we |
Nervous system |
| X794 |
17068 |
Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on glial acidic fibrillary protein (GFAP, a marker of neurotoxicity) concentration in caudate-putamen in 2-4 month old mice, sexes combined, 48 |
Nervous system |
| X1245 |
17069 |
Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP minus saline group) on glial acidic fibrillary protein (GFAP, a marker of neurotoxicity) concentration in caudate-putamen in 2-4 month old mice, |
Nervous system |
| X2048 |
17071 |
Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) Tyrosine Hydroxylase (TH, rate limiting enzyme for catecholamine synthesis) Concentration in Caudate-putamen in 2-4 month old mice, sexes combi |
Nervous system |
| X502 |
17072 |
Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on tyrosine hydroxylase (TH, rate limiting enzyme for catecholamine synthesis) concentration in caudate-putamen (striatum) in 2-4 onth old mice |
Nervous system |
| X2307 |
17074 |
Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on DOPAC/DA (index of presynaptic dopamine utilization) in caudate-putamen in 2-4 month old mice, sexes combined, 48h after injection (MPTP gr |
Nervous system |
| X1827 |
17075 |
Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on DOPAC/DA (index of presynaptic dopamine utilization) in caudate-putamen in 2-4 month old mice, sexes combined, 48h after injection (Saline- |
Nervous system |
| X1149 |
17079 |
Fear conditioning, freezing response time to conditioned cue after 24 hours (data combined from Yang et al 2008, Brigman et al 2009, and Knoll-Levitt 2014) [%] |
Nervous system |
| X3873 |
17454 |
Central nervous system, endocrinology, Air control response, 3a,5a-tetrahydrodeoxycorticosterone (3a,5a-THDOC) in plasma 72 h after the 5th cycle of chronic intermittent air control in 16 to 18 week-old females (2010-2014-2015 data combin |
Nervous system |
| X35 |
17519 |
Object-location paired-associates learning using a touchscreen assay in 3 to 9-month-old females, percentage of trials correct in the first approximately 360 training trials, where higher values means |
Nervous system |
| X57 |
17526 |
TEST |
Other |
